169590-42-5 | 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzene-1-sulfonamide

Packsize	Purity	Availability	Price	Discounted Price
250mg	98%	in stock	$6.00	$4.00
1g	98%	in stock	$8.00	$6.00
10g	98%	in stock	$12.00	$9.00
25g	98%	in stock	$28.00	$19.00
100g	98%	in stock	$108.00	$76.00
500g	98%	in stock	$334.00	$234.00

Description

• Catalog Number: AI38735
• Chemical Name: 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzene-1-sulfonamide
• CAS Number: 169590-42-5
• Molecular Formula: C17H14F3N3O2S
• Molecular Weight: 381.3722
• MDL Number: MFCD00941298
• SMILES: Cc1ccc(cc1)c1cc(nn1c1ccc(cc1)S(=O)(=O)N)C(F)(F)F

Computed Properties

• Complexity: 577
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 26
• Hydrogen Bond Acceptor Count: 7
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 3
• XLogP3: 3.4

Literature

• COX-2 inhibition by celecoxib in epithelial ovarian cancer attenuates E-cadherin suppression through reduced Snail nuclear translocation.

  Chemico-biological interactions 20180825

• Discovery of new indomethacin-based analogs with potentially selective cyclooxygenase-2 inhibition and observed diminishing to PGE2 activities.

  European journal of medicinal chemistry 20171201

• Derivation and Evaluation of Putative Adverse Outcome Pathways for the Effects of Cyclooxygenase Inhibitors on Reproductive Processes in Female Fish.

  Toxicological sciences : an official journal of the Society of Toxicology 20170401

• Involvement of COX-2 in nickel elution from a wire implanted subcutaneously in mice.

  Toxicology 20160701

• Rational Design of Small Peptides for Optimal Inhibition of Cyclooxygenase-2: Development of a Highly Effective Anti-Inflammatory Agent.

  Journal of medicinal chemistry 20160428

• The Role of Prostaglandins and COX-Enzymes in Chondrogenic Differentiation of ATDC5 Progenitor Cells.

  PloS one 20160101

• Taurocholate Induces Cyclooxygenase-2 Expression via the Sphingosine 1-phosphate Receptor 2 in a Human Cholangiocarcinoma Cell Line.

  The Journal of biological chemistry 20151225

• Celecoxib increases lung cancer cell lysis by lymphokine-activated killer cells via upregulation of ICAM-1.

  Oncotarget 20151117

• Towards a systematic analysis of human short-chain dehydrogenases/reductases (SDR): Ligand identification and structure-activity relationships.

  Chemico-biological interactions 20150605

• Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.

  Chemical research in toxicology 20150518

• Celecoxib, but not indomethacin, ameliorates the hypertensive and perivascular fibrotic actions of cyclosporine in rats: role of endothelin signaling.

  Toxicology and applied pharmacology 20150401

• The superoxide anion donor, potassium superoxide, induces pain and inflammation in mice through production of reactive oxygen species and cyclooxygenase-2.

  Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 20150401

• MAPK pathway activation by chronic lead-exposure increases vascular reactivity through oxidative stress/cyclooxygenase-2-dependent pathways.

  Toxicology and applied pharmacology 20150301

• Arsenic sulfide combined with JQ1, chemotherapy agents, or celecoxib inhibit gastric and colon cancer cell growth.

  Drug design, development and therapy 20150101

• Effects of conventional and hydrogen sulfide-releasing non-steroidal anti-inflammatory drugs in rats with stress-induced and epinephrine-induced gastric damage.

  Stress (Amsterdam, Netherlands) 20141201

• Chrysin alleviates testicular dysfunction in adjuvant arthritic rats via suppression of inflammation and apoptosis: comparison with celecoxib.

  Toxicology and applied pharmacology 20140901

• Remedial effects of novel 2,3-disubstituted thiazolidin-4-ones in chemical mediated inflammation.

  Chemico-biological interactions 20140305

• Celecoxib offsets the negative renal influences of cyclosporine via modulation of the TGF-β1/IL-2/COX-2/endothelin ET(B) receptor cascade.

  Toxicology and applied pharmacology 20140301

• Acute exposure to lead acetate activates microglia and induces subsequent bystander neuronal death via caspase-3 activation.

  Neurotoxicology 20140301

• A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans.

  Toxicological sciences : an official journal of the Society of Toxicology 20140101

• Assessing the cardiovascular risk between celecoxib and nonselective nonsteroidal antiinflammatory drugs in patients with rheumatoid arthritis and osteoarthritis.

  Circulation journal : official journal of the Japanese Circulation Society 20140101

• IL-6-mediated induction of matrix metalloproteinase-9 is modulated by JAK-dependent IL-10 expression in macrophages.

  Journal of immunology (Baltimore, Md. : 1950) 20140101

• Comparison of the efficacy and safety profiles of a pelubiprofen versus celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, phase III, non-inferiority clinical trial.

  BMC musculoskeletal disorders 20140101

• Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11).

  Toxicological sciences : an official journal of the Society of Toxicology 20131201

• Induction but not inhibition of COX-2 confers human lung cancer cell apoptosis by celecoxib.

  Journal of lipid research 20131101

• Small molecule activators of the Nrf2-HO-1 antioxidant axis modulate heme metabolism and inflammation in BV2 microglia cells.

  Pharmacological research 20131001

• Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, VII, IX and XII with benzene sulfonamides incorporating 4,5,6,7-tetrabromophthalimide moiety.

  Bioorganic & medicinal chemistry 20131001

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• Mercury induces proliferation and reduces cell size in vascular smooth muscle cells through MAPK, oxidative stress and cyclooxygenase-2 pathways.

  Toxicology and applied pharmacology 20130415

• Synthesis and characterization of celecoxib derivatives as possible anti-inflammatory, analgesic, antioxidant, anticancer and anti-HCV agents.

  Molecules (Basel, Switzerland) 20130321

• An emerging role for anti-inflammatory agents for chemoprevention.

  Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20130101

• COX-2 active agents in the chemoprevention of colorectal cancer.

  Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20130101

• Indomethacin-enhanced anticancer effect of arsenic trioxide in A549 cell line: involvement of apoptosis and phospho-ERK and p38 MAPK pathways.

  BioMed research international 20130101

• Involvement of hypothalamic cyclooxygenase-2, interleukin-1β and melanocortin in the development of docetaxel-induced anorexia in rats.

  Toxicology 20121216

• Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study.

  Journal of affective disorders 20121210

• Transgenic insulin-like growth factor-1 stimulates activation of COX-2 signaling in mammary glands.

  Molecular carcinogenesis 20121201

• Preferential killing of triple-negative breast cancer cells in vitro and in vivo when pharmacological aggravators of endoplasmic reticulum stress are combined with autophagy inhibitors.

  Cancer letters 20121201

• Synthesis, biological evaluation and molecular modeling of dihydro-pyrazolyl-thiazolinone derivatives as potential COX-2 inhibitors.

  Bioorganic & medicinal chemistry 20121115

• Effects of celecoxib on restenosis after coronary intervention and evolution of atherosclerosis (Mini-COREA) trial: celecoxib, a double-edged sword for patients with angina.

  European heart journal 20121101

• Dolastatin 15, a mollusk linear peptide, and Celecoxib, a selective cyclooxygenase-2 inhibitor, prevent preneoplastic colonic lesions and induce apoptosis through inhibition of the regulatory transcription factor NF-κB and an inflammatory protein, iNOS.

  European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) 20121101

• Renal effects of high-dose celecoxib in elderly men with stage D2 prostate carcinoma.

  Clinical nephrology 20121101

• Involvement of PGE2 and RANTES in Staphylococcus aureus-induced fever in rats.

  Journal of applied physiology (Bethesda, Md. : 1985) 20121101

• Synthesis and pharmacological evaluation of N-substituted 2-(2-oxo-2H-chromen-4-yloxy)propanamide as cyclooxygenase inhibitors.

  Bioorganic & medicinal chemistry letters 20121101

• Celecoxib desensitization: continued temozolomide/celecoxib chemotherapy after a celecoxib-induced hypersensitivity reaction.

  Anti-cancer drugs 20121101

• Novel 3-substituted-1-aryl-5-phenyl-6-anilinopyrazolo[3,4-d]pyrimidin-4-ones: docking, synthesis and pharmacological evaluation as a potential anti-inflammatory agents.

  Bioorganic & medicinal chemistry letters 20121101

• AEE788 potentiates celecoxib-induced growth inhibition and apoptosis in human colon cancer cells.

  Life sciences 20121022

• Silymarin potentiates the anti-inflammatory effects of Celecoxib on chemically induced osteoarthritis in rats.

  Phytomedicine : international journal of phytotherapy and phytopharmacology 20121015

• WIN-34B, a new herbal medicine, inhibits the inflammatory response by inactivating IκB-α phosphorylation and mitogen activated protein kinase pathways in fibroblast-like synoviocytes.

  Journal of ethnopharmacology 20121011

• Release profile and characteristics of electrosprayed particles for oral delivery of a practically insoluble drug.

  Journal of the Royal Society, Interface 20121007

• Celecoxib inactivates epithelial-mesenchymal transition stimulated by hypoxia and/or epidermal growth factor in colon cancer cells.

  Molecular carcinogenesis 20121001

• Effect of celecoxib on Ca(2+) handling and viability in human prostate cancer cells (PC3).

  Drug and chemical toxicology 20121001

• Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial.

  Cancer immunology, immunotherapy : CII 20121001

• Non-selective inhibition of cyclooxygenase enzymes by aminoacetylenic isoindoline 1,3-diones.

  Inflammation & allergy drug targets 20121001

• Use of reduced-dose periarticular injection for pain management in simultaneous bilateral total knee arthroplasty.

  The Journal of arthroplasty 20121001

• Celecoxib enhances the anti-inflammatory effects of farnesylthiosalicylic acid on T cells independent of prostaglandin E(2) production.

  Inflammation 20121001

• Celecoxib enhances the effect of reboxetine and fluoxetine on cortical noradrenaline and serotonin output in the rat.

  Progress in neuro-psychopharmacology & biological psychiatry 20121001

• Cell intrinsic role of COX-2 in pancreatic cancer development.

  Molecular cancer therapeutics 20121001

• Celecoxib delays cognitive decline in an animal model of neurodegeneration.

  Behavioural brain research 20121001

• Colorectal polyps in childhood.

  Current opinion in pediatrics 20121001

• The developing Xenopus limb as a model for studies on the balance between inflammation and regeneration.

  Anatomical record (Hoboken, N.J. : 2007) 20121001

• Potent and orally efficacious benzothiazole amides as TRPV1 antagonists.

  Bioorganic & medicinal chemistry letters 20121001

• Reactivity of nonsteroidal anti-inflammatory drugs with peroxidase: a classification of nonsteroidal anti-inflammatory drugs.

  The Journal of pharmacy and pharmacology 20121001

• Cyclooxygenase-2 inhibition for the prevention of subglottic stenosis.

  Archives of otolaryngology--head & neck surgery 20121001

• [Effects of COX-2 inhibitor celecoxib on expressions of VEGF, b-FGF and TGF-β mRNA in acute leukemia cells].

  Zhongguo shi yan xue ye xue za zhi 20121001

• Cyclooxygenase-2 inhibitors modulate skin aging in a catalytic activity-independent manner.

  Experimental & molecular medicine 20120930

• Phospholipase A₂ activities in skin physiology and pathology.

  European journal of pharmacology 20120915

• Inhibition of cyclooxygenase-2 causes regression of gastric adenomas in trefoil factor 1 deficient mice.

  International journal of cancer 20120901

• Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors.

  Pediatric blood & cancer 20120901

• The novel NF-κB inhibitor DHMEQ synergizes with celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism.

  Cancer letters 20120901

• The use of different analgesics in orthodontic tooth movements.

  The Angle orthodontist 20120901

• A patient with Leiden V mutation, multiple sclerosis, psoriasis, and sicca syndrome: could celecoxib and fingolimod adversely affect the heart?

  Cardiovascular toxicology 20120901

• Dermal microdialysis technique to evaluate the trafficking of surface-modified lipid nanoparticles upon topical application.

  Pharmaceutical research 20120901

• Production and actions of the anandamide metabolite prostamide E2 in the renal medulla.

  The Journal of pharmacology and experimental therapeutics 20120901

• Antitumor and anti-metastatic effects of cyclooxygenase-2 inhibition by celecoxib on human colorectal carcinoma xenografts in nude mouse rectum.

  Oncology reports 20120901

• Risk factors associated with a decrease ≥2 g/dL in haemoglobin and/or ≥10% haematocrit in osteoarthritis patients taking celecoxib or a nonselective NSAID plus a PPI in a large randomised controlled trial (CONDOR).

  Alimentary pharmacology & therapeutics 20120901

• New pyrimido[5,4-e]pyrrolo[1,2-c]pyrimidines: synthesis, 2D-QSAR, anti-inflammatory, analgesic and ulcerogenicity studies.

  European journal of medicinal chemistry 20120901

• Acute Ibuprofen intoxication: report on a case and review of the literature.

  The American journal of forensic medicine and pathology 20120901

• Efficacy and safety of celecoxib versus diclofenac and omeprazole in elderly arthritis patients: a subgroup analysis of the CONDOR trial.

  Current medical research and opinion 20120901

• Efficacy and tolerability of celecoxib in the treatment of acute gouty arthritis: a randomized controlled trial.

  The Journal of rheumatology 20120901

• Safety of nonsteroidal antiinflammatory drugs and/or paracetamol in people receiving methotrexate for inflammatory arthritis: a Cochrane systematic review.

  The Journal of rheumatology. Supplement 20120901

• Use of dynamic weight bearing as a novel end-point for the assessment of Freund's Complete Adjuvant induced hypersensitivity in mice.

  Neuroscience letters 20120830

• In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs.

  Chemical research in toxicology 20120820

• Predicting new indications for approved drugs using a proteochemometric method.

  Journal of medicinal chemistry 20120809

• Apricoxib upregulates 15-PGDH and PGT in tobacco-related epithelial malignancies.

  British journal of cancer 20120807

• The effects of NSAIDs on types I, II, and III collagen metabolism in a rat osteoarthritis model.

  Rheumatology international 20120801

• Dosing celecoxib in pediatric patients with juvenile rheumatoid arthritis.

  Journal of clinical pharmacology 20120801

• Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib.

  European heart journal 20120801

• Antiproliferative effects of selective cyclooxygenase-2 inhibitor modulated by nimotuzumab in estrogen-dependent breast cancer cells.

  Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 20120801

• Combination of EGFR and COX-2 inhibitors in breast cancer patient.

  Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 20120801

• Sustained-release celecoxib from incubated acrylic intraocular lenses suppresses lens epithelial cell growth in an ex vivo model of posterior capsule opacity.

  Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20120801

• Expression of selected genes in preterm premature rupture of fetal membranes.

  Acta obstetricia et gynecologica Scandinavica 20120801

• Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model.

  Laboratory investigation; a journal of technical methods and pathology 20120801

• Orally administered rubiscolin-6, a δ opioid peptide derived from Rubisco, stimulates food intake via leptomeningeal lipocallin-type prostaglandin D synthase in mice.

  Molecular nutrition & food research 20120801

• Efficient synthesis and 5-LOX/COX-inhibitory activity of some 3-hydroxybenzo[b]thiophene-2-carboxylic acid derivatives.

  Bioorganic & medicinal chemistry letters 20120801

• Development of novel antibacterial agents against methicillin-resistant Staphylococcus aureus.

  Bioorganic & medicinal chemistry 20120801

• Development of simple and rapid LC-MS/MS method for determination of celecoxib in human plasma and its application to bioequivalence study.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120801

• Indole based cyclooxygenase inhibitors: synthesis, biological evaluation, docking and NMR screening.

  European journal of medicinal chemistry 20120801

• Reduction of DNA damage by curcumin and celecoxib in epithelial cell cultures of the oropharynx after incubation with tobacco smoke condensate.

  Anticancer research 20120801

• Association between COX-2 expression and effectiveness of COX-2 inhibitors in a phase II trial in patients with metastatic colorectal adenocarcinoma.

  Anticancer research 20120801

• Angiogenesis inhibition by green propolis and the angiogenic effect of L-lysine on bladder cancer in rats.

  Acta cirurgica brasileira 20120801

• Economic outcomes for celecoxib: a systematic review of pharmacoeconomic studies.

  Expert review of pharmacoeconomics & outcomes research 20120801

• Primary systemic therapy in HER2-amplified breast cancer: a clinical review.

  Expert review of anticancer therapy 20120801

• NSAIDs in orthodontic tooth movement.

  Journal of pharmacy & bioallied sciences 20120801

• The EP1 receptor for prostaglandin E2 promotes the development and progression of malignant murine skin tumors.

  Molecular carcinogenesis 20120701

• COX-2-independent induction of apoptosis by celecoxib and polyamine naphthalimide conjugate mediated by polyamine depression in colorectal cancer cell lines.

  International journal of colorectal disease 20120701

• Sensitivity of gait parameters to the effects of anti-inflammatory and opioid treatments in knee osteoarthritis patients.

  Journal of orthopaedic research : official publication of the Orthopaedic Research Society 20120701

• Effect of selective and non-selective cyclooxygenase inhibitors on doxorubicin-induced cardiotoxicity and nephrotoxicity in rats.

  Toxicology mechanisms and methods 20120701

• Determination of non-steroidal anti-inflammatory drugs and their metabolites in milk by liquid chromatography-tandem mass spectrometry.

  Analytical and bioanalytical chemistry 20120701

• Role of Sulindac and Celecoxib in the regulation of angiogenesis during the early neoplasm of colon: exploring PI3-K/PTEN/Akt pathway to the canonical Wnt/β-catenin signaling.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20120701

• Celecoxib inhibits growth of human autosomal dominant polycystic kidney cyst-lining epithelial cells through the VEGF/Raf/MAPK/ERK signaling pathway.

  Molecular biology reports 20120701

• Celecoxib enhances the radiosensitizing effect of 7-hydroxystaurosporine (UCN-01) in human lung cancer cell lines.

  International journal of radiation oncology, biology, physics 20120701

• Etodolac, a cyclooxygenase-2 inhibitor, attenuates paclitaxel-induced peripheral neuropathy in a mouse model of mechanical allodynia.

  The Journal of pharmacology and experimental therapeutics 20120701

• Nonsteroidal anti-inflammatory drug-activated gene-1 plays a role in the impairing effects of cyclooxygenase inhibitors on gastric ulcer healing.

  The Journal of pharmacology and experimental therapeutics 20120701

• Dispensed selective and nonselective nonsteroidal anti-inflammatory drugs and the risk of moderate to severe hyperkalemia: a nested case-control study.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20120701

• Cyclooxygenase-2 inhibitors induce anoikis in osteosarcoma via PI3K/Akt pathway.

  Medical hypotheses 20120701

• New quinazolinone-pyrimidine hybrids: synthesis, anti-inflammatory, and ulcerogenicity studies.

  European journal of medicinal chemistry 20120701

• Downregulation of Prominin 1/CD133 expression in colorectal cancer by NSAIDs following short-term preoperative treatment.

  International journal of oncology 20120701

• NSAIDs induce apoptosis in nonproliferating ovarian cancer cells and inhibit tumor growth in vivo.

  IUBMB life 20120701

• Ellagic acid facilitates indomethacin-induced gastric ulcer healing via COX-2 up-regulation.

  Acta biochimica et biophysica Sinica 20120701

• Colon-specific delivery of celecoxib is a potential strategy to improve toxicological and pharmacological properties of the selective Cox-2 inhibitor: implication in treatment of familiar adenomatous polyposis.

  Journal of drug targeting 20120701

• Sulfonamides: a patent review (2008 - 2012).

  Expert opinion on therapeutic patents 20120701

• Activation of mitochondrial apoptosis pathways in cutaneous squamous cell carcinoma cells by diclofenac/hyaluronic acid is related to upregulation of Bad as well as downregulation of Mcl-1 and Bcl-w.

  Experimental dermatology 20120701

• New therapeutic agents in uveal melanoma.

  Anticancer research 20120701

• The HMGA1-COX-2 axis: a key molecular pathway and potential target in pancreatic adenocarcinoma.

  Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 20120701

• Inhibition of COX-2 in colon cancer modulates tumor growth and MDR-1 expression to enhance tumor regression in therapy-refractory cancers in vivo.

  Neoplasia (New York, N.Y.) 20120701

• Use of nonsteroidal anti-inflammatory drugs and risk of basal cell carcinoma in the United States Radiologic Technologists study.

  International journal of cancer 20120615

• Cyclooxygenase-2 prostaglandins mediate anandamide-inhibitory action on nitric oxide synthase activity in the receptive rat uterus.

  European journal of pharmacology 20120615

• Determination of celecoxib in human plasma by liquid chromatography-tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120615

• Synthesis and biological evaluation of derivatives of 2-{2-fluoro-4-[(2-oxocyclopentyl)methyl]phenyl}propanoic acid: nonsteroidal anti-inflammatory drugs with low gastric ulcerogenic activity.

  Journal of medicinal chemistry 20120614

• Development and characterization of a novel drug nanocarrier for oral delivery, based on self-assembled β-casein micelles.

  Journal of controlled release : official journal of the Controlled Release Society 20120610

• (-)-Epigallocatechin-3-gallate, a green tea-derived catechin, synergizes with celecoxib to inhibit IL-1-induced tumorigenic mediators by human pancreatic adenocarcinoma cells Colo357.

  European journal of pharmacology 20120605

• Celecoxib or naproxen treatment does not benefit depressive symptoms in persons age 70 and older: findings from a randomized controlled trial.

  The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 20120601

• Celecoxib, a cyclooxygenase-2 inhibitor, improved upper gastrointestinal lesions in rheumatoid arthritis patients as assessed by endoscopic evaluation.

  Modern rheumatology 20120601

• Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions.

  Gut 20120601

• A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity.

  Rheumatology international 20120601

• Effects of antidepressants and cyclooxygenase-2 inhibitor on cytokines and kynurenines in stimulated in vitro blood culture from depressed patients.

  Inflammopharmacology 20120601

• Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649.

  Clinical pharmacology and therapeutics 20120601

• N-Acetylglucosaminyltransferase V regulates TGF-β response in hepatic stellate cells and the progression of steatohepatitis.

  Glycobiology 20120601

• Adherence to routine use of pharmacological prophylaxis of heterotopic ossification after total hip arthroplasty: results from an Italian multicenter, prospective, observational survey.

  Journal of orthopaedics and traumatology : official journal of the Italian Society of Orthopaedics and Traumatology 20120601

• Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers.

  Angiogenesis 20120601

• Retrospective evaluation of inpatient celecoxib use after total hip and knee arthroplasty at a Veterans Affairs Medical Center.

  The Journal of arthroplasty 20120601

• Recent developments and biological activities of thiazolidinone derivatives: a review.

  Bioorganic & medicinal chemistry 20120601

• Gene expression profile of coronary artery cells treated with nonsteroidal anti-inflammatory drugs reveals off-target effects.

  Journal of cardiovascular pharmacology 20120601

• Celecoxib inhibits invasion and metastasis via a cyclooxygenase 2-independent mechanism in an in vitro model of Ewing sarcoma.

  Journal of pediatric surgery 20120601

• Dual function of tributyrin emulsion: solubilization and enhancement of anticancer effect of celecoxib.

  International journal of pharmaceutics 20120530

• Hybrid nanomaterials that mimic the food effect: controlling enzymatic digestion for enhanced oral drug absorption.

  Angewandte Chemie (International ed. in English) 20120529

• Prostate cancer: celecoxib trampled in the STAMPEDE trial.

  Nature reviews. Urology 20120529

• Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.

  Journal of medicinal chemistry 20120524

• Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line.

  Molecular and cellular endocrinology 20120515

• Synthesis and biological activity of 2-aminothiazoles as novel inhibitors of PGE2 production in cells.

  Bioorganic & medicinal chemistry letters 20120515

• Synthesis, biological evaluation and molecular modeling study of pyrazole and pyrazoline derivatives as selective COX-2 inhibitors and anti-inflammatory agents. Part 2.

  Bioorganic & medicinal chemistry 20120515

• [Inflammation-induced pain. How rheumatism patients profit from the proper NSAID choice].

  MMW Fortschritte der Medizin 20120503

• Vascular COX-2 modulates blood pressure and thrombosis in mice.

  Science translational medicine 20120502

• Inhibition of cyclooxygenase-2 modulates phenotypic switching of vascular smooth muscle cells during increased aortic blood flow.

  Heart and vessels 20120501

• The cyclooxygenase-2 pathway via the PGE₂ EP2 receptor contributes to oligodendrocytes apoptosis in cuprizone-induced demyelination.

  Journal of neurochemistry 20120501

• Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120501

• Febrile response induced by cecal ligation and puncture (CLP) in rats: involvement of prostaglandin E2 and cytokines.

  Medical microbiology and immunology 20120501

• Non-steroidal anti-inflammatory drugs use and risk of upper gastrointestinal adverse events in cirrhotic patients.

  Liver international : official journal of the International Association for the Study of the Liver 20120501

• Chronic anti-inflammatory drug therapy inhibits gel-forming mucin production in a murine xenograft model of human pseudomyxoma peritonei.

  Annals of surgical oncology 20120501

• Chemopreventive efficacy of Targretin in rodent models of urinary bladder, colon/intestine, head and neck and mammary cancers.

  Oncology reports 20120501

• N-succinylaspart-1-yl celecoxib is a potential colon-specific prodrug of celecoxib with improved therapeutic properties.

  Journal of pharmaceutical sciences 20120501

• Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term non-steroidal anti-inflammatory drug (NSAID) therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial.

  Journal of gastroenterology 20120501

• Cyclooxygenase-2 inhibition restores ultraviolet B-induced downregulation of ATP2A2/SERCA2 in keratinocytes: possible therapeutic approach of cyclooxygenase-2 inhibition for treatment of Darier disease.

  The British journal of dermatology 20120501

• The STAMPEDE trial and celecoxib: how to adapt?

  The Lancet. Oncology 20120501

• Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial.

  The Lancet. Oncology 20120501

• Combination chemoprevention: future direction of colorectal cancer prevention.

  European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) 20120501

• Design and synthesis of 4-O-methylhonokiol analogs as inhibitors of cyclooxygenase-2 (COX-2) and PGF₁ production.

  Bioorganic & medicinal chemistry 20120501

• Celecoxib induces apoptosis and cell-cycle arrest in nasopharyngeal carcinoma cell lines via inhibition of STAT3 phosphorylation.

  Acta pharmacologica Sinica 20120501

• Schizophrenia and the immune system: pathophysiology, prevention, and treatment.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20120501

• Inducible cyclooxygenase expression mediating hypoxia/reoxygenation-induced pulmonary vasoconstriction is attenuated by a cyclooxygenase inhibitor in rats.

  Transplantation proceedings 20120501

• Italian guidelines for primary headaches: 2012 revised version.

  The journal of headache and pain 20120501

• Synthesis of novel pyrazole and dihydropyrazoles derivatives as potential anti-inflammatory and analgesic agents.

  Archives of pharmacal research 20120501

• [An experimental study on chemoprevention of esophageal adenocarcinoma by celecoxib, a selective cyclooxygenase-2 inhibitor].

  Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery 20120501

• [Serum levels of cartilage oligomeric matrix protein in the diagnosis of knee osteoarthritis].

  Zhongguo gu shang = China journal of orthopaedics and traumatology 20120501

• [Inhibitory effects of cyclooxygenase-2 selective inhibitor Celecoxib on human nephroblastoma].

  Zhonghua bing li xue za zhi = Chinese journal of pathology 20120501

• Structure-activity relationship of nonacidic quinazolinone inhibitors of human microsomal prostaglandin synthase 1 (mPGES 1).

  Journal of medicinal chemistry 20120426

• Protective role of adiponectin against ethanol-induced gastric injury in mice.

  American journal of physiology. Gastrointestinal and liver physiology 20120415

• Celecoxib and tauro-ursodeoxycholic acid co-treatment inhibits cell growth in familial adenomatous polyposis derived LT97 colon adenoma cells.

  Experimental cell research 20120415

• Molecular cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Malassezia globosa, a potential antidandruff target.

  Journal of medicinal chemistry 20120412

• Pyrazolo[4,3-c][1,2]benzothiazines 5,5-dioxide: a promising new class of Staphylococcus aureus NorA efflux pump inhibitors.

  Journal of medicinal chemistry 20120412

• Cytoprotective effect of nonsteroidal antiinflammatory drugs in rat brain slices subjected to reoxygenation after oxygen-glucose deprivation.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20120411

• Inclusion of celecoxib into fibrous ordered mesoporous carbon for enhanced oral bioavailability and reduced gastric irritancy.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20120411

• A practical model of osteomyelitis-induced bone pain by intra-tibial injection of Staphylococcus aureus in rats.

  Neuroscience letters 20120404

• Enhancement of amorphous celecoxib stability by mixing it with octaacetylmaltose: the molecular dynamics study.

  Molecular pharmaceutics 20120402

• Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial.

  International journal of geriatric psychiatry 20120401

• Effect of nonselective and selective COX-2 inhibitors on memory dysfunction, glutathione system, and tumor necrosis factor alpha level against cerebral ischemia reperfusion injury.

  Drug and chemical toxicology 20120401

• Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome.

  Clinical nutrition (Edinburgh, Scotland) 20120401

• Small bowel injury induced by selective cyclooxygenase-2 inhibitors: a prospective, double-blind, randomized clinical trial comparing celecoxib and meloxicam.

  Journal of gastroenterology 20120401

• Concordance with guideline recommendations: previous and more recent nonsteroidal anti-inflammatory drug prescriptions in Quebec, Canada.

  Pharmacoepidemiology and drug safety 20120401

• Melatonin sensitizes human hepatoma cells to endoplasmic reticulum stress-induced apoptosis.

  Journal of pineal research 20120401

• Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis.

  The Journal of clinical psychiatry 20120401

• Up-regulation of 12(S)-lipoxygenase induces a migratory phenotype in colorectal cancer cells.

  Experimental cell research 20120401

• Glycosylation of human cyclooxygenase-2 (COX-2) decreases the efficacy of certain COX-2 inhibitors.

  Pharmacological research 20120401

• Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis.

  The Journal of pharmacology and experimental therapeutics 20120401

• Effect of non-steroidal anti-inflammatory drugs and new fenamate analogues on TRPC4 and TRPC5 channels.

  Biochemical pharmacology 20120401

• Celecoxib pathways: pharmacokinetics and pharmacodynamics.

  Pharmacogenetics and genomics 20120401

• Inflammation-induced decrease in voluntary wheel running in mice: a nonreflexive test for evaluating inflammatory pain and analgesia.

  Pain 20120401

• Mutation of active site residues Asn67 to Ile, Gln92 to Val and Leu204 to Ser in human carbonic anhydrase II: influences on the catalytic activity and affinity for inhibitors.

  Bioorganic & medicinal chemistry 20120401

• Synthesis and evaluation of fluorobenzoylated di- and tripeptides as inhibitors of cyclooxygenase-2 (COX-2).

  Bioorganic & medicinal chemistry 20120401

• Re: Preventive but not curative efficacy of celecoxib on bladder carcinogenesis in a rat model.

  The Journal of urology 20120401

• CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20120401

• Probable celecoxib-induced hepatorenal syndrome.

  The Annals of pharmacotherapy 20120401

• Automatic filtering and substantiation of drug safety signals.

  PLoS computational biology 20120401

• Phase ii trial of a metronomic schedule of docetaxel and capecitabine with concurrent celecoxib in patients with prior anthracycline exposure for metastatic breast cancer.

  Current oncology (Toronto, Ont.) 20120401

• Role of enhanced visibility in evaluating polyposis syndromes using a newly developed contrast image capsule endoscope.

  Gut and liver 20120401

• Seeing it through: translational validation of new medical imaging modalities.

  Biomedical optics express 20120401

• Role of basic science in the development of new medicines: examples from the eicosanoid field.

  The Journal of biological chemistry 20120323

• Curcumin as anti-endometriotic agent: implication of MMP-3 and intrinsic apoptotic pathway.

  Biochemical pharmacology 20120315

• Novel 5-substituted 1H-tetrazoles as cyclooxygenase-2 (COX-2) inhibitors.

  Bioorganic & medicinal chemistry letters 20120315

• N-1 and C-3 substituted indole Schiff bases as selective COX-2 inhibitors: synthesis and biological evaluation.

  Bioorganic & medicinal chemistry letters 20120315

• Cyclooxygenase-1-selective inhibitors based on the (E)-2'-des-methyl-sulindac sulfide scaffold.

  Journal of medicinal chemistry 20120308

• Effect of celecoxib on proliferation, collagen expression, ERK1/2 and SMAD2/3 phosphorylation in NIH/3T3 fibroblasts.

  European journal of pharmacology 20120305

• Hydrophilic prodrug approach for reduced pigment binding and enhanced transscleral retinal delivery of celecoxib.

  Molecular pharmaceutics 20120305

• Non-steroidal anti-inflammatory drugs and cognitive function: are prostaglandins at the heart of cognitive impairment in dementia and delirium?

  Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 20120301

• Spectrofluorimetric determination of aliskiren in tablets and spiked human plasma through derivatization with dansyl chloride.

  Journal of fluorescence 20120301

• In vitro characterization of chitosan gels for buccal delivery of celecoxib: influence of a penetration enhancer.

  AAPS PharmSciTech 20120301

• A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life.

  Gynecologic oncology 20120301

• Celecoxib suppresses fibroblast proliferation and collagen expression by inhibiting ERK1/2 and SMAD2/3 phosphorylation.

  Molecular medicine reports 20120301

• Low-dose celecoxib improves coronary function after acute myocardial ischaemia in rabbits.

  Clinical and experimental pharmacology & physiology 20120301

• Synthesis of novel 2-mercapto benzothiazole and 1,2,3-triazole based bis-heterocycles: their anti-inflammatory and anti-nociceptive activities.

  European journal of medicinal chemistry 20120301

• The APC and PreSAP trials: a post hoc noninferiority analysis using a comprehensive new measure for gastrointestinal tract injury in 2 randomized, double-blind studies comparing celecoxib and placebo.

  Clinical therapeutics 20120301

• Role of Sulindac and Celecoxib in chemoprevention of colorectal cancer via intrinsic pathway of apoptosis: exploring NHE-1, intracellular calcium homeostasis and Calpain 9.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20120301

• Celecoxib and Bcl-2: emerging possibilities for anticancer drug design.

  Future medicinal chemistry 20120301

• Preemptive analgesic effect of low doses of celecoxib is superior to low doses of traditional nonsteroidal anti-inflammatory drugs.

  The Journal of craniofacial surgery 20120301

• Targeted therapy for hepatocellular carcinoma: novel agents on the horizon.

  Oncotarget 20120301

• Total knee arthroplasty in rheumatoid arthritis.

  Knee surgery & related research 20120301

• Rational approaches to improving selectivity in drug design.

  Journal of medicinal chemistry 20120223

• Oxidative stress-dependent cyclooxygenase-2-derived prostaglandin f(2α) impairs endothelial function in renovascular hypertensive rats.

  Antioxidants & redox signaling 20120215

• Cloning, characterization and sulfonamide inhibition studies of an α-carbonic anhydrase from the living fossil sponge Astrosclera willeyana.

  Bioorganic & medicinal chemistry 20120215

• Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease.

  The Cochrane database of systematic reviews 20120215

• Celecoxib reduces fluidity and decreases metastatic potential of colon cancer cell lines irrespective of COX-2 expression.

  Bioscience reports 20120201

• Synthesis and biological evaluation of some novel sulfamoylphenyl-pyridazinone as anti-inflammatory agents (Part-II * ).

  Journal of enzyme inhibition and medicinal chemistry 20120201

• TERC polymorphisms are associated both with susceptibility to colorectal cancer and with longer telomeres.

  Gut 20120201

• Drug-induced hypersensitivity syndrome followed by persistent arthritis.

  The Journal of dermatology 20120201

• Polymeric nanoparticles for increased oral bioavailability and rapid absorption using celecoxib as a model of a low-solubility, high-permeability drug.

  Pharmaceutical research 20120201

• Pharmacological modulation of peritoneal injury induced by dialysis fluids: is it an option?

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20120201

• Dimethylcelecoxib induces an inhibitory complex consisting of HDAC1/NF-κB(p65)RelA leading to transcriptional downregulation of mPGES-1 and EGR1.

  Cellular signalling 20120201

• Berberine-induced AMPK activation inhibits the metastatic potential of melanoma cells via reduction of ERK activity and COX-2 protein expression.

  Biochemical pharmacology 20120201

• Low-dosage metronomic chemotherapy and angiogenesis: topoisomerase inhibitors irinotecan and mitoxantrone stimulate VEGF-A-mediated angiogenesis.

  APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 20120201

• Fixed drug eruption caused by etoricoxib with tolerance to celecoxib and parecoxib.

  Contact dermatitis 20120201

• Efficacy and safety of additional 200-mg dose of celecoxib in adult patients with postoperative pain following extraction of impacted third mandibular molar: a multicenter, randomized, double-blind, placebo-controlled, phase II study in Japan.

  Clinical therapeutics 20120201

• Early recovery after fast-track Oxford unicompartmental knee arthroplasty. 35 patients with minimal invasive surgery.

  Acta orthopaedica 20120201

• (E)-3,5-Dimethyl-1-p-tolyl-4-(p-tolyl-diazen-yl)-1H-pyrazole.

  Acta crystallographica. Section E, Structure reports online 20120201

• Ethyl 2-[(2,4-difluoro-phen-yl)hydrazinyl-idene]-3-oxobutano-ate.

  Acta crystallographica. Section E, Structure reports online 20120201

• A continuous infusion fascia iliaca compartment block in hip fracture patients: a pilot study.

  Journal of clinical medicine research 20120201

• Novel marine phenazines as potential cancer chemopreventive and anti-inflammatory agents.

  Marine drugs 20120201

• [Clinical efficacy of bushen huoxue qubi decoction on treatment of knee-osteoarthritis and its effect on hemarheology, anti-inflammation and antioxidation].

  Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica 20120201

• [Chemoprevention of oral cancer--clinical and experimental studies].

  Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 20120201

• Enzymatic transformation of caffeic acid with enhanced cyclooxygenase-2 inhibitory activity.

  Bioorganic & medicinal chemistry letters 20120115

• Restoration of tumor suppressor p53 by differentially regulating pro- and anti-p53 networks in HPV-18-infected cervical cancer cells.

  Oncogene 20120112

• Diagnosis and treatment of acute ankle injuries: development of an evidence-based algorithm.

  Orthopedic reviews 20120102

• An experimental study of low-level laser therapy in rat Achilles tendon injury.

  Lasers in medical science 20120101

• Metabolism of tocotrienols in animals and synergistic inhibitory actions of tocotrienols with atorvastatin in cancer cells.

  Genes & nutrition 20120101

• Cooperative enhancement of radiosensitivity after combined treatment of 17-(allylamino)-17-demethoxygeldanamycin and celecoxib in human lung and colon cancer cell lines.

  DNA and cell biology 20120101

• The COX-2 inhibitor Celecoxib enhances the sensitivity of KB/VCR oral cancer cell lines to Vincristine by down-regulating P-glycoprotein expression and function.

  Prostaglandins & other lipid mediators 20120101

• The nonsteroidal anti-inflammatory drug celecoxib suppresses the growth and induces apoptosis of human glioblastoma cells via the NF-κB pathway.

  Journal of neuro-oncology 20120101

• Quality by design approach for developing chitosan-Ca-alginate microspheres for colon delivery of celecoxib-hydroxypropyl-β-cyclodextrin-PVP complex.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20120101

• Nitric oxide synthase inhibition abrogates hydrogen sulfide-induced cardioprotection in mice.

  Molecular and cellular biochemistry 20120101

• Lack of a chondroprotective effect of cyclooxygenase 2 inhibition in a surgically induced model of osteoarthritis in mice.

  Arthritis and rheumatism 20120101

• Changing the outcome of osteoarthritis: still a challenge for cyclooxygenase 2 inhibitors.

  Arthritis and rheumatism 20120101

• Barrier coated drug layered particles for enhanced performance of amorphous solid dispersion dosage form.

  Journal of pharmaceutical sciences 20120101

• Utility of vascular endothelial growth factor inhibitors in the treatment of ovarian cancer: from concept to application.

  Journal of oncology 20120101

• Kv7 potassium channels in airway smooth muscle cells: signal transduction intermediates and pharmacological targets for bronchodilator therapy.

  American journal of physiology. Lung cellular and molecular physiology 20120101

• Tumor angiogenesis as a target for dietary cancer prevention.

  Journal of oncology 20120101

• Molecular pathogenesis of cholangiocarcinoma.

  International journal of hepatology 20120101

• Novel selective COX-1 inhibitors suppress neuroinflammatory mediators in LPS-stimulated N13 microglial cells.

  Pharmacological research 20120101

• Loss of the preconditioning effect of rosuvastatin during sustained therapy: a human in vivo study.

  American journal of physiology. Heart and circulatory physiology 20120101

• Lack of efficacy of combined antiangiogenic therapies in xenografted human melanoma.

  Journal of oncology 20120101

• Lipoprotein lipase as a candidate target for cancer prevention/therapy.

  Biochemistry research international 20120101

• The influence of UGT1A6 variants and aspirin use in a randomized trial of celecoxib for prevention of colorectal adenoma.

  Cancer prevention research (Philadelphia, Pa.) 20120101

• Effects of cyclooxygenase inhibition on cardiovascular function in a hypercholesterolemic swine model of chronic ischemia.

  American journal of physiology. Heart and circulatory physiology 20120101

• The in vivo expression of radiation-induced chromosomal instability has an inflammatory mechanism.

  Radiation research 20120101

• An update on the pathology and clinical management of gouty arthritis.

  Clinical rheumatology 20120101

• Prostaglandin E(2) potentiates methylmalonate-induced seizures.

  Epilepsia 20120101

• Constitutive overexpression of the oncogene Rac1 in the airway of recurrent respiratory papillomatosis patients is a targetable host-susceptibility factor.

  Molecular medicine (Cambridge, Mass.) 20120101

• Peripheral chondrosarcoma progression is associated with increased type X collagen and vascularisation.

  Virchows Archiv : an international journal of pathology 20120101

• Structure based drug design, synthesis and evaluation of 4-(benzyloxy)-1-phenylbut-2-yn-1-ol derivatives as 5-lipoxygenase inhibitors.

  European journal of medicinal chemistry 20120101

• Fragment-based design, docking, synthesis, biological evaluation and structure-activity relationships of 2-benzo/benzisothiazolimino-5-aryliden-4-thiazolidinones as cycloxygenase/lipoxygenase inhibitors.

  European journal of medicinal chemistry 20120101

• A high-fat diet induces bone loss in mice lacking the Alox5 gene.

  Endocrinology 20120101

• A comparison of the therapeutic efficacy of diclofenac in osteoarthritis: a systematic review of randomised controlled trials.

  Current medical research and opinion 20120101

• Adjunct treatments for schizophrenia and bipolar disorder: what to try when you are out of ideas.

  Clinical schizophrenia & related psychoses 20120101

• Effects of combination therapy with celecoxib and doxycycline on neointimal hyperplasia and inflammatory biomarkers in coronary artery disease patients treated with bare metal stents.

  Yonsei medical journal 20120101

• The role of nutraceuticals in chemoprevention and chemotherapy and their clinical outcomes.

  Journal of oncology 20120101

• Comparison of CD63 Upregulation Induced by NSAIDs on Basophils and Monocytes in Patients with NSAID Hypersensitivity.

  Journal of allergy 20120101

• Aspirin: pharmacology and clinical applications.

  Thrombosis 20120101

• Beneficial effect of ultra-low-dose aspirin in platelet activity alterations and haemorrhage observed in experimental portal hypertension.

  Thrombosis 20120101

• A systematic review and meta-analysis of efficacy, cost-effectiveness, and safety of selected complementary and alternative medicine for neck and low-back pain.

  Evidence-based complementary and alternative medicine : eCAM 20120101

• Meloxicam-induced rhabdomyolysis in the context of an acute ross river viral infection.

  Allergy, asthma & immunology research 20120101

• Celecoxib may prevent lung cancer.

  Cancer 20120101

• Factors implicated in radiation therapy failure and radiosensitization of prostate cancer.

  Prostate cancer 20120101

• Effect of prostaglandin E2 injection on the structural properties of the rat patellar tendon.

  Sports medicine, arthroscopy, rehabilitation, therapy & technology : SMARTT 20120101

• Systemic arthritis in children: a review of clinical presentation and treatment.

  International journal of inflammation 20120101

• Interactions between prostaglandins, leukotrienes and HIV-1: possible implications for the central nervous system.

  Retrovirology 20120101

• A novel radioresistant mechanism of galectin-1 mediated by H-Ras-dependent pathways in cervical cancer cells.

  Cell death & disease 20120101

• A 4-trifluoromethyl analogue of celecoxib inhibits arthritis by suppressing innate immune cell activation.

  Arthritis research & therapy 20120101

• [Immunomodulation and antiangiogenesis in cancer therapy. From basic to clinical research].

  Medicina 20120101

• Enhancement of Antinociception by Co-administrations of Nefopam, Morphine, and Nimesulide in a Rat Model of Neuropathic Pain.

  The Korean journal of pain 20120101

• The cost-effectiveness of celecoxib vs diclofenac in the treatment of osteoarthritis in the UK; an update to the NICE model using data from the CONDOR trial.

  Journal of medical economics 20120101

• Resveratrol engages AMPK to attenuate ERK and mTOR signaling in sensory neurons and inhibits incision-induced acute and chronic pain.

  Molecular pain 20120101

• Do nonsteroidal anti-inflammatory drugs affect bone healing? A critical analysis.

  TheScientificWorldJournal 20120101

• Recent advances in morphological cell image analysis.

  Computational and mathematical methods in medicine 20120101

• Expression of COX2 and p53 in Rat Esophageal Cancer Induced by Reflux of Duodenal Contents.

  ISRN gastroenterology 20120101

• Polymeric micelles based on poly(ethylene glycol) block poly(racemic amino acids) hybrid polypeptides: conformation-facilitated drug-loading behavior and potential application as effective anticancer drug carriers.

  International journal of nanomedicine 20120101

• Autocrine prostaglandin E2 signaling promotes tumor cell survival and proliferation in childhood neuroblastoma.

  PloS one 20120101

• Hepatitis C virus to hepatocellular carcinoma.

  Infectious agents and cancer 20120101

• Challenging medical ghostwriting in US courts.

  PLoS medicine 20120101

• Exhaled Eicosanoids following Bronchial Aspirin Challenge in Asthma Patients with and without Aspirin Hypersensitivity: The Pilot Study.

  Journal of allergy 20120101

• Trends in qualifying biomarkers in drug safety. Consensus of the 2011 meeting of the spanish society of clinical pharmacology.

  Frontiers in pharmacology 20120101

• Increased serum sTRAIL levels were correlated with survival in bevacizumab-treated metastatic colon cancer.

  BMC cancer 20120101

• Influence of morphine on pericyte-endothelial interaction: implications for antiangiogenic therapy.

  Journal of oncology 20120101

• Metronomic chemotherapy in advanced oral cancers.

  Journal of cancer research and therapeutics 20120101

• Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer.

  Breast cancer research : BCR 20120101

• [A case of favorable response after combination treatment with interferon-α and cyclooxygenase-2 inhibitor against metastatic renal cell carcinoma].

  Hinyokika kiyo. Acta urologica Japonica 20120101

• Shortening of 3'UTRs correlates with poor prognosis in breast and lung cancer.

  PloS one 20120101

• Regulation of cyclooxygenase-2 expression by heat: a novel aspect of heat shock factor 1 function in human cells.

  PloS one 20120101

• Minocycline and aspirin in the treatment of bipolar depression: a protocol for a proof-of-concept, randomised, double-blind, placebo-controlled, 2x2 clinical trial.

  BMJ open 20120101

• Hemagglutinin from the H5N1 virus activates Janus kinase 3 to dysregulate innate immunity.

  PloS one 20120101

• Arsenic trioxide enhances the radiation sensitivity of androgen-dependent and -independent human prostate cancer cells.

  PloS one 20120101

• The antinociceptive effect of electroacupuncture at different depths of acupoints and under the needling surface.

  Chinese medicine 20120101

• Who fans the flames of Alzheimer's disease brains? Misfolded tau on the crossroad of neurodegenerative and inflammatory pathways.

  Journal of neuroinflammation 20120101

• Murine models of B-cell lymphomas: promising tools for designing cancer therapies.

  Advances in hematology 20120101

• A novel LMP1 antibody synergizes with mitomycin C to inhibit nasopharyngeal carcinoma growth in vivo through inducing apoptosis and downregulating vascular endothelial growth factor.

  International journal of molecular sciences 20120101

• Endogenous opioid and cannabinoid mechanisms are involved in the analgesic effects of celecoxib in the central nervous system.

  Pharmacology 20120101

• Single dose oral celecoxib for acute postoperative pain in adults.

  The Cochrane database of systematic reviews 20120101

• Low levels of Human Cytomegalovirus Infection in Glioblastoma multiforme associates with patient survival; -a case-control study.

  Herpesviridae 20120101

• Celecoxib radiosensitizes the human cervical cancer HeLa cell line via a mechanism dependent on reduced cyclo-oxygenase-2 and vascular endothelial growth factor C expression.

  The Journal of international medical research 20120101

• Non-steroidal anti-inflammatory drugs for the treatment of pain and immobility-associated osteoarthritis: consensus guidance for primary care.

  BMC family practice 20120101

• The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.

  BMC geriatrics 20120101

• Down-regulation of glucose-regulated protein (GRP) 78 potentiates cytotoxic effect of celecoxib in human urothelial carcinoma cells.

  PloS one 20120101

• Nimesulide inhibited the growth of hypopharyngeal carcinoma cells via suppressing Survivin expression.

  Head & neck oncology 20120101

• Minocycline corrects early, pre-plaque neuroinflammation and inhibits BACE-1 in a transgenic model of Alzheimer's disease-like amyloid pathology.

  Journal of neuroinflammation 20120101

• Emerging pharmacotherapies for diabetic macular edema.

  Experimental diabetes research 20120101

• Cellular-based immunotherapies for patients with glioblastoma multiforme.

  Clinical & developmental immunology 20120101

• Effect of GCSB-5, a Herbal Formulation, on Monosodium Iodoacetate-Induced Osteoarthritis in Rats.

  Evidence-based complementary and alternative medicine : eCAM 20120101

• A randomized, double blind, placebo and active comparator controlled pilot study of UP446, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin.

  Nutrition journal 20120101

• Gastrointestinal-sparing effects of novel NSAIDs in rats with compromised mucosal defence.

  PloS one 20120101

• Prostaglandins in cancer cell adhesion, migration, and invasion.

  International journal of cell biology 20120101

• Leptin in anorexia and cachexia syndrome.

  International journal of peptides 20120101

• The role of MAPK in drug-induced kidney injury.

  Journal of signal transduction 20120101

• Fraud in anaesthetic research and publication.

  Indian journal of anaesthesia 20120101

• Pathogenesis of abdominal aortic aneurysms: role of nicotine and nicotinic acetylcholine receptors.

  Mediators of inflammation 20120101

• Current trends in targeted therapies for glioblastoma multiforme.

  Neurology research international 20120101

• Tolfenamic acid induces apoptosis and growth inhibition in head and neck cancer: involvement of NAG-1 expression.

  PloS one 20120101

• Glenohumeral joint preservation: a review of management options for young, active patients with osteoarthritis.

  Advances in orthopedics 20120101

• Neuroprotective effects of meloxicam and selegiline in scopolamine-induced cognitive impairment and oxidative stress.

  International journal of Alzheimer's disease 20120101

• A further piece of the puzzle: positive FOBT, colonoscopy, aspirin and the prevention of colorectal cancer.

  Digestion 20120101

• Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: a multicenter experience.

  Oncology 20120101

• Oxidative stress and microglial cells in Parkinson's disease.

  Mediators of inflammation 20120101

• Cell cycle inhibition without disruption of neurogenesis is a strategy for treatment of aberrant cell cycle diseases: an update.

  TheScientificWorldJournal 20120101

• Efficacy and Safety of Duloxetine in Patients with Chronic Low Back Pain Who Used versus Did Not Use Concomitant Nonsteroidal Anti-Inflammatory Drugs or Acetaminophen: A Post Hoc Pooled Analysis of 2 Randomized, Placebo-Controlled Trials.

  Pain research and treatment 20120101

• Health and cellular impacts of air pollutants: from cytoprotection to cytotoxicity.

  Biochemistry research international 20120101

• A chemocentric approach to the identification of cancer targets.

  PloS one 20120101

• A review: inflammatory process in Alzheimer's disease, role of cytokines.

  TheScientificWorldJournal 20120101

• Influence of Tumor Location on the Composition of Immune Infiltrate and Its Impact on Patient Survival. Lessons from DCBCL and Animal Models.

  Frontiers in immunology 20120101

• Targeting multiple-myeloma-induced immune dysfunction to improve immunotherapy outcomes.

  Clinical & developmental immunology 20120101

• Altered composition of liver proteasome assemblies contributes to enhanced proteasome activity in the exceptionally long-lived naked mole-rat.

  PloS one 20120101

• Selection of metastatic breast cancer cells based on adaptability of their metabolic state.

  PloS one 20120101

• Inhibition of EP4 signaling attenuates aortic aneurysm formation.

  PloS one 20120101

• COX-2 expression and tumor angiogenesis in thyroid carcinoma patients among northeast Chinese population-result of a single-center study.

  International journal of medical sciences 20120101

• Efficacy of etoricoxib, celecoxib, lumiracoxib, non-selective NSAIDs, and acetaminophen in osteoarthritis: a mixed treatment comparison.

  The open rheumatology journal 20120101

• Synthesis and anti-inflammatory evaluation of new substituted 1-(3-chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazole derivatives.

  Acta poloniae pharmaceutica 20120101

• Scientific evidence and rationale for the development of curcumin and resveratrol as nutraceutricals for joint health.

  International journal of molecular sciences 20120101

• Chitosan-hyaluronate hybrid gel intraarticular injection delays osteoarthritis progression and reduces pain in a rat meniscectomy model as compared to saline and hyaluronate treatment.

  Advances in orthopedics 20120101

• Antineuropathic and antinociceptive drugs combination in patients with chronic low back pain: a systematic review.

  Pain research and treatment 20120101

• Drug management of visceral pain: concepts from basic research.

  Pain research and treatment 20120101

• Adverse events in patients with blood loss: a pooled analysis of 51 clinical studies from the celecoxib clinical trial database.

  The open rheumatology journal 20120101

• Induction of selective blood-tumor barrier permeability and macromolecular transport by a biostable kinin B1 receptor agonist in a glioma rat model.

  PloS one 20120101

• Expressions of MMPs and TIMP-1 in gastric ulcers may differentiate H. pylori-infected from NSAID-related ulcers.

  TheScientificWorldJournal 20120101

• Selective COX-2 inhibitor ameliorates osteoarthritis by repressing apoptosis of chondrocyte.

  Medical science monitor : international medical journal of experimental and clinical research 20120101

• Colorectal cancer chemoprevention: is this the future of colorectal cancer prevention?

  TheScientificWorldJournal 20120101

• Low-dose chemotherapy with insulin (insulin potentiation therapy) in combination with hormone therapy for treatment of castration-resistant prostate cancer.

  ISRN urology 20120101

• Treatment-resistant Schizophrenia: Evidence-based Strategies.

  Mens sana monographs 20120101

• Effect of aspirin on cell growth of human MG-63 osteosarcoma line.

  TheScientificWorldJournal 20120101

• The yin and yang of nrf2-regulated selenoproteins in carcinogenesis.

  International journal of cell biology 20120101

• Current knowledge on pancreatic cancer.

  Frontiers in oncology 20120101

• Indomethacin reduces glomerular and tubular damage markers but not renal inflammation in chronic kidney disease patients: a post-hoc analysis.

  PloS one 20120101

• Eicosanoids and respiratory viral infection: coordinators of inflammation and potential therapeutic targets.

  Mediators of inflammation 20120101

• Therapeutic strategies based on polymeric microparticles.

  Journal of biomedicine & biotechnology 20120101

• The molecular biology of soft-tissue sarcomas and current trends in therapy.

  Sarcoma 20120101

• Impact of a preemptive multimodal analgesia plus femoral nerve blockade protocol on rehabilitation, hospital length of stay, and postoperative analgesia after primary total knee arthroplasty: a controlled clinical pilot study.

  TheScientificWorldJournal 20120101

• Modelling the effects of ageing time of starch on the enzymatic activity of three amylolytic enzymes.

  TheScientificWorldJournal 20120101

• Solitary fibrous tumor in the round ligament of the liver: a fortunate intraoperative discovery.

  Case reports in oncology 20120101

• Coauthorship and institutional collaborations on cost-effectiveness analyses: a systematic network analysis.

  PloS one 20120101

• GSK-3β: A Bifunctional Role in Cell Death Pathways.

  International journal of cell biology 20120101

• Transactivation of EGFR by LPS induces COX-2 expression in enterocytes.

  PloS one 20120101

• Topical polyethylene glycol as a novel chemopreventive agent for oral cancer via targeting of epidermal growth factor response.

  PloS one 20120101

• A review of fetal scarless healing.

  ISRN dermatology 20120101

• Microglial KCa3.1 Channels as a Potential Therapeutic Target for Alzheimer's Disease.

  International journal of Alzheimer's disease 20120101

• Radiation, inflammation, and immune responses in cancer.

  Frontiers in oncology 20120101

• Pain from a Bullet Lingers on: An Uncommon Case of Lead Toxicity.

  Case reports in gastroenterology 20120101

• Comment on 'Accentuation of Tumor Growth Secondary to Morphine Administration: The Proneoplastic Role of Morphine besides Its Role in Pain Management'.

  Journal of oncology 20120101

• Cucurbitacin L 2-O-β-Glucoside Demonstrates Apoptogenesis in Colon Adenocarcinoma Cells (HT-29): Involvement of Reactive Oxygen and Nitrogen Species Regulation.

  Evidence-based complementary and alternative medicine : eCAM 20120101

• Celecoxib synergizes human pancreatic ductal adenocarcinoma cells to sorafenib-induced growth inhibition.

  Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 20120101

• Anxiolytic-like effects of compound zhi zhu xiang in rats.

  Evidence-based complementary and alternative medicine : eCAM 20120101

• Extra-abdominal desmoid tumors associated with familial adenomatous polyposis.

  Sarcoma 20120101

• Inhibition of ion channels and heart beat in Drosophila by selective COX-2 inhibitor SC-791.

  PloS one 20120101

• Expression of specificity protein transcription factors in pancreatic cancer and their association in prognosis and therapy.

  Current medicinal chemistry 20120101

• Selective cyclooxygenase-2 inhibitor prevents cisplatin-induced tumorigenesis in A/J mice.

  Acta medica Okayama 20120101

• Inflammation modulates expression of laminin in the central nervous system following ischemic injury.

  Journal of neuroinflammation 20120101

• Long-term disease stabilization in a patient with castration-resistant metastatic prostate cancer by the addition of lenalidomide to low-dose dexamethasone and celecoxib.

  Onkologie 20120101

• In vitro effects of VA441, a new selective cyclooxygenase-2 inhibitor, on human osteoarthritic chondrocytes exposed to IL-1β.

  Journal of pharmacological sciences 20120101

• Activation of diverse eicosanoid pathways in osteoarthritic cartilage: a lipidomic and genomic analysis.

  Bulletin of the NYU hospital for joint diseases 20120101

• Celecoxib and GABA cooperatively prevent the progression of pancreatic cancer in vitro and in xenograft models of stress-free and stress-exposed mice.

  PloS one 20120101

• Molecular mechanism of the inhibition effect of Celecoxib on corneal collagen degradation in three dimensions.

  International journal of ophthalmology 20120101

• Effects of cyclooxygenase inhibitors in combination with taxol on expression of cyclin D1 and Ki-67 in a xenograft model of ovarian carcinoma.

  International journal of molecular sciences 20120101

• In vivo optical molecular imaging of matrix metalloproteinase activity following celecoxib therapy for colorectal cancer.

  Molecular imaging 20120101

• Role of APOE and Age at Enrollment in the Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT).

  Dementia and geriatric cognitive disorders extra 20120101

• Efficacy and tolerability of celecoxib versus naproxen in patients with osteoarthritis of the knee: a randomized, double-blind, double-dummy trial.

  The Journal of international medical research 20120101

• Simultaneous Determination of Celecoxib, Erlotinib, and its Metabolite Desmethyl-Erlotinib (OSI-420) in Rat Plasma by Liquid chromatography/Tandem Mass Spectrometry with Positive/Negative Ion-Switching Electrospray Ionisation.

  Scientia pharmaceutica 20120101

• Comparative study of liposomes, transfersomes and ethosomes as carriers for improving topical delivery of celecoxib.

  Drug delivery 20120101

• [Chronic infection urethroprostatit: a new look at old problem].

  Urologiia (Moscow, Russia : 1999) 20120101

• Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.

  Drugs 20111224

• Inhibition of cyclooxygenase-2 impacts chondrocyte hypertrophic differentiation during endochondral ossification.

  European cells & materials 20111219

• Protection against titanium particle-induced osteoclastogenesis by cyclooxygenase-2 selective inhibitor.

  Journal of biomedical materials research. Part A 20111215

• PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment.

  Cancer research 20111215

• COX-2 inhibition does not reverse the increased sympathetic modulation in MSG obese rats.

  Autonomic neuroscience : basic & clinical 20111207

• Chemopreventive effects of non-steroidal anti-inflammatory drugs in early neoplasm of experimental colorectal cancer: an apoptosome study.

  Journal of gastrointestinal cancer 20111201

• Cancer chemoprevention by targeting the epigenome.

  Current drug targets 20111201

• Cyclooxygenase as a target for colorectal cancer chemoprevention.

  Current drug targets 20111201

• Dual blockade of the EGFR and COX-2 pathways: a phase II trial of cetuximab and celecoxib in patients with chemotherapy refractory metastatic colorectal cancer.

  American journal of clinical oncology 20111201

• Drug-induced Sweet's syndrome by aceclofenac.

  Cutaneous and ocular toxicology 20111201

• Sweet's syndrome associated with the intake of a selective cyclooxygenase-2 (COX-2) inhibitor.

  Cutaneous and ocular toxicology 20111201

• The use of spray-drying to enhance celecoxib solubility.

  Drug development and industrial pharmacy 20111201

• Role of COX-2 in the bioactivation of methylenedianiline and in its proliferative effects in vascular smooth muscle cells.

  Cardiovascular toxicology 20111201

• Non steroidal anti-inflammatory drugs modulate the physicochemical properties of plasma membrane in experimental colorectal cancer: a fluorescence spectroscopic study.

  Molecular and cellular biochemistry 20111201

• Antiangiogenic treatment as a pre-operative management of alveolar soft-part sarcoma.

  Pediatric blood & cancer 20111201

• Celecoxib for recurrent sclerouveitis after syphilitic panuveitis. A case report.

  Journal of ophthalmic inflammation and infection 20111201

• Stroke risk and NSAIDs: a systematic review of observational studies.

  Pharmacoepidemiology and drug safety 20111201

• The role of the EP receptors for prostaglandin E2 in skin and skin cancer.

  Cancer metastasis reviews 20111201

• A fixed-dose combination of naproxen and esomeprazole magnesium has comparable upper gastrointestinal tolerability to celecoxib in patients with osteoarthritis of the knee: results from two randomized, parallel-group, placebo-controlled trials.

  Annals of medicine 20111201

• Synthesis and biological evaluation of some new 2-pyrazolines bearing benzene sulfonamide moiety as potential anti-inflammatory and anti-cancer agents.

  European journal of medicinal chemistry 20111201

• Case scenario: opioid association with serotonin syndrome: implications to the practitioners.

  Anesthesiology 20111201

• Treatment of osteoarthritis with continuous versus intermittent celecoxib.

  The Journal of rheumatology 20111201

• Analysing the role of COX-2 in acute oesophagitis and in melatonin-exerted protection against experimental reflux oesophagitis in rats.

  The Journal of pharmacy and pharmacology 20111201

• Survival and prognostic factors in chondrosarcoma: results in 115 patients with long-term follow-up.

  Acta orthopaedica 20111201

• Why still in hospital after fast-track hip and knee arthroplasty?

  Acta orthopaedica 20111201

• Single-level anterior cervical discectomy and interbody fusion using PEEK anatomical cervical cage and allograft bone.

  Journal of orthopaedics and traumatology : official journal of the Italian Society of Orthopaedics and Traumatology 20111201

• Celecoxib-induced erythema multiforme-type drug eruption with a positive patch test.

  The Journal of dermatology 20111201

• Comparison and validation of data-mining indices for signal detection: using the Korean national health insurance claims database.

  Pharmacoepidemiology and drug safety 20111201

• Pragmatic decisions over nonsteroidal antiinflammatory drug treatment in osteoarthritis--continuous versus intermittent.

  The Journal of rheumatology 20111201

• Pilot study of a pediatric metronomic 4-drug regimen.

  Oncotarget 20111201

• Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

  PLoS computational biology 20111201

• Roles of serotonergic and adrenergic receptors in the antinociception of selective cyclooxygenase-2 inhibitor in the rat spinal cord.

  The Korean journal of pain 20111201

• Is human cytomegalovirus a target in cancer therapy?

  Oncotarget 20111201

• A case of celecoxib induced acute generalized exanthematous pustulosis.

  Annals of dermatology 20111201

• Novel analgesic/anti-inflammatory agents: diarylpyrrole acetic esters endowed with nitric oxide releasing properties.

  Journal of medicinal chemistry 20111124

• Novel selective Cox-2 inhibitors induce apoptosis in Caco-2 colorectal carcinoma cell line.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20111120

• COX-2 inhibitors block chemotherapeutic agent-induced apoptosis prior to commitment in hematopoietic cancer cells.

  Biochemical pharmacology 20111115

• A double prodrug system for colon targeting of benzenesulfonamide COX-2 inhibitors.

  Bioorganic & medicinal chemistry letters 20111115

• Design, synthesis and biological evaluation of pyridine acyl sulfonamide derivatives as novel COX-2 inhibitors.

  Bioorganic & medicinal chemistry 20111115

• Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20111110

• Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis).

  The Cochrane database of systematic reviews 20111109

• Clinical significance of vasculogenic mimicry in human gliomas.

  Journal of neuro-oncology 20111101

• Characteristics and molecular basis of celecoxib modulation on K(v)7 potassium channels.

  British journal of pharmacology 20111101

• A 13-week, multicenter, randomized, double-blind study of lumiracoxib in hip osteoarthritis.

  Clinical rheumatology 20111101

• Elevated macrophage migration inhibitory factor and decreased transforming growth factor-beta levels in major depression--no influence of celecoxib treatment.

  Journal of affective disorders 20111101

• Gastric juice prostaglandins and peptide growth factors as potential markers of chronic atrophic gastritis, intestinal metaplasia and gastric cancer: their potential clinical implications based on this pilot study.

  Digestive diseases and sciences 20111101

• Association of stem-like cells in gender-specific chemoprevention against intestinal neoplasia in MIN mouse.

  Oncology reports 20111101

• Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention.

  Cancer prevention research (Philadelphia, Pa.) 20111101

• The acid sphingomyelinase inhibitors block interferon-α-induced serotonin uptake via a COX-2/Akt/ERK/STAT-dependent pathway in T cells.

  International immunopharmacology 20111101

• A 78-year-old woman with an acute eosinophilic gastroenteritis.

  Clinics and research in hepatology and gastroenterology 20111101

• The structure of NS-398 bound to cyclooxygenase-2.

  Journal of structural biology 20111101

• Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20111101

• Onsenal: marketing authorisation withdrawn in the European Union. Company failed to supply required data.

  Prescrire international 20111101

• [Survivin gene silencing inhibits the proliferation of human gastric cancer MGC-803 cells and enhances their sensitivity to celecoxib].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20111101

• SHINBARO, a new herbal medicine with multifunctional mechanism for joint disease: first therapeutic application for the treatment of osteoarthritis.

  Archives of pharmacal research 20111101

• [Is retardation of radiologic progression of ankylosing spondylitis possible?].

  Vnitrni lekarstvi 20111101

• Chemopreventive activity of vitamin E in breast cancer: a focus on γ- and δ-tocopherol.

  Nutrients 20111101

• A preliminary randomized double-blind clinical trial on the efficacy of celecoxib as an adjunct in the treatment of obsessive-compulsive disorder.

  Psychiatry research 20111030

• A novel inhibitor of focal adhesion signaling induces caspase-independent cell death in diffuse large B-cell lymphoma.

  Blood 20111020

• Use of nonaspirin nonsteroidal anti-inflammatory drugs during pregnancy and the risk of spontaneous abortion.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20111018

• Isomeric acetoxy analogs of celecoxib and their evaluation as cyclooxygenase inhibitors.

  Bioorganic & medicinal chemistry letters 20111015

• Efficient synthesis of apricoxib, CS-706, a selective cyclooxygenase-2 inhibitor, and evaluation of inhibition of prostaglandin E2 production in inflammatory breast cancer cells.

  Bioorganic & medicinal chemistry letters 20111015

• Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases, and cytochromes P450: cross-talk between the eicosanoid and endocannabinoid signaling pathways.

  Chemical reviews 20111012

• Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target.

  The Journal of clinical investigation 20111003

• Titanium, sinusitis, and the yellow nail syndrome.

  Biological trace element research 20111001

• Randomized controlled trial of the efficacy of isosorbide-SR addition to current treatment in medical expulsive therapy for ureteral calculi.

  Urological research 20111001

• The risk of coronary thrombosis with cyclo-oxygenase-2 inhibitors does not vary with polymorphisms in two regions of the cyclo-oxygenase-2 gene.

  British journal of clinical pharmacology 20111001

• Non-steroidal anti-inflammatory drugs and risk of lower gastrointestinal adverse events: a nationwide study in Taiwan.

  Gut 20111001

• Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis.

  Gastroenterology 20111001

• COX-2 regulates the proliferation of glioma stem like cells.

  Neurochemistry international 20111001

• Haemoglobin decreases in NSAID users over time: an analysis of two large outcome trials.

  Alimentary pharmacology & therapeutics 20111001

• Phenylethynylbenzenesulfonamide regioisomers strongly and selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic isoforms I and II.

  Bioorganic & medicinal chemistry letters 20111001

• Celecoxib promotes c-FLIP degradation through Akt-independent inhibition of GSK3.

  Cancer research 20111001

• A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer.

  Cancer prevention research (Philadelphia, Pa.) 20111001

• Boxing bladder cancer with COX-2-specific inhibition.

  Cancer prevention research (Philadelphia, Pa.) 20111001

• Fluorinated COX-2 inhibitors as agents in PET imaging of inflammation and cancer.

  Cancer prevention research (Philadelphia, Pa.) 20111001

• Vascular mechanisms involved in angiotensin II-induced venoconstriction in hypertensive rats.

  Peptides 20111001

• Characterization of a new animal model for evaluation and treatment of back pain due to lumbar facet joint osteoarthritis.

  Arthritis and rheumatism 20111001

• Cutaneous reactions to non-steroidal anti-inflammatory drugs.

  Journal of drugs in dermatology : JDD 20111001

• Enhancing antitumor effects in pancreatic cancer cells by combined use of COX-2 and 5-LOX inhibitors.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20111001

• Ethyl 2-[2-(2-meth-oxy-phen-yl)hydrazinyl-idene]-3-oxobutano-ate.

  Acta crystallographica. Section E, Structure reports online 20111001

• 4-[2-(4-Chloro-phen-yl)hydrazinyl-idene]-3-methyl-5-oxo-4,5-dihydro-1H-pyrazole-1-carbothio-amide.

  Acta crystallographica. Section E, Structure reports online 20111001

• Ethyl 2-[2-(3-meth-oxy-phen-yl)hydrazinyl-idene]-3-oxobutano-ate.

  Acta crystallographica. Section E, Structure reports online 20111001

• Genome protective effect of metformin as revealed by reduced level of constitutive DNA damage signaling.

  Aging 20111001

• [Advances in gastrointestinal disorders associated with non-steroidal antiinflammatory agents and aspirin].

  Gastroenterologia y hepatologia 20111001

• Nitric oxide-releasing aspirin but not conventional aspirin improves healing of experimental colitis.

  World journal of gastroenterology 20110928

• Chemical and in vitro enzymatic stability of newly synthesized celecoxib lipophilic and hydrophilic amides.

  International journal of pharmaceutics 20110915

• Interaction of celecoxib with different anti-cancer drugs is antagonistic in breast but not in other cancer cells.

  Toxicology and applied pharmacology 20110915

• Gastroprotective and safety effects of WIN-34B, a novel treatment for osteoarthritis, compared to NSAIDs.

  Journal of ethnopharmacology 20110902

• Efficacy of celecoxib, meloxicam and paracetamol in elderly Kashin-Beck disease (KBD) patients.

  International orthopaedics 20110901

• The use of etoricoxib and celecoxib for pain prevention after periodontal surgery: a double-masked, parallel-group, placebo-controlled, randomized clinical trial.

  Journal of periodontology 20110901

• Activation of vascular KCNQ (Kv7) potassium channels reverses spasmogen-induced constrictor responses in rat basilar artery.

  British journal of pharmacology 20110901

• Letter to the editor re Mani et al.

  British journal of pharmacology 20110901

• Inhibitory effect of celecoxib in lung carcinoma by regulation of cyclooxygenase-2/cytosolic phospholipase A₂ and peroxisome proliferator-activated receptor gamma.

  Molecular and cellular biochemistry 20110901

• Silica-lipid hybrid (SLH) versus non-lipid formulations for optimising the dose-dependent oral absorption of celecoxib.

  Pharmaceutical research 20110901

• Role of COX-2 in lymphangiogenesis and restoration of lymphatic flow in secondary lymphedema.

  Laboratory investigation; a journal of technical methods and pathology 20110901

• Effectiveness of the association micronized N-Palmitoylethanolamine (PEA)-transpolydatin in the treatment of chronic pelvic pain related to endometriosis after laparoscopic assessment: a pilot study.

  European journal of obstetrics, gynecology, and reproductive biology 20110901

• Synthesis and preliminary in vitro biological evaluation of new carbon-11-labeled celecoxib derivatives as candidate PET tracers for imaging of COX-2 expression in cancer.

  European journal of medicinal chemistry 20110901

• Benefits of prolonged postoperative cyclooxygenase-2 inhibitor administration on total knee arthroplasty recovery: a double-blind, placebo-controlled study.

  The Journal of arthroplasty 20110901

• COX-2 inhibition alters the phenotype of tumor-associated macrophages from M2 to M1 in ApcMin/+ mouse polyps.

  Carcinogenesis 20110901

• Established and novel NF-κB inhibitors lead to downregulation of TLR3 and the proliferation and cytokine secretion in HNSCC.

  Oral oncology 20110901

• Hypercholesterolemia and chronic ischemia alter myocardial responses to selective cyclooxygenase-2 inhibition.

  The Journal of thoracic and cardiovascular surgery 20110901

• Irish Medicines Board safety warnings: do they affect prescribing rates in primary care?

  Pharmacoepidemiology and drug safety 20110901

• The role of morphine in regulation of cancer cell growth.

  Naunyn-Schmiedeberg's archives of pharmacology 20110901

• Potential interaction of natural dietary bioactive compounds with COX-2.

  Journal of molecular graphics & modelling 20110901

• Randomized controlled trials of COX-2 inhibitors: an analysis of doses used and trends over time to investigate implications for comparative safety.

  Drug safety 20110901

• Cost-effectiveness of aspirin, celecoxib, and calcium chemoprevention for colorectal cancer.

  Clinical therapeutics 20110901

• Cox-2 inhibitors induce early c-Myc downregulation and lead to expression of differentiation markers in leukemia cells.

  Cell cycle (Georgetown, Tex.) 20110901

• Phased whole-genome genetic risk in a family quartet using a major allele reference sequence.

  PLoS genetics 20110901

• Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies.

  PLoS medicine 20110901

• Differential effects of treadmill exercise on cyclooxygenase-2 in the rat hippocampus at early and chronic stages of diabetes.

  Laboratory animal research 20110901

• Clinical significance of protein expression of cyclooxygenase-2 and somatostatin receptors in gastroenteropancreatic neuroendocrine tumors.

  Cancer research and treatment : official journal of Korean Cancer Association 20110901

• 4-(5-Phenyl-3-trifluoro-meth-yl-1H-pyrazol-1--yl)benzene-sulfonamide.

  Acta crystallographica. Section E, Structure reports online 20110901

• Clinical significance of anti-mitochondrial antibodies in a patient with chronic graft-versus-host disease following hematopoietic stem cell transplantation.

  The Korean journal of hematology 20110901

• Analysis of angiogenic factors and cyclooxygenase-2 expression in cartilaginous tumors- clinical and histological correlation.

  Clinics (Sao Paulo, Brazil) 20110901

• Profound urinary protein loss and acute renal failure caused by cyclooxygenase-2 inhibitor.

  The Chinese journal of physiology 20110831

• Inhibition studies of the β-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium with sulfonamides and sulfamates.

  Bioorganic & medicinal chemistry 20110815

• Effects of β-glucosidase hydrolyzed products of harpagide and harpagoside on cyclooxygenase-2 (COX-2) in vitro.

  Bioorganic & medicinal chemistry 20110815

• Fragment-based drug design and drug repositioning using multiple ligand simultaneous docking (MLSD): identifying celecoxib and template compounds as novel inhibitors of signal transducer and activator of transcription 3 (STAT3).

  Journal of medicinal chemistry 20110811

• Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2.

  Nature medicine 20110807

• Preoperative chemoradiation for rectal cancer using capecitabine and celecoxib correlated with posttreatment assessment of thymidylate synthase and thymidine phosphorylase expression.

  International journal of radiation oncology, biology, physics 20110801

• Simvastatin improves learning and memory in control but not in olfactory bulbectomized rats.

  Psychopharmacology 20110801

• Clinical and immunomodulatory effects of celecoxib plus interferon-alpha in metastatic renal cell carcinoma patients with COX-2 tumor immunostaining.

  Journal of clinical immunology 20110801

• Celecoxib inhibits interleukin-6/interleukin-6 receptor-induced JAK2/STAT3 phosphorylation in human hepatocellular carcinoma cells.

  Cancer prevention research (Philadelphia, Pa.) 20110801

• Fast-track revision knee arthroplasty. A feasibility study.

  Acta orthopaedica 20110801

• Celecoxib induces cell apoptosis coupled with up-regulation of the expression of VEGF by a mechanism involving ER stress in human colorectal cancer cells.

  Oncology reports 20110801

• Control of experimental pulmonary tuberculosis depends more on immunostimulatory leukotrienes than on the absence of immunosuppressive prostaglandins.

  Prostaglandins, leukotrienes, and essential fatty acids 20110801

• Celecoxib does not alter cardiovascular and renal function during dietary salt loading.

  Clinical and experimental pharmacology & physiology 20110801

• Pharmacology of peripheral opioid receptors.

  Current opinion in anaesthesiology 20110801

• The inhibitory effect of celecoxib and rosiglitazone on experimental endometriosis.

  Fertility and sterility 20110801

• An investigation into the dissolution properties of celecoxib melt extrudates: understanding the role of polymer type and concentration in stabilizing supersaturated drug concentrations.

  Molecular pharmaceutics 20110801

• Plasma levels of vascular endothelial growth factor during and after radiotherapy in combination with celecoxib in patients with advanced head and neck cancer.

  Oral oncology 20110801

• Phase I clinical trial of nasopharyngeal radiotherapy and concurrent celecoxib for patients with locoregionally advanced nasopharyngeal carcinoma.

  Oral oncology 20110801

• Analogue-based design, synthesis and molecular docking analysis of 2,3-diaryl quinazolinones as non-ulcerogenic anti-inflammatory agents.

  Bioorganic & medicinal chemistry 20110801

• Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer.

  Clinical breast cancer 20110801

• High-volume infiltration analgesia in bilateral hip arthroplasty. A randomized, double-blind placebo-controlled trial.

  Acta orthopaedica 20110801

• Multicentre trial in people with arthritis finds increased risk of clinically significant gastrointestinal events with diclofenac plus omeprazole compared with celecoxib.

  Evidence-based medicine 20110801

• Comparison of different loading dose of celecoxib on postoperative anti-inflammation and analgesia in patients undergoing endoscopic nasal surgery-200 mg is equivalent to 400 mg.

  Pain medicine (Malden, Mass.) 20110801

• Cardiovascular risk markers and mechanisms in targeting the COX pathway for colorectal cancer prevention.

  Cancer prevention research (Philadelphia, Pa.) 20110801

• C-reactive protein and risk of colorectal adenoma according to celecoxib treatment.

  Cancer prevention research (Philadelphia, Pa.) 20110801

• Nitric Oxide (NO) and Cyclooxygenase-2 (COX-2) Cross-Talk in Co-Cultures of Tumor Spheroids with Normal Cells.

  Cancer microenvironment : official journal of the International Cancer Microenvironment Society 20110801

• COX-2 inhibitor, celecoxib, may prevent lung cancer.

  Oncology (Williston Park, N.Y.) 20110801

• Up-regulation of cyclooxygenase-2-derived prostaglandin E(2) in colon cancer cells resistant to 5-fluorouracil.

  Journal of the Korean Surgical Society 20110801

• (Z)-Ethyl 2-cyano-2-{2-[5,6-dimethyl-4-(thio-phen-2-yl)-1H-pyrazolo-[3,4-b]pyridin-3-yl]hydrazinylidene}acetate.

  Acta crystallographica. Section E, Structure reports online 20110801

• Chemoprevention in familial adenomatous polyposis.

  Best practice & research. Clinical gastroenterology 20110801

• In vitro and in vivo inhibitory effect of three Cox-2 inhibitors and epithelial-to-mesenchymal transition in human bladder cancer cell lines.

  British journal of cancer 20110726

• The importance of cyclooxygenase 2-mediated oxidative stress in obesity-induced muscular insulin resistance in high-fat-fed rats.

  Life sciences 20110718

• Zinc deficiency activates S100A8 inflammation in the absence of COX-2 and promotes murine oral-esophageal tumor progression.

  International journal of cancer 20110715

• Phase 1 trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer.

  Cancer 20110715

• Synthesis of some new 1,3,5-trisubstituted pyrazolines bearing benzene sulfonamide as anticancer and anti-inflammatory agents.

  Bioorganic & medicinal chemistry letters 20110715

• Discovery and biological evaluation of a novel class of dual microsomal prostaglandin E2 synthase-1/5-lipoxygenase inhibitors based on 2-[(4,6-diphenethoxypyrimidin-2-yl)thio]hexanoic acid.

  Journal of medicinal chemistry 20110714

• Defects in mouse nephrogenesis induced by selective and non-selective cyclooxygenase-2 inhibitors.

  British journal of pharmacology 20110701

• Celecoxib and 2,5-dimethyl-celecoxib prevent cardiac remodeling inhibiting Akt-mediated signal transduction in an inherited dilated cardiomyopathy mouse model.

  The Journal of pharmacology and experimental therapeutics 20110701

• Efficacy of low-dose celecoxib in patients with acute pain.

  The journal of pain : official journal of the American Pain Society 20110701

• Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.

  Drug metabolism and disposition: the biological fate of chemicals 20110701

• Effect of evening primrose oil and ω-3 polyunsaturated fatty acids on the cardiovascular risk of celecoxib in rats.

  Journal of cardiovascular pharmacology 20110701

• SOM230 combined with celecoxib prolongs the survival in nude mice with HepG-2 xenografts.

  Cancer biology & therapy 20110701

• Gastrointestinal tolerability of NSAIDs in elderly patients: a pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs.

  Current medical research and opinion 20110701

• Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: a double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group.

  European journal of cancer (Oxford, England : 1990) 20110701

• Harmful effects of NSAIDs among patients with hypertension and coronary artery disease.

  The American journal of medicine 20110701

• Risk of hospitalization for upper gastrointestinal adverse events associated with nonsteroidal anti-inflammatory drugs: a nationwide case-crossover study in Taiwan.

  Pharmacoepidemiology and drug safety 20110701

• A diazen-1-ium-1,2-diolated nitric oxide donor ester prodrug of 3-(4-hydroxymethylphenyl)-4-(4-methanesulfonylphenyl)-5H-furan-2-one: synthesis, biological evaluation and nitric oxide release studies.

  Bioorganic & medicinal chemistry letters 20110701

• A low carbohydrate, high protein diet slows tumor growth and prevents cancer initiation.

  Cancer research 20110701

• Is there a common upstream link for autophagic and apoptotic cell death in human high-grade gliomas?

  Neuro-oncology 20110701

• Treatment targets in intracerebral hemorrhage.

  Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 20110701

• The dawn of a revolution in personalized lung cancer prevention.

  Cancer prevention research (Philadelphia, Pa.) 20110701

• Lung cancer chemoprevention with celecoxib in former smokers.

  Cancer prevention research (Philadelphia, Pa.) 20110701

• Extended results of the Alzheimer's disease anti-inflammatory prevention trial.

  Alzheimer's & dementia : the journal of the Alzheimer's Association 20110701

• Celecoxib and acetylbritannilactone interact synergistically to suppress breast cancer cell growth via COX-2-dependent and -independent mechanisms.

  Cell death & disease 20110701

• Features of microglia and neuroinflammation relevant to environmental exposure and neurotoxicity.

  International journal of environmental research and public health 20110701

• [Effects of celecoxib combined with radiotherapy on apoptosis of CNE-2Z cell lines].

  Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery 20110701

• Preparation of microspheres containing low solubility drug compound by electrohydrodynamic spraying.

  International journal of pharmaceutics 20110630

• How a new stratified adaptive phase II design could improve targeting population.

  Statistics in medicine 20110615

• Mitragynine inhibits the COX-2 mRNA expression and prostaglandin E₂ production induced by lipopolysaccharide in RAW264.7 macrophage cells.

  Journal of ethnopharmacology 20110614

• Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer.

  British journal of cancer 20110607

• Resveratrol in combination with other dietary polyphenols concomitantly enhances antiproliferation and UGT1A1 induction in Caco-2 cells.

  Life sciences 20110606

• Role of α-relaxation on crystallization of amorphous celecoxib above T(g) probed by dielectric spectroscopy.

  Molecular pharmaceutics 20110606

• Role of COX-2 in tumorospheres derived from a breast cancer cell line.

  The Journal of surgical research 20110601

• Optimization of cell-based assays to quantify the anti-inflammatory/allergic potential of test substances in 96-well format.

  Inflammopharmacology 20110601

• The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study.

  Journal of cancer research and clinical oncology 20110601

• Incidence and influence on referral of primary stabbing headache in an outpatient headache clinic.

  The journal of headache and pain 20110601

• Investigation of atypical dissolution behavior of an encapsulated amorphous solid dispersion.

  Journal of pharmaceutical sciences 20110601

• The prostaglandin E2 receptor, EP2, regulates survivin expression via an EGFR/STAT3 pathway in UVB-exposed mouse skin.

  Molecular carcinogenesis 20110601

• All-cause mortality of elderly Australian veterans using COX-2 selective or non-selective NSAIDs: a longitudinal study.

  British journal of clinical pharmacology 20110601

• IL-17RA aptamer-mediated repression of IL-6 inhibits synovium inflammation in a murine model of osteoarthritis.

  Osteoarthritis and cartilage 20110601

• Celecoxib extends C. elegans lifespan via inhibition of insulin-like signaling but not cyclooxygenase-2 activity.

  Aging cell 20110601

• Clinical characteristics and outcomes in familial adenomatous polyposis patients with a long-term treatment of celecoxib: a matched cohort study.

  Familial cancer 20110601

• Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI.

  Annals of the rheumatic diseases 20110601

• COX-2-dependent and COX-2-independent mode of action of celecoxib in human liver cancer cells.

  Omics : a journal of integrative biology 20110601

• Biology of Cox-2: an application in cancer therapeutics.

  Current drug targets 20110601

• Regression of prostate tumors upon combination of hormone ablation therapy and celecoxib in vivo.

  The Prostate 20110601

• Of timing and surrogates: a way forward for cancer chemoprevention.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110601

• Five-year analysis of the prevention of colorectal sporadic adenomatous polyps trial.

  The American journal of gastroenterology 20110601

• Fixed-dose combination of enteric-coated naproxen and immediate-release esomeprazole has comparable efficacy to celecoxib for knee osteoarthritis: two randomized trials.

  Current medical research and opinion 20110601

• Preoperative taxane-based chemotherapy and celecoxib for carcinoma of the esophagus and gastroesophageal junction: results of a phase 2 trial.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20110601

• 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis.

  Annals of the rheumatic diseases 20110601

• Synthesis and biological evaluation of loxoprofen derivatives.

  Bioorganic & medicinal chemistry 20110601

• Design, synthesis, and biological evaluation of substituted hydrazone and pyrazole derivatives as selective COX-2 inhibitors: Molecular docking study.

  Bioorganic & medicinal chemistry 20110601

• [Low-dose aspirin (LDA)/nonsteroidal anti-inflammatory drugs(NSAIDs)-induced gastrointestinal injury in Japan].

  Nihon rinsho. Japanese journal of clinical medicine 20110601

• Anti-neuroinflammatory effects of psychopharmaceuticals: further than monoamine modulators.

  Mini reviews in medicinal chemistry 20110601

• [Analysis of 76 patients with urticaria and angioedema induced by non-steroidal anti-inflammatory drugs (NSAIDs) in Japan].

  Arerugi = [Allergy] 20110601

• Combined valproic acid and celecoxib treatment induced synergistic cytotoxicity and apoptosis in neuroblastoma cells.

  Anticancer research 20110601

• (3aR,6S,7aR)-7a-Bromo-2-methyl-sulfonyl-1,2,3,6,7,7a-hexa-hydro-3a,6-ep-oxy-isoindole.

  Acta crystallographica. Section E, Structure reports online 20110601

• [Effect of IFN-α combining with celecoxib on K562/A02 cells proliferation and its mechanism].

  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20110601

• Antibiotic treatment with ampicillin accelerates the healing of colonic damage impaired by aspirin and coxib in the experimental colitis. Importance of intestinal bacteria, colonic microcirculation and proinflammatory cytokines.

  Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20110601

• Kainic Acid-induced neurotoxicity: targeting glial responses and glia-derived cytokines.

  Current neuropharmacology 20110601

• Correction of endothelial dysfunction in patients with arterial hypertension.

  Bulletin of experimental biology and medicine 20110601

• Human cyclooxygenase-2 is a sequence homodimer that functions as a conformational heterodimer.

  The Journal of biological chemistry 20110527

• Divergent C-H functionalizations directed by sulfonamide pharmacophores: late-stage diversification as a tool for drug discovery.

  Journal of the American Chemical Society 20110511

• A simple QM/MM approach for capturing polarization effects in protein-ligand binding free energy calculations.

  The journal of physical chemistry. B 20110505

• Tramadol hydrochloride extended-release once-daily in the treatment of osteoarthritis of the knee and/or hip: a double-blind, randomized, dose-ranging trial.

  American journal of therapeutics 20110501

• The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel.

  Annals of the rheumatic diseases 20110501

• Multi-parametric assessment of the anti-angiogenic effects of liposomal glucocorticoids.

  Angiogenesis 20110501

• Bone metabolism and quality-of-life of postmenopausal women with invasive breast cancer receiving neoadjuvant hormonal therapy: sub-analyses from celecoxib anti-aromatase neoadjuvant (CAAN) trial.

  The Journal of steroid biochemistry and molecular biology 20110501

• Effects of intervention with sulindac and inulin/VSL#3 on mucosal and luminal factors in the pouch of patients with familial adenomatous polyposis.

  International journal of colorectal disease 20110501

• Paracetamol reduces influenza-induced immunopathology in a mouse model of infection without compromising virus clearance or the generation of protective immunity.

  Thorax 20110501

• Roles of prostaglandin E2-EP3/EP4 receptor signaling in the enhancement of lymphangiogenesis during fibroblast growth factor-2-induced granulation formation.

  Arteriosclerosis, thrombosis, and vascular biology 20110501

• Enhancement of photodynamic therapy by 2,5-dimethyl celecoxib, a non-cyclooxygenase-2 inhibitor analog of celecoxib.

  Cancer letters 20110501

• Interaction between adipose tissue stromal cells and gastric cancer cells in vitro.

  Cell and tissue research 20110501

• Synthesis, anti-inflammatory activity and COX-1/COX-2 inhibition of novel substituted cyclic imides. Part 1: Molecular docking study.

  European journal of medicinal chemistry 20110501

• The potential of celecoxib-loaded hydroxyapatite-chitosan nanocomposite for the treatment of colon cancer.

  Biomaterials 20110501

• Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group.

  Leukemia & lymphoma 20110501

• Efficient sequential synthesis of PET Probes of the COX-2 inhibitor [11C]celecoxib and its major metabolite [11C]SC-62807 and in vivo PET evaluation.

  Bioorganic & medicinal chemistry 20110501

• Arsenic trioxide inhibits invasion/migration in SGC-7901 cells by activating the reactive oxygen species-dependent cyclooxygenase-2/matrix metalloproteinase-2 pathway.

  Experimental biology and medicine (Maywood, N.J.) 20110501

• Aspirin and familial adenomatous polyposis: coming full circle.

  Cancer prevention research (Philadelphia, Pa.) 20110501

• Evaluation of gastrointestinal injury and blood flow of small bowel during low-dose aspirin administration.

  Journal of clinical biochemistry and nutrition 20110501

• Study on cow ghee versus soybean oil on 7,12-dimethylbenz(a)-anthracene induced mammary carcinogenesis & expression of cyclooxygenase-2 & peroxisome proliferators activated receptor-γ in rats.

  The Indian journal of medical research 20110501

• [Effect of combination of taxol and celecoxib on reversing multidrug resistance human breast cancer cells (MCF-7/ Taxol) and explore its underlying mechanism].

  Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20110501

• Synthesis and structure-activity relationship studies of urea-containing pyrazoles as dual inhibitors of cyclooxygenase-2 and soluble epoxide hydrolase.

  Journal of medicinal chemistry 20110428

• Suppressing inflammatory cascade by cyclo-oxygenase inhibitors attenuates quinolinic acid induced Huntington's disease-like alterations in rats.

  Life sciences 20110425

• [Effect of cycloxygenase 2 inhibitor on levels of prostaglandin E2 in plasma and in local infiltrated fluid after functional endoscopic sinus surgery].

  Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences 20110418

• Celecoxib inhibits STAT3 phosphorylation and suppresses cell migration and colony forming ability in rhabdomyosarcoma cells.

  Biochemical and biophysical research communications 20110415

• Microsomal prostaglandin E synthase-1 enhances bone cancer growth and bone cancer-related pain behaviors in mice.

  Life sciences 20110411

• An straightforward entry to new pyrazolo-fused dibenzo[1,4]diazepines.

  Organic & biomolecular chemistry 20110407

• High-dose ketorolac affects adult spinal fusion: a meta-analysis of the effect of perioperative nonsteroidal anti-inflammatory drugs on spinal fusion.

  Spine 20110401

• Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma.

  Journal of neuro-oncology 20110401

• A novel COX-2 inhibitor pyrazole derivative proven effective as an anti-inflammatory and analgesic drug.

  Basic & clinical pharmacology & toxicology 20110401

• Antiproliferative effects of COX-2 inhibitor celecoxib on human breast cancer cell lines.

  Molecular and cellular biochemistry 20110401

• 'War and Peace' with Barrett's esophagus.

  Digestive diseases and sciences 20110401

• Multimodal analgesic approach incorporating paravertebral blocks for open radical retropubic prostatectomy: a randomized double-blind placebo-controlled study.

  Canadian journal of anaesthesia = Journal canadien d'anesthesie 20110401

• Potential molecular targets in chemopreventative action of celecoxib: a proteomics analysis of J774.A1 macrophage-like cell line.

  Molecular bioSystems 20110401

• COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells.

  Cancer research 20110401

• Cyclooxygenase 2 promotes parathyroid hyperplasia in ESRD.

  Journal of the American Society of Nephrology : JASN 20110401

• Inhibition of highly pathogenic avian H5N1 influenza virus propagation by RNA oligonucleotides targeting the PB2 gene in combination with celecoxib.

  The journal of gene medicine 20110401

• Prescription pattern of NSAIDs and the prevalence of NSAID-induced gastrointestinal risk factors of orthopaedic patients in clinical practice in Korea.

  Journal of Korean medical science 20110401

• Newer molecules in the treatment of schizophrenia: A clinical update.

  Indian journal of pharmacology 20110401

• Effect of Phellodendron amurense in protecting human osteoarthritic cartilage and chondrocytes.

  Journal of ethnopharmacology 20110324

• Chemoprevention: First line of defence.

  Nature 20110324

• Accelerated drug approval: FDA may get tougher; companies cite hurdles.

  Journal of the National Cancer Institute 20110316

• Maturation and fertilization of nonhuman primate oocytes are compromised by oral administration of a cyclooxygenase-2 inhibitor.

  Fertility and sterility 20110315

• Syntheses and characterization of nimesulide derivatives for dual enzyme inhibitors of both cyclooxygenase-1/2 and 5-lipoxygenase.

  Bioorganic & medicinal chemistry 20110315

• A rat model of bone inflammation-induced pain by intra-tibial complete Freund's adjuvant injection.

  Neuroscience letters 20110303

• Finding drugs against CD133+ glioma subpopulations.

  Journal of neurosurgery 20110301

• Celecoxib and radioresistant glioblastoma-derived CD133+ cells: improvement in radiotherapeutic effects. Laboratory investigation.

  Journal of neurosurgery 20110301

• Value of information in the osteoarthritis setting: cost effectiveness of COX-2 selective inhibitors, traditional NSAIDs and proton pump inhibitors.

  PharmacoEconomics 20110301

• Effects of non-steroidal anti-inflammatory drugs on proliferation, differentiation and migration in equine mesenchymal stem cells.

  Cell biology international 20110301

• Cyclooxygenase-2 inhibitor blocks the production of West Nile virus-induced neuroinflammatory markers in astrocytes.

  The Journal of general virology 20110301

• Celecoxib antagonizes the cytotoxicity of cisplatin in human esophageal squamous cell carcinoma cells by reducing intracellular cisplatin accumulation.

  Molecular pharmacology 20110301

• HuR keeps an angiogenic switch on by stabilising mRNA of VEGF and COX-2 in tumour endothelium.

  British journal of cancer 20110301

• Investigations on cytotoxicity and anti-inflammatory potency of licofelone derivatives.

  European journal of medicinal chemistry 20110301

• Naproxen/esomeprazole fixed-dose combination: for the treatment of arthritic symptoms and to reduce the risk of gastric ulcers.

  Drugs & aging 20110301

• Predictors of response to cyclo-oxygenase-2 inhibitors in osteoarthritis: pooled results from two identical trials comparing etoricoxib, celecoxib, and placebo.

  Pain medicine (Malden, Mass.) 20110301

• Pharmacokinetics of a combination of Δ9-tetrahydro-cannabinol and celecoxib in a porcine model of hemorrhagic shock.

  Biopharmaceutics & drug disposition 20110301

• Mitochondrial disorders in NSAIDs-induced small bowel injury.

  Journal of clinical biochemistry and nutrition 20110301

• Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.

  Oncotarget 20110301

• Diagnosis and treatment of degenerative joint disease in a captive male chimpanzee (Pan troglodytes).

  Journal of the American Association for Laboratory Animal Science : JAALAS 20110301

• Inflammation in depression: is adiposity a cause?

  Dialogues in clinical neuroscience 20110301

• Rat model of lumbar facet joint osteoarthritis associated with facet-mediated mechanical hyperalgesia induced by intra-articular injection of monosodium iodoacetate.

  Journal of the Formosan Medical Association = Taiwan yi zhi 20110301

• Phase I/II trial of a COX-2 inhibitor with limited field radiation for intermediate prognosis patients who have locally advanced non-small-cell lung cancer: radiation therapy oncology group 0213.

  Clinical lung cancer 20110301

• Decisions that put patients at risk.

  Prescrire international 20110301

• Analysis of Relationship between Levofloxacin and Corrected QT Prolongation Using a Clinical Data Warehouse.

  Healthcare informatics research 20110301

• Bioactive compounds from the fern Lepisorus contortus.

  Journal of natural products 20110225

• Cannabinoid system and cyclooxygenases inhibitors.

  Journal of medicine and life 20110215

• Potential role of cyclooxygenase-2 on the regulation of the drug efflux transporter ABCG2 in breast cancer cell lines.

  Journal of cancer research and clinical oncology 20110201

• Role of capsaicin-sensitive primary afferent neurons and non-protein sulphydryl groups on gastroprotective effect of amifostine against ethanol-induced gastric damage in rats.

  Digestive diseases and sciences 20110201

• Selective cyclooxygenase-2 (COX-2) inhibitors and breast cancer risk.

  Breast (Edinburgh, Scotland) 20110201

• ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis.

  Annals of the rheumatic diseases 20110201

• Evaluation of the role of oxidative stress in chemopreventive action of fish oil and celecoxib in the initiation phase of 7,12-dimethyl benz(α)anthracene-induced mammary carcinogenesis.

  Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 20110201

• Cyclooxygenase 2 plays a role in Emdogain-induced proliferation.

  Journal of periodontal research 20110201

• Interleukin-17A induces cathepsin K and MMP-9 expression in osteoclasts via celecoxib-blocked prostaglandin E2 in osteoblasts.

  Biochimie 20110201

• Pharmacological characterization of KLYP961, a dual inhibitor of inducible and neuronal nitric-oxide synthases.

  The Journal of pharmacology and experimental therapeutics 20110201

• Further qualification of a therapeutic responder index for patients with chronic low back pain.

  The Journal of rheumatology 20110201

• Prostaglandin E₂ signaling and bacterial infection recruit tumor-promoting macrophages to mouse gastric tumors.

  Gastroenterology 20110201

• Phase II trial of Uracil/Tegafur plus leucovorin and celecoxib combined with radiotherapy in locally advanced pancreatic cancer.

  Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20110201

• Use of nonsteroidal antiinflammatory drugs: is there a change in patient risk profile after withdrawal of rofecoxib?

  The Journal of rheumatology 20110201

• Persistence with non-selective NSAIDs and celecoxib among patients with gastroesophageal reflux disease and osteoarthritis or rheumatoid arthritis.

  Current medical research and opinion 20110201

• The effects of oral ibuprofen and celecoxib in preventing pain, improving recovery outcomes and patient satisfaction after ambulatory surgery.

  Anesthesia and analgesia 20110201

• Celecoxib induces heme oxygenase-1 expression in macrophages and vascular smooth muscle cells via ROS-dependent signaling pathway.

  Naunyn-Schmiedeberg's archives of pharmacology 20110201

• COX-2 inhibition and inhibition of cytosolic phospholipase A2 increase CD36 expression and foam cell formation in THP-1 cells.

  Lipids 20110201

• New cancer treatment strategy using combination of green tea catechins and anticancer drugs.

  Cancer science 20110201

• Effect of Helicobacter pylori infection on Barrett's esophagus and esophageal adenocarcinoma formation in a rat model of chronic gastroesophageal reflux.

  Helicobacter 20110201

• Celecoxib impairs heart development via inhibiting cyclooxygenase-2 activity in zebrafish embryos.

  Anesthesiology 20110201

• A new β-carbonic anhydrase from Brucella suis, its cloning, characterization, and inhibition with sulfonamides and sulfamates, leading to impaired pathogen growth.

  Bioorganic & medicinal chemistry 20110201

• Inhibition of Nox2 oxidase activity ameliorates influenza A virus-induced lung inflammation.

  PLoS pathogens 20110201

• Effect of celecoxib on the antihypertensive effect of losartan in a rat model of renovascular hypertension.

  Canadian journal of physiology and pharmacology 20110201

• Effects of celecoxib in young rats: histopathological changes in tissues and alterations of oxidative stress/antioxidant defense system.

  Archives of pharmacal research 20110201

• p73 as a pharmaceutical target for cancer therapy.

  Current pharmaceutical design 20110201

• Role of nitric oxide-synthase and cyclooxygenase/lipooxygenase systems in development of experimental ulcerative colitis.

  Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20110201

• Nitric oxide (NO)-releasing aspirin exhibits a potent esophagoprotection in experimental model of acute reflux esophagitis. Role of nitric oxide and proinflammatory cytokines.

  Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20110201

• A double-blind, randomized, multicentric, placebo-controlled clinical trial of antarth, a phytomedicine, in the treatment of osteoarthritis.

  Indian journal of pharmacology 20110201

• [Effect of celecoxib on pulmonary hypertension of chronic hypoxia and hypercapnic rats].

  Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology 20110201

• Increased 5α-reductase type 2 expression in human breast carcinoma following aromatase inhibitor therapy: the correlation with decreased tumor cell proliferation.

  Hormones & cancer 20110201

• ACP Journal Club. Celecoxib reduced GI events more than diclofenac plus omeprazole in patients with osteoarthritis or rheumatoid arthritis.

  Annals of internal medicine 20110118

• Arzanol, a prenylated heterodimeric phloroglucinyl pyrone, inhibits eicosanoid biosynthesis and exhibits anti-inflammatory efficacy in vivo.

  Biochemical pharmacology 20110115

• Gender-based effect of statins on functional decline in amyotrophic lateral sclerosis.

  Journal of the neurological sciences 20110115

• Carbonic anhydrase inhibitors. Inhibition studies with anions and sulfonamides of a new cytosolic enzyme from the scleractinian coral Stylophora pistillata.

  Bioorganic & medicinal chemistry letters 20110115

• Measurement of cyclooxygenase inhibition using liquid chromatography-tandem mass spectrometry.

  Journal of pharmaceutical and biomedical analysis 20110105

• Evaluation of management of desmoid tumours associated with familial adenomatous polyposis in Dutch patients.

  British journal of cancer 20110104

• Health-Beneficial Phenolic Aldehyde in Antigonon leptopus Tea.

  Evidence-based complementary and alternative medicine : eCAM 20110101

• Meta-analysis of the related nutritional supplements dimethyl sulfoxide and methylsulfonylmethane in the treatment of osteoarthritis of the knee.

  Evidence-based complementary and alternative medicine : eCAM 20110101

• Aqueous extract of brazilian green propolis: primary components, evaluation of inflammation and wound healing by using subcutaneous implanted sponges.

  Evidence-based complementary and alternative medicine : eCAM 20110101

• Red Mold Rice Mitigates Oral Carcinogenesis in 7,12-Dimethyl-1,2-Benz[a]anthracene-Induced Oral Carcinogenesis in Hamster.

  Evidence-based complementary and alternative medicine : eCAM 20110101

• Preventing chemoresistance of human breast cancer cell line, MCF-7 with celecoxib.

  Journal of cancer research and clinical oncology 20110101

• Antitumoral and antimetastatic effects of metronomic chemotherapy with cyclophosphamide combined with celecoxib on murine mammary adenocarcinomas.

  Journal of cancer research and clinical oncology 20110101

• Antiangiogenic combination therapy after local radiotherapy with topotecan radiosensitizer improved quality of life for children with inoperable brainstem gliomas.

  Acta paediatrica (Oslo, Norway : 1992) 20110101

• Anti-apoptotic Bcl-2 fails to form efficient complexes with pro-apoptotic Bak to protect from Celecoxib-induced apoptosis.

  Biochemical pharmacology 20110101

• Amelioration of cisplatin nephrotoxicity by genetic or pharmacologic blockade of prostaglandin synthesis.

  Kidney international 20110101

• Preclinical evaluation of a gene therapy treatment for transitional cell carcinoma.

  Cancer gene therapy 20110101

• Effects of celecoxib on major prostaglandins in asthma.

  Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 20110101

• The endoplasmic reticulum protein folding factory and its chaperones: new targets for drug discovery?

  British journal of pharmacology 20110101

• Berberine, an isoquinoline alkaloid, inhibits melanoma cancer cell migration by reducing the expressions of cyclooxygenase-2, prostaglandin E₂ and prostaglandin E₂ receptors.

  Carcinogenesis 20110101

• Efficacy and safety of the selective cyclooxygenase-2 inhibitor celecoxib in the treatment of rheumatoid arthritis and osteoarthritis in Japan.

  Digestion 20110101

• Pharmacotherapy of low back pain: targeting nociceptive and neuropathic pain components.

  Current medical research and opinion 20110101

• Induction of a fast inactivation gating on delayed rectifier Shab K(+) channels by the anti-inflammatory drug celecoxib.

  Channels (Austin, Tex.) 20110101

• Gait analysis and pain response of two rodent models of osteoarthritis.

  Pharmacology, biochemistry, and behavior 20110101

• Kainic acid-induced neurodegenerative model: potentials and limitations.

  Journal of biomedicine & biotechnology 20110101

• Current therapeutic approaches in metastatic and recurrent ewing sarcoma.

  Sarcoma 20110101

• Coxibs strike back.

  Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 20110101

• Salvianolic Acid B, a potential chemopreventive agent, for head and neck squamous cell cancer.

  Journal of oncology 20110101

• COX-2 expression in papillary thyroid carcinoma (PTC) in cytological material obtained by fine needle aspiration biopsy (FNAB).

  Thyroid research 20110101

• Aspirin-exacerbated respiratory disease: evaluation and management.

  Allergy, asthma & immunology research 20110101

• A case of chlorpheniramine maleate-induced hypersensitivity with aspirin intolerance.

  Allergy, asthma & immunology research 20110101

• Cyclooxygenase-2 up-regulates vascular endothelial growth factor via a protein kinase C pathway in non-small cell lung cancer.

  Journal of experimental & clinical cancer research : CR 20110101

• Celecoxib can induce vascular endothelial growth factor expression and tumor angiogenesis.

  Molecular cancer therapeutics 20110101

• A human ribonuclease induces apoptosis associated with p21WAF1/CIP1 induction and JNK inactivation.

  BMC cancer 20110101

• The assessment of renal function in relation to the use of drugs in elderly in nursing homes; a cohort study.

  BMC geriatrics 20110101

• Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis.

  BMJ (Clinical research ed.) 20110101

• Hyaluronidase recruits mesenchymal-like cells to the lung and ameliorates fibrosis.

  Fibrogenesis & tissue repair 20110101

• α-Tocopheryloxyacetic acid: a novel chemotherapeutic that stimulates the antitumor immune response.

  Breast cancer research : BCR 20110101

• Effects of selective cyclooxygenase-2 and nonselective cyclooxygenase inhibition on myocardial function and perfusion.

  Journal of cardiovascular pharmacology 20110101

• Surmounting chemotherapy and radioresistance in chondrosarcoma: molecular mechanisms and therapeutic targets.

  Sarcoma 20110101

• Celecoxib enhances radiation response of secondary bone tumors of a human non-small cell lung cancer via antiangiogenesis in vivo.

  Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 20110101

• Selective inhibition of cyclooxygenase-2 suppresses metastatic disease without affecting primary tumor growth in a murine model of Ewing sarcoma.

  Journal of pediatric surgery 20110101

• Animal products, diseases and drugs: a plea for better integration between agricultural sciences, human nutrition and human pharmacology.

  Lipids in health and disease 20110101

• Rodent preclinical models for developing novel antiarthritic molecules: comparative biology and preferred methods for evaluating efficacy.

  Journal of biomedicine & biotechnology 20110101

• Safe administration of celecoxib to a patient with repeated episodes of nephrotic syndrome induced by NSAIDs.

  Clinical drug investigation 20110101

• Animal models of colitis-associated carcinogenesis.

  Journal of biomedicine & biotechnology 20110101

• Use of non-steroidal anti-inflammatory drugs and prostate cancer risk: a population-based nested case-control study.

  PloS one 20110101

• Prostaglandin E2 synthesizing enzymes in rheumatoid arthritis B cells and the effects of B cell depleting therapy on enzyme expression.

  PloS one 20110101

• High-dose enalapril treatment reverses myocardial fibrosis in experimental uremic cardiomyopathy.

  PloS one 20110101

• Reciprocal relationship between APP positioning relative to the membrane and PS1 conformation.

  Molecular neurodegeneration 20110101

• The effect of hypoxia and cycloxygenase inhibitors on nasal polyp derived fibroblasts.

  American journal of otolaryngology 20110101

• Immunotherapy for lung cancers.

  Journal of biomedicine & biotechnology 20110101

• The endotoxin-induced neuroinflammation model of Parkinson's disease.

  Parkinson's disease 20110101

• Experimental trauma models: an update.

  Journal of biomedicine & biotechnology 20110101

• Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on ovarian carcinoma in vivo.

  International journal of molecular sciences 20110101

• NSAID use selectively increases the risk of non-fatal myocardial infarction: a systematic review of randomised trials and observational studies.

  PloS one 20110101

• RNAi-mediated knockdown of cyclooxygenase2 inhibits the growth, invasion and migration of SaOS2 human osteosarcoma cells: a case control study.

  Journal of experimental & clinical cancer research : CR 20110101

• EGFR and COX-2 protein expression in non-small cell lung cancer and the correlation with clinical features.

  Journal of experimental & clinical cancer research : CR 20110101

• Topical preparations for pain relief: efficacy and patient adherence.

  Journal of pain research 20110101

• Examination of thromboxane synthase as a prognostic factor and therapeutic target in non-small cell lung cancer.

  Molecular cancer 20110101

• 'Gut health': a new objective in medicine?

  BMC medicine 20110101

• Chondrosarcoma: with updates on molecular genetics.

  Sarcoma 20110101

• Parkinson's disease and systemic inflammation.

  Parkinson's disease 20110101

• Sex differences in drug disposition.

  Journal of biomedicine & biotechnology 20110101

• Nuclear factor-kappa B activity regulates brain expression of P-glycoprotein in the kainic acid-induced seizure rats.

  Mediators of inflammation 20110101

• Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer.

  PloS one 20110101

• Effect of hookworm infection on wheat challenge in celiac disease--a randomised double-blinded placebo controlled trial.

  PloS one 20110101

• The cyclooxygenase-2 inhibitor celecoxib and alveolar osteitis.

  Journal of the Irish Dental Association 20110101

• Sustained remission of rheumatoid arthritis with a specific serotonin reuptake inhibitor antidepressant: a case report and review of the literature.

  Journal of medical case reports 20110101

• Apoptotic Cell Death and Inhibition of Wnt/β-Catenin Signaling Pathway in Human Colon Cancer Cells by an Active Fraction (HS7) from Taiwanofungus camphoratus.

  Evidence-based complementary and alternative medicine : eCAM 20110101

• Antitumor activity of Noscapine in combination with Doxorubicin in triple negative breast cancer.

  PloS one 20110101

• Common secondary causes of resistant hypertension and rational for treatment.

  International journal of hypertension 20110101

• Preparation and in vitro evaluation of anti-VCAM-1-Fab'-conjugated liposomes for the targeted delivery of the poorly water-soluble drug celecoxib.

  Journal of microencapsulation 20110101

• Neurovascular dysfunction, inflammation and endothelial activation: implications for the pathogenesis of Alzheimer's disease.

  Journal of neuroinflammation 20110101

• Role of HCV Core gene of genotype 1a and 3a and host gene Cox-2 in HCV-induced pathogenesis.

  Virology journal 20110101

• Role of the kidneys in resistant hypertension.

  International journal of hypertension 20110101

• Osteoarthritis subpopulations and implications for clinical trial design.

  Arthritis research & therapy 20110101

• The cyclooxygenase-2 inhibitor celecoxib attenuates hepatocellular carcinoma growth and c-Met expression in an orthotopic mouse model.

  Oncology research 20110101

• Temporal profiles of age-dependent changes in cytokine mRNA expression and glial cell activation after status epilepticus in postnatal rat hippocampus.

  Journal of neuroinflammation 20110101

• Risk of second primary colorectal cancer among colorectal cancer cases: a population-based analysis.

  Journal of carcinogenesis 20110101

• The AOM/DSS murine model for the study of colon carcinogenesis: From pathways to diagnosis and therapy studies.

  Journal of carcinogenesis 20110101

• Clinical trials update: Tertiary prevention of colorectal cancer.

  Journal of carcinogenesis 20110101

• Prescription patterns and appropriateness of NSAID therapy according to gastrointestinal risk and cardiovascular history in patients with diagnoses of osteoarthritis.

  BMC medicine 20110101

• A novel domperidone hydrogel: preparation, characterization, pharmacokinetic, and pharmacodynamic properties.

  Journal of drug delivery 20110101

• Apoptotic sphingolipid ceramide in cancer therapy.

  Journal of lipids 20110101

• Optimization of the balanced steady state free precession (bSSFP) pulse sequence for magnetic resonance imaging of the mouse prostate at 3T.

  PloS one 20110101

• In vitro permeation and in vivo anti-inflammatory and analgesic properties of nanoscaled emulsions containing ibuprofen for topical delivery.

  International journal of nanomedicine 20110101

• A synergistic antiproliferation effect of curcumin and docosahexaenoic acid in SK-BR-3 breast cancer cells: unique signaling not explained by the effects of either compound alone.

  BMC cancer 20110101

• Etoricoxibium picrate.

  Acta crystallographica. Section E, Structure reports online 20110101

• Increased short-term variability of the QT interval in professional soccer players: possible implications for arrhythmia prediction.

  PloS one 20110101

• Vascular endothelial growth factor receptor-2 couples cyclo-oxygenase-2 with pro-angiogenic actions of leptin on human endothelial cells.

  PloS one 20110101

• Cancer stem cell subsets and their relationships.

  Journal of translational medicine 20110101

• Gene expression following exposure to celecoxib in humans: pathways of inflammation and carcinogenesis are activated in tumors but not normal tissues.

  Digestion 20110101

• Lipoxins, the novel mediators of gastroprotection and gastric adaptation to ulcerogenic action of aspirin.

  Current pharmaceutical design 20110101

• Codeine did not increase analgesic efficacy of coxibs in contrast to that of paracetamol or ibuprofen: isobolographic analysis in mice.

  Neuro endocrinology letters 20110101

• Biological Markers in DCIS and Risk of Breast Recurrence: A Systematic Review.

  Journal of Cancer 20110101

• The effect of combined tocolysis on in vitro uterine contractility in preterm labour.

  Advances in medical sciences 20110101

• Toward an anti-inflammatory strategy for depression.

  Frontiers in behavioral neuroscience 20110101

• Diclofenac epolamine topical patch relieves pain associated with ankle sprain.

  Journal of pain research 20110101

• Create a translational medicine knowledge repository--research downsizing, mergers and increased outsourcing have reduced the depth of in-house translational medicine expertise and institutional memory at many pharmaceutical and biotech companies: how will they avoid relearning old lessons?

  Journal of translational medicine 20110101

• Prostaglandin E(2) binding peptide screened by phage displaying: a new therapeutic strategy in rheumatoid arthritis.

  Lipids in health and disease 20110101

• Beyond DNA binding - a review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation, and cancers.

  Cell communication and signaling : CCS 20110101

• Osteopoikilosis: pain as a presenting symptom in three family members.

  Clinical medicine insights. Arthritis and musculoskeletal disorders 20110101

• Two-stage revision surgery with preformed spacers and cementless implants for septic hip arthritis: a prospective, non-randomized cohort study.

  BMC infectious diseases 20110101

• Altered mRNA editing and expression of ionotropic glutamate receptors after kainic acid exposure in cyclooxygenase-2 deficient mice.

  PloS one 20110101

• Using clinical trial data and linked administrative health data to reduce the risk of adverse events associated with the uptake of newly released drugs by older Australians: a model process.

  BMC public health 20110101

• Nanoprodrugs of NSAIDs: Preparation and Characterization of Flufenamic Acid Nanoprodrugs.

  Journal of drug delivery 20110101

• Peripheral inflammation increases the damage in animal models of nigrostriatal dopaminergic neurodegeneration: possible implication in Parkinson's disease incidence.

  Parkinson's disease 20110101

• Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy?

  Parkinson's disease 20110101

• Combined use of low level laser therapy and cyclooxygenase-2 selective inhibition on skin incisional wound reepithelialization in mice: a preclinical study.

  Anais brasileiros de dermatologia 20110101

• Intraoperative local infiltration analgesia for early analgesia after total hip arthroplasty: a randomized, double-blind, placebo-controlled trial.

  Regional anesthesia and pain medicine 20110101

• Interpreting clinical assays for histone deacetylase inhibitors.

  Cancer management and research 20110101

• Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients.

  BMC cancer 20110101

• Capecitabine in the management of colorectal cancer.

  Cancer management and research 20110101

• Importance of pre-analytical steps for transcriptome and RT-qPCR analyses in the context of the phase II randomised multicentre trial REMAGUS02 of neoadjuvant chemotherapy in breast cancer patients.

  BMC cancer 20110101

• α-Mangostin extracted from the pericarp of the mangosteen (Garcinia mangostana Linn) reduces tumor growth and lymph node metastasis in an immunocompetent xenograft model of metastatic mammary cancer carrying a p53 mutation.

  BMC medicine 20110101

• Celecoxib attenuates liver steatosis and inflammation in non-alcoholic steatohepatitis induced by high-fat diet in rats.

  Molecular medicine reports 20110101

• Dual roles of immune cells and their factors in cancer development and progression.

  International journal of biological sciences 20110101

• The Bone Niche of Chondrosarcoma: A Sanctuary for Drug Resistance, Tumour Growth and also a Source of New Therapeutic Targets.

  Sarcoma 20110101

• Evaluation of drug-excipient interaction in the formulation of celecoxib tablets.

  Acta poloniae pharmaceutica 20110101

• Cell cycle and aging, morphogenesis, and response to stimuli genes are individualized biomarkers of glioblastoma progression and survival.

  BMC medical genomics 20110101

• Combined parecoxib and I.V. paracetamol provides additional analgesic effect with better postoperative satisfaction in patients undergoing anterior cruciate ligament reconstruction.

  Saudi journal of anaesthesia 20110101

• Early and late postnatal myocardial and vascular changes in a protein restriction rat model of intrauterine growth restriction.

  PloS one 20110101

• Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines.

  Journal of translational medicine 20110101

• Feasibility of Predicting MCI/AD Using Neuropsychological Tests and Serum β-Amyloid.

  International journal of Alzheimer's disease 20110101

• Aliskiren: An orally active renin inhibitor.

  Journal of pharmacy & bioallied sciences 20110101

• Hyperforin, an Anti-Inflammatory Constituent from St. John's Wort, Inhibits Microsomal Prostaglandin E(2) Synthase-1 and Suppresses Prostaglandin E(2) Formation in vivo.

  Frontiers in pharmacology 20110101

• Prostacyclin: an inflammatory paradox.

  Frontiers in pharmacology 20110101

• Selective cyclooxygenase-2 inhibitor cross-reactivity in aspirin-exacerbated respiratory disease.

  Allergy and asthma proceedings 20110101

• Efficacy of methylsulfonylmethane supplementation on osteoarthritis of the knee: a randomized controlled study.

  BMC complementary and alternative medicine 20110101

• Metformin poisoning: A complex presentation.

  Indian journal of anaesthesia 20110101

• Defining the role of polyamines in colon carcinogenesis using mouse models.

  Journal of carcinogenesis 20110101

• Perspective: Chemoprevention of colorectal neoplasia: Translating scientific promise into clinical practice.

  Journal of carcinogenesis 20110101

• Therapeutic prevention of colorectal carcinogenesis.

  Journal of carcinogenesis 20110101

• Vasectomy and vasectomy reversal: An update.

  Indian journal of urology : IJU : journal of the Urological Society of India 20110101

• The quest for targeted delivery in colon cancer: mucoadhesive valdecoxib microspheres.

  International journal of nanomedicine 20110101

• Cancer-induced bone pain sequentially activates the ERK/MAPK pathway in different cell types in the rat spinal cord.

  Molecular pain 20110101

• Atlantoaxial subluxation as an early manifestation in an adolescent with undifferentiated spondyloarthritis: a case report and review of the literature.

  Journal of medical case reports 20110101

• A rare retroperitoneal tumor.

  Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association 20110101

• Ayurveda GCP Guidelines: Need for freedom from RCT ascendancy in favor of whole system approach.

  Journal of Ayurveda and integrative medicine 20110101

• Cause for concern in the use of non-steroidal anti-inflammatory medications in the community--a population-based study.

  BMC family practice 20110101

• Resveratrol inhibits Cdk5 activity through regulation of p35 expression.

  Molecular pain 20110101

• Grape seed proanthocyanidins inhibit melanoma cell invasiveness by reduction of PGE2 synthesis and reversal of epithelial-to-mesenchymal transition.

  PloS one 20110101

• Regulation of bombesin-stimulated cyclooxygenase-2 expression in prostate cancer cells.

  BMC molecular biology 20110101

• Treat ankylosing spondylitis with methazolamide.

  International journal of medical sciences 20110101

• Nonsteroidal anti-inflammatory drug gastropathy: new avenues for safety.

  Clinical interventions in aging 20110101

• Safety aspects and rational use of a naproxen + esomeprazole combination in the treatment of rheumatoid disease.

  Drug, healthcare and patient safety 20110101

• Effect of 5-aminolevulinic acid-based photodynamic therapy via reactive oxygen species in human cholangiocarcinoma cells.

  International journal of nanomedicine 20110101

• Involvement of COX-2/PGE(2) Pathway in the Upregulation of MMP-9 Expression in Pancreatic Cancer.

  Gastroenterology research and practice 20110101

• Leaf Extracts of Calocedrus formosana (Florin) Induce G2/M Cell Cycle Arrest and Apoptosis in Human Bladder Cancer Cells.

  Evidence-based complementary and alternative medicine : eCAM 20110101

• Flavocoxid inhibits phospholipase A2, peroxidase moieties of the cyclooxygenases (COX), and 5-lipoxygenase, modifies COX-2 gene expression, and acts as an antioxidant.

  Mediators of inflammation 20110101

• Glial cells in amyotrophic lateral sclerosis.

  Neurology research international 20110101

• Longitudinal numbers-needed-to-treat (NNT) for achieving various levels of analgesic response and improvement with etoricoxib, naproxen, and placebo in ankylosing spondylitis.

  BMC musculoskeletal disorders 20110101

• Medical research: Is everything all right?

  Journal of anaesthesiology, clinical pharmacology 20110101

• Effect of pretreatment with ketorolac tromethamine on operative pain during periodontal surgery: A case-control study.

  Journal of Indian Society of Periodontology 20110101

• Effects of Gum acacia aqueous extract on the histology of the intestine and enzymes of both the intestine and the pancreas of albino rats treated with Meloxicam.

  Pharmacognosy research 20110101

• Cost-Effectiveness Evaluation of Etoricoxib versus Celecoxib and Nonselective NSAIDs in the Treatment of Ankylosing Spondylitis in Norway.

  International journal of rheumatology 20110101

• Cardiorenal Effects of Newer NSAIDs (Celecoxib) versus Classic NSAIDs (Ibuprofen) in Patients with Arthritis.

  Journal of toxicology 20110101

• Anti-cancer natural products isolated from chinese medicinal herbs.

  Chinese medicine 20110101

• ZLJ-6, a novel COX/5-LOX inhibitor, attenuates TNF-α-induced endothelial E-selectin, ICAM-1 and VCAM-1 expression and monocyte-endothelial interactions via a COX/5-LOX-independent mechanism.

  Vascular pharmacology 20110101

• Bacterial carbonic anhydrases as drug targets: toward novel antibiotics?

  Frontiers in pharmacology 20110101

• Smoking and COX-2 functional polymorphisms interact to increase the risk of gastric cardia adenocarcinoma in Chinese population.

  PloS one 20110101

• Haptenation: chemical reactivity and protein binding.

  Journal of allergy 20110101

• Antiamnesic activity of an ayurvedic formulation chyawanprash in mice.

  Evidence-based complementary and alternative medicine : eCAM 20110101

• A biological pathway linking inflammation and depression: activation of indoleamine 2,3-dioxygenase.

  Neuropsychiatric disease and treatment 20110101

• Evaluation of CYP450 inhibitory effects and steady-state pharmacokinetics of genistein in combination with cholecalciferol and citrated zinc bisglycinate in postmenopausal women.

  International journal of women's health 20110101

• Colon-targeted celecoxib-loaded Eudragit® S100-coated poly-ε-caprolactone microparticles: preparation, characterization and in vivo evaluation in rats.

  Drug delivery 20110101

• A targeted lipidomics approach to the study of eicosanoid release in synovial joints.

  Arthritis research & therapy 20110101

• Molecular simulation of hydroxypropyl-beta-cyclodextrin with hydrophobic selective Cox-II chemopreventive agent using host-guest phenomena.

  Acta poloniae pharmaceutica 20110101

• Characterization of chromosomal instability in murine colitis-associated colorectal cancer.

  PloS one 20110101

• Diclofenac topical solution compared with oral diclofenac: a pooled safety analysis.

  Journal of pain research 20110101

• Spherical harmonics coefficients for ligand-based virtual screening of cyclooxygenase inhibitors.

  PloS one 20110101

• Impact of Celecoxib restrictions in medicare beneficiaries with arthritis.

  The American journal of managed care 20110101

• Drug therapy for hereditary cancers.

  Hereditary cancer in clinical practice 20110101

• Effects of Glucosamine and Chondroitin Sulfate on Cartilage Metabolism in OA: Outlook on Other Nutrient Partners Especially Omega-3 Fatty Acids.

  International journal of rheumatology 20110101

• Autoimmunity in amyotrophic lateral sclerosis: past and present.

  Neurology research international 20110101

• Bioincompatible impact of different peritoneal dialysis fluid components and therapeutic interventions as tested in a rat peritoneal dialysis model.

  International journal of nephrology 20110101

• The cyclooxygenase-2 inhibitor celecoxib and alveolar osteitis (Journal of the Irish Dental Association 2011; 57 (1): 50-53).

  Journal of the Irish Dental Association 20110101

• Peripheral anti-inflammatory effects explain the ginsenosides paradox between poor brain distribution and anti-depression efficacy.

  Journal of neuroinflammation 20110101

• Pulmonary oxidative stress is increased in cyclooxygenase-2 knockdown mice with mild pulmonary hypertension induced by monocrotaline.

  PloS one 20110101

• Morphine use in cancer surgery.

  Frontiers in pharmacology 20110101

• Apoptosis induced by piroxicam plus cisplatin combined treatment is triggered by p21 in mesothelioma.

  PloS one 20110101

• Collagen induced arthritis increases secondary metastasis in MMTV-PyV MT mouse model of mammary cancer.

  BMC cancer 20110101

• Potential applications of curcumin and its novel synthetic analogs and nanotechnology-based formulations in cancer prevention and therapy.

  Chinese medicine 20110101

• Vascular endothelial growth factor regulates melanoma cell adhesion and growth in the bone marrow microenvironment via tumor cyclooxygenase-2.

  Journal of translational medicine 20110101

• Early detection of tumor response by FLT/microPET Imaging in a C26 murine colon carcinoma solid tumor animal model.

  Journal of biomedicine & biotechnology 20110101

• Design, synthesis and biological evaluation of new 5,5-diarylhydantoin derivatives as selective cyclooxygenase-2 inhibitors.

  Scientia pharmaceutica 20110101

• Synthesis of Diarylpyrazoles Containing a Phenylsulphone or Carbonitrile Moiety and their Chalcones as Possible Anti-Inflammatory Agents.

  Scientia pharmaceutica 20110101

• Celecoxib, a selective cyclooxygenase-2 inhibitor, attenuates renal injury in a rat model of Cisplatin-induced nephrotoxicity.

  Chemotherapy 20110101

• Pregabalin in acute and chronic pain.

  Journal of anaesthesiology, clinical pharmacology 20110101

• Osteoarthritis accelerates and exacerbates Alzheimer's disease pathology in mice.

  Journal of neuroinflammation 20110101

• Single dose oral analgesics for acute postoperative pain in adults.

  The Cochrane database of systematic reviews 20110101

• Cell-specific aptamers as emerging therapeutics.

  Journal of nucleic acids 20110101

• Gene expression and biological pathways in tissue of men with prostate cancer in a randomized clinical trial of lycopene and fish oil supplementation.

  PloS one 20110101

• 5-α reductase inhibitors and prostate cancer prevention: where do we turn now?

  BMC medicine 20110101

• Combinatorial effect of non-steroidal anti-inflammatory drugs and NF-κB inhibitors in ovarian cancer therapy.

  PloS one 20110101

• Regulation by glycogen synthase kinase-3 of inflammation and T cells in CNS diseases.

  Frontiers in molecular neuroscience 20110101

• Pathobiology and chemoprevention of bladder cancer.

  Journal of oncology 20110101

• Tissue factor, blood coagulation, and beyond: an overview.

  International journal of inflammation 20110101

• Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data.

  BMC blood disorders 20110101

• Celecoxib: considerations regarding its potential disease-modifying properties in osteoarthritis.

  Arthritis research & therapy 20110101

• Quality of online pharmacies and websites selling prescription drugs: a systematic review.

  Journal of medical Internet research 20110101

• Skeletal muscle protein metabolism in the elderly: Interventions to counteract the 'anabolic resistance' of ageing.

  Nutrition & metabolism 20110101

• Inhibition of cyclo-oxygenase 2 reduces tumor metastasis and inflammatory signaling during blockade of vascular endothelial growth factor.

  Vascular cell 20110101

• Targeting KSHV/HHV-8 latency with COX-2 selective inhibitor nimesulide: a potential chemotherapeutic modality for primary effusion lymphoma.

  PloS one 20110101

• Hypertonic stress induces VEGF production in human colon cancer cell line Caco-2: inhibitory role of autocrine PGE₂.

  PloS one 20110101

• Serum NGAL to Clinically Distinguish Cholangiocarcinoma from Benign Biliary Tract Diseases.

  International journal of hepatology 20110101

• Osteoimmunology and osteoporosis.

  Arthritis research & therapy 20110101

• The rat intervertebral disk degeneration pain model: relationships between biological and structural alterations and pain.

  Arthritis research & therapy 20110101

• Optimizing therapeutic efficacy of chemopreventive agents: A critical review of delivery strategies in oral cancer chemoprevention clinical trials.

  Journal of carcinogenesis 20110101

• Fabrication, modeling and characterization of multi-crosslinked methacrylate copolymeric nanoparticles for oral drug delivery.

  International journal of molecular sciences 20110101

• Non-steroidal anti-inflammatory drug (NSAID) related inhibition of aldosterone glucuronidation and arterial dysfunction in patients with rheumatoid arthritis: a cross-sectional clinical study.

  BMJ open 20110101

• Complex regional pain syndrome.

  Indian journal of plastic surgery : official publication of the Association of Plastic Surgeons of India 20110101

• Buccal mucosa urethroplasty for adult urethral strictures.

  Indian journal of urology : IJU : journal of the Urological Society of India 20110101

• Green tea catechins reduce invasive potential of human melanoma cells by targeting COX-2, PGE2 receptors and epithelial-to-mesenchymal transition.

  PloS one 20110101

• Anti-inflammatory effects of fermented and non-fermented Sophora flavescens: a comparative study.

  BMC complementary and alternative medicine 20110101

• Drug discovery for Duchenne muscular dystrophy via utrophin promoter activation screening.

  PloS one 20110101

• Viscum album exerts anti-inflammatory effect by selectively inhibiting cytokine-induced expression of cyclooxygenase-2.

  PloS one 20110101

• Inhibition of HERG potassium channels by celecoxib and its mechanism.

  PloS one 20110101

• The vitamin E analog, alpha-tocopheryloxyacetic acid enhances the anti-tumor activity of trastuzumab against HER2/neu-expressing breast cancer.

  BMC cancer 20110101

• HMGA1 drives stem cell, inflammatory pathway, and cell cycle progression genes during lymphoid tumorigenesis.

  BMC genomics 20110101

• Nucleus caudalis lesioning: Case report of chronic traumatic headache relief.

  Surgical neurology international 20110101

• Lumiracoxib for acute postoperative dental pain: a systematic review of randomized clinical trials.

  Sao Paulo medical journal = Revista paulista de medicina 20110101

• Altered membrane lipid dynamics and chemoprevention by non-steroidal anti inflammatory drugs during colon carcinogenesis.

  Nutricion hospitalaria 20110101

• In situ formation of nanocrystals from a self-microemulsifying drug delivery system to enhance oral bioavailability of fenofibrate.

  International journal of nanomedicine 20110101

• Exemestane in the adjuvant treatment of breast cancer in postmenopausal women.

  Breast cancer : basic and clinical research 20110101

• Treatment with etanercept in a patient with rheumatoid arthritis-associated interstitial lung disease.

  Clinical medicine insights. Case reports 20110101

• Efficacy and Safety of COX-2 Inhibitors in the Clinical Management of Arthritis: Mini Review.

  ISRN pharmacology 20110101

• Acupuncture as analgesia for low back pain, ankle sprain and migraine in emergency departments: study protocol for a randomized controlled trial.

  Trials 20110101

• Pathway profiling and rational trial design for studies in advanced stage cervical carcinoma: a review and a perspective.

  ISRN oncology 20110101

• Low intracellular ATP levels exacerbate carcinogen-induced inflammatory stress response and inhibit in vitro tubulogenesis in human brain endothelial cells.

  Journal of inflammation research 20110101

• Systematic analyses of genes associated with radiosensitizing effect by celecoxib, a specific cyclooxygenase-2 inhibitor.

  Journal of radiation research 20110101

• Metachronous merkel cell carcinoma: a case report.

  Case reports in dermatology 20110101

• Paracetamol and the placebo effect in osteoarthritis trials: a missing link?

  Pain research and treatment 20110101

• A randomised feasibility study of EPA and Cox-2 inhibitor (Celebrex) versus EPA, Cox-2 inhibitor (Celebrex), resistance training followed by ingestion of essential amino acids high in leucine in NSCLC cachectic patients--ACCeRT study.

  BMC cancer 20110101

• Why we need easy access to all data from all clinical trials and how to accomplish it.

  Trials 20110101

• Preparation of polylactide-co-glycolide nanoparticles incorporating celecoxib and their antitumor activity against brain tumor cells.

  International journal of nanomedicine 20110101

• An observational study of the discrediting of COX-2 NSAIDs in Australia: Vioxx or class effect?

  BMC public health 20110101

• Virtual screening of 2,3-disubstituted-4(3H)-quinazolinones possessing benzenesulfonamide moiety for COX-2 inhibitor.

  Bioinformation 20110101

• Obesity, inflammation, and postmenopausal breast cancer: therapeutic implications.

  TheScientificWorldJournal 20110101

• The promise of neuroprotective agents in Parkinson's disease.

  Frontiers in neurology 20110101

• Bridging health technology assessment (HTA) with multicriteria decision analyses (MCDA): field testing of the EVIDEM framework for coverage decisions by a public payer in Canada.

  BMC health services research 20110101

• Potential Therapeutic Roles for Inhibition of the PI3K/Akt/mTOR Pathway in the Pathophysiology of Diabetic Retinopathy.

  Journal of ophthalmology 20110101

• The haematopoietic stem cell niche: new insights into the mechanisms regulating haematopoietic stem cell behaviour.

  Stem cells international 20110101

• Comparison of published orthopaedic trauma trials following registration in Clinicaltrials.gov.

  BMC musculoskeletal disorders 20110101

• [Bringing evidence to practice: obstacles and barriers].

  Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen 20110101

• Enhanced bioavailability of sirolimus via preparation of solid dispersion nanoparticles using a supercritical antisolvent process.

  International journal of nanomedicine 20110101

• Tumor cells and tumor-associated macrophages: secreted proteins as potential targets for therapy.

  Clinical & developmental immunology 20110101

• Alzheimer's - Looking beyond plaques.

  F1000 medicine reports 20110101

• Optimal management of Barrett's esophagus: pharmacologic, endoscopic, and surgical interventions.

  Therapeutics and clinical risk management 20110101

• Mining relational paths in integrated biomedical data.

  PloS one 20110101

• Protein kinase A antagonist inhibits β-catenin nuclear translocation, c-Myc and COX-2 expression and tumor promotion in Apc(Min/+) mice.

  Molecular cancer 20110101

• The utility of Aspirin in Dukes C and High Risk Dukes B Colorectal cancer--the ASCOLT study: study protocol for a randomized controlled trial.

  Trials 20110101

• Identification and manipulation of tumor associated macrophages in human cancers.

  Journal of translational medicine 20110101

• Cannabinoid CB2 receptors contribute to upregulation of β-endorphin in inflamed skin tissues by electroacupuncture.

  Molecular pain 20110101

• Chemopreventive effects of NSAIDs on cytokines and transcription factors during the early stages of colorectal cancer.

  Pharmacological reports : PR 20110101

• Apoptosis induction and tumor cell repopulation: the yin and yang of radiotherapy.

  Radiation oncology (London, England) 20110101

• Effects on muscle performance of NSAID treatment with piroxicam versus placebo in geriatric patients with acute infection-induced inflammation. A double blind randomized controlled trial.

  BMC musculoskeletal disorders 20110101

• Differential effects of pravastatin and simvastatin on the growth of tumor cells from different organ sites.

  PloS one 20110101

• Pharmacokinetic evaluation of Paclitaxel in South Indian cancer patients: a prospective study.

  Journal of young pharmacists : JYP 20110101

• Dietary phytochemicals, HDAC inhibition, and DNA damage/repair defects in cancer cells.

  Clinical epigenetics 20110101

• Alzheimer's Disease: APP, Gamma Secretase, APOE, CLU, CR1, PICALM, ABCA7, BIN1, CD2AP, CD33, EPHA1, and MS4A2, and Their Relationships with Herpes Simplex, C. Pneumoniae, Other Suspect Pathogens, and the Immune System.

  International journal of Alzheimer's disease 20110101

• Efficacy and safety of concurrent chemoradiation with weekly cisplatin ± low-dose celecoxib in locally advanced undifferentiated nasopharyngeal carcinoma: a phase II-III clinical trial.

  Journal of cancer research and therapeutics 20110101

• Fernblock, a nutriceutical with photoprotective properties and potential preventive agent for skin photoaging and photoinduced skin cancers.

  International journal of molecular sciences 20110101

• Systematic review of herbals as potential anti-inflammatory agents: Recent advances, current clinical status and future perspectives.

  Pharmacognosy reviews 20110101

• Observation of curative efficacy and prognosis following combination chemotherapy with celecoxib in the treatment of advanced colorectal cancer.

  The Journal of international medical research 20110101

• Pain in blood cancers.

  Indian journal of palliative care 20110101

• Acute generalized exanthematous pustulosis-like, folliculitic drug reaction pattern caused by celecoxib.

  Dermatologic therapy 20110101

• A novel potent tumour promoter aberrantly overexpressed in most human cancers.

  Scientific reports 20110101

• Drug-target network in myocardial infarction reveals multiple side effects of unrelated drugs.

  Scientific reports 20110101

• Overexpression of COX-2 in oral squamous cell carcinoma patients undergoing chemoradiotherapy.

  National journal of maxillofacial surgery 20110101

• Extended hildebrand solubility approach: satranidazole in mixtures of dioxane and water.

  Indian journal of pharmaceutical sciences 20110101

• Chronic inflammation in cancer development.

  Frontiers in immunology 20110101

• Nonsurgical Management of Severe Osteonecrosis of the Knee in an HIV-Positive Patient: A Case Report.

  Case reports in infectious diseases 20110101

• The effect of Frankincense in the treatment of moderate plaque-induced gingivitis: a double blinded randomized clinical trial.

  Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences 20110101

• Phase I study of celecoxib with concurrent irinotecan, Cisplatin, and radiation therapy for patients with unresectable locally advanced non-small cell lung cancer.

  Frontiers in oncology 20110101

• Therapeutic targeting of cancer stem cells.

  Frontiers in oncology 20110101

• ERK/ribosomal S6 kinase (RSK) signaling positively regulates death receptor 5 expression through co-activation of CHOP and Elk1.

  The Journal of biological chemistry 20101231

• ['Rheumatic pain'. Joint is painfully swollen overnight].

  MMW Fortschritte der Medizin 20101216

• Chemoprevention, risk reduction, therapeutic prevention, or preventive therapy?

  Journal of the National Cancer Institute 20101215

• Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial.

  Journal of the National Cancer Institute 20101215

• Increase of core temperature induced by corticotropin-releasing factor and urocortin: a comparative study.

  Regulatory peptides 20101210

• Inhibition of cyclooxygenase-2-dependent survivin mediates decursin-induced apoptosis in human KBM-5 myeloid leukemia cells.

  Cancer letters 20101208

• Synthesis and evaluation of the anti-inflammatory properties of selenium-derivatives of celecoxib.

  Chemico-biological interactions 20101205

• An open-label pilot study evaluating by magnetic resonance imaging the potential for a disease-modifying effect of celecoxib compared to a modelized historical control cohort in the treatment of knee osteoarthritis.

  Seminars in arthritis and rheumatism 20101201

• Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma.

  Journal of neuro-oncology 20101201

• Selective COX-2 inhibition affects fatty acids, but not COX mRNA expression in patients with FAP.

  Familial cancer 20101201

• Are COX-2 inhibitors preferable to combined NSAID and PPI in countries with moderate health service expenditures?

  Journal of evaluation in clinical practice 20101201

• Effect of selective COX-2 inhibitor, celecoxib on adjuvant-induced arthritis model in irradiated rats.

  International journal of radiation biology 20101201

• Activation of ceramide synthase 6 by celecoxib leads to a selective induction of C16:0-ceramide.

  Biochemical pharmacology 20101201

• A predictive ligand-based Bayesian model for human drug-induced liver injury.

  Drug metabolism and disposition: the biological fate of chemicals 20101201

• Celecoxib blocks cardiac Kv1.5, Kv4.3 and Kv7.1 (KCNQ1) channels: effects on cardiac action potentials.

  Journal of molecular and cellular cardiology 20101201

• COX-2 is a novel target in therapy of mycosis fungoides.

  Leukemia 20101201

• Expression and possible role of non-steroidal anti-inflammatory drug-activated gene-1 (NAG-1) in the human endometrium and endometriosis.

  Human reproduction (Oxford, England) 20101201

• Synthesis and biological evaluation of some thiazolylpyrazole derivatives as dual anti-inflammatory antimicrobial agents.

  European journal of medicinal chemistry 20101201

• The novel benzopyran class of selective cyclooxygenase-2 inhibitors-part I: the first clinical candidate.

  Bioorganic & medicinal chemistry letters 20101201

• Increased expression of cyclooxygenase-2 is associated with the progression to cirrhosis.

  The Korean journal of internal medicine 20101201

• OSU-03012, a novel celecoxib derivative, induces cell swelling and shortens action potential duration in mouse ventricular cells.

  Biomedical research (Tokyo, Japan) 20101201

• [Effects of celecoxib combined with fluvastatin on tumor growth and cell apoptosis in a xenograft model of hepatocellular carcinoma].

  Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 20101201

• Roles of opioid receptor subtype in the spinal antinociception of selective cyclooxygenase 2 inhibitor.

  The Korean journal of pain 20101201

• [Effect of cyclooxygenase-2 inhibitor on expression of matrix metalloproteinase-2 and invasion of tongue squamous cell carcinoma cell line Tca8113].

  Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology 20101201

• Etoricoxib-induced life-threatening hyperkalemia and acute kidney dysfunction against the background of telmisartan and a low sodium diet.

  International journal of emergency medicine 20101201

• Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.

  Healthcare informatics research 20101201

• Formulation of microemulsion gel systems for transdermal delivery of celecoxib: In vitro permeation, anti-inflammatory activity and skin irritation tests.

  Drug discoveries & therapeutics 20101201

• Role of leukotriene B4 in celecoxib-mediated anticancer effect.

  Biochemical and biophysical research communications 20101112

• Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer.

  British journal of cancer 20101109

• Mechanism of K(v)2.1 channel inhibition by a selective COX-2 inhibitor SC-791-modification of gating.

  Brain research 20101104

• Evaluation of analgesic efficacy, gastrotoxicity and nephrotoxicity of fixed-dose combinations of nonselective, preferential and selective cyclooxygenase inhibitors with paracetamol in rats.

  Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie 20101101

• Celecoxib enhances radiosensitivity in medulloblastoma-derived CD133-positive cells.

  Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 20101101

• Preemptive multimodal pain regimen reduces opioid analgesia for patients undergoing robotic-assisted laparoscopic radical prostatectomy.

  Urology 20101101

• Is the sulphonamide radical in the celecoxib molecule essential for its analgesic activity?

  Pharmacological research 20101101

• Pharmacological modulation by celecoxib of cachexia associated with experimental arthritis and atherosclerosis in rabbits.

  British journal of pharmacology 20101101

• Indomethacin promotes adipogenesis of mesenchymal stem cells through a cyclooxygenase independent mechanism.

  Journal of cellular biochemistry 20101101

• Dimethylcelecoxib inhibits mPGES-1 promoter activity by influencing EGR1 and NF-κB.

  Biochemical pharmacology 20101101

• Celecoxib induces tolerance in a model of peripheral inflammatory pain in rats.

  Neuropharmacology 20101101

• Human skin retention and penetration of a copper tripeptide in vitro as function of skin layer towards anti-inflammatory therapy.

  Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20101101

• Mechanisms involved in IL-6-induced muscular mechanical hyperalgesia in mice.

  Pain 20101101

• Inhibitive effect of celecoxib on the adhesion and invasion of human tongue squamous carcinoma cells to extracellular matrix via down regulation of MMP-2 expression.

  Prostaglandins & other lipid mediators 20101101

• A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma.

  Neuro-oncology 20101101

• Effects of selective cyclooxygenase-2 and nonselective cyclooxygenase inhibition on ischemic myocardium.

  The Journal of thoracic and cardiovascular surgery 20101101

• COX-2-mediated regulation of VEGF-C in association with lymphangiogenesis and lymph node metastasis in lung cancer.

  Anatomical record (Hoboken, N.J. : 2007) 20101101

• Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.

  Bioorganic & medicinal chemistry letters 20101101

• Use of transgenic mice as models for prostate cancer chemoprevention.

  Current molecular medicine 20101101

• Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301).

  Gut 20101101

• NS-398 (a selective cyclooxygenase-2 inhibitor) decreases agonist-induced contraction of the human ureter via calcium channel inhibition.

  Journal of endourology 20101101

• Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase.

  British journal of cancer 20101101

• Using non-steroidal anti-inflammatory drugs in the treatment of depression.

  Psychiatria Danubina 20101101

• Physicochemical characterization and drug-release properties of celecoxib hot-melt extruded glass solutions.

  The Journal of pharmacy and pharmacology 20101101

• Pyrazolobenzotriazinone derivatives as COX inhibitors: synthesis, biological activity, and molecular-modeling studies.

  Archiv der Pharmazie 20101101

• [The expression of hepatitis B virus X protein and cyclooxygenase-2 in hepatitis B virus-related hepatocellular carcinoma: correlation with microangiogenesis and metastasis, and what is the possible mechanism].

  Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 20101101

• [Influence of celecoxib on invasiveness of human high-metastatic nasopharyngeal carcinoma cell line CNE-2Z].

  Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery 20101101

• Advances in understanding and treating cardiac cachexia: highlights from the 5th Cachexia Conference.

  International journal of cardiology 20101029

• Molecular dynamics and physical stability of amorphous anti-inflammatory drug: celecoxib.

  The journal of physical chemistry. B 20101014

• Electroacupuncture versus celecoxib for neuropathic pain in rat SNL model.

  Neuroscience 20101013

• The effects of COX-2 inhibitor during osteogenic differentiation of bone marrow-derived human mesenchymal stem cells.

  Stem cells and development 20101001

• Pathological and biochemical effects of therapeutic and supratherapeutic doses of celecoxib in Wistar albino male rats.

  Drug and chemical toxicology 20101001

• Delivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin (STZ) model of diabetic retinopathy (DR).

  Investigative ophthalmology & visual science 20101001

• The role of NF-κB and PPARγ in experimentally induced colorectal cancer and chemoprevention by cyclooxygenase-2 inhibitors.

  Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 20101001

• Are Cox-2 drugs the second line option in indomethacin responsive headaches?

  The journal of headache and pain 20101001

• Celecoxib combined with atorvastatin prevents progression of atherosclerosis.

  The Journal of surgical research 20101001

• COX-2 inhibitor nimesulide analogs are aromatase suppressors in breast cancer cells.

  The Journal of steroid biochemistry and molecular biology 20101001

• ErbB4 promotes cyclooxygenase-2 expression and cell survival in colon epithelial cells.

  Laboratory investigation; a journal of technical methods and pathology 20101001

• Melatonin and celecoxib improve the outcomes in hamsters with experimental pancreatic cancer.

  Journal of pineal research 20101001

• Topical diclofenac epolamine patch 1.3% for treatment of acute pain caused by soft tissue injury.

  International journal of clinical practice 20101001

• Overexpression of COX-2 in celecoxib-resistant breast cancer cell lines.

  The Journal of surgical research 20101001

• Pre-surgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer.

  Breast cancer research and treatment 20101001

• Cyclooxygenase-independent inhibitory effects on T cell activation of novel 4,5-dihydro-3 trifluoromethyl pyrazole cyclooxygenase-2 inhibitors.

  International immunopharmacology 20101001

• Celecoxib inhibits cell proliferation through the activation of ERK and p38 MAPK in head and neck squamous cell carcinoma cell lines.

  Anti-cancer drugs 20101001

• Does administration of non-steroidal anti-inflammatory drug determine morphological changes in adrenal cortex: ultrastructural studies.

  Protoplasma 20101001

• Development of an online p38α mitogen-activated protein kinase binding assay and integration of LC-HR-MS.

  Analytical and bioanalytical chemistry 20101001

• Anti-cancer effects of celecoxib on nasopharyngeal carcinoma HNE-1 cells expressing COX-2 oncoprotein.

  Cytotechnology 20101001

• Etiology and outcome of patients with upper gastrointestinal bleeding: a study from South of Iran.

  Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association 20101001

• Should nonsteroidal anti-inflammatory drugs (NSAIDs) be prescribed to the older adult?

  Drugs & aging 20101001

• Low risk of thromboembolic complications after fast-track hip and knee arthroplasty.

  Acta orthopaedica 20101001

• Multimodal prevention of pain, nausea and vomiting after breast cancer surgery.

  Minerva anestesiologica 20101001

• Are current available therapies disease-modifying in spondyloarthritis?

  Best practice & research. Clinical rheumatology 20101001

• Antiproliferative effects of rapamycin and celecoxib in angiosarcoma cell lines.

  Anticancer research 20101001

• [Effect of celecoxib and adriamycin on proliferation and apoptosis of Raji cells and its mechanism].

  Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 20101001

• Short-term therapy with celecoxib and lansoprazole modulates Th1/ Th2 immune response in human gastric mucosa.

  Helicobacter 20101001

• Celecoxib mitigates cigarette smoke induced oxidative stress in mice.

  Indian journal of biochemistry & biophysics 20101001

• A molecular signature of normal breast epithelial and stromal cells from Li-Fraumeni syndrome mutation carriers.

  Oncotarget 20101001

• Cyclooxygenase-2 expression and its association with thyroid lesions.

  Archives of medical science : AMS 20101001

• Selective cyclooxygenase-2 silencing mediated by engineered E. coli and RNA interference induces anti-tumour effects in human colon cancer cells.

  British journal of cancer 20100928

• Synthesis, anti-inflammatory activity, and in vitro antitumor effect of a novel class of cyclooxygenase inhibitors: 4-(aryloyl)phenyl methyl sulfones.

  Journal of medicinal chemistry 20100923

• The analgesic and anti-inflammatory effect of WIN-34B, a new herbal formula for osteoarthritis composed of Lonicera japonica Thunb and Anemarrhena asphodeloides BUNGE in vivo.

  Journal of ethnopharmacology 20100915

• Nonsteroidal anti-inflammatory drugs increase TNF production in rheumatoid synovial membrane cultures and whole blood.

  Journal of immunology (Baltimore, Md. : 1950) 20100915

• Cox-2 inhibition attenuates cardiovascular and inflammatory aspects in monosodium glutamate-induced obese rats.

  Life sciences 20100911

• A rapid recovery program: early home and pain free.

  Orthopedics 20100907

• [Comparing the analgesic efficacy of continuous femoral nerve blockade and continuous intravenous analgesia after total knee arthroplasty].

  Zhonghua yi xue za zhi 20100907

• Celecoxib increases retinoid sensitivity in human colon cancer cell lines.

  Cellular & molecular biology letters 20100901

• Celecoxib, but not rofecoxib or naproxen, attenuates cardiac hypertrophy and fibrosis induced in vitro by angiotensin and aldosterone.

  Clinical and experimental pharmacology & physiology 20100901

• Excess risk of hospital admission for cardiovascular disease within the first 7 years from onset of inflammatory polyarthritis.

  Annals of the rheumatic diseases 20100901

• Overexpression of 5-lipoxygenase in sporadic colonic adenomas and a possible new aspect of colon carcinogenesis.

  International journal of colorectal disease 20100901

• cPLA2 is protective against COX inhibitor-induced intestinal damage.

  Toxicological sciences : an official journal of the Society of Toxicology 20100901

• Antioxidants can inhibit basal autophagy and enhance neurodegeneration in models of polyglutamine disease.

  Human molecular genetics 20100901

• IL-17A stimulates the expression of inflammatory cytokines via celecoxib-blocked prostaglandin in MC3T3-E1 cells.

  Archives of oral biology 20100901

• Targeting the prostaglandin E2 EP1 receptor and cyclooxygenase-2 in the amygdala kindling model in mice.

  Epilepsy research 20100901

• Increased risk of stroke associated with nonsteroidal anti-inflammatory drugs: a nationwide case-crossover study.

  Stroke 20100901

• Discovery and structure-activity relationships of a series of pyroglutamic acid amide antagonists of the P2X7 receptor.

  Bioorganic & medicinal chemistry letters 20100901

• Design, synthesis and biological evaluation of new (E)- and (Z)-1,2,3-triaryl-2-propen-1-ones as selective COX-2 inhibitors.

  European journal of medicinal chemistry 20100901

• Septic versus aseptic hip revision: how different?

  Journal of orthopaedics and traumatology : official journal of the Italian Society of Orthopaedics and Traumatology 20100901

• Identifying early prescribers of cycloxygenase-2 inhibitors (COX-2s) in Nova Scotia, Canada: Considerations for targeted academic detailing.

  Research in social & administrative pharmacy : RSAP 20100901

• Antinociceptive Effect of Memantine and Morphine on Vincristine-induced Peripheral Neuropathy in Rats.

  The Korean journal of pain 20100901

• Spontaneous retropharyngeal hematoma - a case report -.

  The Korean journal of pain 20100901

• Loxoprofen Sodium, a Non-Selective NSAID, Reduces Atherosclerosis in Mice by Reducing Inflammation.

  Journal of clinical biochemistry and nutrition 20100901

• Design, synthesis, and biological evaluation of 1,5-diaryl-1,2,4-triazole derivatives as selective cyclooxygenase-2 inhibitors.

  Archiv der Pharmazie 20100901

• [Application and effect of auricular acupoint pressing for analgesia in perioperative period of total knee joint replacement].

  Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine 20100901

• Abstracts of the 5(th) Cachexia Conference, Barcelona, Spain, December 5-8, 2009.

  Journal of cachexia, sarcopenia and muscle 20100901

• Drug interaction between celecoxib and methotrexate in organic anion transporter 3-transfected renal cells and in rats in vivo.

  European journal of pharmacology 20100825

• Comparison of cyclooxygenase-1 crystal structures: cross-talk between monomers comprising cyclooxygenase-1 homodimers.

  Biochemistry 20100824

• Design, synthesis, and biological evaluation of ketoprofen analogs as potent cyclooxygenase-2 inhibitors.

  Bioorganic & medicinal chemistry 20100815

• Preventive effects of COX-2 inhibitor, celecoxib on renal tubular injury induced by shock wave lithotriptor.

  Urological research 20100801

• Suppression of human lung cancer cell growth and migration by berbamine.

  Cytotechnology 20100801

• Inhibitory effects of norcantharidin against human lung cancer cell growth and migration.

  Cytotechnology 20100801

• Celecoxib enhances the inhibitory effect of cisplatin on Tca8113 cells in human tongue squamous cell carcinoma in vivo and in vitro.

  Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 20100801

• Role of COX-2 in nonsteroidal anti-inflammatory drug enteropathy in rodents.

  Scandinavian journal of gastroenterology 20100801

• Anti-inflammatory effects of celecoxib in rat lungs with smoke-induced emphysema.

  American journal of physiology. Lung cellular and molecular physiology 20100801

• Acute pain after total hip arthroplasty does not predict the development of chronic postsurgical pain 6 months later.

  Journal of anesthesia 20100801

• Do the blood pressure effects of nonsteroidal antiinflammatory drugs influence cardiovascular morbidity and mortality?

  Current hypertension reports 20100801

• Antifibrotic and fibrolytic properties of celecoxib in liver damage induced by carbon tetrachloride in the rat.

  Liver international : official journal of the International Association for the Study of the Liver 20100801

• Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT.

  Annals of the rheumatic diseases 20100801

• A comparison of the chronic effects of human pharmaceuticals on two cladocerans, Daphnia magna and Ceriodaphnia dubia.

  Chemosphere 20100801

• Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment.

  Schizophrenia research 20100801

• Celecoxib prodrugs possessing a diazen-1-ium-1,2-diolate nitric oxide donor moiety: synthesis, biological evaluation and nitric oxide release studies.

  Bioorganic & medicinal chemistry letters 20100801

• Effect of celecoxib combined with thoracic epidural analgesia on pain after thoracotomy.

  British journal of anaesthesia 20100801

• Carbonic anhydrase inhibitors. The X-ray crystal structure of human isoform II in adduct with an adamantyl analogue of acetazolamide resides in a less utilized binding pocket than most hydrophobic inhibitors.

  Bioorganic & medicinal chemistry letters 20100801

• Synthesis and biological evaluation of novel pyrazole compounds.

  Bioorganic & medicinal chemistry 20100801

• Mutation of Phe91 to Asn in human carbonic anhydrase I unexpectedly enhanced both catalytic activity and affinity for sulfonamide inhibitors.

  Bioorganic & medicinal chemistry 20100801

• The inhibitory effect of celecoxib on mouse hepatoma H22 cell line on the arachidonic acid metabolic pathway.

  Biochemistry and cell biology = Biochimie et biologie cellulaire 20100801

• The post-operative analgesic efficacy of celecoxib compared with placebo and parecoxib after total hip or knee arthroplasty.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20100801

• [High-performance liquid chromatography for determining celecoxib concentration in hamster tongue tissue after oral local application].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20100801

• 1-(3,5-Diethyl-1H-pyrazol-1-yl)-3-phenyl-isoquinoline.

  Acta crystallographica. Section E, Structure reports online 20100801

• Combination chemotherapy for influenza.

  Viruses 20100801

• Treatment strategies for osteoarthritis patients with pain and hypertension.

  Therapeutic advances in musculoskeletal disease 20100801

• NSAIDs and risk of lower gastrointestinal bleeding.

  Lancet (London, England) 20100717

• Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.

  Lancet (London, England) 20100717

• Synthesis, characterization and preliminary analysis of in vivo biological activity of chitosan/celecoxib microcapsules.

  Bioorganic & medicinal chemistry letters 20100715

• 1,5-Diarylimidazoles with strong inhibitory activity against COX-2 catalyzed PGE2 production from LPS-induced RAW 264.7 cells.

  Bioorganic & medicinal chemistry letters 20100715

• Cyclooxygenase inhibitors suppress the expression of P2X(3) receptors in the DRG and attenuate hyperalgesia following chronic constriction injury in rats.

  Neuroscience letters 20100705

• Synthesis and antitumor properties of selenocoxib-1 against rat prostate adenocarcinoma cells.

  International journal of cancer 20100701

• Vascular endothelial growth factor and not cyclooxygenase 2 promotes endothelial cell viability in the pancreatic tumor microenvironment.

  Pancreas 20100701

• Far-distant metastases along the CSF pathway of glioblastoma multiforme during continuous low-dose chemotherapy with temozolomide and celecoxib.

  Neurosurgical review 20100701

• Nanoparticles for local drug delivery to the oral mucosa: proof of principle studies.

  Pharmaceutical research 20100701

• Synergistic effect of celecoxib on TRAIL-induced apoptosis in hepatocellular carcinoma cells.

  Cancer investigation 20100701

• Translocation of cell penetrating peptide engrafted nanoparticles across skin layers.

  Biomaterials 20100701

• A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients.

  Breast cancer research and treatment 20100701

• Antitumor effects of inhibitors of nitric oxide synthase or cyclooxygenase-2 on human KB carcinoma cells overexpressing COX-2.

  Oncology reports 20100701

• Preparation and evaluation of celecoxib transdermal patches.

  Pakistan journal of pharmaceutical sciences 20100701

• Analgesic use and the risk for progression of chronic kidney disease.

  Pharmacoepidemiology and drug safety 20100701

• Increased risk of hospitalization for acute hepatitis in patients with previous exposure to NSAIDs.

  Pharmacoepidemiology and drug safety 20100701

• Serum cytokine analysis in a positive chemoprevention trial: selenium, interleukin-2, and an association with squamous preneoplastic disease.

  Cancer prevention research (Philadelphia, Pa.) 20100701

• Celecoxib treatment restores pharmacosensitivity in a rat model of pharmacoresistant epilepsy.

  British journal of pharmacology 20100701

• Apoptotic Effect of Tolfenamic Acid in KB Human Oral Cancer Cells: Possible Involvement of the p38 MAPK Pathway.

  Journal of clinical biochemistry and nutrition 20100701

• Cardiovascular safety of celecoxib on top of dual antiplatelet therapy.

  Korean circulation journal 20100701

• Celecoxib does not attenuate the antiplatelet effects of aspirin and clopidogrel in healthy volunteers.

  Korean circulation journal 20100701

• Incidence and possible risk factors for clinical upper gastrointestinal events in patients taking selective cyclooxygenase-2 inhibitors: A prospective, observational, cohort study in Taiwan.

  Clinical therapeutics 20100701

• Antiproliferative effect of a novel nitro-oxy derivative of celecoxib in human colon cancer cells: role of COX-2 and nitric oxide.

  Anticancer research 20100701

• [Effects of EGFR inhibitor AG1478 in combination with celecoxib on the growth of gastric cancer cells].

  Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20100701

• Exploiting cyclooxygenase-(in)dependent properties of COX-2 inhibitors for malignant glioma therapy.

  Anti-cancer agents in medicinal chemistry 20100701

• Formation of celecoxib nanoparticles from volatile microemulsions.

  International journal of pharmaceutics 20100630

• Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma.

  British journal of cancer 20100629

• Effects of treadmill exercise on cyclooxygenase-2 in the hippocampus in type 2 diabetic rats: correlation with the neuroblasts.

  Brain research 20100623

• Peripheral mu-, kappa- and delta-opioid receptors mediate the hypoalgesic effect of celecoxib in a rat model of thermal hyperalgesia.

  Life sciences 20100619

• Protection of Monascus-fermented dioscorea against DMBA-induced oral injury in hamster by anti-inflammatory and antioxidative potentials.

  Journal of agricultural and food chemistry 20100609

• Celecoxib-loaded liposomes: effect of cholesterol on encapsulation and in vitro release characteristics.

  Bioscience reports 20100603

• Anti-inflammatory treatment in AD mice protects against neuronal pathology.

  Experimental neurology 20100601

• Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.

  American journal of clinical oncology 20100601

• Patient-reported-outcomes in subjects with painful lumbar or cervical radiculopathy treated with pregabalin: evidence from medical practice in primary care settings.

  Rheumatology international 20100601

• A phase I study of capecitabine, irinotecan, celecoxib, and radiation as neoadjuvant therapy of patients with locally advanced rectal cancer.

  American journal of clinical oncology 20100601

• Concentration-dependent differing actions of the nonsteroidal anti-inflammatory drug, celecoxib, in distearoyl phosphatidylcholine multilamellar vesicles.

  Journal of liposome research 20100601

• Cyclooxygenase-2 preserves flow-mediated remodelling in old obese Zucker rat mesenteric arteries.

  Cardiovascular research 20100601

• Protective effect of rebamipide against celecoxib-induced gastric mucosal cell apoptosis.

  Biochemical pharmacology 20100601

• Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers.

  Journal of controlled release : official journal of the Controlled Release Society 20100601

• Rofecoxib, but not celecoxib, increases the risk of thromboembolic cardiovascular events in young adults-a nationwide registry-based study.

  European journal of clinical pharmacology 20100601

• Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding.

  Arthritis and rheumatism 20100601

• Focus on therapy: hemicrania continua and new daily persistent headache.

  The journal of headache and pain 20100601

• Timing of ibuprofen use and bone mineral density adaptations to exercise training.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20100601

• The safety and efficacy of celecoxib in children with familial adenomatous polyposis.

  The American journal of gastroenterology 20100601

• Cyclooxygenase-derived mediators regulate the immunological control of Strongyloides venezuelensis infection.

  FEMS immunology and medical microbiology 20100601

• Novel anti-inflammatory functions for endothelial and myeloid cyclooxygenase-2 in a new mouse model of Crohn's disease.

  American journal of physiology. Gastrointestinal and liver physiology 20100601

• Renal hyperfiltration is a determinant of endothelial function responses to cyclooxygenase 2 inhibition in type 1 diabetes.

  Diabetes care 20100601

• Chemoprevention strategies for pancreatic cancer.

  Nature reviews. Gastroenterology & hepatology 20100601

• Update on antithrombotic therapy for stroke prevention in atrial fibrillation.

  Current treatment options in cardiovascular medicine 20100601

• A nonhormonal model for emergency contraception: prostaglandin synthesis inhibitor effects on luteal function and lifespan, a pilot study.

  Contraception 20100601

• Celecoxib may decrease some skin cancers.

  The Nurse practitioner 20100601

• Persistent cyclooxygenase-2 inhibition downregulates NF-{kappa}B, resulting in chronic intestinal inflammation in the min/+ mouse model of colon tumorigenesis.

  Cancer research 20100601

• Long-term outcome of adjunctive celecoxib treatment after paclitaxel-eluting stent implantation for the complex coronary lesions: two-year clinical follow-up of COREA-TAXUS trial.

  Circulation. Cardiovascular interventions 20100601

• Combination effects of salvianolic acid B with low-dose celecoxib on inhibition of head and neck squamous cell carcinoma growth in vitro and in vivo.

  Cancer prevention research (Philadelphia, Pa.) 20100601

• Colon carcinoma cell interaction with liver sinusoidal endothelium inhibits organ-specific antitumor immunity through interleukin-1-induced mannose receptor in mice.

  Hepatology (Baltimore, Md.) 20100601

• The effects of paracetamol, ketorolac, and paracetamol plus morphine on pain control after thyroidectomy.

  The Korean journal of pain 20100601

• Activated PI3K/Akt/COX-2 pathway induces resistance to radiation in human cervical cancer HeLa cells.

  Cancer biotherapy & radiopharmaceuticals 20100601

• Chemoprevention of colorectal cancer: systematic review and economic evaluation.

  Health technology assessment (Winchester, England) 20100601

• Neuropathologic and clinical features of human medial temporal lobe epilepsy.

  Journal of clinical neurology (Seoul, Korea) 20100601

• Effect of treatment based on syndrome differentiation by Chinese medicine on post-traumatic elbow arthritis.

  Chinese journal of integrative medicine 20100601

• Antiamnesic effect of stevioside in scopolamine-treated rats.

  Indian journal of pharmacology 20100601

• [Risk of anastomotic leakage in postoperative treatment with non-steroidal anti-inflammatory drugs].

  Ugeskrift for laeger 20100531

• Colloid formation by drugs in simulated intestinal fluid.

  Journal of medicinal chemistry 20100527

• Wettability and surface chemistry of crystalline and amorphous forms of a poorly water soluble drug.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20100512

• Microsomal prostaglandin E synthase-1 inhibition blocks proliferation and enhances apoptosis in oesophageal adenocarcinoma cells without affecting endothelial prostacyclin production.

  International journal of cancer 20100501

• Treatment of atypical central neurocytoma in a child with high dose chemotherapy and autologous stem cell rescue.

  Journal of neuro-oncology 20100501

• Synergistic anticancer effects of combined gamma-tocotrienol and celecoxib treatment are associated with suppression in Akt and NFkappaB signaling.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20100501

• Infliximab for the treatment of refractory scleritis.

  The British journal of ophthalmology 20100501

• TLR4-dependent induction of vascular adhesion molecule-1 in rheumatoid arthritis synovial fibroblasts: Roles of cytosolic phospholipase A(2)alpha/cyclooxygenase-2.

  Journal of cellular physiology 20100501

• Delivery of celecoxib for treating diseases of the eye: influence of pigment and diabetes.

  Expert opinion on drug delivery 20100501

• Synthesis of new 2,3-dihydroquinazolin-4(1H)-one derivatives for analgesic and anti-inflammatory evaluation.

  Archiv der Pharmazie 20100501

• Pharmacotherapy for inherited colorectal cancer.

  Expert opinion on pharmacotherapy 20100501

• Statin use and colorectal adenoma risk: results from the adenoma prevention with celecoxib trial.

  Cancer prevention research (Philadelphia, Pa.) 20100501

• Statins and the colorectum: hope for chemoprevention?

  Cancer prevention research (Philadelphia, Pa.) 20100501

• Balancing gastrointestinal benefit-risk in individuals who are prescribed NSAIDs for arthritis.

  Rheumatology (Oxford, England) 20100501

• Patient benefit-risk in arthritis--a rheumatologist's perspective.

  Rheumatology (Oxford, England) 20100501

• Identifying and assessing benefit-risk in primary care--a family physician's perspective.

  Rheumatology (Oxford, England) 20100501

• A review of the gastrointestinal safety data--a gastroenterologist's perspective.

  Rheumatology (Oxford, England) 20100501

• Genomic characterization of the inflammatory response initiated by surgical intervention and the effect of perioperative cyclooxygenase 2 blockade.

  The Journal of thoracic and cardiovascular surgery 20100501

• Effects of short-term celecoxib treatment in patients with invasive transitional cell carcinoma of the urinary bladder.

  Molecular cancer therapeutics 20100501

• Progression from chronic atrophic gastritis to gastric cancer; tangle, toggle, tackle with Korea red ginseng.

  Journal of clinical biochemistry and nutrition 20100501

• Deciphering diseases and biological targets for environmental chemicals using toxicogenomics networks.

  PLoS computational biology 20100501

• The effects of lumiracoxib 100 mg once daily vs. ibuprofen 600 mg three times daily on the blood pressure profiles of hypertensive osteoarthritis patients taking different classes of antihypertensive agents.

  International journal of clinical practice 20100501

• Incidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac: pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritis.

  International journal of rheumatic diseases 20100501

• Diffuse rash and cough in elderly woman with a UTI.

  The Journal of family practice 20100501

• Metronomic cyclophosphamide in elderly patients with advanced, castration-resistant prostate cancer.

  Journal of the American Geriatrics Society 20100501

• Inflammatory pathogenesis of prostate cancer and celecoxib.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100420

• Celecoxib activates PI-3K/Akt and mitochondrial redox signaling to enhance heme oxygenase-1-mediated anti-inflammatory activity in vascular endothelium.

  Free radical biology & medicine 20100415

• Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard care.

  British journal of cancer 20100413

• Silica nanoparticles to control the lipase-mediated digestion of lipid-based oral delivery systems.

  Molecular pharmaceutics 20100405

• Celecoxib inhibits MDR1 expression through COX-2-dependent mechanism in human hepatocellular carcinoma (HepG2) cell line.

  Cancer chemotherapy and pharmacology 20100401

• Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100401

• Biotransformation of celecoxib using microbial cultures.

  Applied biochemistry and biotechnology 20100401

• Effect of AEE788 and/or Celecoxib on colon cancer cell morphology using advanced microscopic techniques.

  Micron (Oxford, England : 1993) 20100401

• Compressive force induces osteoclast differentiation via prostaglandin E(2) production in MC3T3-E1 cells.

  Connective tissue research 20100401

• Prostaglandin E2 prevents Helicobacter-induced gastric preneoplasia and facilitates persistent infection in a mouse model.

  Gastroenterology 20100401

• A phase 2 pilot trial of low-dose, continuous infusion, or 'metronomic' paclitaxel and oral celecoxib in patients with metastatic melanoma.

  Cancer 20100401

• Celecoxib activates Stat5 and restores or increases the expression of growth hormone-regulated genes in hepatocarcinogenesis.

  Anti-cancer drugs 20100401

• A prospective evaluation of 2 different pain management protocols for total hip arthroplasty.

  The Journal of arthroplasty 20100401

• Dextran carrier macromolecule for colon specific delivery of celecoxib.

  Current drug delivery 20100401

• Hypertrophic cranial pachymeningitis induced by long-term administration of nonsteroidal antiinflammatory drugs.

  The Annals of pharmacotherapy 20100401

• Synthesis and biological evaluation of N-difluoromethyl-1,2-dihydropyrid-2-one acetic acid regioisomers: dual inhibitors of cyclooxygenases and 5-lipoxygenase.

  Bioorganic & medicinal chemistry letters 20100401

• The effects of radix curcumae extract on expressions of VEGF, COX-2 and PCNA in gastric mucosa of rats fed with MNNG.

  Current pharmaceutical biotechnology 20100401

• Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer.

  Journal of clinical gastroenterology 20100401

• Novel combination of celecoxib and proteasome inhibitor MG132 provides synergistic antiproliferative and proapoptotic effects in human liver tumor cells.

  Cell cycle (Georgetown, Tex.) 20100401

• Effect of recombinant human epidermal growth factor against cutaneous scar formation in murine full-thickness wound healing.

  Journal of Korean medical science 20100401

• Comparison of the causes and clinical features of drug rash with eosinophilia and systemic symptoms and stevens-johnson syndrome.

  Allergy, asthma & immunology research 20100401

• Nonsteroidal anti-inflammatory therapy and recurrent acute anterior uveitis.

  Ocular immunology and inflammation 20100401

• Chemoprophylaxis in colorectal cancer: current concepts and a practical algorithm for use.

  Expert opinion on investigational drugs 20100401

• [Influence of celecoxib combined with IFN-alpha on proliferation, apoptosis, cell cycle and CD117 expression of K562 cells].

  Zhongguo shi yan xue ye xue za zhi 20100401

• Cdh11 acts as a tumor suppressor in a murine retinoblastoma model by facilitating tumor cell death.

  PLoS genetics 20100401

• The analgesic and anti-inflammatory effects of 7-oxosandaracopimaric acid isolated from the roots of Aralia cordata.

  Archives of pharmacal research 20100401

• Effect of non-steroidal anti-inflammatory drugs on behavioral actions of diazepam in mice.

  Neurosciences (Riyadh, Saudi Arabia) 20100401

• The PI3K/Akt/FOXO3a/p27Kip1 signaling contributes to anti-inflammatory drug-suppressed proliferation of human osteoblasts.

  Biochemical pharmacology 20100315

• Cloning, characterization, and inhibition studies of a beta-carbonic anhydrase from Brucella suis.

  Journal of medicinal chemistry 20100311

• Rosuvastatin prevents conduit artery endothelial dysfunction induced by ischemia and reperfusion by a cyclooxygenase-2-dependent mechanism.

  Journal of the American College of Cardiology 20100309

• Inhibition of secretion of interleukin (IL)-12/IL-23 family cytokines by 4-trifluoromethyl-celecoxib is coupled to degradation via the endoplasmic reticulum stress protein HERP.

  The Journal of biological chemistry 20100305

• Potential Use of Plectranthus amboinicus in the Treatment of Rheumatoid Arthritis.

  Evidence-based complementary and alternative medicine : eCAM 20100301

• Hematopoietic progenitor kinase 1 is a critical component of prostaglandin E2-mediated suppression of the anti-tumor immune response.

  Cancer immunology, immunotherapy : CII 20100301

• Clinical relevance of C-reactive protein in ankylosing spondylitis and evaluation of the NSAIDs/coxibs' treatment effect on C-reactive protein.

  Rheumatology (Oxford, England) 20100301

• Preliminary assessment of celecoxib and microdiode pulse laser treatment of diabetic macular edema.

  Retina (Philadelphia, Pa.) 20100301

• In vitro and in vivo evaluation of proniosomes containing celecoxib for oral administration.

  AAPS PharmSciTech 20100301

• Uterine-specific p53 deficiency confers premature uterine senescence and promotes preterm birth in mice.

  The Journal of clinical investigation 20100301

• Markedly reduced toxicity of a hydrogen sulphide-releasing derivative of naproxen (ATB-346).

  British journal of pharmacology 20100301

• Synthesis and biological evaluation of novel pyrazolyl-2,4-thiazolidinediones as anti-inflammatory and neuroprotective agents.

  Bioorganic & medicinal chemistry 20100301

• Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100301

• Chronic cyclooxygenase-2 inhibition promotes myofibroblast-associated intestinal fibrosis.

  Cancer prevention research (Philadelphia, Pa.) 20100301

• Risk factors of drug interaction between warfarin and nonsteroidal anti-inflammatory drugs in practical setting.

  Journal of Korean medical science 20100301

• Effect of celecoxib on proliferation, apoptosis, and survivin expression in human glioma cell line U251.

  Chinese journal of cancer 20100301

• Celecoxib in a 12-year-old boy with familial adenomatous polyposis.

  International journal of clinical pharmacology and therapeutics 20100301

• Antiangiogenic activities of 2,5-dimethyl-celecoxib on the tumor vasculature.

  Molecular cancer therapeutics 20100301

• Hospitalizations for gastrointestinal and cardiovascular events in the CADEUS cohort of traditional or Coxib NSAID users.

  British journal of clinical pharmacology 20100301

• Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. nonselective COX-2 inhibitors.

  British journal of clinical pharmacology 20100301

• [Celecoxib induces cell cycle arrest and apoptosis in human tongue squamous carcinoma cell line Tca8113].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20100301

• Cyclooxygenase-2 expression in retinoblastoma: an immunohistochemical analysis.

  Current eye research 20100301

• Cyclooxygenase and neuroinflammation in Parkinson's disease neurodegeneration.

  Current neuropharmacology 20100301

• Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model.

  Cancer letters 20100227

• Anti-cancer effects of celecoxib in head and neck carcinoma.

  Molecules and cells 20100227

• Celecoxib inhibits Helicobacter pylori colonization-related factors.

  World journal of gastroenterology 20100221

• Reversal of gene expression changes in the colorectal normal-adenoma pathway by NS398 selective COX2 inhibitor.

  British journal of cancer 20100216

• Synergistic actions of atorvastatin with gamma-tocotrienol and celecoxib against human colon cancer HT29 and HCT116 cells.

  International journal of cancer 20100215

• The effects of nepafenac and amfenac on retinal angiogenesis.

  Brain research bulletin 20100215

• Celecoxib analogs possessing a N-(4-nitrooxybutyl)piperidin-4-yl or N-(4-nitrooxybutyl)-1,2,3,6-tetrahydropyridin-4-yl nitric oxide donor moiety: synthesis, biological evaluation and nitric oxide release studies.

  Bioorganic & medicinal chemistry letters 20100215

• Proteomic analysis in NSAIDs-treated primary cardiomyocytes.

  Journal of proteomics 20100210

• Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice.

  Annals of the rheumatic diseases 20100201

• A COX-2 inhibitor reduces muscle soreness, but does not influence recovery and adaptation after eccentric exercise.

  Scandinavian journal of medicine & science in sports 20100201

• Comparison of mechanical allodynia and the affective component of inflammatory pain in rats.

  Neuropharmacology 20100201

• Cytotoxic effects of celecoxib on Raji lymphoma cells correlate with aggravated endoplasmic reticulum stress but not with inhibition of cyclooxygenase-2.

  Leukemia research 20100201

• Effect of a cyclooxygenase-2 inhibitor on postexercise muscle protein synthesis in humans.

  American journal of physiology. Endocrinology and metabolism 20100201

• COX-2 expression in chondrosarcoma: a role for celecoxib treatment?

  European journal of cancer (Oxford, England : 1990) 20100201

• Recruited bone marrow cells expressing the EP3 prostaglandin E receptor subtype enhance angiogenesis during chronic inflammation.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20100201

• Cytokine profiles induced by the novel swine-origin influenza A/H1N1 virus: implications for treatment strategies.

  The Journal of infectious diseases 20100201

• Host prostaglandin EP3 receptor signaling relevant to tumor-associated lymphangiogenesis.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20100201

• Suppressive effect of COX2 inhibitor on the progression of adipose inflammation in high-fat-induced obese rats.

  European journal of clinical investigation 20100201

• Influence of LOX/COX inhibitors on cell differentiation induced by all-trans retinoic acid in neuroblastoma cell lines.

  International journal of molecular medicine 20100201

• Pharmacophore modeling and virtual screening for designing potential 5-lipoxygenase inhibitors.

  Bioorganic & medicinal chemistry letters 20100201

• Absorption and distribution of etoricoxib in plasma, CSF, and wound tissue in patients following hip surgery--a pilot study.

  Naunyn-Schmiedeberg's archives of pharmacology 20100201

• Design, synthesis and biological evaluation of new 2,3-diarylquinoline derivatives as selective cyclooxygenase-2 inhibitors.

  Bioorganic & medicinal chemistry 20100201

• Severe adverse skin reactions to nonsteroidal antiinflammatory drugs: A review of the literature.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20100201

• Biological activity of celecoxib in the bronchial epithelium of current and former smokers.

  Cancer prevention research (Philadelphia, Pa.) 20100201

• Cyclooxygenase-2 inhibition for the prophylaxis and treatment of preinvasive breast cancer in a her-2/neu mouse model.

  Cancer prevention research (Philadelphia, Pa.) 20100201

• Assessing efficacy in early-phase cancer prevention clinical trials: the case of ki-67 in the lung.

  Cancer prevention research (Philadelphia, Pa.) 20100201

• Celecoxib-induced apoptosis is enhanced by ABT-737 and by inhibition of autophagy in human colorectal cancer cells.

  Autophagy 20100201

• Nonsteroidal antiinflammatory drugs and prostaglandin E(2) modulate the synthesis of osteoprotegerin and RANKL in the cartilage of patients with severe knee osteoarthritis.

  Arthritis and rheumatism 20100201

• [Selective inhibitors of cyclooxygenase-2 (COX-2), celecoxib and parecoxib: a systematic review].

  Drugs of today (Barcelona, Spain : 1998) 20100201

• Biomarkers of inflammation in cattle determining the effectiveness of anti-inflammatory drugs.

  Journal of veterinary pharmacology and therapeutics 20100201

• Naproxen aggravates doxorubicin-induced cardiomyopathy in rats.

  Indian journal of pharmacology 20100201

• Prostaglandin E2 upregulates survivin expression via the EP1 receptor in hepatocellular carcinoma cells.

  Life sciences 20100130

• Novel ester and acid derivatives of the 1,5-diarylpyrrole scaffold as anti-inflammatory and analgesic agents. Synthesis and in vitro and in vivo biological evaluation.

  Journal of medicinal chemistry 20100128

• Toward safer processes for C-C biaryl bond construction: catalytic direct C-H arylation and tin-free radical coupling in the synthesis of pyrazolophenanthridines.

  The Journal of organic chemistry 20100115

• Discovery of 3-(4-bromophenyl)-6-nitrobenzo[1.3.2]dithiazolium ylide 1,1-dioxide as a novel dual cyclooxygenase/5-lipoxygenase inhibitor that also inhibits tumor necrosis factor-alpha production.

  Bioorganic & medicinal chemistry 20100115

• Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention.

  Journal of the National Cancer Institute 20100106

• [11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease?

  Parkinsonism & related disorders 20100101

• Celecoxib prevents tumor growth in an animal model by a COX-2 independent mechanism.

  Cancer chemotherapy and pharmacology 20100101

• Nanoemulsion: a promising tool for solubility and dissolution enhancement of celecoxib.

  Pharmaceutical development and technology 20100101

• Celecoxib reduces the effects of acute and chronic UVB exposure in mice treated with therapeutically relevant immunosuppressive drugs.

  International journal of cancer 20100101

• Differential effects of anti-apoptotic Bcl-2 family members Mcl-1, Bcl-2, and Bcl-xL on celecoxib-induced apoptosis.

  Biochemical pharmacology 20100101

• Short-term celecoxib to regress long-term persistent gastric intestinal metaplasia after Helicobacter pylori eradication.

  Journal of gastroenterology and hepatology 20100101

• Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia.

  Journal of molecular medicine (Berlin, Germany) 20100101

• A novel composite endpoint to evaluate the gastrointestinal (GI) effects of nonsteroidal antiinflammatory drugs through the entire GI tract.

  The Journal of rheumatology 20100101

• KO-202125, a sauristolactam derivate, induces apoptosis to prevent KB human oral squamous carcinoma cells through inhibition of cyclooxygenase-2 expression.

  European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) 20100101

• Criterion for excipients screening in the development of nanoemulsion formulation of three anti-inflammatory drugs.

  Pharmaceutical development and technology 20100101

• The murine cerebral malaria phenomenon.

  Trends in parasitology 20100101

• Mechanisms of Kv2.1 channel inhibition by celecoxib--modification of gating and channel block.

  British journal of pharmacology 20100101

• Basal cell carcinoma chemoprevention with nonsteroidal anti-inflammatory drugs in genetically predisposed PTCH1+/- humans and mice.

  Cancer prevention research (Philadelphia, Pa.) 20100101

• Overexpression of cyclooxygenase-2 in rat oral cancers and prevention of oral carcinogenesis in rats by selective and nonselective COX inhibitors.

  Cancer prevention research (Philadelphia, Pa.) 20100101

• Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independence.

  Cancer prevention research (Philadelphia, Pa.) 20100101

• Effectiveness of diclofenac versus acetaminophen in primary care patients with knee osteoarthritis: [NTR1485], DIPA-trial: design of a randomized clinical trial.

  BMC musculoskeletal disorders 20100101

• Water displacement leg volumetry in clinical studies--a discussion of error sources.

  BMC medical research methodology 20100101

• Antivascular therapy for epithelial ovarian cancer.

  Journal of oncology 20100101

• Celecoxib inhibits CD133-positive cell migration via reduction of CCR2 in Helicobacter pylori-infected Mongolian gerbils.

  Digestion 20100101

• Progressive changes in microglia and macrophages in spinal cord and peripheral nerve in the transgenic rat model of amyotrophic lateral sclerosis.

  Journal of neuroinflammation 20100101

• Synergistic effect of gefitinib and rofecoxib in mesothelioma cells.

  Molecular cancer 20100101

• Chronic infection during placental malaria is associated with up-regulation of cycloxygenase-2.

  Malaria journal 20100101

• Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection.

  BMC medicine 20100101

• In-vivo transfection of pcDNA3.1-IGFBP7 inhibits melanoma growth in mice through apoptosis induction and VEGF downexpression.

  Journal of experimental & clinical cancer research : CR 20100101

• Progress in COX-2 inhibitors: a journey so far.

  Current medicinal chemistry 20100101

• Acute NMDA toxicity in cultured rat cerebellar granule neurons is accompanied by autophagy induction and late onset autophagic cell death phenotype.

  BMC neuroscience 20100101

• Prevalence of genetic polymorphisms in the promoter region of the alpha-1 antitrypsin (SERPINA1) gene in chronic liver disease: a case control study.

  BMC gastroenterology 20100101

• Elevated ratio of urinary metabolites of thromboxane and prostacyclin is associated with adverse cardiovascular events in ADAPT.

  PloS one 20100101

• Effects of Liver x receptor agonist treatment on signal transduction pathways in acute lung inflammation.

  Respiratory research 20100101

• Insight in modulation of inflammation in response to diclofenac intervention: a human intervention study.

  BMC medical genomics 20100101

• Cyclooxygenase-2 enhances alpha2beta1 integrin expression and cell migration via EP1 dependent signaling pathway in human chondrosarcoma cells.

  Molecular cancer 20100101

• [Reducing effect of curcumin on expressions of TNF-alpha, IL-6 and IL-8 in rats with chronic nonbacterial prostatitis].

  Zhonghua nan ke xue = National journal of andrology 20100101

• Nonsteroidal Anti-Inflammatory Drugs: A survey of practices and concerns of pediatric medical and surgical specialists and a summary of available safety data.

  Pediatric rheumatology online journal 20100101

• Low direct cytotoxicity of loxoprofen on gastric mucosal cells.

  Biological & pharmaceutical bulletin 20100101

• Prescriptions for selective cyclooxygenase-2 inhibitors, non-selective non-steroidal anti-inflammatory drugs, and risk of breast cancer in a population-based case-control study.

  Breast cancer research : BCR 20100101

• Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis.

  PharmacoEconomics 20100101

• Multimodal therapy for synergic inhibition of tumour cell invasion and tumour-induced angiogenesis.

  BMC cancer 20100101

• Downregulation of Epidermal Growth Factor Receptor Expression Contributes to alpha-TEA's Proapoptotic Effects in Human Ovarian Cancer Cell Lines.

  Journal of oncology 20100101

• A phase II study of high-dose celecoxib and metronomic 'low-dose' cyclophosphamide and methotrexate in patients with relapsed and refractory lymphoma.

  Hematology/oncology and stem cell therapy 20100101

• Reduced uptake of the proliferation-seeking radiotracer technetium-99m-labelled pentavalent dimercaptosuccinic acid in a 47-year-old woman with severe breast epithelial hyperplasia taking ibuprofen: a case report.

  Journal of medical case reports 20100101

• The cytoprotective drug amifostine modifies both expression and activity of the pro-angiogenic factor VEGF-A.

  BMC medicine 20100101

• The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies.

  International journal of cell biology 20100101

• Expression and prognostic significance of Cox-2 and p-53 in Hodgkin lymphomas: a retrospective study.

  Diagnostic pathology 20100101

• Tamoxifen enhances the Hsp90 molecular chaperone ATPase activity.

  PloS one 20100101

• Reporting bias in medical research - a narrative review.

  Trials 20100101

• Cyclooxygenase-2 expression in oligodendrocytes increases sensitivity to excitotoxic death.

  Journal of neuroinflammation 20100101

• Effect of celecoxib, a selective cyclooxygenase-2 inhibitor on carbon tetrachloride intoxication in rats.

  Biological & pharmaceutical bulletin 20100101

• Antiangiogenic therapy and mechanisms of tumor resistance in malignant glioma.

  Journal of oncology 20100101

• Effects of selective and non-selective cyclooxygenase (COX) inhibitors on postoperative adhesion formation in a rat uterine horn model.

  Clinical and experimental obstetrics & gynecology 20100101

• Tumor tissue-derived formaldehyde and acidic microenvironment synergistically induce bone cancer pain.

  PloS one 20100101

• BCAN Think Tank session 3: Prevention of bladder cancer.

  Urologic oncology 20100101

• [The assessment of oral NSAID use in patients with rheumatoid arthritis in Hungary--a cross sectional non interventional study].

  Acta pharmaceutica Hungarica 20100101

• Architectural heterogeneity in tumors caused by differentiation alters intratumoral drug distribution and affects therapeutic synergy of antiangiogenic organoselenium compound.

  Journal of oncology 20100101

• Enhancement of ATRA-induced differentiation of neuroblastoma cells with LOX/COX inhibitors: an expression profiling study.

  Journal of experimental & clinical cancer research : CR 20100101

• The effects of COX-2 anti-inflammatory drugs on soft tissue healing: a review of the literature.

  Journal of biological regulators and homeostatic agents 20100101

• Etoricoxib--preemptive and postoperative analgesia (EPPA) in patients with laparotomy or thoracotomy--design and protocols.

  Trials 20100101

• COX-2 as a target for cancer chemotherapy.

  Pharmacological reports : PR 20100101

• Optical tomographic imaging discriminates between disease-modifying anti-rheumatic drug (DMARD) and non-DMARD efficacy in collagen antibody-induced arthritis.

  Arthritis research & therapy 20100101

• Role and rationale for the use of milnacipran in the management of fibromyalgia.

  Neuropsychiatric disease and treatment 20100101

• Design of group IIA secreted/synovial phospholipase A(2) inhibitors: an oxadiazolone derivative suppresses chondrocyte prostaglandin E(2) secretion.

  PloS one 20100101

• Use of nonsteroidal anti-inflammatory drugs in patients with cardiovascular disease: a cautionary tale.

  Cardiology in review 20100101

• Targeting the tumor microenvironment using photodynamic therapy combined with inhibitors of cyclooxygenase-2 or vascular endothelial growth factor.

  Methods in molecular biology (Clifton, N.J.) 20100101

• Presenilin/gamma-Secretase and Inflammation.

  Frontiers in aging neuroscience 20100101

• Curcumin mediated suppression of nuclear factor-κB promotes chondrogenic differentiation of mesenchymal stem cells in a high-density co-culture microenvironment.

  Arthritis research & therapy 20100101

• A female with rash and facial swelling.

  Journal of emergencies, trauma, and shock 20100101

• Single dose oral lumiracoxib for postoperative pain in adults.

  The Cochrane database of systematic reviews 20100101

• Influence of cyclodextrin complexation with NSAIDs on NSAID/cold stress-induced gastric ulceration in rats.

  International journal of medical sciences 20100101

• Therapeutic cancer vaccines in combination with conventional therapy.

  Journal of biomedicine & biotechnology 20100101

• RNAi-based strategies for cyclooxygenase-2 inhibition in cancer.

  Journal of biomedicine & biotechnology 20100101

• Establishing a distributed system for the simple representation and integration of diverse scientific assertions.

  Journal of biomedical semantics 20100101

• Decreased risk of squamous cell carcinoma of the head and neck in users of nonsteroidal anti-inflammatory drugs.

  International journal of otolaryngology 20100101

• Comparison of glucose derivatives effects on cartilage degradation.

  BMC musculoskeletal disorders 20100101

• Vane's blood-bathed organ technique adapted to examine the endothelial effects of cardiovascular drugs in vivo.

  Pharmacological reports : PR 20100101

• The Analgesic Activity of Bestatin as a Potent APN Inhibitor.

  Frontiers in neuroscience 20100101

• The role of prostaglandin E2 (PGE 2) in toll-like receptor 4 (TLR4)-mediated colitis-associated neoplasia.

  BMC gastroenterology 20100101

• Current implications of cyclophilins in human cancers.

  Journal of experimental & clinical cancer research : CR 20100101

• Caffeine: a potential complexing agent for solubility and dissolution enhancement of celecoxib.

  Pharmaceutical biology 20100101

• Rhizoma Coptidis inhibits LPS-induced MCP-1/CCL2 production in murine macrophages via an AP-1 and NFkappaB-dependent pathway.

  Mediators of inflammation 20100101

• Price regulation, new entry, and information shock on pharmaceutical market in Taiwan: a nationwide data-based study from 2001 to 2004.

  BMC health services research 20100101

• Pharmacologic inhibition of COX-1 and COX-2 in influenza A viral infection in mice.

  PloS one 20100101

• Association of sulfotransferase SULT1A1 with breast cancer risk: a meta-analysis of case-control studies with subgroups of ethnic and menopausal statue.

  Journal of experimental & clinical cancer research : CR 20100101

• Subchondral bone microstructural damage by increased remodelling aggravates experimental osteoarthritis preceded by osteoporosis.

  Arthritis research & therapy 20100101

• Role of COX-2 in cough reflex sensitivity to inhaled capsaicin in patients with sinobronchial syndrome.

  Cough (London, England) 20100101

• Targeting DNA damage and repair by curcumin.

  Breast cancer : basic and clinical research 20100101

• Parthenolide induces proliferation inhibition and apoptosis of pancreatic cancer cells in vitro.

  Journal of experimental & clinical cancer research : CR 20100101

• Are NSAIDs useful to treat Alzheimer's disease or mild cognitive impairment?

  Frontiers in aging neuroscience 20100101

• A multiparameter approach to monitor disease activity in collagen-induced arthritis.

  Arthritis research & therapy 20100101

• Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated.

  Molecular cancer 20100101

• Tumour suppressor function of MDA-7/IL-24 in human breast cancer.

  Cancer cell international 20100101

• Rationale of using different biological therapies in rheumatoid arthritis.

  Arthritis research & therapy 20100101

• Neuroinflammation, microglia and implications for anti-inflammatory treatment in Alzheimer's disease.

  International journal of Alzheimer's disease 20100101

• Animal models of ischemic stroke. Part one: modeling risk factors.

  The open neurology journal 20100101

• COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function.

  BMC cancer 20100101

• Small-bowel capsule endoscopy in patients with suspected Crohn's disease-diagnostic value and complications.

  Diagnostic and therapeutic endoscopy 20100101

• Primary stabbing headache.

  Handbook of clinical neurology 20100101

• Saccharomyces cerevisiae β-carbonic anhydrase: inhibition and activation studies.

  Current pharmaceutical design 20100101

• Coordinated increased expression of Cyclooxygenase2 and nuclear factor κB is a steady feature of urinary bladder carcinogenesis.

  Advances in urology 20100101

• The ketogenic diet reverses gene expression patterns and reduces reactive oxygen species levels when used as an adjuvant therapy for glioma.

  Nutrition & metabolism 20100101

• Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma.

  PloS one 20100101

• Inhibitory effect of selective cyclooxygenase-2 inhibitor lumiracoxib on human organic anion transporters hOAT1 and hOAT3.

  Drug metabolism and pharmacokinetics 20100101

• The use of in vitro technologies coupled with high resolution accurate mass LC-MS for studying drug metabolism in equine drug surveillance.

  Drug testing and analysis 20100101

• Evaluation of the effect of intrathecal clonidine to decrease shoulder tip pain in laparoscopy under spinal anaesthesia.

  Indian journal of anaesthesia 20100101

• Curcumin protects intestinal mucosal barrier function of rat enteritis via activation of MKP-1 and attenuation of p38 and NF-κB activation.

  PloS one 20100101

• Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs.

  Nutrition and cancer 20100101

• Celecoxib inhibits β-catenin-dependent survival of the human osteosarcoma MG-63 cell line.

  The Journal of international medical research 20100101

• Efficacy of a multimodal analgesia protocol in total knee arthroplasty: a randomized, controlled trial.

  The Journal of international medical research 20100101

• Combined inhibitory effects of celecoxib and fluvastatin on the growth of human hepatocellular carcinoma xenografts in nude mice.

  The Journal of international medical research 20100101

• Effects of Garlic on Cytochromes P450 2C9- and 3A4-Mediated Drug Metabolism in Human Hepatocytes.

  Scientia pharmaceutica 20100101

• Materials for pharmaceutical dosage forms: molecular pharmaceutics and controlled release drug delivery aspects.

  International journal of molecular sciences 20100101

• Abalone visceral extract inhibit tumor growth and metastasis by modulating Cox-2 levels and CD8+ T cell activity.

  BMC complementary and alternative medicine 20100101

• Comparing etoricoxib and celecoxib for preemptive analgesia for acute postoperative pain in patients undergoing arthroscopic anterior cruciate ligament reconstruction: a randomized controlled trial.

  BMC musculoskeletal disorders 20100101

• α-TEA-induced death receptor dependent apoptosis involves activation of acid sphingomyelinase and elevated ceramide-enriched cell surface membranes.

  Cancer cell international 20100101

• Alkylation of the tumor suppressor PTEN activates Akt and β-catenin signaling: a mechanism linking inflammation and oxidative stress with cancer.

  PloS one 20100101

• Feasibility of incorporating genomic knowledge into electronic medical records for pharmacogenomic clinical decision support.

  BMC bioinformatics 20100101

• Old and new insights in the treatment of thyroid carcinoma.

  Journal of thyroid research 20100101

• Effects of alpha-calcitonin gene-related peptide on osteoprotegerin and receptor activator of nuclear factor-κB ligand expression in MG-63 osteoblast-like cells exposed to polyethylene particles.

  Journal of orthopaedic surgery and research 20100101

• Effects of capecitabine and celecoxib in experimental pancreatic cancer.

  Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 20100101

• Synergistic effect of celecoxib on 5-fluorouracil-induced apoptosis in hepatocellular carcinoma patients.

  Annals of hepatology 20100101

• Comparative efficacy and tolerability of 5-Loxin and AflapinAgainst osteoarthritis of the knee: a double blind, randomized, placebo controlled clinical study.

  International journal of medical sciences 20100101

• 25-Hydroxycholesterol exerts both a cox-2-dependent transient proliferative effect and cox-2-independent cytotoxic effect on bovine endothelial cells in a time- and cell-type-dependent manner.

  Journal of angiogenesis research 20100101

• Curcumin activates the p38MPAK-HSP25 pathway in vitro but fails to attenuate diabetic nephropathy in DBA2J mice despite urinary clearance documented by HPLC.

  BMC complementary and alternative medicine 20100101

• COX-2 activation is associated with Akt phosphorylation and poor survival in ER-negative, HER2-positive breast cancer.

  BMC cancer 20100101

• Could chiropractors screen for adverse drug events in the community? Survey of US chiropractors.

  Chiropractic & osteopathy 20100101

• Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.

  Journal of neuroinflammation 20100101

• Defining a minimal clinically important difference for endometriosis-associated pelvic pain measured on a visual analog scale: analyses of two placebo-controlled, randomized trials.

  Health and quality of life outcomes 20100101

• Maintenance therapy of celecoxib for major depression with mimicking neuropsychological dysfunction.

  General hospital psychiatry 20100101

• Topical piroxicam in vitro release and in vivo anti-inflammatory and analgesic effects from palm oil esters-based nanocream.

  International journal of nanomedicine 20100101

• [Prevention of NSAID gastropathy: the difference between a coxibs and the addition of a PPI].

  Nederlands tijdschrift voor geneeskunde 20100101

• The effect of phosphorylated Akt inhibition on posterior capsule opacification in an ex vivo canine model.

  Molecular vision 20100101

• Deciphering the pathogenesis of tendinopathy: a three-stages process.

  Sports medicine, arthroscopy, rehabilitation, therapy & technology : SMARTT 20100101

• Changes in Physical Activity Involvement and Attitude to Physical Activity in a 16-Year Follow-Up Study among the Elderly.

  Journal of aging research 20100101

• Existing data sources for clinical epidemiology: Aarhus University Prescription Database.

  Clinical epidemiology 20100101

• Cyclin D1 expression and the inhibitory effect of celecoxib on ovarian tumor growth in vivo.

  International journal of molecular sciences 20100101

• Efficacy of intra-articular injection of celecoxib in a rabbit model of osteoarthritis.

  International journal of molecular sciences 20100101

• Staging anti-inflammatory therapy in Alzheimer's disease.

  Frontiers in aging neuroscience 20100101

• Efficacy and safety of Ayurvedic medicines: Recommending equivalence trial design and proposing safety index.

  International journal of Ayurveda research 20100101

• DNA aptamers as molecular probes for colorectal cancer study.

  PloS one 20100101

• Pharmacophore elucidation and molecular docking studies on 5-phenyl-1-(3-pyridyl)-1h-1,2,4-triazole-3-carboxylic acid derivatives as COX-2 inhibitors.

  Scientia pharmaceutica 20100101

• Preparation and in vivo evaluation of indomethacin loaded true nanoemulsions.

  Scientia pharmaceutica 20100101

• Optimal management of cancer anorexia-cachexia syndrome.

  Cancer management and research 20100101

• Suppression of tumorigenesis: modulation of inflammatory cytokines by oral administration of microencapsulated probiotic yogurt formulation.

  International journal of inflammation 20100101

• Anticonvulsant effect of celecoxib on pentylenetetrazole-induced convulsion: Modulation by NO pathway.

  Acta neurobiologiae experimentalis 20100101

• Intravenous ibuprofen: the first injectable product for the treatment of pain and fever.

  Journal of pain research 20100101

• Pilot study: rapidly cycling hypobaric pressure improves pain after 5 days in adiposis dolorosa.

  Journal of pain research 20100101

• Investigational pharmacology for low back pain.

  Journal of pain research 20100101

• Topical nonsteroidal anti-inflammatory drugs for the treatment of pain due to soft tissue injury: diclofenac epolamine topical patch.

  Journal of pain research 20100101

• Natural anti-inflammatory agents for pain relief.

  Surgical neurology international 20100101

• Treatment of cachexia in oncology.

  Indian journal of palliative care 20100101

• Formulation and evaluation of extended-release solid dispersion of metformin hydrochloride.

  Journal of young pharmacists : JYP 20100101

• COX-2 Inhibition by Use of Rofecoxib or High Dose Aspirin Enhances ADP-Induced Platelet Aggregation in Fresh Blood.

  The open cardiovascular medicine journal 20100101

• Cytotoxicity of apigenin on leukemia cell lines: implications for prevention and therapy.

  Cell death & disease 20100101

• Preventive but not curative efficacy of celecoxib on bladder carcinogenesis in a rat model.

  Mediators of inflammation 20100101

• Cyclooxygenase-2 inhibition restored endothelium-mediated relaxation in old obese zucker rat mesenteric arteries.

  Frontiers in physiology 20100101

• Vitamin B12 Deficiency due to Chlorofluorocarbon: A Case Report.

  Case reports in medicine 20100101

• Mechanism of dissolution enhancement and bioavailability of poorly water soluble celecoxib by preparing stable amorphous nanoparticles.

  Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 20100101

• Docosahexaenoic acid reduces amyloid-β(1-42) secretion in human AβPP-transfected CHO-cells by mechanisms other than inflammation related to PGE₂.

  Journal of Alzheimer's disease : JAD 20100101

• Revisiting the association between candidal infection and carcinoma, particularly oral squamous cell carcinoma.

  Journal of oral microbiology 20100101

• Ayurveda-modern medicine interface: A critical appraisal of studies of Ayurvedic medicines to treat osteoarthritis and rheumatoid arthritis.

  Journal of Ayurveda and integrative medicine 20100101

• Colon delivery of budesonide using solid dispersion in dextran for the treatment and secondary prevention of ulcerative colitis in rat.

  International journal of preventive medicine 20100101

• New and improved strategies for the treatment of gout.

  International journal of nephrology and renovascular disease 20100101

• The Murine Angiotensin II-Induced Abdominal Aortic Aneurysm Model: Rupture Risk and Inflammatory Progression Patterns.

  Frontiers in pharmacology 20100101

• Risk of Upper Gastrointestinal Bleeding in a Cohort of New Users of Low-Dose ASA for Secondary Prevention of Cardiovascular Outcomes.

  Frontiers in pharmacology 20100101

• Cognitive psychiatry in India.

  Indian journal of psychiatry 20100101

• Microsomal prostaglandin e synthase-1 in rheumatic diseases.

  Frontiers in pharmacology 20100101

• Curcumin-the paradigm of a multi-target natural compound with applications in cancer prevention and treatment.

  Toxins 20100101

• Recent trends in the impurity profile of pharmaceuticals.

  Journal of advanced pharmaceutical technology & research 20100101

• Might salicylate exert benefits against childhood cancer?

  Ecancermedicalscience 20100101

• Lidocaine 5% patch for localized neuropathic pain: progress for the patient, a new approach for the physician.

  Clinical pharmacology : advances and applications 20100101

• The effect of full length and mature NAG-1 protein overexpression on cytotoxicity of celecoxib, tamoxifen and doxorubicin in HT1080.

  Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences 20100101

• A protocol for labrador retrievers?

  Lancet (London, England) 20091219

• Matrix metalloproteinase (MMP)-1 and MMP-3 induce macrophage MMP-9: evidence for the role of TNF-alpha and cyclooxygenase-2.

  Journal of immunology (Baltimore, Md. : 1950) 20091215

• NSAID prescribing precautions.

  American family physician 20091215

• Novel nitro-oxy derivatives of celecoxib for the regulation of colon cancer cell growth.

  Chemico-biological interactions 20091210

• [Rheumatoid arthritis and depression].

  MMW Fortschritte der Medizin 20091210

• Synthesis, biological evaluation, and molecular modeling of oleuropein and its semisynthetic derivatives as cyclooxygenase inhibitors.

  Journal of agricultural and food chemistry 20091209

• Spectroscopic study on the interaction of celecoxib with human carbonic anhydrase II: thermodynamic characterization of the binding process.

  Journal of photochemistry and photobiology. B, Biology 20091202

• Protective effect of cyclooxygenase (COX)-inhibitors against drug-induced catatonia and MPTP-induced striatal lesions in rats.

  Pharmacology, biochemistry, and behavior 20091201

• Celecoxib treatment reduces peritoneal fibrosis and angiogenesis and prevents ultrafiltration failure in experimental peritoneal dialysis.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20091201

• Cyclooxygenase-2 plays a critical role in retinal ganglion cell death after transient ischemia: real-time monitoring of RGC survival using Thy-1-EGFP transgenic mice.

  Neuroscience research 20091201

• Cyclooxygenase-2 inhibitor: a potential therapeutic strategy for ultrafiltration failure in peritoneal dialysis.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20091201

• Complement C5a stimulates food intake via a prostaglandin D(2)- and neuropeptide Y-dependent mechanism in mice.

  Prostaglandins & other lipid mediators 20091201

• PC-407, a celecoxib derivative, inhibited the growth of colorectal tumor in vitro and in vivo.

  Cancer science 20091201

• NSAID switching and short-term gastrointestinal outcome rates after the withdrawal of rofecoxib.

  Pharmacoepidemiology and drug safety 20091201

• Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, Rv3588c.

  Bioorganic & medicinal chemistry letters 20091201

• Discovery of benzo[g]indol-3-carboxylates as potent inhibitors of microsomal prostaglandin E(2) synthase-1.

  Bioorganic & medicinal chemistry 20091201

• Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis.

  Journal of hypertension 20091201

• High celecoxib-loaded nanoparticles prepared by a vibrating nozzle device.

  Journal of microencapsulation 20091201

• Update on the management of pain in arthritis and the use of cyclooxygenase-2 inhibitors.

  Current pain and headache reports 20091201

• Pregabalin, celecoxib, and their combination for treatment of chronic low-back pain.

  Journal of orthopaedics and traumatology : official journal of the Italian Society of Orthopaedics and Traumatology 20091201

• COX-2 inhibitors are contraindicated for treatment of combined injury.

  Radiation research 20091201

• Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs.

  Pharmacotherapy 20091201

• The effect of cyclooxygenase-2 expression on tumor volume response in patients treated with radiotherapy for uterine cervical cancer.

  Journal of Korean medical science 20091201

• A comparison of cost effectiveness using data from randomized trials or actual clinical practice: selective cox-2 inhibitors as an example.

  PLoS medicine 20091201

• Inhibitory Effect of IFN-beta, on the Antitumor Activity of Celecoxib in U87 Glioma Model.

  Journal of Korean Neurosurgical Society 20091201

• Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20091201

• New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I.

  Current drug metabolism 20091201

• Potential of ezetimibe in memory deficits associated with dementia of Alzheimer's type in mice.

  Indian journal of pharmacology 20091201

• [Celecoxib increased cellular ATRA sensitivity of human colon cancer cell lines through COX-2-independent mechanisms].

  Yao xue xue bao = Acta pharmaceutica Sinica 20091201

• Promising therapy for Alzheimer's disease targeting angiotensinconverting enzyme and the cyclooxygense-2 isoform.

  Drug discoveries & therapeutics 20091201

• COX-2 inhibitors in patients with sensitivity to nonselective NSAIDs.

  The New England journal of medicine 20091126

• Protective activity of Theobroma cacao L. phenolic extract on AML12 and MLP29 liver cells by preventing apoptosis and inducing autophagy.

  Journal of agricultural and food chemistry 20091125

• Clinical trial: the impact of cyclooxygenase inhibitors on gastrointestinal recovery after major surgery - a randomized double blind controlled trial of celecoxib or diclofenac vs. placebo.

  Alimentary pharmacology & therapeutics 20091115

• Silibinin prevents TPA-induced MMP-9 expression by down-regulation of COX-2 in human breast cancer cells.

  Journal of ethnopharmacology 20091112

• Celecoxib induces hepatic stellate cell apoptosis through inhibition of Akt activation and suppresses hepatic fibrosis in rats.

  Gut 20091101

• Inhibition of 12-LOX and COX-2 reduces the proliferation of human epidermoid carcinoma cells (A431) by modulating the ERK and PI3K-Akt signalling pathways.

  Experimental dermatology 20091101

• Comparison of microsomal prostaglandin E synthase-1 deletion and COX-2 inhibition in acute cardiac ischemia in mice.

  Prostaglandins & other lipid mediators 20091101

• Celecoxib in the management of acute renal colic: a randomized controlled clinical trial.

  Urology 20091101

• Differential effects of selective cyclooxygenase-2 inhibitors on vascular smooth muscle ion channels may account for differences in cardiovascular risk profiles.

  Molecular pharmacology 20091101

• Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease.

  Pharmacoepidemiology and drug safety 20091101

• Inhibition of prostaglandin E(2) signaling through the EP(1) receptor does not affect prostacyclin production in human endothelial cells.

  Prostaglandins & other lipid mediators 20091101

• An ion channel hypothesis to explain divergent cardiovascular safety of cyclooxygenase-2 inhibitors: the answer to a hotly debated puzzle?

  Molecular pharmacology 20091101

• Nature meets nurture: molecular genetics of gastric cancer.

  Human genetics 20091101

• Prolonged low-dose administration of the cyclooxygenase-2 inhibitor celecoxib enhances the antitumor activity of irinotecan against neuroblastoma xenografts.

  Cancer science 20091101

• Synthesis of carbon-11 labeled celecoxib derivatives as new candidate PET radioligands for imaging of inflammation.

  Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 20091101

• APC10.1 cells as a model for assessing the efficacy of potential chemopreventive agents in the Apc(Min) mouse model in vivo.

  European journal of cancer (Oxford, England : 1990) 20091101

• The use of selective cyclooxygenase-2 inhibitors and the risk of acute myocardial infarction in Saskatchewan, Canada.

  Pharmacoepidemiology and drug safety 20091101

• Double blind randomized phase II study with radiation+5-fluorouracil+/-celecoxib for resectable rectal cancer.

  Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20091101

• Chemoprevention of colonic polyps with balsalazide: an exploratory, double-blind, placebo-controlled study.

  Digestive diseases and sciences 20091101

• Genome wide analysis and comparative docking studies of new diaryl furan derivatives against human cyclooxygenase-2, lipoxygenase, thromboxane synthase and prostacyclin synthase enzymes involved in inflammatory pathway.

  Journal of molecular graphics & modelling 20091101

• Synergistic effects of lovastatin and celecoxib on caveolin-1 and its down-stream signaling molecules: Implications for colon cancer prevention.

  International journal of oncology 20091101

• Effect of celecoxib on emotional stress and pain-related behaviors evoked by experimental tooth movement in the rat.

  The Angle orthodontist 20091101

• Pharmacological inhibition of 5-lipoxygenase accelerates and enhances fracture-healing.

  The Journal of bone and joint surgery. American volume 20091101

• Effects of No.2 Renal Failure Recipe on expressions of cyclooxygenase-2 and -1 mRNAs in rats with chronic renal failure.

  Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine 20091101

• [Inhibitory effects of COX-2 inhibitor on migration of human tongue squamous cell carcinoma Tca8113 cells].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20091101

• [Celecoxib inhibits gastric adenocarcinoma growth via inducing expression of human nonsteroidal anti-inflammatory drug activated gene].

  Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20091101

• Changes in physicians' practice of prescribing cyclooxygenase-2 inhibitor after market withdrawal of rofecoxib: a retrospective study of physician-patient pairs in Taiwan.

  Clinical therapeutics 20091101

• Metabolomics in drug intolerance.

  Current drug metabolism 20091101

• The effect of dietary and topical celecoxib on 4-nitroquinoline-1-oxide-induced lingual epithelium alternations in rat.

  JPMA. The Journal of the Pakistan Medical Association 20091101

• Short-term celecoxib intervention is a safe and effective chemopreventive for gastric carcinogenesis based on a Mongolian gerbil model.

  World journal of gastroenterology 20091021

• Tom MacDonald replies to Marisa de Andrade.

  BMJ (Clinical research ed.) 20091021

• Informative clinical investigation: a demanding taskmaster.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091020

• Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091020

• NFAT signalling is a novel target of oncogenic BRAF in metastatic melanoma.

  British journal of cancer 20091020

• Inhibition of azoxymethane-induced colorectal cancer by CP-31398, a TP53 modulator, alone or in combination with low doses of celecoxib in male F344 rats.

  Cancer research 20091015

• Pyridine analogues of nimesulide: design, synthesis, and in vitro and in vivo pharmacological evaluation as promising cyclooxygenase 1 and 2 inhibitors.

  Journal of medicinal chemistry 20091008

• Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group.

  British journal of cancer 20091006

• Effects of chronic celecoxib on testicular function in normal and lipopolysaccharide-treated rats.

  International journal of andrology 20091001

• Parecoxib has non-significant long-term effects on bone healing in rats when administered for a short period after fracture.

  Archives of orthopaedic and trauma surgery 20091001

• Patient preferences for the chemoprevention of colorectal cancer.

  Digestive diseases and sciences 20091001

• Regulation of peroxisome proliferator-activated receptor-beta/delta by the APC/beta-CATENIN pathway and nonsteroidal antiinflammatory drugs.

  Molecular carcinogenesis 20091001

• Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease.

  Acta neuropathologica 20091001

• Selective and non-selective non-steroidal anti-inflammatory drugs and the risk of acute kidney injury.

  Pharmacoepidemiology and drug safety 20091001

• Cellular membranes function as a storage compartment for celecoxib.

  Journal of molecular medicine (Berlin, Germany) 20091001

• Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via VEGF-C.

  Anatomical record (Hoboken, N.J. : 2007) 20091001

• Celecoxib reduces symptoms in men with difficult chronic pelvic pain syndrome (Category IIIA).

  Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 20091001

• The effects of celecoxib, a COX-2 selective inhibitor, on acute inflammation induced in irradiated rats.

  Inflammopharmacology 20091001

• Differential effects of non-steroidal anti-inflammatory drugs on mitochondrial dysfunction during oxidative stress.

  Archives of biochemistry and biophysics 20091001

• [Inhibiting cyclooxygenase and 5-lipoxygenase activities is an anti-inflammatory mechanism of Huzhang Gout Granule].

  Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine 20091001

• Cyclin-mediated G1 arrest by celecoxib differs in low-versus high-grade bladder cancer.

  Anticancer research 20091001

• Delayed onset nodules from liquid injectable silicone: report of a case, evaluation of associated histopathology and results of treatment with minocycline and celocoxib.

  Journal of drugs in dermatology : JDD 20091001

• A comparison of the effects of ibuprofen and rofecoxib on rabbit fibula osteotomy healing.

  Acta orthopaedica 20091001

• A reciprocal relationship exists between non-steroidal anti-inflammatory drug-activated gene-1 (NAG-1) and cyclooxygenase-2.

  Cancer letters 20090918

• Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials.

  The Lancet. Oncology 20090909

• Enhanced killing of chemo-resistant breast cancer cells via controlled aggravation of ER stress.

  Cancer letters 20090908

• Therapeutic effect of Aralia cordata extracts on cartilage protection in collagenase-induced inflammatory arthritis rabbit model.

  Journal of ethnopharmacology 20090907

• Research Ethics . In clear sight.

  BMJ (Clinical research ed.) 20090902

• The role of celecoxib in Rad51 expression and cell survival affected by gefitinib in human non-small cell lung cancer cells.

  Lung cancer (Amsterdam, Netherlands) 20090901

• Kaposiform hemangioendothelioma in multiple spinal levels without skin changes.

  Clinical orthopaedics and related research 20090901

• Fenbufen based 3-[5-(substituted aryl)-1,3,4-oxadiazol-2-yl]-1-(biphenyl-4-yl)propan-1-ones as safer antiinflammatory and analgesic agents.

  European journal of medicinal chemistry 20090901

• Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20090901

• Recruitment strategies for a lung cancer chemoprevention trial involving ex-smokers.

  Contemporary clinical trials 20090901

• Celecoxib enhanced the sensitivity of cancer cells to anticancer drugs by inhibition of the expression of P-glycoprotein through a COX-2-independent manner.

  Journal of cellular biochemistry 20090901

• The search for new COX-2 inhibitors: a review of 2002 - 2008 patents.

  Expert opinion on therapeutic patents 20090901

• Anti-inflammatory, anti-proliferative and antioxidant profiles of selective cyclooxygenase-2 inhibition as chemoprevention for rat bladder carcinogenesis.

  Cancer biology & therapy 20090901

• Adding gabapentin to a multimodal regimen does not reduce acute pain, opioid consumption or chronic pain after total hip arthroplasty.

  Acta anaesthesiologica Scandinavica 20090901

• Effect of selective inhibitors of inflammation on oral mucositis: preclinical studies.

  Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20090901

• Early response to COX-2 inhibitors as a predictor of overall response in osteoarthritis: pooled results from two identical trials comparing etoricoxib, celecoxib and placebo.

  Rheumatology (Oxford, England) 20090901

• Preparation and evaluation of celecoxib-loaded microcapsules with self-microemulsifying core.

  Journal of microencapsulation 20090901

• Modulation of ionizing radiation-induced G2 arrest by cyclooxygenase-2 and its inhibitor celecoxib.

  International journal of radiation oncology, biology, physics 20090901

• Structure activity relationship of antiproliferative agents using multiple linear regression.

  Chemical biology & drug design 20090901

• Study on mechanism for amorphous drug stabilization using gelucire 50/13.

  Chemical & pharmaceutical bulletin 20090901

• 18F-FLT and 18F-FDG PET to measure response to radiotherapy combined with celecoxib in two colorectal xenograft models.

  International journal of radiation biology 20090901

• Regression of recurrent respiratory papillomatosis with celecoxib and erlotinib combination therapy.

  Chest 20090901

• Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective.

  Journal of medical economics 20090901

• Celecoxib antagonizes perifosine's anticancer activity involving a cyclooxygenase-2-dependent mechanism.

  Molecular cancer therapeutics 20090901

• Cyclooxygenase 2 modulates killing of cytotoxic T lymphocytes by colon cancer cells.

  Journal of clinical biochemistry and nutrition 20090901

• Preliminary trial of rebamipide for prevention of low-dose aspirin-induced gastric injury in healthy subjects: a randomized, double-blind, placebo-controlled, cross-over study.

  Journal of clinical biochemistry and nutrition 20090901

• [Chemoprevention of Barrett's esophagus by celecoxib in rats].

  Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences 20090901

• The impact of neuroimmune dysregulation on neuroprotection and neurotoxicity in psychiatric disorders--relation to drug treatment.

  Dialogues in clinical neuroscience 20090901

• Trial publication after registration in ClinicalTrials.Gov: a cross-sectional analysis.

  PLoS medicine 20090901

• Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance.

  Current drug metabolism 20090901

• [The effect of simultaneously blocking target epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2 on the growth of NPC cell].

  Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery 20090901

• Synthesis, ex vivo and in vitro hydrolysis study of an indoline derivative designed as an anti-inflammatory with reduced gastric ulceration properties.

  Molecules (Basel, Switzerland) 20090826

• Celecoxib-induced cholestatic liver failure requiring orthotopic liver transplantation.

  World journal of gastroenterology 20090821

• Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme.

  British journal of cancer 20090818

• Effects of short-term acetaminophen and celecoxib treatment on orthodontic tooth movement and neuronal activation in rat.

  Brain research bulletin 20090814

• Regulation of the apoptosis-inducing kinase DRAK2 by cyclooxygenase-2 in colorectal cancer.

  British journal of cancer 20090804

• Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study.

  Breast cancer research and treatment 20090801

• Topical chemoprevention of skin cancer in mice, using combined inhibitors of 5-lipoxygenase and cyclo-oxygenase-2.

  The Journal of laryngology and otology 20090801

• Eggshell membrane in the treatment of pain and stiffness from osteoarthritis of the knee: a randomized, multicenter, double-blind, placebo-controlled clinical study.

  Clinical rheumatology 20090801

• Global variation in CYP2C8-CYP2C9 functional haplotypes.

  The pharmacogenomics journal 20090801

• Metronomic chemotherapy-induced bilateral subdural hematoma in a child with meningeal carcinomatosis.

  Pediatric blood & cancer 20090801

• Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature.

  The Journal of clinical psychiatry 20090801

• Subcellular movement and expression of HSP27, alphaB-crystallin, and HSP70 after two bouts of eccentric exercise in humans.

  Journal of applied physiology (Bethesda, Md. : 1985) 20090801

• Inability of celecoxib to prevent fibrosis in bile duct-ligated rat liver.

  Liver international : official journal of the International Association for the Study of the Liver 20090801

• Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhibitors.

  Bioorganic & medicinal chemistry letters 20090801

• The hepatic safety and tolerability of the cyclooxygenase-2 selective NSAID celecoxib: pooled analysis of 41 randomized controlled trials.

  Current medical research and opinion 20090801

• An update on the efficacy of non-steroidal anti-inflammatory drugs in Alzheimer's disease.

  Expert opinion on investigational drugs 20090801

• Design and synthesis of new 1,3-benzthiazinan-4-one derivatives as selective cyclooxygenase (COX-2) inhibitors.

  Bioorganic & medicinal chemistry 20090801

• Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090801

• First experiences with low-dose anti-angiogenic treatment in gliomatosis cerebri with signs of angiogenic activity.

  Anticancer research 20090801

• Cyclooxygenase-2 (COX-2) negatively regulates expression of epidermal growth factor receptor and causes resistance to gefitinib in COX-2-overexpressing cancer cells.

  Molecular cancer research : MCR 20090801

• Regression of follicular lymphoma with Devil's Claw: coincidence or causation?

  Current oncology (Toronto, Ont.) 20090801

• Selective cyclooxygenase-2 inhibition reduces endothelial dysfunction and improves inflammatory status in patients with intermittent claudication.

  Revista espanola de cardiologia 20090801

• Celecoxib potentiates the anticancer effect of cisplatin on vulvar cancer cells independently of cyclooxygenase.

  Annals of the New York Academy of Sciences 20090801

• [Multimodal effect of celecoxib on the perioperative analgesia in orthopaedic surgery].

  Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 20090801

• [Effect of Celecoxib on cycloxygenase-2 expression and inducing apoptosis in Tca8113 cell lines].

  Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology 20090801

• [Effects of celecoxib on the proliferation and apoptosis of human nasopharyngeal carcinoma cell line CNE-2].

  Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery 20090801

• Anti-inflammatory effects of low molecular weight heparin derivative in a rat model of carrageenan-induced pleurisy.

  Journal of cellular and molecular medicine 20090801

• 1-(3,5-Dimethyl-1H-pyrazol-1-yl)-3-phenyl-isoquinoline.

  Acta crystallographica. Section E, Structure reports online 20090801

• Kinetic cell-based morphological screening: prediction of mechanism of compound action and off-target effects.

  Chemistry & biology 20090731

• Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis.

  Drugs 20090730

• Diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of 5-(4-carboxymethylphenyl)-1-(4-methanesulfonylphenyl)-3-trifluoromethyl-1H-pyrazole and its aminosulfonyl analog: Synthesis, biological evaluation and nitric oxide release studies.

  Bioorganic & medicinal chemistry 20090715

• Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides.

  Bioorganic & medicinal chemistry 20090715

• Synthesis, biological evaluation and docking studies of novel benzopyranone congeners for their expected activity as anti-inflammatory, analgesic and antipyretic agents.

  Bioorganic & medicinal chemistry 20090715

• Synthesis and biological evaluation of new 4-carboxyl quinoline derivatives as cyclooxygenase-2 inhibitors.

  Bioorganic & medicinal chemistry 20090715

• Advantages of celecoxib nanosuspension formulation and transformation into tablets.

  International journal of pharmaceutics 20090706

• Anticancer effect of celecoxib via COX-2 dependent and independent mechanisms in human gastric cancers cells.

  Digestive diseases and sciences 20090701

• Mechanism of action of celecoxib on normal and acid-challenged gastric mucosa.

  Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie 20090701

• Antagonism by haloperidol and its metabolites of mechanical hypersensitivity induced by intraplantar capsaicin in mice: role of sigma-1 receptors.

  Psychopharmacology 20090701

• Synergistic inhibition effect of tumor growth by using celecoxib in combination with oxaliplatin.

  Cancer investigation 20090701

• Down-regulation of the HGF/MET autocrine loop induced by celecoxib and mediated by P-gp in MDR-positive human hepatocellular carcinoma cell line.

  Biochemical pharmacology 20090701

• Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides.

  Bioorganic & medicinal chemistry 20090701

• Chronic pretreatment with celecoxib reduces infarct size.

  Journal of cardiovascular pharmacology 20090701

• Prostaglandin E(2) synthase inhibition as a therapeutic target.

  Expert opinion on therapeutic targets 20090701

• Effects of steroidal and nonsteroidal drugs on tooth movement and root resorption in the rat molar.

  The Angle orthodontist 20090701

• Effect of cyclooxygenase-2 on ischemic preconditioning of skin flaps.

  Annals of plastic surgery 20090701

• Lymphoblastic T-cell lymphoma in mice is unaffected by Celecoxib as single agent or in combination with cyclophosphamide.

  Leukemia & lymphoma 20090701

• Cyclooxygenase-2 up-regulates ataxia telangiectasia and Rad3 related through extracellular signal-regulated kinase activation.

  Molecular cancer research : MCR 20090701

• Harvesting candidate genes responsible for serious adverse drug reactions from a chemical-protein interactome.

  PLoS computational biology 20090701

• [Study on the mechanism of preventing alcholic liver disease by selective cyclooxygenase 2 inhibitor].

  Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 20090701

• Cardiovascular safety of celecoxib in acute myocardial infarction patients: a nested case-control study.

  Heart international 20090630

• Protective effects of butanol fraction from Betula platyphyla var. japonica on cartilage alterations in a rabbit collagenase-induced osteoarthritis.

  Journal of ethnopharmacology 20090625

• Dipyridamole inhibits cobalt chloride-induced osteopontin expression in NRK52E cells.

  European journal of pharmacology 20090624

• Pharmacological modulation of movement-evoked pain in a rat model of osteoarthritis.

  European journal of pharmacology 20090624

• Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study.

  Cancer 20090615

• Design and synthesis of 3-alkyl-2-aryl-1,3-thiazinan-4-one derivatives as selective cyclooxygenase (COX-2) inhibitors.

  Bioorganic & medicinal chemistry letters 20090615

• Pattern recognition analysis for the prediction of adverse effects by nonsteroidal anti-inflammatory drugs using 1H NMR-based metabolomics in rats.

  Analytical chemistry 20090615

• Changes in gene expression predicting local control in cervical cancer: results from Radiation Therapy Oncology Group 0128.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090615

• Anti-Helicobacter pylori therapy followed by celecoxib on progression of gastric precancerous lesions.

  World journal of gastroenterology 20090614

• Chronic treatment with celecoxib reverses chronic unpredictable stress-induced depressive-like behavior via reducing cyclooxygenase-2 expression in rat brain.

  European journal of pharmacology 20090610

• T-regulatory cell modulation: the future of cancer immunotherapy?

  British journal of cancer 20090602

• A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer.

  British journal of cancer 20090602

• Treatment in advanced colorectal cancer: what, when and how?

  British journal of cancer 20090602

• Enhancement of the action of the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA; ASA404) by non-steroidal anti-inflammatory drugs.

  Investigational new drugs 20090601

• Efficacy of signal pathway inhibitors alone and in combination with Cisplatin varies between human non-small cell lung cancer lines.

  The Journal of surgical research 20090601

• Experimental rat bladder urothelial cell carcinoma models.

  World journal of urology 20090601

• Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma.

  Gastroenterology 20090601

• Functional coupling expression of COX-2 and cPLA2 induced by ATP in rat vascular smooth muscle cells: role of ERK1/2, p38 MAPK, and NF-kappaB.

  Cardiovascular research 20090601

• COX-2-mediated inflammation in fat is crucial for obesity-linked insulin resistance and fatty liver.

  Obesity (Silver Spring, Md.) 20090601

• The impact of selective and non-selective non-steroid anti-inflammatory drugs on secondary hemostasis in healthy volunteers.

  Thrombosis research 20090601

• Anti-tumoral effect of a celecoxib low dose on a model of human medullary thyroid cancer in nude mice.

  Thyroid : official journal of the American Thyroid Association 20090601

• Hepatic stellate cells promote hepatocyte engraftment in rat liver after prostaglandin-endoperoxide synthase inhibition.

  Gastroenterology 20090601

• Desmoids: a revelation in biology and treatment.

  Annals of surgical oncology 20090601

• Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine?

  Expert opinion on drug metabolism & toxicology 20090601

• Cyclo-oxygenase 2 inhibitors and the risk of anastomotic leakage after fast-track colonic surgery.

  The British journal of surgery 20090601

• Nonsteroidal anti-inflammatory drugs and lower gastrointestinal complications.

  Gastroenterology clinics of North America 20090601

• Gastrocnemius vs. soleus strain: how to differentiate and deal with calf muscle injuries.

  Current reviews in musculoskeletal medicine 20090601

• What is the optimal therapy for patients with H5N1 influenza?

  PLoS medicine 20090601

• Trends in the molecular pathogenesis and clinical therapeutics of common neurodegenerative disorders.

  International journal of molecular sciences 20090601

• Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention.

  Dialogues in clinical neuroscience 20090601

• Mechanism-based treatments for Alzheimer's disease.

  Dialogues in clinical neuroscience 20090601

• The effects of cardiovascular risk factors on cognitive compromise.

  Dialogues in clinical neuroscience 20090601

• [Celecoxib promotes apoptosis of breast cancer cell line MDA-MB-231 through down-regulation of the NF-kappaB pathway].

  Ai zheng = Aizheng = Chinese journal of cancer 20090601

• Celecoxib in the treatment of primary dysmenorrhea: results from two randomized, double-blind, active- and placebo-controlled, crossover studies.

  Clinical therapeutics 20090601

• 3-(3-Chloro-anilino)-1-(3,5-dimethyl-1H-pyrazol-1-yl)propan-1-one.

  Acta crystallographica. Section E, Structure reports online 20090601

• Celecoxib enhances the detoxification of diethylnitrosamine in rat liver cancer.

  World journal of gastroenterology 20090521

• Prophylactic ciprofloxacin treatment prevented high mortality, and modified systemic and intestinal immune function in tumour-bearing rats receiving dose-intensive CPT-11 chemotherapy.

  British journal of cancer 20090519

• Effect of dietary and topical Celecoxib on expression of bcl-2, bax, c-erb-B2 and Ki67 in carcinogen-induced tongue carcinoma in rat.

  Pakistan journal of biological sciences : PJBS 20090515

• Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.

  Journal of medicinal chemistry 20090514

• Cyclooxygenase inhibitors differentially modulate p73 isoforms in neuroblastoma.

  Oncogene 20090514

• The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs.

  Annals of the rheumatic diseases 20090501

• Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies.

  Cancer chemotherapy and pharmacology 20090501

• Salvianolic acid B inhibits growth of head and neck squamous cell carcinoma in vitro and in vivo via cyclooxygenase-2 and apoptotic pathways.

  International journal of cancer 20090501

• Synthesis, pharmacological evaluation and docking studies of new sulindac analogues.

  European journal of medicinal chemistry 20090501

• Characterization and pharmacological evaluation of febrile response on zymosan-induced arthritis in rats.

  American journal of physiology. Regulatory, integrative and comparative physiology 20090501

• Inflammatory mediators released following application of irritants on the rat injured incisors. The effect of treatment with anti-inflammatory drugs.

  Cytokine 20090501

• Phase II study of celecoxib with cisplatin plus etoposide in extensive-stage small cell lung cancer.

  Cancer investigation 20090501

• Postoperative recovery profile after elective abdominal hysterectomy: a prospective, observational study of a multimodal anaesthetic regime.

  European journal of anaesthesiology 20090501

• The additional loss of Bak and not the lack of the protein tyrosine kinase p56/Lck in one JCaM1.6 subclone caused pronounced apoptosis resistance in response to stimuli of the intrinsic pathway.

  Apoptosis : an international journal on programmed cell death 20090501

• The importance of brain PGE2 inhibition versus paw PGE2 inhibition as a mechanism for the separation of analgesic and antipyretic effects of lornoxicam in rats with paw inflammation.

  The Journal of pharmacy and pharmacology 20090501

• Subacute pain and function after fast-track hip and knee arthroplasty.

  Anaesthesia 20090501

• Effects of non-cytotoxic drugs on the growth of multidrug-resistance human gastric carcinoma cell line.

  Journal of digestive diseases 20090501

• Spindle epithelial tumor with thymus-like elements of the thyroid: a multi-institutional case series and review of the literature.

  Journal of pediatric surgery 20090501

• A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer.

  Anticancer research 20090501

• Cyclooxygenase-2 inhibitor celecoxib in a rat model of hindlimb ischemia reperfusion.

  Canadian journal of physiology and pharmacology 20090501

• Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.

  Circulation. Cardiovascular quality and outcomes 20090501

• Importance of cyclooxygenase 2-mediated low-grade inflammation in the development of fructose-induced insulin resistance in rats.

  The Chinese journal of physiology 20090430

• Anti-inflammatory drugs suppress proliferation and induce apoptosis through altering expressions of cell cycle regulators and pro-apoptotic factors in cultured human osteoblasts.

  Toxicology 20090428

• Molecular cloning, characterization, and inhibition studies of the Rv1284 beta-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate.

  Journal of medicinal chemistry 20090423

• Effects of celecoxib on volumes of hematoma and edema in patients with primary intracerebral hemorrhage.

  Journal of the neurological sciences 20090415

• Synthesis and anti-inflammatory activity of the major metabolites of imrecoxib.

  Bioorganic & medicinal chemistry letters 20090415

• Determination of two COX-2 inhibitors in serum and synovial fluid of patients with inflammatory arthritis by ultra performance liquid chromatography-inductively coupled plasma mass spectroscopy and quadrupole time-of-flight mass spectrometry.

  Journal of pharmaceutical and biomedical analysis 20090405

• The chondroprotective effect of selective COX-2 inhibition in osteoarthritis: ex vivo evaluation of human cartilage tissue after in vivo treatment.

  Osteoarthritis and cartilage 20090401

• Celecoxib exacerbates hepatic fibrosis and induces hepatocellular necrosis in rats treated with porcine serum.

  Prostaglandins & other lipid mediators 20090401

• COX-2 expression in highly aggressive thyroid malignancies - indication for a possible therapeutic option?

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20090401

• Evaluation of different methods used to assess disease activity in rheumatoid arthritis: analyses of abatacept clinical trial data.

  Annals of the rheumatic diseases 20090401

• Prediction of the effects of genetic polymorphism on the pharmacokinetics of CYP2C9 substrates from in vitro data.

  Pharmaceutical research 20090401

• Mechanisms operated by endothelin ETA and ETB receptors in the trigeminal ganglion contribute to orofacial thermal hyperalgesia induced by infraorbital nerve constriction in rats.

  Neuropeptides 20090401

• Gemcitabine, irinotecan and celecoxib in patients with biliary cancer.

  Anti-cancer drugs 20090401

• A randomized, placebo-controlled study of the effects of naproxen, aspirin, celecoxib or clopidogrel on gastroduodenal mucosal healing.

  Alimentary pharmacology & therapeutics 20090401

• Role of systemic and local administration of selective inhibitors of cyclo-oxygenase 1 and 2 in an experimental model of periodontal disease in rats.

  Journal of periodontal research 20090401

• Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090401

• Mechanisms underlying the nociceptive responses induced by platelet-activating factor (PAF) in the rat paw.

  Biochemical pharmacology 20090401

• Celecoxib-associated anaphylaxis.

  The Annals of pharmacotherapy 20090401

• Induction of prostaglandin E2 pathway promotes gastric hamartoma development with suppression of bone morphogenetic protein signaling.

  Cancer research 20090401

• The human cytomegalovirus-encoded chemokine receptor US28 promotes angiogenesis and tumor formation via cyclooxygenase-2.

  Cancer research 20090401

• Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis.

  American heart journal 20090401

• New, long-term insights from the Adenoma Prevention with Celecoxib Trial on a promising but troubled class of drugs.

  Cancer prevention research (Philadelphia, Pa.) 20090401

• Levels of prostaglandin E metabolite and leukotriene E(4) are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway.

  Cancer prevention research (Philadelphia, Pa.) 20090401

• Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial.

  Cancer prevention research (Philadelphia, Pa.) 20090401

• Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung.

  Inflammopharmacology 20090401

• Etodolac attenuates mechanical allodynia in a mouse model of neuropathic pain.

  Journal of pharmacological sciences 20090401

• Can treatment with nonsteroidal anti-inflammatory drugs protect from dementia?

  Archives of neurology 20090401

• Economic evaluation of nonsteroidal anti-inflammatory drug strategies in rheumatoid arthritis.

  International journal of technology assessment in health care 20090401

• Prevention of seizure-induced up-regulation of endothelial P-glycoprotein by COX-2 inhibition.

  Neuropharmacology 20090401

• Enhanced anti-inflammatory effects of celecoxib from a transdermally applied nanoemulsion.

  Die Pharmazie 20090401

• [Short-term preoperative treatment of celecoxib, a selective cyclooxygenase-2 inhibitor, on E-cadherin expression in gastric carcinoma tissues].

  Ai zheng = Aizheng = Chinese journal of cancer 20090401

• Cases of pediatric ingestion of celecoxib reported to Texas poison control centers in 2000-2007.

  Human & experimental toxicology 20090401

• Matrine suppresses breast cancer cell proliferation and invasion via VEGF-Akt-NF-kappaB signaling.

  Cytotechnology 20090401

• A role for cyclooxygenase-1 in beta-amyloid-induced neuroinflammation.

  Aging 20090401

• AMP kinase/cyclooxygenase-2 pathway regulates proliferation and apoptosis of cancer cells treated with quercetin.

  Experimental & molecular medicine 20090331

• Synthesis of celecoxib analogues possessing a N-difluoromethyl-1,2-dihydropyrid-2-one 5-lipoxygenase pharmacophore: biological evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity.

  Journal of medicinal chemistry 20090326

• A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090315

• Prominent celecoxib researcher admits fabricating data in 21 articles.

  BMJ (Clinical research ed.) 20090309

• Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients.

  Annals of the rheumatic diseases 20090301

• In vitro and in vivo inhibitory effect evaluation of cyclooxygenase-2 inhibitors, antisense cyclooxygenase-2 cDNA, and their combination on the growth of human bladder cancer cells.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20090301

• Anti-gastric cancer effects of celecoxib, a selective COX-2 inhibitor, through inhibition of Akt signaling.

  Journal of gastroenterology and hepatology 20090301

• Combined action of celecoxib and ionizing radiation in prostate cancer cells is independent of pro-apoptotic Bax.

  Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20090301

• Mechanisms involved in the rat peritoneal leukocyte migration induced by a Kunitz-type inhibitor isolated from Dimorphandra mollis seeds.

  Toxicon : official journal of the International Society on Toxinology 20090301

• Cyclooxygenase-2 mediates dialysate-induced alterations of the peritoneal membrane.

  Journal of the American Society of Nephrology : JASN 20090301

• The analgesic actions of centrally administered celecoxib are mediated by endogenous opioids.

  Pain 20090301

• Inhibition of iNOS and COX-2 in human whole blood ex vivo and monocyte-macrophage J774 cells by a new group of aminothiopyrimidone derivatives.

  Bioorganic & medicinal chemistry 20090301

• Pooled analysis of GI tolerability of 21 randomized controlled trials of celecoxib and nonselective NSAIDs.

  Current medical research and opinion 20090301

• Meeting the challenge of influenza pandemic preparedness in developing countries.

  Emerging infectious diseases 20090301

• Molecular targets for cancer chemoprevention.

  Nature reviews. Drug discovery 20090301

• Synthesis and biological evaluation of novel pyrazole derivatives as anti-inflammatory antimicrobial agents.

  Medicinal chemistry (Shariqah (United Arab Emirates)) 20090301

• Efficacy of celecoxib on controlling irregular uterine bleeding secondary to Jadelle use.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20090301

• [Effects of celecoxib on PGE2 synthesis and COX-2 and VEGF-C mRNA expression in Tca8113 cell lines].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20090301

• Nitrooxymethyl-substituted analogues of celecoxib: synthesis and pharmacological characterization.

  Chemistry & biodiversity 20090301

• Alzheimer's Disease Anti-inflammatory Prevention Trial: design, methods, and baseline results.

  Alzheimer's & dementia : the journal of the Alzheimer's Association 20090301

• Selective cyclooxygenase-2 inhibition protects against myocardial damage in experimental acute ischemia.

  Clinics (Sao Paulo, Brazil) 20090301

• Celecoxib does not delay cutaneous wound healing in haemophilia B mice.

  Haemophilia : the official journal of the World Federation of Hemophilia 20090301

• Comparison of the effectiveness of six and two acupuncture point regimens in osteoarthritis of the knee: a randomised trial.

  Acupuncture in medicine : journal of the British Medical Acupuncture Society 20090301

• [Celecoxib enhances the lethal effects of bleomycin in human tongue squamous carcinoma cell line Tca8113].

  Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology 20090301

• Prostaglandin involvement in hyperthermia induced by sleep deprivation: a pharmacological and autoradiographic study.

  Life sciences 20090227

• Reactions of functionalized sulfonamides: application to lowering the lipophilicity of cytosolic phospholipase A2alpha inhibitors.

  Journal of medicinal chemistry 20090226

• Celecoxib does not appear to affect prosthesis fixation in total knee replacement: A randomized study using radiostereometry in 50 patients.

  Acta orthopaedica 20090226

• Silica-lipid hybrid (SLH) microcapsules: a novel oral delivery system for poorly soluble drugs.

  Journal of controlled release : official journal of the Controlled Release Society 20090220

• Up-regulation of S100P expression by non-steroidal anti-inflammatory drugs and its role in anti-tumorigenic effects.

  The Journal of biological chemistry 20090213

• Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis.

  British journal of cancer 20090210

• Effects of nonselective and selective cyclooxygenase inhibitors on small intestinal motility in the horse.

  Research in veterinary science 20090201

• Raft aggregation with specific receptor recruitment is required for microglial phagocytosis of Abeta42.

  Glia 20090201

• Inflammatory processes of prostate tissue microenvironment drive rat prostate carcinogenesis: preventive effects of celecoxib.

  The Prostate 20090201

• Cyclooxygenase-2 inhibition increases lipopolysaccharide-induced atherosclerosis in mice.

  Cardiovascular research 20090201

• Mechanism of drug release from polymethacrylate-based extrudates and milled strands prepared by hot-melt extrusion.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20090201

• Effects of nicotine and lipopolysaccharide on the expression of matrix metalloproteinases, plasminogen activators, and their inhibitors in human osteoblasts.

  Archives of oral biology 20090201

• Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study.

  Clinical pharmacology and therapeutics 20090201

• Effect of diabetes on transscleral delivery of celecoxib.

  Pharmaceutical research 20090201

• Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial.

  BJU international 20090201

• Efficacy and mechanism of action of KHBJ-9B, a new herbal medicine, and its major compound triterpenoids in human cartilage culture and in a rabbit model of collagenase-induced osteoarthritis.

  International immunopharmacology 20090201

• Carbonic anhydrase inhibitors: inhibition of the beta-class enzyme from the yeast Saccharomyces cerevisiae with sulfonamides and sulfamates.

  Bioorganic & medicinal chemistry 20090201

• Synthesis of 1-(methanesulfonyl- and aminosulfonylphenyl)acetylenes that possess a 2-(N-difluoromethyl-1,2-dihydropyridin-2-one) pharmacophore: evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity.

  Bioorganic & medicinal chemistry letters 20090201

• Antinociceptive effect of a novel tosylpyrazole compound in mice.

  Basic & clinical pharmacology & toxicology 20090201

• Synthesis and cyclooxygenase inhibition of various (aryl-1,2,3-triazole-1-yl)-methanesulfonylphenyl derivatives.

  Bioorganic & medicinal chemistry 20090201

• Prospective randomized study of 2 different techniques for endoscopic iliopsoas tendon release in the treatment of internal snapping hip syndrome.

  Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association 20090201

• Prevention of tumorigenesis in p53-null mammary epithelium by rexinoid bexarotene, tyrosine kinase inhibitor gefitinib, and celecoxib.

  Cancer prevention research (Philadelphia, Pa.) 20090201

• Identification of modulated genes by three classes of chemopreventive agents at preneoplastic stages in a p53-null mouse mammary tumor model.

  Cancer prevention research (Philadelphia, Pa.) 20090201

• Combination therapies that inhibit cyclooxygenase-2 and leukotriene synthesis prevent disease in murine collagen induced arthritis.

  Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20090201

• Inflammatory and oxidative stress markers in experimental crystalopathy: their modification by photostimulation.

  Photomedicine and laser surgery 20090201

• A short-term rat mammary carcinogenesis model for the prevention of hormonally responsive and nonresponsive in situ carcinomas.

  Cancer prevention research (Philadelphia, Pa.) 20090201

• Impressive regression of visceral and cerebral melanoma metastases under combination treatment including dacarbacine, radiotherapy and celecoxib.

  International journal of dermatology 20090201

• Colon cancer: preventive agents and the present status of chemoprevention.

  Expert opinion on pharmacotherapy 20090201

• Estrogen sulfotransferases in breast and endometrial cancers.

  Annals of the New York Academy of Sciences 20090201

• Bartter's syndrome with type 2 diabetes mellitus.

  Journal of the Chinese Medical Association : JCMA 20090201

• Celecoxib administration exhibits tissue specific effect on 3H-benzo(a)pyrene-DNA adduct formation in cigarette smoke inhaling mice.

  Indian journal of experimental biology 20090201

• [Effect of cyclooxygenase-2 on vascular endothelial cell apoptosis induced by cigarette smoke extract].

  Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases 20090201

• Cyclooxygenase-1 null mice show reduced neuroinflammation in response to beta-amyloid.

  Aging 20090201

• Cyclo-oxygenase-1-selective inhibitor SC-560.

  Acta crystallographica. Section E, Structure reports online 20090201

• Kinetic modelling of NSAID action on COX-1: focus on in vitro/in vivo aspects and drug combinations.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20090131

• Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure.

  Archives of internal medicine 20090126

• Treatment for familial amyotrophic lateral sclerosis/motor neuron disease.

  The Cochrane database of systematic reviews 20090121

• Celecoxib plays a multiple role to peripheral blood lymphocytes and allografts in acute rejection in rats after cardiac transplantation.

  Chinese medical journal 20090120

• Differences in long-term disease activity and treatment of adult patients with childhood- and adult-onset systemic lupus erythematosus.

  Arthritis and rheumatism 20090115

• [Effects of perioperative administration of celecoxib on pain management and recovery of function after total knee replacement].

  Zhonghua wai ke za zhi [Chinese journal of surgery] 20090115

• The antecedents of biliary cancer: a primary care case-control study in the United Kingdom.

  British journal of cancer 20090113

• Increased phospholipase A2 activity and inflammatory response but decreased nerve growth factor expression in the olfactory bulbectomized rat model of depression: effects of chronic ethyl-eicosapentaenoate treatment.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20090107

• Suppression of Wnt/beta-catenin signaling inhibits prostate cancer cell proliferation.

  European journal of pharmacology 20090105

• The anti-inflammatory effect of celecoxib does not prevent liver fibrosis in bile duct-ligated rats.

  Liver international : official journal of the International Association for the Study of the Liver 20090101

• Potent cell growth inhibitory effects in hepatitis B virus X protein positive hepatocellular carcinoma cells by the selective cyclooxygenase-2 inhibitor celecoxib.

  Molecular carcinogenesis 20090101

• Celecoxib inhibits serum amyloid a-induced matrix metalloproteinase-10 expression in human endothelial cells.

  Journal of vascular research 20090101

• Inhibition of cyclooxygenase 2 expression by diallyl sulfide on joint inflammation induced by urate crystal and IL-1beta.

  Osteoarthritis and cartilage 20090101

• The selective COX-2 inhibitor celecoxib modulates sphingolipid synthesis.

  Journal of lipid research 20090101

• Combined preoperative use of celecoxib and gabapentin in the management of postoperative pain.

  Aesthetic plastic surgery 20090101

• Prostaglandin E2 acts via multiple receptors to regulate plasminogen-dependent proteolysis in the primate periovulatory follicle.

  Endocrinology 20090101

• Reversibility of aberrant global DNA and estrogen receptor-alpha gene methylation distinguishes colorectal precancer from cancer.

  International journal of clinical and experimental pathology 20090101

• Vascular permeability, neutrophil migration and edematogenic effects induced by the latex of Cryptostegia grandiflora.

  Toxicon : official journal of the International Society on Toxinology 20090101

• Synthesis and antiinflammatory activity of some new 1,3,5-trisubstituted pyrazolines bearing benzene sulfonamide.

  Bioorganic & medicinal chemistry letters 20090101

• A prospective study comparing celecoxib with naproxen in children with juvenile rheumatoid arthritis.

  The Journal of rheumatology 20090101

• Modeling using baseline characteristics in a small multicenter clinical trial for Barrett's esophagus.

  Contemporary clinical trials 20090101

• Discovery of novel analgesic and anti-inflammatory 3-arylamine-imidazo[1,2-a]pyridine symbiotic prototypes.

  Bioorganic & medicinal chemistry 20090101

• Expression pattern and functional relevance of epidermal growth factor receptor and cyclooxygenase-2: novel chemotherapeutic targets in pancreatic endocrine tumors?

  The American journal of gastroenterology 20090101

• Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition.

  Journal of immunology (Baltimore, Md. : 1950) 20090101

• Immune complex/Ig negatively regulate TLR4-triggered inflammatory response in macrophages through Fc gamma RIIb-dependent PGE2 production.

  Journal of immunology (Baltimore, Md. : 1950) 20090101

• Frequency of ill-founded off-label prescribing in Dutch general practice.

  Pharmacoepidemiology and drug safety 20090101

• Death following bilateral complete Achilles tendon rupture in a patient on fluoroquinolone therapy: a case report.

  Journal of medical case reports 20090101

• A review of the benefits and risks of nonsteroidal anti-inflammatory drugs in the management of mild-to-moderate osteoarthritis.

  Osteopathic medicine and primary care 20090101

• Hypothesis: primary antiangiogenic method proposed to treat early stage breast cancer.

  BMC cancer 20090101

• Augmented lung inflammation protects against influenza A pneumonia.

  PloS one 20090101

• Dramatic pain relief and resolution of bone inflammation following pamidronate in 9 pediatric patients with persistent chronic recurrent multifocal osteomyelitis (CRMO).

  Pediatric rheumatology online journal 20090101

• n3 and n6 polyunsaturated fatty acids differentially modulate prostaglandin E secretion but not markers of lipogenesis in adipocytes.

  Nutrition & metabolism 20090101

• Recent advances of novel targeted therapy in non-small cell lung cancer.

  Journal of hematology & oncology 20090101

• A randomized, multicentre, double-blind, parallel-group study to assess the adverse event-related discontinuation rate with celecoxib and diclofenac in elderly patients with osteoarthritis.

  Scandinavian journal of rheumatology 20090101

• Porcine sclera as a model of human sclera for in vitro transport experiments: histology, SEM, and comparative permeability.

  Molecular vision 20090101

• Amyotrophic lateral sclerosis.

  Orphanet journal of rare diseases 20090101

• Effects of celecoxib and nordihydroguaiaretic acid on puromycin aminonucleoside-induced nephrosis in the rat.

  Journal of Korean medical science 20090101

• The effect of selective cyclooxygenase-2 inhibitor on human osteoclast precursors to influence osteoclastogenesis in vitro.

  Modern rheumatology 20090101

• Does celecoxib have a role in the treatment of patients with colorectal cancer?

  Clinical colorectal cancer 20090101

• Developments in the clinical understanding of osteoarthritis.

  Arthritis research & therapy 20090101

• Metabolic profiling of the response to an oral glucose tolerance test detects subtle metabolic changes.

  PloS one 20090101

• Systematic review on quality control for drug management programs: is quality reported in the literature?

  BMC health services research 20090101

• Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers.

  Oncology 20090101

• Relationship between the expression of cyclooxygenase-2 and survivin in primary pterygium.

  Molecular vision 20090101

• Information about ADRs explored by pharmacovigilance approaches: a qualitative review of studies on antibiotics, SSRIs and NSAIDs.

  BMC clinical pharmacology 20090101

• A MT1-MMP/NF-kappaB signaling axis as a checkpoint controller of COX-2 expression in CD133+ U87 glioblastoma cells.

  Journal of neuroinflammation 20090101

• Asthmatic reaction induced by celecoxib in a patient with aspirin-induced asthma.

  Journal of investigational allergology & clinical immunology 20090101

• The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells.

  Journal of immunotherapy (Hagerstown, Md. : 1997) 20090101

• Celecoxib and melatonin in prevention of female rat mammary carcinogenesis.

  Neoplasma 20090101

• Identification of novel cyclooxygenase-2-dependent genes in Helicobacter pylori infection in vivo.

  Molecular cancer 20090101

• Anti-inflammatory and antiarthritic effects of piperine in human interleukin 1beta-stimulated fibroblast-like synoviocytes and in rat arthritis models.

  Arthritis research & therapy 20090101

• Effects of celecoxib on the expression of osteoprotegerin, energy metabolism and cell viability in cultured human osteoblastic cells.

  Clinical and experimental rheumatology 20090101

• Passage and concentration-dependent effects of Indomethacin on tendon derived cells.

  Journal of orthopaedic surgery and research 20090101

• Competition between COX-2 inhibitors and some other drugs for binding sites on human serum albumin.

  Drug metabolism and drug interactions 20090101

• Effects of naltrexone on pain sensitivity and mood in fibromyalgia: no evidence for endogenous opioid pathophysiology.

  PloS one 20090101

• Antibiotic and anti-inflammatory use and the risk of prostate cancer.

  BMC research notes 20090101

• Prophylaxis of heterotopic ossification - an updated review.

  Journal of orthopaedic surgery and research 20090101

• Iatrogenic effects of COX-2 inhibitors in the US population: findings from the Medical Expenditure Panel Survey.

  Drug safety 20090101

• Interleukin-1beta and fibroblast growth factor receptor 1 cooperate to induce cyclooxygenase-2 during early mammary tumourigenesis.

  Breast cancer research : BCR 20090101

• t10c12 conjugated linoleic acid suppresses HER2 protein and enhances apoptosis in SKBr3 breast cancer cells: possible role of COX2.

  PloS one 20090101

• Apigenin, a non-mutagenic dietary flavonoid, suppresses lupus by inhibiting autoantigen presentation for expansion of autoreactive Th1 and Th17 cells.

  Arthritis research & therapy 20090101

• Data mining in pharmacovigilance--detecting the unexpected: the role of index of suspicion of the reporter.

  Drug safety 20090101

• [The effects of Celebrex on mammary tumorigenesis and aging in HER2/neu transgenic mice].

  Voprosy onkologii 20090101

• Regular use of traditional analgesics predicts major coronary events: A cohort study.

  Therapeutics and clinical risk management 20090101

• Treatment and chemoprevention of NSAID-associated gastrointestinal complications.

  Therapeutics and clinical risk management 20090101

• Progress in spondylarthritis. Mechanisms of new bone formation in spondyloarthritis.

  Arthritis research & therapy 20090101

• IL-1beta stimulates the expression of prostaglandin receptor EP4 in human chondrocytes by increasing production of prostaglandin E2.

  Connective tissue research 20090101

• Label-free global serum proteomic profiling reveals novel celecoxib-modulated proteins in familial adenomatous polyposis patients.

  Cancer genomics & proteomics 20090101

• A gene expression profiling approach assessing celecoxib in a randomized controlled trial in prostate cancer.

  Cancer genomics & proteomics 20090101

• A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases.

  BMC cancer 20090101

• Pharmacological Treatment of Alzheimer's Disease: Is it Progressing Adequately?

  The open neurology journal 20090101

• The effect of newer anti-rheumatic drugs on osteogenic cell proliferation: an in-vitro study.

  Journal of orthopaedic surgery and research 20090101

• Multifocal fixed drug eruption due to celecoxib.

  Dermatitis : contact, atopic, occupational, drug 20090101

• Bilateral infraorbital nerve blocks decrease postoperative pain but do not reduce time to discharge following outpatient nasal surgery.

  Canadian journal of anaesthesia = Journal canadien d'anesthesie 20090101

• Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors.

  Vascular health and risk management 20090101

• Twelve years' experience with direct-to-consumer advertising of prescription drugs in Canada: a cautionary tale.

  PloS one 20090101

• Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial.

  Depression and anxiety 20090101

• Chemoprevention by celecoxib in reflux-induced gastric adenocarcinoma in Wistar rats that underwent gastrojejunostomy.

  Acta cirurgica brasileira 20090101

• Effects of rich-in-fat diets and highly selective COX-2 inhibitors on 7,12-dimethylbenz-(A)-anthracene-induced tumor growth.

  International journal of immunopathology and pharmacology 20090101

• Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development.

  Current medicinal chemistry 20090101

• Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial.

  Trials 20090101

• Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases.

  Arthritis research & therapy 20090101

• Ultra low-dose naloxone and tramadol/acetaminophen in elderly patients undergoing joint replacement surgery: a pilot study.

  Pain research & management 20090101

• Preclinical safety pharmacological studies on the amorphous formulation of celecoxib.

  Arzneimittel-Forschung 20090101

• Discrepancy among observational studies: example of naproxen-associated adverse events.

  The open rheumatology journal 20090101

• Gabapentin decreases morphine consumption and improves functional recovery following total knee arthroplasty.

  Pain research & management 20090101

• Treatment of pediatric pulmonary hypertension.

  Vascular health and risk management 20090101

• Eggshell membrane: a possible new natural therapeutic for joint and connective tissue disorders. Results from two open-label human clinical studies.

  Clinical interventions in aging 20090101

• Barrett's esophagus: where do we stand?

  Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association 20090101

• Essentials for starting a pediatric clinical study (4): Clinical pediatric safety planning based on preclinical toxicity studies and pediatric pharmacovigilance guidance.

  The Journal of toxicological sciences 20090101

• Whole genome expression analysis within the angiotensin II-apolipoprotein E deficient mouse model of abdominal aortic aneurysm.

  BMC genomics 20090101

• Single dose oral etodolac for acute postoperative pain in adults.

  The Cochrane database of systematic reviews 20090101

• Molecular fingerprinting of radiation resistant tumors: can we apprehend and rehabilitate the suspects?

  BMC cancer 20090101

• Molecular therapies for systemic lupus erythematosus: clinical trials and future prospects.

  Arthritis research & therapy 20090101

• Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations.

  Journal of translational medicine 20090101

• Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis.

  BMJ (Clinical research ed.) 20090101

• Examination of effects of GSK3beta phosphorylation, beta-catenin phosphorylation, and beta-catenin degradation on kinetics of Wnt signaling pathway using computational method.

  Theoretical biology & medical modelling 20090101

• An exploration of the ability of tepoxalin to ameliorate the degradation of articular cartilage in a canine in vitro model.

  BMC veterinary research 20090101

• Gastroesophageal reflux leads to esophageal cancer in a surgical model with mice.

  BMC gastroenterology 20090101

• TNF-alpha mediated apoptosis plays an important role in the development of early diabetic retinopathy and long-term histopathological alterations.

  Molecular vision 20090101

• Breast-cancer-associated metastasis is significantly increased in a model of autoimmune arthritis.

  Breast cancer research : BCR 20090101

• Are all n-3 polyunsaturated fatty acids created equal?

  Lipids in health and disease 20090101

• Antisense gapmers selectively suppress individual oncogenic p73 splice isoforms and inhibit tumor growth in vivo.

  Molecular cancer 20090101

• A novel approach to management of nocturia in patients with benign prostatic hyperplasia.

  Indian journal of urology : IJU : journal of the Urological Society of India 20090101

• Multiparameter phospho-flow analysis of lymphocytes in early rheumatoid arthritis: implications for diagnosis and monitoring drug therapy.

  PloS one 20090101

• Biomolecular markers in cancer of the tongue.

  Journal of oncology 20090101

• Enhanced sensitivity of celecoxib in human glioblastoma cells: Induction of DNA damage leading to p53-dependent G1 cell cycle arrest and autophagy.

  Molecular cancer 20090101

• Rho iso-alpha acids from hops inhibit the GSK-3/NF-kappaB pathway and reduce inflammatory markers associated with bone and cartilage degradation.

  Journal of inflammation (London, England) 20090101

• Health-state utilities in a prisoner population: a cross-sectional survey.

  Health and quality of life outcomes 20090101

• Effects of genetic deficiency of cyclooxygenase-1 or cyclooxygenase-2 on functional and histological outcomes following traumatic brain injury in mice.

  BMC neuroscience 20090101

• Effect of Genistein on vasculogenic mimicry formation by human uveal melanoma cells.

  Journal of experimental & clinical cancer research : CR 20090101

• Potential prescription patterns and errors in elderly adult patients attending public primary health care centers in Mexico City.

  Clinical interventions in aging 20090101

• Suppressive effect of secretory phospholipase A2 inhibitory peptide on interleukin-1beta-induced matrix metalloproteinase production in rheumatoid synovial fibroblasts, and its antiarthritic activity in hTNFtg mice.

  Arthritis research & therapy 20090101

• Efficacy of antibiotic therapy for SAPHO syndrome is lost after its discontinuation: an interventional study.

  Arthritis research & therapy 20090101

• Suppression of growth, migration and invasion of highly-metastatic human breast cancer cells by berbamine and its molecular mechanisms of action.

  Molecular cancer 20090101

• Drugs associated with more suicidal ideations are also associated with more suicide attempts.

  PloS one 20090101

• Chemopreventive effect of nonsteroidal anti-inflammatory drugs on 9,10-dimethylbenz[a]anthracene-induced lung carcinogenesis in mice.

  Oncology research 20090101

• Tumor-shed PGE(2) impairs IL2Rgammac-signaling to inhibit CD4 T cell survival: regulation by theaflavins.

  PloS one 20090101

• Bradykinin receptor antagonists and cyclooxygenase inhibitors in vincristine- and streptozotocin-induced hyperalgesia.

  Pharmacological reports : PR 20090101

• Role of lipoxygenases and the lipoxin A(4)/annexin 1 receptor in ischemia-reperfusion-induced gastric mucosal damage in rats.

  Pharmacology 20090101

• Familial adenomatous polyposis.

  Orphanet journal of rare diseases 20090101

• Evaluation of Mangosteen juice blend on biomarkers of inflammation in obese subjects: a pilot, dose finding study.

  Nutrition journal 20090101

• Role of lipoxygenases and lipoxin A(4)/annexin-1 receptor in gastric protection induced by 20% ethanol or sodium salicylate in rats.

  Pharmacology 20090101

• Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias.

  Clinical interventions in aging 20090101

• Guaifenesin enhances the analgesic potency of ibuprofen, nimesulide and celecoxib in mice.

  Neuro endocrinology letters 20090101

• Microstructure and mineral composition of dystrophic calcification associated with the idiopathic inflammatory myopathies.

  Arthritis research & therapy 20090101

• Study of the expression of CD30 in pterygia compared to healthy conjunctivas.

  Molecular vision 20090101

• Insulin-like growth factor binding protein-3 has dual effects on gastrointestinal stromal tumor cell viability and sensitivity to the anti-tumor effects of imatinib mesylate in vitro.

  Molecular cancer 20090101

• Efficacy of epicutaneous Diractin (ketoprofen in Transfersome gel) for the treatment of pain related to eccentric muscle contractions.

  Drug design, development and therapy 20090101

• Cyclooxygenase-2 mediated regulation of E-cadherin occurs in conventional but not early-onset gastric cancer cell lines.

  Cellular oncology : the official journal of the International Society for Cellular Oncology 20090101

• Celecoxib in arthritis: relative risk management profile and implications for patients.

  Therapeutics and clinical risk management 20090101

• Prediction of pharmacological and xenobiotic responses to drugs based on time course gene expression profiles.

  PloS one 20090101

• Efficacy of plasma vascular endothelial growth factor in monitoring first-line chemotherapy in patients with advanced non-small cell lung cancer.

  BMC cancer 20090101

• Drug-induced hematologic syndromes.

  Advances in hematology 20090101

• Current and emerging treatments for amyotrophic lateral sclerosis.

  Neuropsychiatric disease and treatment 20090101

• Eradication of intracellular Francisella tularensis in THP-1 human macrophages with a novel autophagy inducing agent.

  Journal of biomedical science 20090101

• Phytalgic, a food supplement, vs placebo in patients with osteoarthritis of the knee or hip: a randomised double-blind placebo-controlled clinical trial.

  Arthritis research & therapy 20090101

• Association of KCNB1 to rheumatoid arthritis via interaction with HLA-DRB1.

  BMC proceedings 20090101

• [Effect of sutent and celecoxib on the properties of endothelial cells in vitro].

  Voprosy onkologii 20090101

• MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer.

  Journal of oncology 20090101

• Safety, tolerability and biological effects of long-term metronomic administration of non-cytotoxic anti-angiogenic agents.

  Oncology 20090101

• Myeloperoxidase content is a marker of systemic inflammation in a chronic condition: the example given by the periodontal disease in rats.

  Mediators of inflammation 20090101

• The effectiveness of a weak opioid medication versus a cyclo-oxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug in treating flare-up of chronic low-back pain: results from two randomized, double-blind, 6-week studies.

  The Journal of international medical research 20090101

• Efficacy and safety of celecoxib in the treatment of acute pain due to ankle sprain in a Latin American and Middle Eastern population.

  The Journal of international medical research 20090101

• Development and evaluation of transdermal patches of celecoxib.

  PDA journal of pharmaceutical science and technology 20090101

• IL-1beta suppresses the formation of osteoclasts by increasing OPG production via an autocrine mechanism involving celecoxib-related prostaglandins in chondrocytes.

  Mediators of inflammation 20090101

• Na(+)-stimulated Na+/H+ exchange and an unfavorable Ca2+ homeostasis initiate the cycloxygenase-2 inhibitors-induced apoptotic signals in colonic epithelial cells during the early stage of colon carcinogenesis.

  Oncology research 20090101

• Joint assessment of intended and unintended effects of medications: an example using vascular endothelial growth factor inhibitors for neovascular age-related macular degeneration.

  Journal of ophthalmology 20090101

• Role of neo-adjuvant hormonal therapy in the treatment of breast cancer: a review of clinical trials.

  International journal of general medicine 20090101

• Stabilization of quinapril by incorporating hydrogen bonding interactions.

  Indian journal of pharmaceutical sciences 20090101

• Neurobiology of inflammation-associated anorexia.

  Frontiers in neuroscience 20090101

• Targeted therapies in the management of colorectal carcinoma: role of bevacizumab.

  OncoTargets and therapy 20090101

• Current status of treatment of metastatic colorectal cancer with special reference to cetuximab and elderly patients.

  OncoTargets and therapy 20090101

• Targeted therapy in the treatment of malignant gliomas.

  OncoTargets and therapy 20090101

• Management of Barrett's oesophagus.

  F1000 medicine reports 20090101

• Recent advances in peptic ulcer bleeding.

  F1000 medicine reports 20090101

• Effects of celecoxib and ly117018 combination on human breast cancer cells in vitro.

  Breast cancer : basic and clinical research 20090101

• Enhanced dissolution rate of felodipine using spherical agglomeration with Inutec SP1 by quasi emulsion solvent diffusion method.

  Research in pharmaceutical sciences 20090101

• Developments in treating metastatic colorectal cancer: Recent international reports from ASCO 2007 and 2008.

  Clinical and experimental gastroenterology 20090101

• Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors.

  Drug, healthcare and patient safety 20090101

• Phase II study of 'high-dose' celecoxib and metronomic 'low-dose' cyclophosphamide and methotrexate in patients with relapsed and refractory lymphoma.

  Ecancermedicalscience 20090101

• Role of traditional and new biomarkers in breast carcinogenesis.

  Ecancermedicalscience 20090101

• Stability of celecoxib oral suspension.

  The Canadian journal of hospital pharmacy 20090101

• Celecoxib-induced degradation of T-cell factors-1 and -4 in human colon cancer cells.

  Biochemical and biophysical research communications 20081226

• Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase.

  Journal of medicinal chemistry 20081225

• Enhanced surface attachment of protein-type targeting ligands to poly(lactide-co-glycolide) nanoparticles using variable expression of polymeric acid functionality.

  Journal of biomedical materials research. Part A 20081215

• OSU03012 activates Erk1/2 and Cdks leading to the accumulation of cells in the S-phase and apoptosis.

  International journal of cancer 20081215

• Sensitivity to the non-COX inhibiting celecoxib derivative, OSU03012, is p21(WAF1/CIP1) dependent.

  International journal of cancer 20081215

• 2,3,5-Substituted tetrahydrofurans: COX-2 inhibitory activities of 5-hydroxymethyl-/carboxyl-2,3-diaryl-tetrahydro-furan-3-ols.

  European journal of medicinal chemistry 20081201

• Pancreatic cancer: from molecular signature to target therapy.

  Critical reviews in oncology/hematology 20081201

• Long-term NSAID treatment directly decreases COX-2 and mPGES-1 production in the articular cartilage of patients with osteoarthritis.

  Osteoarthritis and cartilage 20081201

• NFAT regulates induction of COX-2 and apoptosis of keratinocytes in response to ultraviolet radiation exposure.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20081201

• Effects of a selective cyclooxygenase-2 inhibitor on endometrial epithelial cells from patients with endometriosis.

  Human reproduction (Oxford, England) 20081201

• The risk of acute myocardial infarction with etodolac is not increased compared to naproxen: a historical cohort analysis of a generic COX-2 selective inhibitor.

  Journal of cardiovascular pharmacology and therapeutics 20081201

• Induction of multidrug resistance proteins in lymphocytes from patients with arthritic disorders.

  Clinical and experimental medicine 20081201

• Inflammatory mediators involved in the nociceptive and oedematogenic responses induced by Tityus serrulatus scorpion venom injected into rat paws.

  Toxicon : official journal of the International Society on Toxinology 20081201

• Selective COX-2 inhibitors modulate cellular senescence in human dermal fibroblasts in a catalytic activity-independent manner.

  Mechanisms of ageing and development 20081201

• Synthesis of celecoxib analogs that possess a N-hydroxypyrid-2(1H)one 5-lipoxygenase pharmacophore: biological evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity.

  Bioorganic & medicinal chemistry letters 20081201

• Small-molecule inhibitors of PDK1.

  ChemMedChem 20081201

• Celecoxib nanoemulsion: skin permeation mechanism and bioavailability assessment.

  Journal of drug targeting 20081201

• Postdischarge complications and rehabilitation after ambulatory surgery.

  Current opinion in anaesthesiology 20081201

• Prioritizing future research on off-label prescribing: results of a quantitative evaluation.

  Pharmacotherapy 20081201

• Nonselective and cyclooxygenase-2-selective NSAIDs and acute kidney injury.

  The American journal of medicine 20081201

• Cognitive and cerebral metabolic effects of celecoxib versus placebo in people with age-related memory loss: randomized controlled study.

  The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 20081201

• Nifedipine enhances the relaxant effects of cyclo-oxygenase inhibitors on the bovine ciliary muscle.

  Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20081201

• Glutathione Peroxidase 2 Inhibits Cyclooxygenase-2-Mediated Migration and Invasion of HT-29 Adenocarcinoma Cells but Supports Their Growth as Tumors in Nude Mice.

  Cancer research 20081201

• Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20081201

• A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors.

  Molecular cancer therapeutics 20081201

• Cyclooxygenase inhibitors: instrumental drugs to understand cardiovascular homeostasis and arterial thrombosis.

  Cardiovascular & hematological disorders drug targets 20081201

• Low-level laser therapy improves bone repair in rats treated with anti-inflammatory drugs.

  Journal of oral rehabilitation 20081201

• Combination of an EGFR blocker and a COX-2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma.

  Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 20081201

• [Effect of a selective COX-2 inhibitor on cell proliferation and apoptosis in human gastric cancer cell line BGC-823].

  Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 20081201

• [COX-2 or nNOS mediates cardioprotection during the final stage of the late phase of ischemic preconditioning].

  Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi 20081201

• Comparison of the effectiveness and tolerability of lidocaine patch 5% versus celecoxib for osteoarthritis-related knee pain: post hoc analysis of a 12 week, prospective, randomized, active-controlled, open-label, parallel-group trial in adults.

  Clinical therapeutics 20081201

• Effect of celecoxib on anticonvulsant activity of carbamazepine against maximal electroshock-induced convulsions in mice.

  Methods and findings in experimental and clinical pharmacology 20081201

• Systems biology: a therapeutic target for tumor therapy.

  Cancer microenvironment : official journal of the International Cancer Microenvironment Society 20081201

• Current migraine management - patient acceptability and future approaches.

  Neuropsychiatric disease and treatment 20081201

• Renin inhibition with aliskiren in hypertension: focus on aliskiren/hydrochlorothiazide combination therapy.

  Vascular health and risk management 20081201

• Topical nepafenac in the treatment of diabetic macular edema.

  Clinical ophthalmology (Auckland, N.Z.) 20081201

• The target of arachidonic acid pathway is a new anticancer strategy for human prostate cancer.

  Biologics : targets & therapy 20081201

• First-line therapeutic strategies in metastatic colorectal cancer.

  Oncology (Williston Park, N.Y.) 20081130

• Co-localization of glucocorticoid metabolizing and prostaglandin synthesizing enzymes in rat kidney and liver.

  Life sciences 20081121

• Differential involvement of cyclooxygenase isoforms in neutrophil migration in vivo and in vitro.

  European journal of pharmacology 20081119

• Changing perceptions and practices regarding aspirin, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs among US primary care providers.

  Alimentary pharmacology & therapeutics 20081115

• Diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of 5-(4-hydroxymethylphenyl)-1-(4-aminosulfonylphenyl)-3-trifluoromethyl-1H-pyrazole and its methanesulfonyl analog: synthesis, biological evaluation and nitric oxide release studies.

  Bioorganic & medicinal chemistry 20081115

• OSU-03012, a novel celecoxib derivative, induces reactive oxygen species-related autophagy in hepatocellular carcinoma.

  Cancer research 20081115

• Responder analysis and correlation of outcome measures: pooled results from two identical studies comparing etoricoxib, celecoxib, and placebo in osteoarthritis.

  Osteoarthritis and cartilage 20081101

• Intraperitoneal inflammation decreases endometriosis in a mouse model.

  Human reproduction (Oxford, England) 20081101

• COX-1, and not COX-2 activity, regulates airway function: relevance to aspirin-sensitive asthma.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20081101

• Non-steroidal anti-inflammatory drugs and cardiac failure: meta-analyses of observational studies and randomised controlled trials.

  European journal of heart failure 20081101

• Altered gene expression profiles define pathways in colorectal cancer cell lines affected by celecoxib.

  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20081101

• Phase II study of docetaxel and celecoxib, a cyclooxygenase-2 inhibitor, in elderly or poor performance status (PS2) patients with advanced non-small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20081101

• Cyclooxygenase-2 inhibitor inhibits hippocampal synaptic reorganization in pilocarpine-induced status epilepticus rats.

  Journal of Zhejiang University. Science. B 20081101

• Selective COX2 inhibition improves whole body and muscular insulin resistance in fructose-fed rats.

  European journal of clinical investigation 20081101

• Importance of Bak for celecoxib-induced apoptosis.

  Biochemical pharmacology 20081030

• Celecoxib induces p53-PUMA pathway for apoptosis in human colorectal cancer cells.

  Chemico-biological interactions 20081022

• Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.

  Journal of medicinal chemistry 20081009

• Insights into inflammation and influenza.

  The New England journal of medicine 20081009

• Single dose oral celecoxib for acute postoperative pain in adults.

  The Cochrane database of systematic reviews 20081008

• Cytokine-induced neutrophil chemoattractant (CINC)-1 induces fever by a prostaglandin-dependent mechanism in rats.

  Brain research 20081003

• Celecoxib inhibits growth of tumors in a syngeneic rat liver metastases model for colorectal cancer.

  Cancer chemotherapy and pharmacology 20081001

• Celecoxib inhibits 5-lipoxygenase.

  Biochemical pharmacology 20081001

• Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled study.

  Urology 20081001

• Hospitalization for peptic ulcer and bleeding in users of selective COX-2 inhibitors and nonselective NSAIDs with special reference to celecoxib.

  Pharmacoepidemiology and drug safety 20081001

• STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer--a multi-arm multi-stage randomised controlled trial.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20081001

• Dopaminergic but not glutamatergic neurotransmission is increased in the striatum after selective cyclooxygenase-2 inhibition in normal and hemiparkinsonian rats.

  Basic & clinical pharmacology & toxicology 20081001

• In-vivo effects and mechanisms of celecoxib-reduced growth of cyclooxygenase-2 (COX-2)-expressing versus COX-2-deleted human HCC xenografts in nude mice.

  Anti-cancer drugs 20081001

• Chemoprevention and Barrett's esophagus: decisions, decisions.

  The American journal of gastroenterology 20081001

• Patient preferences for the chemoprevention of esophageal adenocarcinoma in Barrett's esophagus.

  The American journal of gastroenterology 20081001

• Synthesis of new 4-[2-(4-methyl(amino)sulfonylphenyl)-5-trifluoromethyl-2H-pyrazol-3-yl]-1,2,3,6-tetrahydropyridines: a search for novel nitric oxide donor anti-inflammatory agents.

  Bioorganic & medicinal chemistry 20081001

• Prostaglandin E2 exerts catabolic effects in osteoarthritis cartilage: evidence for signaling via the EP4 receptor.

  Journal of immunology (Baltimore, Md. : 1950) 20081001

• Effect of celecoxib and the novel anti-cancer agent, dimethylamino-parthenolide, in a developmental model of pancreatic cancer.

  Pancreas 20081001

• The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial.

  Arthritis and rheumatism 20081001

• The effects of selective COX-2 inhibitor/celecoxib and omega-3 fatty acid on matrix metalloproteinases, TIMP-1, and laminin-5gamma2-chain immunolocalization in experimental periodontitis.

  Journal of periodontology 20081001

• A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions.

  Cancer prevention research (Philadelphia, Pa.) 20081001

• The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction.

  Vascular health and risk management 20081001

• Intrathecal corticosteroids might slow Alzheimer's disease progression.

  Neuropsychiatric disease and treatment 20081001

• Risk management profile of etoricoxib: an example of personalized medicine.

  Therapeutics and clinical risk management 20081001

• [Postoperative analgesia after laparoscopic cholecystectomy: comparison of the preoperative administration of celecoxib with paracetamol?].

  La Tunisie medicale 20081001

• Neuropharmacology.

  Indian journal of pharmacology 20081001

• Synergistic anti-hyperalgesia of electroacupuncture and low dose of celecoxib in monoarthritic rats: involvement of the cyclooxygenase activity in the spinal cord.

  Brain research bulletin 20080930

• Electrochemical detection of celecoxib at a polyaniline grafted multiwall carbon nanotubes modified electrode.

  Analytica chimica acta 20080919

• Review: celecoxib increases risk for cardiovascular events; risks are greatest with higher doses.

  ACP journal club 20080916

• Ibuprofen administration attenuates serum TNF-alpha levels, hepatic glutathione depletion, hepatic apoptosis and mouse mortality after Fas stimulation.

  Toxicology and applied pharmacology 20080915

• Characterization of eltenac and novel COX-2 selective thiopheneacetic acid analogues in vitro and in vivo.

  Biochemical pharmacology 20080915

• TRAIL-mediated apoptosis in malignant glioma cells is augmented by celecoxib through proteasomal degradation of survivin.

  Neuroscience letters 20080912

• Speeding up the evaluation of new agents in cancer.

  Journal of the National Cancer Institute 20080903

• Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells.

  British journal of cancer 20080902

• Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation.

  Cancer chemotherapy and pharmacology 20080901

• Celecoxib has potent antitumour effects as a single agent and in combination with BCG immunotherapy in a model of urothelial cell carcinoma.

  European urology 20080901

• Editorial comment on: celecoxib has potent antitumour effects as a single agent and in combination with BCG immunotherapy in a model of urothelial cell carcinoma.

  European urology 20080901

• Effects of short- and long-term celecoxib on orthodontic tooth movement.

  The Angle orthodontist 20080901

• The use of medication and nutritional supplements during FIFA World Cups 2002 and 2006.

  British journal of sports medicine 20080901

• Celecoxib but not the combination of celecoxib+atorvastatin prevents the development of monocrotaline-induced pulmonary hypertension in the rat.

  Naunyn-Schmiedeberg's archives of pharmacology 20080901

• Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention.

  International journal of cancer 20080901

• Cyclooxygenase 2-selective and nonselective nonsteroidal anti-inflammatory drugs induce oxidative stress by up-regulating vascular NADPH oxidases.

  The Journal of pharmacology and experimental therapeutics 20080901

• Cyclooxygenase inhibitors down regulate P-glycoprotein in human colorectal Caco-2 cell line.

  Pharmaceutical research 20080901

• Cancer is a preventable disease that requires major lifestyle changes.

  Pharmaceutical research 20080901

• Celecoxib potently inhibits TNFalpha-induced nuclear translocation and activation of NF-kappaB.

  Biochemical pharmacology 20080901

• CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS.

  Nature clinical practice. Oncology 20080901

• Novel chemotherapy approaches in chemoradiation protocols.

  Gynecologic oncology 20080901

• Adaptation of Bayesian data mining algorithms to longitudinal claims data: coxib safety as an example.

  Medical care 20080901

• Synthesis, in vitro, and in vivo biological evaluation and molecular docking simulations of chiral alcohol and ether derivatives of the 1,5-diarylpyrrole scaffold as novel anti-inflammatory and analgesic agents.

  Bioorganic & medicinal chemistry 20080901

• Celecoxib for lupus.

  Arthritis and rheumatism 20080901

• Anti-inflammatory drugs fall short in Alzheimer's disease.

  Nature medicine 20080901

• A ligand-based approach to mining the chemogenomic space of drugs.

  Combinatorial chemistry & high throughput screening 20080901

• [Controlled clinical trials on the effects of Chinese traditional medicine for the treatment of osteoarthritis of knee joint at early stage and its MRI changes].

  Zhongguo gu shang = China journal of orthopaedics and traumatology 20080901

• Celecoxib, NSAIDs and the skeleton.

  Drugs of today (Barcelona, Spain : 1998) 20080901

• Synthesis, biological evaluation, and enzyme docking simulations of 1,5-diarylpyrrole-3-alkoxyethyl ethers as selective cyclooxygenase-2 inhibitors endowed with anti-inflammatory and antinociceptive activity.

  Journal of medicinal chemistry 20080814

• Possible glutamatergic and lipid signalling mechanisms in ECT-induced retrograde amnesia: experimental evidence for involvement of COX-2, and review of literature.

  Journal of psychiatric research 20080801

• Effects of selective vs. nonselective cyclooxygenase inhibition on dynamic renal potassium excretion: a randomized trial.

  Clinical pharmacology and therapeutics 20080801

• The pattern of use of non-steroidal anti-inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million people.

  Pharmacoepidemiology and drug safety 20080801

• Atorvastatin and celecoxib: a future role in cancer chemoprevention.

  International journal of cancer 20080801

• Was the thrombotic risk of rofecoxib predictable from the French Pharmacovigilance Database before 30 September 2004?

  European journal of clinical pharmacology 20080801

• Short-term administration of non-selective and selective COX-2 NSAIDs do not interfere with bone repair in rats.

  Journal of molecular histology 20080801

• Can drug removals involving cyclooxygenase-2 inhibitors be avoided? A plea for human pharmacology.

  Trends in pharmacological sciences 20080801

• A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS.

  Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases 20080801

• Improvement of thyroid eye disease following treatment with the cyclooxygenase-2 selective inhibitor celecoxib.

  Thyroid : official journal of the American Thyroid Association 20080801

• Celecoxib pre-treatment in human colorectal adenocarcinoma patients is associated with gene expression alterations suggestive of diminished cellular proliferation.

  European journal of cancer (Oxford, England : 1990) 20080801

• [Analgesic effects of electroacupuncture combined with Celebrex on rats with tibial cancer pain].

  Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine 20080801

• Progressive metaplastic and dysplastic changes in mouse pancreas induced by cyclooxygenase-2 overexpression.

  Neoplasia (New York, N.Y.) 20080801

• Suppression of tumor formation by a cyclooxygenase-2 inhibitor and a peroxisome proliferator-activated receptor gamma agonist in an in vivo mouse model of spontaneous breast cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080801

• Celecoxib upregulates multidrug resistance proteins in colon cancer: lack of synergy with standard chemotherapy.

  Current cancer drug targets 20080801

• Cyclooxygenase-2 inhibitors in colorectal cancer prevention: point.

  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20080801

• Histological analysis of orthodontic root resorption in rats treated with the cyclooxygenase-2 (COX-2) inhibitor celecoxib.

  Orthodontics & craniofacial research 20080801

• The combined effects of celecoxib and minocycline hydrochloride on inhibiting the osseous metastasis of breast cancer in nude mice.

  Cancer biotherapy & radiopharmaceuticals 20080801

• Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man.

  Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20080801

• In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions.

  Basic & clinical pharmacology & toxicology 20080801

• [Xiaojin Wan inhibits the expression of COX-2 in prostate tissues of prostatitis pain rats].

  Zhonghua nan ke xue = National journal of andrology 20080801

• Present and prospective clinical therapeutic regimens for Alzheimer's disease.

  Neuropsychiatric disease and treatment 20080801

• [Efficacy of Lugua polypeptide injection on active rheumatoid arthritis].

  Zhongguo gu shang = China journal of orthopaedics and traumatology 20080801

• Combination chemoprevention of HER2/neu-induced breast cancer using a cyclooxygenase-2 inhibitor and a retinoid X receptor-selective retinoid.

  Cancer prevention research (Philadelphia, Pa.) 20080801

• Comment re: 'Sporadic aberrant crypt foci are not a surrogate endpoint for colorectal adenoma prevention' and 'Aberrant crypt foci in the adenoma prevention with celecoxib trial'.

  Cancer prevention research (Philadelphia, Pa.) 20080801

• Allosteric modulation of SULT2A1 by celecoxib and nimesulide: computational analyses.

  Drug metabolism letters 20080801

• Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention.

  World journal of gastroenterology 20080728

• Effects of celecoxib on ionic currents and spontaneous firing in rat retinal neurons.

  Neuroscience 20080717

• Reduced expression of cyclooxygenase-2 in primary breast cancer.

  Journal of the National Cancer Institute 20080716

• The anti-proliferative potency of celecoxib is not a class effect of coxibs.

  Biochemical pharmacology 20080715

• [American judge preserves confidentiality in the peer review process].

  Nederlands tijdschrift voor geneeskunde 20080712

• Efficacy and safety of a novel synergistic drug candidate, CRx-102, in hand osteoarthritis.

  Annals of the rheumatic diseases 20080701

• Celecoxib-induced growth inhibition in SW480 colon cancer cells is associated with activation of protein kinase G.

  Molecular carcinogenesis 20080701

• Late-onset celecoxib-induced combined hepato-nephrotoxicity.

  British journal of clinical pharmacology 20080701

• Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis.

  Annals of surgical oncology 20080701

• A celecoxib derivative inhibits focal adhesion signaling and induces caspase-8-dependent apoptosis in human acute myeloid leukemia cells.

  International journal of cancer 20080701

• Nonaspirin NSAIDs, cyclooxygenase 2 inhibitors, and the risk for stroke.

  Stroke 20080701

• Evidence for the role of neurogenic inflammation components in trypsin-elicited scratching behaviour in mice.

  British journal of pharmacology 20080701

• Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib.

  Archives of neurology 20080701

• Dimethylcelecoxib inhibits prostaglandin E2 production.

  Biochemical pharmacology 20080701

• Anticholinergic activity of 107 medications commonly used by older adults.

  Journal of the American Geriatrics Society 20080701

• Diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of 1-(4-methanesulfonylphenyl)-5-aryl-1H-pyrazol-3-carboxylic acids: synthesis, nitric oxide release studies and anti-inflammatory activities.

  Bioorganic & medicinal chemistry 20080701

• Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer.

  The Journal of steroid biochemistry and molecular biology 20080701

• Celecoxib as an in vivo probe of cyclooxygenase-2 mechanisms underlying retrograde amnesia in an animal model of ECT.

  Journal of neural transmission (Vienna, Austria : 1996) 20080701

• Involvement of subcellular organelles in inflammatory pain-induced oxidative stress and apoptosis in the rat hepatocytes.

  Archives of Iranian medicine 20080701

• The safety of celecoxib in ankylosing spondylitis treatment.

  Expert opinion on drug safety 20080701

• A new knee surgery model in rats to evaluate functional measures of postoperative pain.

  Anesthesia and analgesia 20080701

• Therapeutic effect of Siegesbeckia pubescens on cartilage protection in a rabbit collagenase-induced model of osteoarthritis.

  Journal of pharmacological sciences 20080701

• Cyclooxygenase inhibitors block uterine tumorigenesis in HMGA1a transgenic mice and human xenografts.

  Molecular cancer therapeutics 20080701

• Metronomic etoposide/cyclophosphamide/celecoxib regimen given to children and adolescents with refractory cancer: a preliminary monocentric study.

  Clinical therapeutics 20080701

• Effects of a cyclooxygenase 2 inhibitor on fracture healing in a rat model.

  American journal of orthopedics (Belle Mead, N.J.) 20080701

• Metastatic hepatic epithelioid hemangioendothelioma in a teenage girl.

  Journal of pediatric hematology/oncology 20080701

• Indole cytosolic phospholipase A2 alpha inhibitors: discovery and in vitro and in vivo characterization of 4-{3-[5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]propyl}benzoic acid, efipladib.

  Journal of medicinal chemistry 20080626

• [A phase II clinical trial of celecoxib combined with platinum-based chemotherapy in the treatment of patients with advanced NSCLC as first-line treatment.].

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20080620

• Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).

  Journal of medicinal chemistry 20080612

• Drugs to prevent colon cancer show promise, but hurdles remain for chemoprevention.

  Journal of the National Cancer Institute 20080604

• [Postoperative inconveniences after breast cancer surgery].

  Ugeskrift for laeger 20080602

• [Multimodal treatment of pain and nausea in breast cancer surgery].

  Ugeskrift for laeger 20080602

• Exploration of physicochemical properties and molecular modelling studies of 2-sulfonyl-phenyl-3-phenyl-indole analogs as cyclooxygenase-2 inhibitors.

  European journal of medicinal chemistry 20080601

• Celecoxib inhibits production of MMP and NO via down-regulation of NF-kappaB and JNK in a PGE2 independent manner in human articular chondrocytes.

  Rheumatology international 20080601

• Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1.

  Leukemia research 20080601

• Development and validation of a sensitive LC-MS/MS method with electrospray ionization for quantitation of rhein in human plasma: application to a pharmacokinetic study.

  Biomedical chromatography : BMC 20080601

• Validating the effects of drug treatment on blood pressure in the General Practice Research Database.

  Pharmacoepidemiology and drug safety 20080601

• Exploitation of HIV protease inhibitor Indinavir as a memory restorative agent in experimental dementia.

  Pharmacology, biochemistry, and behavior 20080601

• Inhibition of mouse osteoblast proliferation and prostaglandin E2 synthesis by Ulmus davidiana Planch (Ulmaceae).

  Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20080601

• Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis.

  Pharmacoepidemiology and drug safety 20080601

• Selective COX-2 inhibitors, NSAIDs and congestive heart failure: differences between new and recurrent cases.

  British journal of clinical pharmacology 20080601

• Renal hemodynamic effect of cyclooxygenase 2 inhibition in young men and women with uncomplicated type 1 diabetes mellitus.

  American journal of physiology. Renal physiology 20080601

• Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults.

  Neuro-oncology 20080601

• Central ghrelin gastroprotection involves nitric oxide/prostaglandin cross-talk.

  British journal of pharmacology 20080601

• Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer.

  Head & neck 20080601

• Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 versus COX-1 in healthy subjects.

  Journal of clinical pharmacology 20080601

• Towards the first inhibitors of trihydroxynaphthalene reductase from Curvularia lunata: synthesis of artificial substrate, homology modelling and initial screening.

  Bioorganic & medicinal chemistry 20080601

• Does celecoxib have pre-emptive analgesic effect after Caesarean section surgery?

  British journal of anaesthesia 20080601

• Current methods for predicting human food effect.

  The AAPS journal 20080601

• Clinical trials update from the American College of Cardiology 2008: CARISMA, TRENDS, meta-analysis of Cox-2 studies, HAT, ON-TARGET, HYVET, ACCOMPLISH, MOMENTUM, PROTECT, HORIZON-HF and REVERSE.

  European journal of heart failure 20080601

• Multimodal analgesia without parenteral narcotics for total knee arthroplasty.

  The Journal of arthroplasty 20080601

• Modulation of the expression of the invasion-suppressor CRMP-1 by cyclooxygenase-2 inhibition via reciprocal regulation of Sp1 and C/EBPalpha.

  Molecular cancer therapeutics 20080601

• Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer.

  Molecular cancer therapeutics 20080601

• Selective inhibition of cyclooxygenase-2 suppresses the growth of pancreatic cancer cells in vitro and in vivo.

  The Tohoku journal of experimental medicine 20080601

• Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome induced by celecoxib and anti-tuberculosis drugs.

  Journal of Korean medical science 20080601

• Celecoxib: new indication. Ankylosing spondylitis: no pain justifies the use of a cox-2 inhibitor. Patients still exposed to unjustified risks.

  Prescrire international 20080601

• [Effects of a selective cyclooxygenase 2 inhibitor celecoxib on the proliferation and apoptosis of human prostate cancer cell line PC-3].

  Zhonghua nan ke xue = National journal of andrology 20080601

• Antiatherosclerotic activity of ibuprofen, a non-selective COX inhibitor--an animal study.

  Indian journal of experimental biology 20080601

• Cardiovascular co-morbidity in rheumatic diseases.

  Vascular health and risk management 20080601

• [Celecoxib induces apoptosis and inhibits angiogenesis in gastric cancer].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20080601

• Aberrant crypt foci in the adenoma prevention with celecoxib trial.

  Cancer prevention research (Philadelphia, Pa.) 20080601

• Musculoskeletal performance and hydration status.

  Current reviews in musculoskeletal medicine 20080601

• Heterogeneous gene expression changes in colorectal cancer cells share the WNT pathway in response to growth suppression by APHS-mediated COX-2 inhibition.

  Biologics : targets & therapy 20080601

• Evaluation of antidepressant activity of tramadol in mice.

  Indian journal of pharmacology 20080601

• Circulating neutrophils maintain physiological blood pressure by suppressing bacteria and IFNgamma-dependent iNOS expression in the vasculature of healthy mice.

  Blood 20080515

• Novel anti-inflammatory agents based on pyridazinone scaffold; design, synthesis and in vivo activity.

  Bioorganic & medicinal chemistry 20080515

• TTX-R Na+ current-reduction by celecoxib correlates with changes in PGE(2) and CGRP within rat DRG neurons during acute incisional pain.

  Brain research 20080513

• Advanced small cell carcinoma of the ovary in a seventeen-year-old female, successfully treated with surgery and multi-agent chemotherapy.

  Pediatric blood & cancer 20080501

• Arachidonic acid pathway activates multidrug resistance related protein in cultured human lung cells.

  Archives of toxicology 20080501

• The select cyclooxygenase-2 inhibitor celecoxib reduced the extent of atherosclerosis in apo E-/- mice.

  The Journal of surgical research 20080501

• Pharmaceutical particle engineering via spray drying.

  Pharmaceutical research 20080501

• Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080501

• Celecoxib, a cyclooxygenase-2 inhibitor, induces apoptosis in human osteosarcoma cell line MG-63 via down-regulation of PI3K/Akt.

  Cell biology international 20080501

• Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling.

  Molecular pharmacology 20080501

• Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells.

  International journal of cancer 20080501

• Celecoxib is a CYP1A2 inhibitor in vitro but not in vivo.

  European journal of clinical pharmacology 20080501

• Predictors of orphan drug approval in the European Union.

  European journal of clinical pharmacology 20080501

• Changes in gene expression induced by chemoradiation in advanced cervical carcinoma: a microarray study of RTOG C-0128.

  Gynecologic oncology 20080501

• Evaluating drug toxicity signals: is a hierarchical classification of evidence useful or a hindrance?

  Pharmacoepidemiology and drug safety 20080501

• Safety, efficacy and anti-inflammatory activity of rho iso-alpha-acids from hops.

  Phytochemistry 20080501

• Diacerein has a weak effect on the catabolic pathway of human osteoarthritis synovial fibroblast--comparison to its effects on osteoarthritic chondrocytes.

  Rheumatology (Oxford, England) 20080501

• Exploring the mechanisms behind S-adenosylmethionine (SAMe) in the treatment of osteoarthritis.

  Critical reviews in food science and nutrition 20080501

• Can celecoxib affect P-glycoprotein-mediated drug efflux? A microPET study.

  Nuclear medicine and biology 20080501

• By the way, doctor. Celebrex and bleeding.

  Harvard health letter 20080501

• Celecoxib and ankylosing spondylitis.

  Expert review of clinical immunology 20080501

• Preserving confidentiality in the peer review process.

  JAMA 20080423

• Phellinus linteus suppresses growth, angiogenesis and invasive behaviour of breast cancer cells through the inhibition of AKT signalling.

  British journal of cancer 20080422

• A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients.

  British journal of cancer 20080422

• Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis.

  Circulation 20080422

• Posttranscriptional regulation of the telomerase hTERT by gambogic acid in human gastric carcinoma 823 cells.

  Cancer letters 20080418

• Celecoxib and a novel COX-2 inhibitor ON09310 upregulate death receptor 5 expression via GADD153/CHOP.

  Oncogene 20080417

• Development of a rapidly dispersing tablet of a poorly wettable compound: formulation DOE and mechanistic study of effect of formulation excipients on wetting of celecoxib.

  International journal of pharmaceutics 20080402

• GSK-3beta regulates cyclin D1 expression: a new target for chemotherapy.

  Cellular signalling 20080401

• Modulation of dopaminergic neurotransmission in rat striatum upon in vitro and in vivo diclofenac treatment.

  Journal of neurochemistry 20080401

• OSU-03012 stimulates PKR-like endoplasmic reticulum-dependent increases in 70-kDa heat shock protein expression, attenuating its lethal actions in transformed cells.

  Molecular pharmacology 20080401

• [Changes in quality of life in patients with osteoarthritis treated with celecoxib: the Qualice study].

  Presse medicale (Paris, France : 1983) 20080401

• Cardiac remodelling hinders activation of cyclooxygenase-2, diminishing protection by delayed pharmacological preconditioning: role of HIF1 alpha and CREB.

  Cardiovascular research 20080401

• Design, synthesis, and biological evaluation of 1-(4-sulfamylphenyl)-3-trifluoromethyl-5-indolyl pyrazolines as cyclooxygenase-2 (COX-2) and lipoxygenase (LOX) inhibitors.

  Bioorganic & medicinal chemistry 20080401

• Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma.

  Neuro-oncology 20080401

• The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs.

  Gastroenterology 20080401

• Celecoxib modulates hypertrophic signalling and prevents load-induced cardiac dysfunction.

  European journal of heart failure 20080401

• Pharmacological treatment of heterotopic ossification following hip and acetabular surgery.

  Expert opinion on pharmacotherapy 20080401

• A prospective randomized trial on the role of perioperative celecoxib administration for total knee arthroplasty: improving clinical outcomes.

  Anesthesia and analgesia 20080401

• Stimulating catheters for continuous femoral nerve blockade after total knee arthroplasty: a randomized, controlled, double-blinded trial.

  Anesthesia and analgesia 20080401

• The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers.

  The American journal of cardiology 20080401

• Celecoxib and hypertension-insights from the effect of celecoxib on restenosis after coronary angioplasty with a taxus stent trial.

  The American journal of cardiology 20080401

• Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080401

• The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080401

• Pilot randomized phase II study of celecoxib in oral premalignant lesions.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080401

• Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial.

  American journal of clinical oncology 20080401

• Chemoprevention of colorectal neoplasia: the potential for personalized medicine.

  Gastroenterology 20080401

• Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.

  Health technology assessment (Winchester, England) 20080401

• Cyclooxygenase-2 dependent and independent antitumor effects induced by celecoxib in urinary bladder cancer cells.

  Molecular cancer therapeutics 20080401

• [Mechanism of exacerbation of colonic damage in experimental colitis treated with celecoxib].

  Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences 20080401

• Applying blood-brain barrier in vitro models to study the influence of drugs on endothelial cells--effects of selected COX-inhibitors.

  Die Pharmazie 20080401

• Review of the cardiovascular safety of COXIBs compared to NSAIDS.

  Cardiovascular journal of Africa 20080401

• Celecoxib: still around, unfortunately.

  Prescrire international 20080401

• [Tolerance to celecoxib and meloxicam in patients with intolerance to nonsteroidal anti-inflammatory drugs].

  Anales de medicina interna (Madrid, Spain : 1984) 20080401

• Efficacy and tolerability of lumiracoxib, a highly selective cyclo-oxygenase-2 (COX2) inhibitor, in the management of pain and osteoarthritis.

  Therapeutics and clinical risk management 20080401

• Altered GABAergic neurotransmission is associated with increased kainate-induced seizure in prostaglandin-endoperoxide synthase-2 deficient mice.

  Brain research bulletin 20080328

• CS-706, a novel cyclooxygenase-2 selective inhibitor, prolonged the survival of tumor-bearing mice when treated alone or in combination with anti-tumor chemotherapeutic agents.

  International journal of cancer 20080315

• Diazen-1-ium-1,2-diolated and nitrooxyethyl nitric oxide donor ester prodrugs of anti-inflammatory (E)-2-(aryl)-3-(4-methanesulfonylphenyl)acrylic acids: synthesis, cyclooxygenase inhibition, and nitric oxide release studies.

  Bioorganic & medicinal chemistry 20080315

• Cytotoxicity and proteomics analyses of OSU03013 in lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080315

• Treatment of advanced hormone-sensitive breast cancer in postmenopausal women with exemestane alone or in combination with celecoxib.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080310

• Crunch time for peer review in lawsuit.

  Nature 20080306

• Synthesis and biological evaluation of some thiazolyl and thiadiazolyl derivatives of 1H-pyrazole as anti-inflammatory antimicrobial agents.

  European journal of medicinal chemistry 20080301

• Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study.

  Annals of the rheumatic diseases 20080301

• Endoscopic ulcer rates in healthy subjects associated with use of aspirin (81 mg q.d.) alone or coadministered with celecoxib or naproxen: a randomized, 1-week trial.

  Digestive diseases and sciences 20080301

• Cyclooxygenase-2 mediates the delayed cardioprotection induced by hydrogen sulfide preconditioning in isolated rat cardiomyocytes.

  Pflugers Archiv : European journal of physiology 20080301

• Pro-inflammatory effect in mice of CvL, a lectin from the marine sponge Cliona varians.

  Comparative biochemistry and physiology. Toxicology & pharmacology : CBP 20080301

• Prevention of upper aerodigestive tract cancer in zinc-deficient rodents: inefficacy of genetic or pharmacological disruption of COX-2.

  International journal of cancer 20080301

• Clinical use and pharmacological properties of selective COX-2 inhibitors.

  European journal of clinical pharmacology 20080301

• The effects of COX-1 and COX-2 inhibitors on prostaglandin synthesis and the formation of heterotopic bone in a rat model.

  Archives of orthopaedic and trauma surgery 20080301

• Selective COX-2 inhibitors. Part 2: synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides.

  Bioorganic & medicinal chemistry 20080301

• A COX-2 inhibitor combined with chemoradiation of locally advanced rectal cancer: a phase II trial.

  International journal of colorectal disease 20080301

• The effect of cyclooxygenase-2 inhibition on renal hemodynamic function in humans with type 1 diabetes.

  Diabetes 20080301

• Celecoxib modulates adhesion of HT29 colon cancer cells to vascular endothelial cells by inhibiting ICAM-1 and VCAM-1 expression.

  British journal of pharmacology 20080301

• Celecoxib decreases expression of the adhesion molecules ICAM-1 and VCAM-1 in a colon cancer cell line (HT29).

  British journal of pharmacology 20080301

• The effects of cyclooxygenase-2 expression in prostate cancer cells: modulation of response to cytotoxic agents.

  The Journal of pharmacology and experimental therapeutics 20080301

• Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study.

  Human psychopharmacology 20080301

• Endothelin-1 increases expression of cyclooxygenase-2 and production of interlukin-8 in hunan pulmonary epithelial cells.

  Peptides 20080301

• NSAIDs and breast cancer: a possible prevention and treatment strategy.

  International journal of clinical practice 20080301

• Modulation of celecoxib- and streptozotocin-induced experimental dementia of Alzheimer's disease by pitavastatin and donepezil.

  Journal of psychopharmacology (Oxford, England) 20080301

• A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with allopurinol, celecoxib and cimetidine in healthy subjects.

  Current medical research and opinion 20080301

• Cyclooxygenase-2/PGE2 pathway facilitates pentylenetetrazol-induced seizures.

  Epilepsy research 20080301

• Perioperative versus postoperative celecoxib on patient outcomes after major plastic surgery procedures.

  Anesthesia and analgesia 20080301

• The effects of intrathecal cyclooxygenase-1, cyclooxygenase-2, or nonselective inhibitors on pain behavior and spinal Fos-like immunoreactivity.

  Anesthesia and analgesia 20080301

• Impact of prescriber nonresponse on patient representativeness.

  Epidemiology (Cambridge, Mass.) 20080301

• Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer.

  Experimental oncology 20080301

• Informatic tools and approaches in postmarketing pharmacovigilance used by FDA.

  The AAPS journal 20080301

• Pharmacogenetic and metabolic differences between dog breeds: their impact on canine medicine and the use of the dog as a preclinical animal model.

  The AAPS journal 20080301

• Novel strategies for the treatment of lung cancer: modulation of eicosanoids.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080220

• Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080220

• Synthesis and cyclooxygenase inhibitory activities of linear 1-(methanesulfonylphenyl or benzenesulfonamido)-2-(pyridyl)acetylene regioisomers.

  Bioorganic & medicinal chemistry 20080215

• Design and synthesis of 1,3-diarylurea derivatives as selective cyclooxygenase (COX-2) inhibitors.

  Bioorganic & medicinal chemistry letters 20080215

• Cyclooxygenase-2 inhibition inhibits c-Met kinase activity and Wnt activity in colon cancer.

  Cancer research 20080215

• Involvement of endogenous prostaglandin F2alpha on kainic acid-induced seizure activity through FP receptor: the mechanism of proconvulsant effects of COX-2 inhibitors.

  Brain research 20080208

• Alterations in spontaneous contractions of rat ileum and jejunum after peritonitis.

  European journal of pharmacology 20080202

• Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer.

  Cancer chemotherapy and pharmacology 20080201

• A comparison of the effectiveness of selected non-steroidal anti-inflammatory drugs and their derivatives against cancer cells in vitro.

  Cancer chemotherapy and pharmacology 20080201

• Dose-dependent reduction of 3,2'-dimethyl-4-aminobiphenyl-derived DNA adducts in colon and liver of rats administered celecoxib.

  Mutation research 20080201

• 5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid.

  Journal of neurochemistry 20080201

• Celecoxib inhibits proliferation of retinal pigment epithelial and choroid-retinal endothelial cells by a cyclooxygenase-2-independent mechanism.

  The Journal of pharmacology and experimental therapeutics 20080201

• Morphine and ABT-594 (a nicotinic acetylcholine agonist) exert centrally mediated antinociception in the rat cyclophosphamide cystitis model of visceral pain.

  The journal of pain : official journal of the American Pain Society 20080201

• Vitamin E analog, alpha-tocopherol ether-linked acetic acid analog, alone and in combination with celecoxib, reduces multiplicity of ultraviolet-induced skin cancers in mice.

  Anti-cancer drugs 20080201

• Biologic markers of angiogenesis: circulating endothelial cells in patients with advanced malignancies treated on phase I protocol with metronomic chemotherapy and celecoxib.

  Cancer investigation 20080201

• Celecoxib to prevent restenosis--results from the COREA-TAXUS trial.

  Expert opinion on pharmacotherapy 20080201

• Differential effects of selective cyclooxygenase-2 inhibitors in inhibiting proliferation and induction of apoptosis in oral squamous cell carcinoma.

  Oncology reports 20080201

• Antiproliferative and proapoptotic effects of rapamycin and celecoxib in malignant melanoma cell lines.

  Oncology reports 20080201

• Cyclooxygenase-2 deficiency enhances Th2 immune responses and impairs neutrophil recruitment in hepatic ischemia/reperfusion injury.

  Journal of immunology (Baltimore, Md. : 1950) 20080201

• Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment.

  European journal of clinical pharmacology 20080201

• Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs.

  Expert opinion on investigational drugs 20080201

• Erectile dysfunction induced probably by celecoxib.

  Pharmacoepidemiology and drug safety 20080201

• Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib.

  Cancer research 20080201

• Metformin-induced lactic acidosis and acute pancreatitis precipitated by diuretic, celecoxib, and candesartan-associated acute kidney dysfunction.

  Clinical toxicology (Philadelphia, Pa.) 20080201

• Oral celecoxib versus oral diclofenac for post-perineal repair analgesia after spontaneous vaginal birth: a randomised trial.

  The Australian & New Zealand journal of obstetrics & gynaecology 20080201

• [Pre-clinical and clinical profiles of celecoxib, a new specific cyclooxygenase-2 inhibitor].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20080201

• Update on rifampin and rifabutin drug interactions.

  The American journal of the medical sciences 20080201

• Cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) selectivity of COX inhibitors.

  Prostaglandins, leukotrienes, and essential fatty acids 20080201

• Recurrent postoperative CRPS I in patients with abnormal preoperative sympathetic function.

  The Journal of hand surgery 20080201

• Effects of selective and non-selective COX inhibitors on antigen-induced release of prostanoid mediators and bronchoconstriction in the isolated perfused and ventilated guinea pig lung.

  Prostaglandins, leukotrienes, and essential fatty acids 20080201

• Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080201

• Inhibition of delayed rectifier potassium channels and induction of arrhythmia: a novel effect of celecoxib and the mechanism underlying it.

  The Journal of biological chemistry 20080118

• [Allergic reactions to nonsteroidal anti-inflammatory drugs].

  Revue medicale suisse 20080116

• Celecoxib transiently inhibits cellular protein synthesis.

  Biochemical pharmacology 20080115

• Interaction between celecoxib and docetaxel or cisplatin in human cell lines of ovarian cancer and colon cancer is independent of COX-2 expression levels.

  Biochemical pharmacology 20080115

• New celecoxib derivatives as anti-inflammatory agents.

  Journal of medicinal chemistry 20080110

• Mathematical analysis of involvement ratio between central and peripheral COX-2 in rat pain models with two types of COX-2 inhibitors with different distribution, celecoxib and CIAA.

  European journal of pharmacology 20080106

• Preclinical pharmacology profile of CS-706, a novel cyclooxygenase-2 selective inhibitor, with potent antinociceptive and anti-inflammatory effects.

  European journal of pharmacology 20080106

• Nanostructured lipid carrier (NLC) based gel of celecoxib.

  International journal of pharmaceutics 20080104

• 2-Amino-5-thiazolyl motif: a novel scaffold for designing anti-inflammatory agents of diverse structures.

  European journal of medicinal chemistry 20080101

• Synthesis and release of human cartilage matrix proteoglycans are differently regulated by nitric oxide and prostaglandin-E2.

  Annals of the rheumatic diseases 20080101

• Prostaglandin E2 systemic production in patients with asthma with and without aspirin hypersensitivity.

  Thorax 20080101

• Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract.

  Head & neck 20080101

• Chemoprevention with special reference to inherited colorectal cancer.

  Familial cancer 20080101

• Involvement of LTB4 in zymosan-induced joint nociception in mice: participation of neutrophils and PGE2.

  Journal of leukocyte biology 20080101

• Lumiracoxib 400 mg compared with celecoxib 400 mg and placebo for treating pain following dental surgery: a randomized, controlled trial.

  The journal of pain : official journal of the American Pain Society 20080101

• Synthesis and biological evaluation of 2-trifluoromethyl/sulfonamido-5,6-diaryl substituted imidazo[2,1-b]-1,3,4-thiadiazoles: a novel class of cyclooxygenase-2 inhibitors.

  Bioorganic & medicinal chemistry 20080101

• The resistance to the tumor suppressive effects of COX inhibitors and COX-2 gene disruption in TRAMP mice is associated with the loss of COX expression in prostate tissue.

  Carcinogenesis 20080101

• Celecoxib disrupts the canonical apoptotic network in HTLV-I cells through activation of Bax and inhibition of PKB/Akt.

  Apoptosis : an international journal on programmed cell death 20080101

• Effect of cyclooxygenase and nitric oxide synthase inhibitors on streptozotocin-induced hyperalgesia in rats.

  Pharmacology 20080101

• Effects of nonsteroidal anti-inflammatory drugs on the expression of urokinase plasminogen activator and inhibitor and gelatinases in the early osteoarthritic knee of humans.

  Clinical biochemistry 20080101

• Celecoxib induced tumor cell radiosensitization by inhibiting radiation induced nuclear EGFR transport and DNA-repair: a COX-2 independent mechanism.

  International journal of radiation oncology, biology, physics 20080101

• Renal functional responses to ischaemia-reperfusion injury in normotensive and hypertensive rats following non-selective and selective cyclo-oxygenase inhibition with nitric oxide donation.

  Clinical and experimental pharmacology & physiology 20080101

• The effects of prostaglandin inhibition on whole-body ischemia-reperfusion in swine.

  The American journal of emergency medicine 20080101

• Prostaglandin inhibition and ischemia: where are the data?

  The American journal of emergency medicine 20080101

• Chemoprevention of arylamine-induced colorectal aberrant crypts.

  Experimental biology and medicine (Maywood, N.J.) 20080101

• Use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs in high doses increases mortality and risk of reinfarction in patients with prior myocardial infarction.

  The Journal of cardiovascular nursing 20080101

• The effect of a selective cyclooxygenase-2 inhibitor (celecoxib) on chronic periodontitis.

  Journal of periodontology 20080101

• Response to Ray and colleagues: the called-for large clinical trial is already ongoing.

  Gastroenterology 20080101

• Modeling of corneal and retinal pharmacokinetics after periocular drug administration.

  Investigative ophthalmology & visual science 20080101

• Effect of eye pigmentation on transscleral drug delivery.

  Investigative ophthalmology & visual science 20080101

• Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study.

  Medical oncology (Northwood, London, England) 20080101

• Urinary human L-FABP is a potential biomarker to predict COX-inhibitor-induced renal injury.

  Nephron. Experimental nephrology 20080101

• Etoricoxib-induced erythema-multiforme-like eruption.

  Dermatology (Basel, Switzerland) 20080101

• Use of cox-2 inhibitors in patients with retinal venous occlusive disease.

  Retina (Philadelphia, Pa.) 20080101

• Interpleural analgesia in breast reconstruction.

  Scandinavian journal of plastic and reconstructive surgery and hand surgery 20080101

• Costs and effects of various analgesic treatments for patients with rheumatoid arthritis and osteoarthritis in the Netherlands.

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20080101

• Prevalence of anaemia in older persons: systematic review.

  BMC geriatrics 20080101

• Rethinking the threats to scientific balance in contexts of litigation and regulation.

  Environmental health perspectives 20080101

• Faecal blood loss with aspirin, nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors: systematic review of randomized trials using autologous chromium-labelled erythrocytes.

  Arthritis research & therapy 20080101

• Key regulatory molecules of cartilage destruction in rheumatoid arthritis: an in vitro study.

  Arthritis research & therapy 20080101

• No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial.

  PloS one 20080101

• Intracellular effects of NSAIDs/ASA in oxidatively stressed human lens epithelial cells in culture.

  Ophthalmic research 20080101

• Cyclooxygenase-2 overexpression is common in serrated and non-serrated colorectal adenoma, but uncommon in hyperplastic polyp and sessile serrated polyp/adenoma.

  BMC cancer 20080101

• Neoadjuvant therapy with celecoxib to women with early stage breast cancer.

  Neoplasma 20080101

• Are N-of-1 trials an economically viable option to improve access to selected high cost medications? The Australian experience.

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20080101

• NF-kappa B genes have a major role in inflammatory breast cancer.

  BMC cancer 20080101

• What do we know about communicating risk? A brief review and suggestion for contextualising serious, but rare, risk, and the example of cox-2 selective and non-selective NSAIDs.

  Arthritis research & therapy 20080101

• OTC analgesics and drug interactions: clinical implications.

  Osteopathic medicine and primary care 20080101

• Protective effects of cyclooxygenase-2 inhibitors on narrow-band ultraviolet B-irradiated epidermal Ia+ Langerhans cells and Thy-1+ dendritic epidermal T cells in mice.

  Photochemistry and photobiology 20080101

• Cyclooxygenase-2 inhibitor nimesulide blocks ultraviolet B-induced photocarcinogenesis in SKH-1 hairless mice.

  Photochemistry and photobiology 20080101

• Celecoxib concentration predicts decrease in prostaglandin E2 concentrations in nipple aspirate fluid from high risk women.

  BMC cancer 20080101

• Design, power, and interpretation of studies in the standard murine model of ALS.

  Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases 20080101

• Chemopreventive effects of celecoxib are limited to hormonally responsive mammary carcinomas in the neu-induced retroviral rat model.

  Breast cancer research : BCR 20080101

• Comparison of protein expression by isotope-coded affinity tag labeling.

  Methods in molecular biology (Clifton, N.J.) 20080101

• Compositions for treatment of cancer and inflammation.

  Recent patents on anti-cancer drug discovery 20080101

• Selective cyclooxygenase-2 inhibitor prevents reduction of trabecular bone mass in collagen-induced arthritic mice in association with suppression of RANKL/OPG ratio and IL-6 mRNA expression in synovial tissues but not in bone marrow cells.

  Journal of bone and mineral metabolism 20080101

• The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective.

  Journal of neuroinflammation 20080101

• Preoperative treatment with a non-steroidal anti-inflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer.

  Cancer immunity 20080101

• Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study.

  Arthritis research & therapy 20080101

• Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis.

  BMC musculoskeletal disorders 20080101

• Nimesulide is a selective COX-2 inhibitory, atypical non-steroidal anti-inflammatory drug.

  Current medicinal chemistry 20080101

• Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration.

  Molecular vision 20080101

• Preclinical and clinical studies of novel breast cancer drugs targeting molecules involved in protein kinase C signaling, the putative metastasis-suppressor gene Cap43 and the Y-box binding protein-1.

  Current medicinal chemistry 20080101

• Analgesic effectiveness of celecoxib and diclofenac in patients with osteoarthritis of the hip requiring joint replacement surgery: a 12-week, multicenter, randomized, double-blind, parallel-group, double-dummy, noninferiority study.

  Clinical therapeutics 20080101

• Malignant transformation of normal enterocytes following downregulation of Bak expression.

  Digestion 20080101

• Extract of radix curcumae prevents gastric cancer in rats.

  Digestion 20080101

• Interventions designed to improve the quality and efficiency of medication use in managed care: a critical review of the literature - 2001-2007.

  BMC health services research 20080101

• Effect of nonsteroidal anti-inflammatory drugs and the procarcinogen 1,2-dimethylhydrazine on the antioxidant defense system.

  International journal of toxicology 20080101

• Diabetic retinopathy: an update.

  Indian journal of ophthalmology 20080101

• Discontinuation rates in clinical trials in musculoskeletal pain: meta-analysis from etoricoxib clinical trial reports.

  Arthritis research & therapy 20080101

• Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy.

  BMC cancer 20080101

• Dissemination of Strongyloides stercoralis in a patient with systemic lupus erythematosus after initiation of albendazole: a case report.

  Journal of medical case reports 20080101

• COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro.

  Molecular cancer 20080101

• Neuroinflammatory response to lipopolysaccharide is exacerbated in mice genetically deficient in cyclooxygenase-2.

  Journal of neuroinflammation 20080101

• Molecular analysis of the effects of Piroxicam and Cisplatin on mesothelioma cells growth and viability.

  Journal of translational medicine 20080101

• Patients with rheumatoid arthritis have an altered circulatory aggrecan profile.

  BMC musculoskeletal disorders 20080101

• Perioperative celecoxib administration for pain management after total knee arthroplasty - a randomized, controlled study.

  BMC musculoskeletal disorders 20080101

• Quantitative endoscopy in the chemoprevention of Barrett's Esophagus Trial.

  Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus 20080101

• Use and misuse of the p-value.

  Bulletin of the NYU hospital for joint diseases 20080101

• Superiority, equivalence, and non-inferiority trials.

  Bulletin of the NYU hospital for joint diseases 20080101

• Antioxidative effects of nonsteroidal anti-inflammatory drugs during the initiation stages of experimental colon carcinogenesis in rats.

  Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer 20080101

• Peroxisome proliferator-activated receptors and progression of colorectal cancer.

  PPAR research 20080101

• Episode-specific differential gene expression of peripheral blood mononuclear cells in rapid cycling supports novel treatment approaches.

  Molecular medicine (Cambridge, Mass.) 20080101

• Fibrin sealant does not decrease seroma output or time to drain removal following inguino-femoral lymph node dissection in melanoma patients: a randomized controlled trial (NCT00506311).

  World journal of surgical oncology 20080101

• Quality of anticoagulation and use of warfarin-interacting medications in long-term care: a chart review.

  BMC geriatrics 20080101

• Effect of different non-steroidal anti-inflammatory drugs, aspirin, nimesulide and celecoxib on the disaccharide hydrolases and histoarchitecture of the rat intestinal brush border membrane.

  Nutricion hospitalaria 20080101

• Skin permeation mechanism and bioavailability enhancement of celecoxib from transdermally applied nanoemulsion.

  Journal of nanobiotechnology 20080101

• Cancer chemoprevention: a summary of the current evidence.

  Anticancer research 20080101

• Pro-apoptotic effect of nonsteroidal anti-inflammatory drugs on synovial fibroblasts.

  Modern rheumatology 20080101

• PPAR Ligands as Potential Modifiers of Breast Carcinoma Outcomes.

  PPAR research 20080101

• A pharmacological analysis of the possible role of vasoactive mediators in compensatory coronary blood flow.

  Experimental and clinical cardiology 20080101

• A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee.

  Arthritis research & therapy 20080101

• Clinical effects of Garcinia kola in knee osteoarthritis.

  Journal of orthopaedic surgery and research 20080101

• Role of peroxisome proliferator-activated receptor alpha in the control of cyclooxygenase 2 and vascular endothelial growth factor: involvement in tumor growth.

  PPAR research 20080101

• Effects of COX-2 inhibition on expression of vascular endothelial growth factor and interleukin-8 in lung cancer cells.

  BMC cancer 20080101

• Virtual screening for novel COX-2 inhibitors using the ZINC database.

  Bioinformation 20080101

• Ameliorative role of Atorvastatin and Pitavastatin in L-Methionine induced vascular dementia in rats.

  BMC pharmacology 20080101

• Cigarette smoke induces endoplasmic reticulum stress and the unfolded protein response in normal and malignant human lung cells.

  BMC cancer 20080101

• Similar reductions in the risk of human colon cancer by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors.

  BMC cancer 20080101

• Micro-CT imaging analysis for the effect of celecoxib, a cyclooxygenase-2 inhibitor, on inflammatory bone destruction in adjuvant arthritis rats.

  Journal of bone and mineral metabolism 20080101

• Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients.

  Arthritis research & therapy 20080101

• Anti-inflammatory effects of Radix Gentianae Macrophyllae (Qinjiao), Rhizoma Coptidis (Huanglian) and Citri Unshiu Pericarpium (Wenzhou migan) in animal models.

  Chinese medicine 20080101

• Potential effects of chondroitin sulfate on joint swelling: a GAIT report.

  Osteoarthritis and cartilage 20080101

• A 6-week, multicentre, randomised, double-blind, double-dummy, active-controlled, clinical safety study of lumiracoxib and rofecoxib in osteoarthritis patients.

  BMC musculoskeletal disorders 20080101

• Fast track open partial nephrectomy: reduced postoperative length of stay with a goal-directed pathway does not compromise outcome.

  Advances in urology 20080101

• Long-term efficacy and safety of lumiracoxib 100 mg: an open-label extension of a 13-week randomized controlled trial in patients with primary osteoarthritis of the knee.

  Clinical and experimental rheumatology 20080101

• Non-steroidal anti-inflammatory drugs, Cyclooxygenase-2 inhibitors and paracetamol use in Queensland and in the whole of Australia.

  BMC health services research 20080101

• Lipooxygenase inhibition in osteoarthritis: a potential symptomatic and disease modifying effect?

  Arthritis research & therapy 20080101

• Effects of celecoxib and nimesulide on the proliferation of ectopic endometrial stromal cells in vitro.

  The Journal of international medical research 20080101

• Anti cancer effects of curcumin: cycle of life and death.

  Cell division 20080101

• Concomitant use of gastroprotective drugs among elderly NSAID/COX-2 selective inhibitor users: a nationwide register-based study.

  Clinical drug investigation 20080101

• NSAID use in individuals at risk of renal adverse events: an observational study to investigate trends in Australian veterans.

  Drug safety 20080101

• Takotsubo cardiomyopathy associated with anesthesia: three case reports.

  Cases journal 20080101

• Three-dimensional growth as multicellular spheroid activates the proangiogenic phenotype of colorectal carcinoma cells via LFA-1-dependent VEGF: implications on hepatic micrometastasis.

  Journal of translational medicine 20080101

• uPA is upregulated by high dose celecoxib in women at increased risk of developing breast cancer.

  BMC cancer 20080101

• HPV16 E7-dependent transformation activates NHE1 through a PKA-RhoA-induced inhibition of p38alpha.

  PloS one 20080101

• Finding multiple target optimal intervention in disease-related molecular network.

  Molecular systems biology 20080101

• Celecoxib inhibits apurinic/apyrimidinic endonuclease-1 expression and prevents gastric cancer in Helicobacter pylori-infected mongolian gerbils.

  Digestion 20080101

• Antitumor enhancement of celecoxib, a selective Cyclooxygenase-2 inhibitor, in a Lewis lung carcinoma expressing Cyclooxygenase-2.

  Journal of experimental & clinical cancer research : CR 20080101

• Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis.

  Nutrition and cancer 20080101

• New horizons and perspectives in the treatment of osteoarthritis.

  Arthritis research & therapy 20080101

• Nitric oxide and cardiovascular effects: new insights in the role of nitric oxide for the management of osteoarthritis.

  Arthritis research & therapy 20080101

• Inflammaging as a prodrome to Alzheimer's disease.

  Journal of neuroinflammation 20080101

• Cost-effectiveness analysis for joint pain treatment in patients with osteoarthritis treated at the Instituto Mexicano del Seguro Social (IMSS): Comparison of nonsteroidal anti-inflammatory drugs (NSAIDs) vs. cyclooxygenase-2 selective inhibitors.

  Cost effectiveness and resource allocation : C/E 20080101

• Celecoxib accelerates functional recovery after sciatic nerve crush in the rat.

  Journal of brachial plexus and peripheral nerve injury 20080101

• PPARgamma and Agonists against Cancer: Rational Design of Complementation Treatments.

  PPAR research 20080101

• Discrepancies in sample size calculations and data analyses reported in randomised trials: comparison of publications with protocols.

  BMJ (Clinical research ed.) 20080101

• The NIH Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT).

  Journal of pain & palliative care pharmacotherapy 20080101

• Effect of cyclooxygenase and nitric oxide synthase inhibitors on vincristine induced hyperalgesia in rats.

  Pharmacological reports : PR 20080101

• Overuse of non-prescription analgesics by dental clinic patients.

  BMC oral health 20080101

• Incremental cost effectiveness of proton pump inhibitors for the prevention of non-steroidal anti-inflammatory drug ulcers: a pharmacoeconomic analysis linked to a case-control study.

  Arthritis research & therapy 20080101

• Quantitative effects of tumescent infiltration and bupivicaine injection in decreasing postoperative pain in submuscular breast augmentation.

  Aesthetic surgery journal 20080101

• Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system.

  BMC musculoskeletal disorders 20080101

• Evaluation of GW406381 for treatment of osteoarthritis of the knee: two randomized, controlled studies.

  Medscape journal of medicine 20080101

• [Cardiovascular risk of cyclooxygenase selective inhibitors].

  Revista medica del Instituto Mexicano del Seguro Social 20080101

• Effect of non-steroidal anti-inflammatory drugs and the pro-carcinogen 1,2 dimethylhydrazine on the rat intestinal membrane structure and function.

  Nutricion hospitalaria 20080101

• Low-dose oral metronomic chemotherapy prevents mobilization of endothelial progenitor cells into the blood of cancer patients.

  In vivo (Athens, Greece) 20080101

• Factors influencing effects of specific COX-2 inhibitor NSAIDs on growth and differentiation of mouse osteoblasts on titanium surfaces.

  The International journal of oral & maxillofacial implants 20080101

• Combination Therapy of PPARgamma Ligands and Inhibitors of Arachidonic Acid in Lung Cancer.

  PPAR research 20080101

• Influence of COX-2-induced PGE2 on the initiation and progression of tail regeneration in Northern House Gecko, Hemidactylus flaviviridis.

  Folia biologica 20080101

• FTIR studies on differential intermolecular association in crystalline and amorphous states of structurally related non-steroidal anti-inflammatory drugs.

  Molecular pharmaceutics 20080101

• Local massage with topical analgesic, a novel treatment modality for temporomandibular muscular pain, a case study report of 5 consecutive cases.

  The open orthopaedics journal 20080101

• Continuing medical education.

  Indian journal of psychiatry 20080101

• Antidepressant-like activity of tramadol in mice.

  Indian journal of psychiatry 20080101

• Molecular mechanisms underlying electroconvulsive therapy-induced amnestic deficits: A decade of research.

  Indian journal of psychiatry 20080101

• Antiinflammatory, analgesic and antipyretic activity of certain thiazolidinones.

  Indian journal of pharmaceutical sciences 20080101

• Dose-response assessment of the anti-cancer efficacy of soy isoflavones in dimethylhydrazine-treated rats fed 6% fructooligosaccharide.

  Nutrition research and practice 20080101

• Novel colon targeted drug delivery system using natural polymers.

  Indian journal of pharmaceutical sciences 20080101

• Psychological factors in asthma.

  Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 20080101

• Aspirin-exacerbated asthma.

  Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 20080101

• Relationship between arachidonic acid pathway and human renal cell carcinoma.

  OncoTargets and therapy 20080101

• Preemptive versus postoperative lumiracoxib for analgesia in ambulatory arthroscopic knee surgery.

  Journal of pain research 20080101

• Response Surface Methodology for the Optimization of Celecoxib Self-microemulsifying Drug delivery System.

  Indian journal of pharmaceutical sciences 20080101

• Potential contribution of aspirin to cancer control programmes.

  Ecancermedicalscience 20080101

• Rethinking statistical approaches to evaluating drug safety.

  Yonsei medical journal 20071231

• Sulindac prevents esophageal adenocarcinomas induced by gastroduodenal reflux in rats.

  Yonsei medical journal 20071231

• Pharmacological nature of nicotine-induced contraction in the rat basilar artery: involvement of arachidonic acid metabolites.

  European journal of pharmacology 20071222

• Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?

  Lancet (London, England) 20071222

• Selective inhibition of cyclooxygenase-2 exacerbates methamphetamine-induced dopamine depletion in the striatum in rats.

  Neuroscience 20071219

• Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor.

  Cancer 20071215

• Structure-based design, synthesis, and biological evaluation of indomethacin derivatives as cyclooxygenase-2 inhibiting nitric oxide donors.

  Journal of medicinal chemistry 20071213

• Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy.

  British journal of cancer 20071203

• COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia.

  British journal of cancer 20071203

• Osteoid osteoma of the dens axis.

  European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society 20071201

• A comparison of the efficacy and safety of celecoxib 200 mg and celecoxib 400 mg once daily in treating the signs and symptoms of psoriatic arthritis.

  Seminars in arthritis and rheumatism 20071201

• Low-intensity pulsed ultrasound and nonsteroidal anti-inflammatory drugs have opposing effects during stress fracture repair.

  Journal of orthopaedic research : official publication of the Orthopaedic Research Society 20071201

• Protective effects of cyclooxygenase-2 gene inactivation against peripheral nerve dysfunction and intraepidermal nerve fiber loss in experimental diabetes.

  Diabetes 20071201

• Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides.

  Bioorganic & medicinal chemistry 20071201

• Orthodontic tooth movement after different coxib therapies.

  European journal of orthodontics 20071201

• Potent inhibition of in vivo angiogenesis and tumor growth by a novel cyclooxygenase-2 inhibitor, enoic acanthoic acid.

  Cancer science 20071201

• The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer.

  International journal of clinical practice 20071201

• Effects of selective COX-2 inhibition on prostanoids and platelet physiology in young healthy volunteers.

  Journal of thrombosis and haemostasis : JTH 20071201

• Effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs on urinary sodium excretion, blood pressure, and other renal function indicators in elderly subjects consuming a controlled sodium diet.

  Journal of clinical pharmacology 20071201

• Synthesis, in vitro inhibitory activity towards COX-2 and haemolytic activity of derivatives of esculentoside A.

  Bioorganic & medicinal chemistry letters 20071201

• Early detection of adverse drug events within population-based health networks: application of sequential testing methods.

  Pharmacoepidemiology and drug safety 20071201

• Patterns of analgesic and anti-inflammatory medicine use by Australian veterans.

  Internal medicine journal 20071201

• A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20071201

• Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs.

  Anesthesia and analgesia 20071201

• Lipoperoxidation and cyclooxygenase enzyme inhibitory piperidine alkaloids from Cassia spectabilis green fruits.

  Journal of natural products 20071201

• Hyperexpression of cyclooxygenase 2 in the lupus immune system and effect of cyclooxygenase 2 inhibitor diet therapy in a murine model of systemic lupus erythematosus.

  Arthritis and rheumatism 20071201

• Collagen-induced arthritis as a model of hyperalgesia: functional and cellular analysis of the analgesic actions of tumor necrosis factor blockade.

  Arthritis and rheumatism 20071201

• Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients--results of a phase II study.

  Onkologie 20071201

• Aliskiren--an orally active renin inhibitor. Review of pharmacology, pharmacodynamics, kinetics, and clinical potential in the treatment of hypertension.

  Vascular health and risk management 20071201

• Glucosamine hydrochloride for the treatment of osteoarthritis symptoms.

  Clinical interventions in aging 20071201

• The effects of some nonsteroidal anti-inflammatory drugs on experimental induced gastric ulcers in rats.

  Inflammopharmacology 20071201

• [What is new about nonsteroidal antiinflamatory drugs?].

  Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 20071201

• Update on the treatment of ankylosing spondylitis.

  Therapeutics and clinical risk management 20071201

• Anti-inflammatory and immune therapy for Alzheimer's disease: current status and future directions.

  Current neuropharmacology 20071201

• Cyclooxygenase-2 overexpression abrogates the antiproliferative effects of TGF-beta.

  British journal of cancer 20071119

• Hospitalization for gastrointestinal adverse events attributable to the use of low-dose aspirin among patients 50 years or older also using non-steroidal anti-inflammatory drugs: a retrospective cohort study.

  Alimentary pharmacology & therapeutics 20071115

• Gene expression analysis proposes alternative pathways for the mechanism by which celecoxib selectively inhibits the growth of transformed but not normal enterocytes.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20071115

• Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study.

  British journal of cancer 20071105

• Role of oxidative stress in celecoxib-induced renal damage in wistar rats.

  Digestive diseases and sciences 20071101

• What happened to the prescribing of other COX-2 inhibitors, paracetamol and non-steroidal anti-inflammatory drugs when rofecoxib was withdrawn in Australia?

  Pharmacoepidemiology and drug safety 20071101

• 2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl} acetamide (OSU-03012), a celecoxib derivative, directly targets p21-activated kinase.

  Molecular pharmacology 20071101

• CCAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction and ubiquitin/proteasome-mediated cellular FLICE-inhibitory protein down-regulation contribute to enhancement of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by dimethyl-celecoxib in human non small-cell lung cancer cells.

  Molecular pharmacology 20071101

• Inhibition of RIP and c-FLIP enhances TRAIL-induced apoptosis in pancreatic cancer cells.

  Cellular signalling 20071101

• Novel therapeutic strategies combining antihormonal and biological targeted therapies in breast cancer: focus on clinical trials and perspectives.

  Critical reviews in oncology/hematology 20071101

• Effects of anti-inflammatory drugs on proliferation, cytotoxicity and osteogenesis in bone marrow mesenchymal stem cells.

  Biochemical pharmacology 20071101

• Apoptosis of murine lupus T cells induced by the selective cyclooxygenase-2 inhibitor celecoxib: molecular mechanisms and therapeutic potential.

  International immunopharmacology 20071101

• Influence of polymers on the bioavailability of microencapsulated celecoxib.

  Journal of microencapsulation 20071101

• Celecoxib after the onset of reperfusion reduces apoptosis in the amygdala.

  Apoptosis : an international journal on programmed cell death 20071101

• Cytometric assessment of DNA damage by exogenous and endogenous oxidants reports aging-related processes.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20071101

• Electrical impedance myography to assess outcome in amyotrophic lateral sclerosis clinical trials.

  Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology 20071101

• Cardiovascular effects of cyclooxygenase-2 inhibitors.

  Current opinion in gastroenterology 20071101

• Action of celecoxib on hepatic metabolic changes induced by the Walker-256 tumour in rats.

  Basic & clinical pharmacology & toxicology 20071101

• CYP2C9 structure-metabolism relationships: substrates, inhibitors, and metabolites.

  Journal of medicinal chemistry 20071101

• Cyclooxygenase-2 inhibitors. 1,5-diarylpyrrol-3-acetic esters with enhanced inhibitory activity toward cyclooxygenase-2 and improved cyclooxygenase-2/cyclooxygenase-1 selectivity.

  Journal of medicinal chemistry 20071101

• Effect of celecoxib and novel agent LC-1 in a hamster model of lung cancer.

  The Journal of surgical research 20071101

• Preoperative growth inhibition of human gastric adenocarcinoma treated with a combination of celecoxib and octreotide.

  Acta pharmacologica Sinica 20071101

• Celecoxib prevented development of heterotopic ossification better than Ibuprofen after total hip replacement.

  The Journal of bone and joint surgery. American volume 20071101

• Clinical inquiries. Do COX-2 inhibitors worsen renal function?

  The Journal of family practice 20071101

• Liver transplantation for nonsteroidal anti-inflammatory drug-induced liver failure: nimesulide as the first implicated compound.

  European journal of gastroenterology & hepatology 20071101

• Effects of aspirin and celecoxib on rigidity in a rat model of Parkinson's disease.

  Pakistan journal of biological sciences : PJBS 20071101

• Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071020

• The effect of celecoxib on tissue factor expression in pancreatic cancer cells.

  Chinese medical journal 20071020

• In vitro and in vivo reversal of resistance to 5-fluorouracil in colorectal cancer cells with a novel stealth double-liposomal formulation.

  British journal of cancer 20071008

• Cultivars of apple fruits that are not marketed with potential for anthocyanin production.

  Journal of agricultural and food chemistry 20071003

• Relative non-steroidal anti-inflammatory drug (NSAID) antiproliferative activity is mediated through p21-induced G1 arrest and E2F inhibition.

  Molecular carcinogenesis 20071001

• Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations.

  Journal of pharmaceutical sciences 20071001

• Covalent binding of rofecoxib, but not other cyclooxygenase-2 inhibitors, to allysine aldehyde in elastin of human aorta.

  Drug metabolism and disposition: the biological fate of chemicals 20071001

• The cardioprotection of the late phase of ischemic preconditioning is enhanced by postconditioning via a COX-2-mediated mechanism in conscious rats.

  American journal of physiology. Heart and circulatory physiology 20071001

• Effects of celecoxib on the reversal of multidrug resistance in human gastric carcinoma by downregulation of the expression and activity of P-glycoprotein.

  Anti-cancer drugs 20071001

• COX-2 inhibitor.

  Rheumatology (Oxford, England) 20071001

• Radiosensitization of human glioma cells by cyclooxygenase-2 (COX-2) inhibition: independent on COX-2 expression and dependent on the COX-2 inhibitor and sequence of administration.

  International journal of radiation biology 20071001

• Effect of hypericin-mediated photodynamic therapy on the expression of vascular endothelial growth factor in human nasopharyngeal carcinoma.

  International journal of molecular medicine 20071001

• Preliminary results of the Prostacox phase II trial in hormonal refractory prostate cancer.

  BJU international 20071001

• Celecoxib versus magnesium sulfate to arrest preterm labor: randomized trial.

  The journal of obstetrics and gynaecology research 20071001

• Exisulind in combination with celecoxib modulates epidermal growth factor receptor, cyclooxygenase-2, and cyclin D1 against prostate carcinogenesis: in vivo evidence.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20071001

• Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer.

  Cancer research 20071001

• Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial.

  Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20071001

• COX-2 and NF-KB overexpression is common in pancreatic cancer but does not predict for COX-2 inhibitors activity in combination with gemcitabine and oxaliplatin.

  American journal of clinical oncology 20071001

• [Current issues of NSAID-induced gastrointestinal ulcer in Japan].

  Nihon rinsho. Japanese journal of clinical medicine 20071001

• [The choice of selective COX-2 inhibitors].

  Nihon rinsho. Japanese journal of clinical medicine 20071001

• [Inhibitory effects of cyclooxygenase-2 inhibitor celecoxib on the proliferation of hepatocellular carcinoma cells].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20071001

• Effects of celecoxib on blood loss, pain, and recovery of function after total knee replacement: a randomized placebo-controlled trial.

  Acta orthopaedica 20071001

• Niosomal gel for site-specific sustained delivery of anti-arthritic drug: in vitro-in vivo evaluation.

  Current drug delivery 20071001

• Selective COX-2 inhibitors, NSAIDs and cardiovascular events - is celecoxib the safest choice?

  Therapeutics and clinical risk management 20071001

• Progress update: Pharmacological treatment of Alzheimer's disease.

  Neuropsychiatric disease and treatment 20071001

• Celecoxib induces MRP-4 in lung cancer cells: therapeutic implications.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070920

• A cyclooxygenase-2 inhibitor ameliorates behavioral impairments induced by striatal administration of epidermal growth factor.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20070919

• 'Bridged' stilbene derivatives as selective cyclooxygenase-1 inhibitors.

  Bioorganic & medicinal chemistry 20070915

• Atorvastatin and celecoxib inhibit prostate PC-3 tumors in immunodeficient mice.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070915

• PDK-1/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound.

  British journal of cancer 20070911

• CYP2C9 structure-metabolism relationships: optimizing the metabolic stability of COX-2 inhibitors.

  Journal of medicinal chemistry 20070906

• Efficacy and safety of epicutaneous ketoprofen in Transfersome (IDEA-033) versus oral celecoxib and placebo in osteoarthritis of the knee: multicentre randomised controlled trial.

  Annals of the rheumatic diseases 20070901

• The ubiquitin- and proteasome-dependent degradation of COX-2 is regulated by the COP9 signalosome and differentially influenced by coxibs.

  Journal of molecular medicine (Berlin, Germany) 20070901

• Aggravation by selective COX-1 and COX-2 inhibitors of dextran sulfate sodium (DSS)-induced colon lesions in rats.

  Digestive diseases and sciences 20070901

• Reduced survivin expression and tumor cell survival during chronic hypoxia and further cytotoxic enhancement by the cyclooxygenase-2 inhibitor celecoxib.

  Journal of biomedical science 20070901

• Efficacy and patterns of failure for locally advanced cancer of the cervix treated with celebrex (celecoxib) and chemoradiotherapy in RTOG 0128.

  International journal of radiation oncology, biology, physics 20070901

• Selective COX-2 inhibitors, eicosanoid synthesis and clinical outcomes: a case study of system failure.

  Lipids 20070901

• Signaling pathways involved in cyclooxygenase-2 induction by hepatocyte growth factor in non small-cell lung cancer.

  Molecular pharmacology 20070901

• DNA-PKcs-dependent modulation of cellular radiosensitivity by a selective cyclooxygenase-2 inhibitor.

  International journal of radiation oncology, biology, physics 20070901

• Obturator versus femoral nerve block for analgesia after total knee arthroplasty.

  Anesthesia and analgesia 20070901

• Effects of celecoxib on voltage-gated calcium channel currents in rat pheochromocytoma (PC12) cells.

  Pharmacological research 20070901

• OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence.

  Osteoarthritis and cartilage 20070901

• Randomised, open label, controlled trial of celecoxib in the treatment of acute migraine.

  Singapore medical journal 20070901

• Safety of intravitreal injections in patients receiving warfarin anticoagulation.

  American journal of ophthalmology 20070901

• Development of spray-dried co-precipitate of amorphous celecoxib containing storage and compression stabilizers.

  Acta pharmaceutica (Zagreb, Croatia) 20070901

• Design, development and evaluation of novel nanoemulsion formulations for transdermal potential of celecoxib.

  Acta pharmaceutica (Zagreb, Croatia) 20070901

• Resolution of hydronephrosis due to massive mesenteric fibromatosis using cyclo-oxygenase 2 inhibitors.

  Urology 20070901

• Rosiglitazone: a disappointing DREAM.

  Future cardiology 20070901

• Cyclooxygenase-2 promotes cell proliferation, migration and invasion in U2OS human osteosarcoma cells.

  Experimental & molecular medicine 20070831

• COX2 genetic variation, NSAIDs, and advanced prostate cancer risk.

  British journal of cancer 20070820

• Coronary restenosis: a new strategy for the future?

  Lancet (London, England) 20070818

• Effect of celecoxib on restenosis after coronary angioplasty with a Taxus stent (COREA-TAXUS trial): an open-label randomised controlled study.

  Lancet (London, England) 20070818

• Synergistic antitumor effects of celecoxib with 5-fluorouracil depend on IFN-gamma.

  International journal of cancer 20070815

• OSU-03012, a novel celecoxib derivative, is cytotoxic to myeloma cells and acts through multiple mechanisms.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070815

• Cyclooxygenase-2 inhibitor ameliorates ureteric damage in rats with obstructed uropathy.

  European journal of pharmacology 20070813

• Cyclovirobuxine D ameliorates acute myocardial ischemia by K(ATP) channel opening, nitric oxide release and anti-thrombosis.

  European journal of pharmacology 20070813

• CCR1 and CCR5 chemokine receptors are involved in fever induced by LPS (E. coli) and RANTES in rats.

  Brain research 20070803

• Channelling of COX-2 inhibitors to patients at higher gastrointestinal risk but not at lower cardiovascular risk: the Cox2 inhibitors and tNSAIDs description of users (CADEUS) study.

  Pharmacoepidemiology and drug safety 20070801

• Cyclo-oxygenase-independent inhibition of apoptosis and stimulation of proliferation by leptin in human colon cancer cells.

  Digestive diseases and sciences 20070801

• Dipyrone elicits substantial inhibition of peripheral cyclooxygenases in humans: new insights into the pharmacology of an old analgesic.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20070801

• Antiinflammatory effects of a combined herbal preparation (RAH13) of Phellodendron amurense and Coptis chinensis in animal models of inflammation.

  Phytotherapy research : PTR 20070801

• The effects of common anti-inflammatory drugs on the healing rat patellar tendon.

  The American journal of sports medicine 20070801

• Possible cross-regulation of the E prostanoid receptors.

  Molecular carcinogenesis 20070801

• Effects of nimesulide on pain and on synovial fluid concentrations of substance P, interleukin-6 and interleukin-8 in patients with knee osteoarthritis: comparison with celecoxib.

  International journal of clinical practice 20070801

• Design, synthesis and pharmacological evaluation of 4-[2-alkylthio-5(4)-(4-substitutedphenyl)imidazole-4(5)yl]benzenesulfonamides as selective COX-2 inhibitors.

  Acta pharmacologica Sinica 20070801

• Celebrex: new ad, with questionable claims.

  Consumer reports 20070801

• Subclinical carotid atherosclerosis in a patient with systemic lupus erythematosus.

  Nature clinical practice. Rheumatology 20070801

• Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms.

  Gastroenterology 20070801

• Clinical pharmacology of celecoxib, a COX-2 selective inhibitor.

  Expert opinion on pharmacotherapy 20070801

• Multivesicular liposomes bearing celecoxib-beta-cyclodextrin complex for transdermal delivery.

  Drug delivery 20070801

• Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182-185.

  Current oncology (Toronto, Ont.) 20070801

• [Induction of NAG-1 gene expression in colon cancer cells by non-steroidal anti-inflammatory drugs].

  Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi 20070801

• Estimation of proinflammatory biomarkers of skin irritation by dermal microdialysis following exposure with irritant chemicals.

  Toxicology 20070731

• The pain game.

  Nature 20070726

• Celecoxib dilates guinea-pig coronaries and rat aortic rings and amplifies NO/cGMP signaling by PDE5 inhibition.

  Cardiovascular research 20070715

• Expression of a cyclo-oxygenase-2 transgene in murine liver causes hepatitis.

  Gut 20070701

• The anti-cancer effect of COX-2 inhibitors on gastric cancer cells.

  Digestive diseases and sciences 20070701

• Cholesterol-like effects of selective cyclooxygenase inhibitors and fibrates on cellular membranes and amyloid-beta production.

  Molecular pharmacology 20070701

• Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.

  Neuro-oncology 20070701

• Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials.

  Pharmacoepidemiology and drug safety 20070701

• Tolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs): a systematic structured review of the literature.

  Archives of dermatological research 20070701

• Concurrent celecoxib versus placebo in patients with stage II-III non-small cell lung cancer: a randomised phase II trial.

  Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20070701

• Activation of p38 mitogen-activated protein kinase by celecoxib oppositely regulates survivin and gamma-H2AX in human colorectal cancer cells.

  Toxicology and applied pharmacology 20070701

• Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review.

  Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20070701

• Survivin is a downstream target and effector of sulindac-sensitive oncogenic Stat3 signalling in head and neck cancer.

  International journal of oral and maxillofacial surgery 20070701

• Evaluating the analgesic efficacy of administering celecoxib as a component of multimodal analgesia for outpatient anterior cruciate ligament reconstruction surgery.

  Anesthesia and analgesia 20070701

• The effect of initiating a preventive multimodal analgesic regimen on long-term patient outcomes for outpatient anterior cruciate ligament reconstruction surgery.

  Anesthesia and analgesia 20070701

• Administration of cyclooxygenase-2 inhibitor reduces joint inflammation but exacerbates osteopenia in IL-1 alpha transgenic mice due to GM-CSF overproduction.

  Journal of immunology (Baltimore, Md. : 1950) 20070701

• Up-to-date information on gastric mucosal lesions from long-term NSAID therapy in orthopedic outpatients: a study using logistic regression analysis.

  Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association 20070701

• A retrospective analysis of cardiovascular morbidity in metastatic hormone-refractory prostate cancer patients on high doses of the selective COX-2 inhibitor celecoxib.

  Expert opinion on pharmacotherapy 20070701

• [Selective COX-2 inhibitor delays experimental gastric ulcer healing by stimulating gastric acid secretion in rats].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20070701

• [Celecoxib-induced apoptosis in acute promyelocytic leukemia cell line MR2 and its mechanism].

  Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences 20070701

• Celecoxib induces apoptosis in COX-2 deficient human gastric cancer cells through Akt/GSK3beta/NAG-1 pathway.

  Cancer letters 20070628

• [Effective also in Bechterew disease].

  MMW Fortschritte der Medizin 20070621

• Pressure application measurement (PAM): a novel behavioural technique for measuring hypersensitivity in a rat model of joint pain.

  Journal of neuroscience methods 20070615

• Celecoxib induces apoptosis by inhibiting the expression of survivin in HeLa cells.

  Biochemical and biophysical research communications 20070615

• Do proton-pump inhibitors confer additional gastrointestinal protection in patients given celecoxib?

  Arthritis and rheumatism 20070615

• A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma.

  Cancer chemotherapy and pharmacology 20070601

• The effects of COX-2 selective and non-selective NSAIDs on the initiation and progression of atherosclerosis in ApoE-/- mice.

  Journal of molecular medicine (Berlin, Germany) 20070601

• Depletion of CD4+ cells exacerbates the cutaneous response to acute and chronic UVB exposure.

  The Journal of investigative dermatology 20070601

• Characterizing early prescribers of newly marketed drugs in Canada: a population-based study.

  European journal of clinical pharmacology 20070601

• New diagnosis of hypertension among celecoxib and nonselective NSAID users: a population-based cohort study.

  The Annals of pharmacotherapy 20070601

• Chemoprevention of colorectal cancer - a new target needed?

  Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland 20070601

• Spherical crystals of celecoxib to improve solubility, dissolution rate and micromeritic properties.

  Acta pharmaceutica (Zagreb, Croatia) 20070601

• Balancing the risks and benefits of celecoxib.

  The American journal of medicine 20070601

• Induction of apoptosis by celecoxib in cell culture: an uncertain role for cyclooxygenase-2.

  Cancer research 20070601

• Preliminary development of a responder index for chronic low back pain.

  The Journal of rheumatology 20070601

• Influence of He-Ne laser therapy on the dynamics of wound healing in mice treated with anti-inflammatory drugs.

  Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 20070601

• Effect of a selective nonsteroidal anti-inflammatory drug, celecoxib, on the reproductive function of female mice.

  Journal of the Chinese Medical Association : JCMA 20070601

• [The growth inhibitory effect of non-steroid anti-inflammatory drugs on ovarian cancer].

  Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20070601

• The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial.

  Current oncology (Toronto, Ont.) 20070601

• Canadian recommendations for the treatment of glioblastoma multiforme.

  Current oncology (Toronto, Ont.) 20070601

• Neuropsychiatric manifestations of depression in multiple sclerosis: neuroinflammatory, neuroendocrine, and neurotrophic mechanisms in the pathogenesis of immune-mediated depression.

  Dialogues in clinical neuroscience 20070601

• Tourette's syndrome: clinical features, pathophysiology, and therapeutic approaches.

  Dialogues in clinical neuroscience 20070601

• Hypoxia-Inducible Factor (HIF)-1 regulatory pathway and its potential for therapeutic intervention in malignancy and ischemia.

  The Yale journal of biology and medicine 20070601

• Formulation and development of floating capsules of celecoxib: in vitro and in vivo evaluation.

  AAPS PharmSciTech 20070601

• Incidence of spontaneous notifications of adverse reactions with aceclofenac, meloxicam, and rofecoxib during the first year after marketing in the United Kingdom.

  Therapeutics and clinical risk management 20070601

• Tramadol extended-release in the management of chronic pain.

  Therapeutics and clinical risk management 20070601

• A review of the role of capecitabine in the treatment of colorectal cancer.

  Therapeutics and clinical risk management 20070601

• Current aproach to cancer pain management: Availability and implications of different treatment options.

  Therapeutics and clinical risk management 20070601

• Targeting inhibition of COX-2: a review of patents, 2002-2006.

  Recent patents on inflammation & allergy drug discovery 20070601

• Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial.

  Neurology 20070522

• A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer.

  British journal of cancer 20070521

• Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy.

  Alimentary pharmacology & therapeutics 20070515

• Enhancement of docetaxel-induced cytotoxicity by blocking epidermal growth factor receptor and cyclooxygenase-2 pathways in squamous cell carcinoma of the head and neck.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070515

• P-glycoprotein mediates celecoxib-induced apoptosis in multiple drug-resistant cell lines.

  Cancer research 20070515

• Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial.

  Lancet (London, England) 20070512

• [Cardiovascular and gastrointestinal risks associated with selective and non-selective NSAIDs].

  Nederlands tijdschrift voor geneeskunde 20070512

• Involvement of up-regulation of PUMA in non-steroidal anti-inflammatory drug-induced apoptosis.

  Biochemical and biophysical research communications 20070511

• Celecoxib inhibits Na+ currents in rat dorsal root ganglion neurons.

  Brain research 20070507

• A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer.

  British journal of cancer 20070507

• Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.

  Pharmacoepidemiology and drug safety 20070501

• The CADEUS study: methods and logistics.

  Pharmacoepidemiology and drug safety 20070501

• Use of calcined Mg-Al-hydrotalcite to enhance the stability of celecoxib in the amorphous form.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20070501

• Determination of lefucoxib in rat plasma, urine, and feces by high-performance liquid chromatography with fluorescence detection: application in pharmacokinetic studies.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070501

• Celecoxib inhibits the expression of survivin via the suppression of promoter activity in human colon cancer cells.

  Biochemical pharmacology 20070501

• R-Etodolac decreases beta-catenin levels along with survival and proliferation of hepatoma cells.

  Journal of hepatology 20070501

• Increased expression of cyclooxygenase-2 correlates with resistance to radiation in human prostate adenocarcinoma cells.

  The Journal of urology 20070501

• A shot in the dark: failing to recognize the link between physical and mental illness.

  Journal of general internal medicine 20070501

• Celecoxib decreases fatty acid synthase expression via down-regulation of c-Jun N-terminal kinase-1.

  Experimental biology and medicine (Maywood, N.J.) 20070501

• The role of the Back Rx exercise program in diskogenic low back pain: a prospective randomized trial.

  Archives of physical medicine and rehabilitation 20070501

• Effect of short-term postoperative celecoxib administration on patient outcome after outpatient laparoscopic surgery.

  Canadian journal of anaesthesia = Journal canadien d'anesthesie 20070501

• Simultaneous measurements of K+ and calcein release from liposomes and the determination of pore size formed in a membrane.

  Analytical sciences : the international journal of the Japan Society for Analytical Chemistry 20070501

• No proof of cross-reactivity between celecoxib and antibiotic sulfonamides.

  Internal medicine journal 20070501

• Assessment of comparative pain relief and tolerability of SKI306X compared with celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, double-dummy, phase III, noninferiority clinical trial.

  Clinical therapeutics 20070501

• JP-8 jet fuel exposure rapidly induces high levels of IL-10 and PGE2 secretion and is correlated with loss of immune function.

  Toxicology and industrial health 20070501

• Risk of congestive heart failure with nonsteroidal antiinflammatory drugs and selective Cyclooxygenase 2 inhibitors: a class effect?

  Arthritis and rheumatism 20070415

• Celecoxib toxicity is cell cycle phase specific.

  Cancer research 20070415

• Celecoxib attenuates 5-fluorouracil-induced apoptosis in HCT-15 and HT-29 human colon cancer cells.

  World journal of gastroenterology 20070407

• [Further definition of the role of COX-2 inhibitors and NSAIDs in patients with nociceptive pain].

  Nederlands tijdschrift voor geneeskunde 20070407

• NO-donor COX-2 inhibitors. New nitrooxy-substituted 1,5-diarylimidazoles endowed with COX-2 inhibitory and vasodilator properties.

  Journal of medicinal chemistry 20070405

• Lipoperoxidation and cyclooxygenases 1 and 2 inhibitory compounds from Iryanthera juruensis.

  Journal of agricultural and food chemistry 20070404

• Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial.

  Journal of the National Cancer Institute 20070404

• Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.

  Pharmacoepidemiology and drug safety 20070401

• A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer.

  Investigational new drugs 20070401

• Characterizing new users of NSAIDs before and after rofecoxib withdrawal.

  British journal of clinical pharmacology 20070401

• Celecoxib and CVS risk--lessons from the APC and PreSAP studies.

  Rheumatology (Oxford, England) 20070401

• Structural pathology in a rodent model of osteoarthritis is associated with neuropathic pain: increased expression of ATF-3 and pharmacological characterisation.

  Pain 20070401

• Surface phospholipids in gastric injury and protection when a selective cyclooxygenase-2 inhibitor (Coxib) is used in combination with aspirin.

  British journal of pharmacology 20070401

• MR monitoring of cyclooxygenase-2 inhibition of angiogenesis in a human breast cancer model in rats.

  Radiology 20070401

• Failure of apoptosis and activation on NFkappaB by celecoxib and aspirin in lung cancer cell lines.

  Oncology reports 20070401

• Combinatorial prevention of carcinogenic risk in a model for familial colon cancer.

  Oncology reports 20070401

• Down-regulation of PGE2 by physiologic levels of celecoxib is not sufficient to induce apoptosis or inhibit cell proliferation in human colon carcinoma cell lines.

  Digestive diseases and sciences 20070401

• In vivo effects of amtolmetin guacyl on lipid peroxidation and antioxidant defence systems. Comparison with non-selective and COX-2 selective NSAIDs.

  Autonomic & autacoid pharmacology 20070401

• A reduction of cyclooxygenase 2 gene dosage counters the ovarian morphological aging and tumor phenotype in Wv mice.

  The American journal of pathology 20070401

• Angiogenic inhibition reduces germinal matrix hemorrhage.

  Nature medicine 20070401

• Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC).

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20070401

• [Effects of selective cyclooxygenase-2 inhibitor on proliferation and apoptosis of human bladder cancer cell line T24].

  Ai zheng = Aizheng = Chinese journal of cancer 20070401

• Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib.

  Molecular cancer therapeutics 20070401

• The effect of 2 Hz and 100 Hz electrical stimulation of acupoint on ankle sprain in rats.

  Journal of Korean medical science 20070401

• Cyclooxygenase-2 induction by arsenite through the IKKbeta/NFkappaB pathway exerts an antiapoptotic effect in mouse epidermal Cl41 cells.

  Environmental health perspectives 20070401

• Effect of low-level laser therapy on hemorrhagic lesions induced by immune complex in rat lungs.

  Photomedicine and laser surgery 20070401

• Letter by Cen regarding article, 'Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas'.

  Circulation 20070327

• Sulfonation of 17beta-estradiol and inhibition of sulfotransferase activity by polychlorobiphenylols and celecoxib in channel catfish, Ictalurus punctatus.

  Aquatic toxicology (Amsterdam, Netherlands) 20070310

• Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies.

  Rheumatology (Oxford, England) 20070301

• Adjusted indirect comparison of celecoxib versus rofecoxib on cardiovascular risk.

  Rheumatology international 20070301

• Up-regulation of 150-kDa oxygen-regulated protein by celecoxib in human gastric carcinoma cells.

  Molecular pharmacology 20070301

• Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system.

  Journal of neurochemistry 20070301

• Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.

  Rheumatology (Oxford, England) 20070301

• Design, synthesis, and biological evaluation of substituted 2-alkylthio-1,5-diarylimidazoles as selective COX-2 inhibitors.

  Bioorganic & medicinal chemistry 20070301

• Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: inhibition of tumor angiogenesis with extensive tumor necrosis.

  International journal of radiation oncology, biology, physics 20070301

• Cyclooxygenase-2 inhibition increases gastric tone and delays gastric emptying in rats.

  Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20070301

• When is a neoplasm not a neoplasm? When it is a desmoid.

  Journal of surgical oncology 20070301

• Dose and time-dependent effects of cyclooxygenase-2 inhibition on fracture-healing.

  The Journal of bone and joint surgery. American volume 20070301

• Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070301

• Does the consumption of green tea reduce the risk of lung cancer among smokers?

  Evidence-based complementary and alternative medicine : eCAM 20070301

• The selective cyclooxygenase-2 inhibitor celecoxib reduces bone resorption, but not bone formation, in ovariectomized mice in vivo.

  The Tohoku journal of experimental medicine 20070301

• Short-term efficacy of rofecoxib and diclofenac in acute shoulder pain: a placebo-controlled randomized trial.

  PLoS clinical trials 20070301

• Dynamic simulations on the arachidonic acid metabolic network.

  PLoS computational biology 20070301

• Adenoviral pneumonia during etanercept treatment in a patient with rheumatoid arthritis.

  The Korean journal of internal medicine 20070301

• [Role of cyclooxygenase-2 in pulmonary microcirculation disorder in rats with acute pancreatitis].

  Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20070301

• Eosinophilic fasciitis in a 57-year-old Japanese-American woman.

  Hawaii medical journal 20070301

• Selective inhibition of prostacyclin synthase activity by rofecoxib.

  Journal of cellular and molecular medicine 20070301

• Expression of cyclooxygenase-2 in osteosarcoma of bone.

  Applied immunohistochemistry & molecular morphology : AIMM 20070301

• A randomized, double-blind, celecoxib- and placebo-controlled study of the effectiveness of CS-706 in acute postoperative dental pain.

  Clinical therapeutics 20070301

• Acetaminophen is as good as celecoxib for degenerative joint disease.

  The Journal of family practice 20070301

• Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model.

  Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 20070301

• [Antitumor effects of specific cyclooxygenase inhibitors combined with chemotherapeutic agents on gastric cancer cells in vitro].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20070301

• Motexafin gadolinium injection for the treatment of brain metastases in patients with non-small cell lung cancer.

  International journal of nanomedicine 20070301

• Activity and potential role of licofelone in the management of osteoarthritis.

  Clinical interventions in aging 20070301

• 3-Phosphoinositide-dependent protein kinase-1/Akt signalling and inhibition in a canine prostate carcinoma cell line.

  Veterinary and comparative oncology 20070301

• Studies in 3,4-diaryl-1,2,5-oxadiazoles and their N-oxides: search for better COX-2 inhibitors.

  Acta pharmaceutica (Zagreb, Croatia) 20070301

• Physicochemical characterization and in vitro dissolution behaviour of celecoxib-beta-cyclodextrin inclusion complexes.

  Acta pharmaceutica (Zagreb, Croatia) 20070301

• Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer.

  British journal of cancer 20070226

• 5-Heteroatom substituted pyrazoles as canine COX-2 inhibitors. Part III: molecular modeling studies on binding contribution of 1-(5-methylsulfonyl)pyrid-2-yl and 4-nitrile.

  Bioorganic & medicinal chemistry letters 20070215

• A novel copper complex of 3-benzoyl-alpha methyl benzene acetic acid with antitumor activity mediated via cyclooxygenase pathway.

  International journal of cancer 20070215

• Synthesis and biological evaluation of some 5-ethoxycarbonyl-6-isopropylamino-4-(substitutedphenyl)aminopyrimidines as potent analgesic and anti-inflammatory agents.

  Bioorganic & medicinal chemistry letters 20070215

• Chronic celecoxib users more often show regression of gastric intestinal metaplasia after Helicobacter pylori eradication.

  Alimentary pharmacology & therapeutics 20070215

• Cyclooxygenase inhibitors and cardiovascular risk.

  JAMA 20070214

• Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck.

  British journal of cancer 20070212

• Additive interaction of intraperitoneal dexmedetomidine and topical nimesulide, celecoxib, and DFU for antinociception.

  European journal of pharmacology 20070205

• Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study.

  Rheumatology (Oxford, England) 20070201

• The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction.

  Heart (British Cardiac Society) 20070201

• Revised statistical motor unit number estimation in the Celecoxib/ALS trial.

  Muscle & nerve 20070201

• Risk and risk reduction involving arginine intake and meat consumption in colorectal tumorigenesis and survival.

  International journal of cancer 20070201

• Elevated expression of cyclooxygenase-2 is a negative prognostic factor for overall survival in intrahepatic cholangiocarcinoma.

  Virchows Archiv : an international journal of pathology 20070201

• Celecoxib inhibits meningioma tumor growth in a mouse xenograft model.

  Cancer 20070201

• Chemoprevention by cyclooxygenase-2 inhibition reduces immature myeloid suppressor cell expansion.

  International immunopharmacology 20070201

• Inhibition of cyclooxygenase-2 activity by celecoxib does not lead to radiosensitization of human prostate cancer cells in vitro.

  Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20070201

• Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial.

  Schizophrenia research 20070201

• Effect of celecoxib on E-cadherin, VEGF, Microvessel density and apoptosis in gastric cancer.

  Cancer biology & therapy 20070201

• Effect of different cyclooxygenase inhibitors on gastric adaptive cytoprotection induced by 20% ethanol.

  Digestive diseases and sciences 20070201

• Effects of cyclooxygenase-2 inhibitor on glucagon-induced delayed gastric emptying and gastric dysrhythmia in dogs.

  Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20070201

• Racial/ethnic differences in the use of complementary and alternative medicine in patients with arthritis.

  Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20070201

• Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070201

• Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070201

• RE: 'Transfer of celecoxib into human milk'.

  Journal of human lactation : official journal of International Lactation Consultant Association 20070201

• The adenoma prevention with celecoxib and prevention of colorectal sporadic adenomatous polyps trials: stepping stones to progress.

  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20070201

• COX-2 inhibition: a possible role in the management of prostate cancer?

  Journal of chemotherapy (Florence, Italy) 20070201

• The coxibs and traditional nonsteroidal anti-inflammatory drugs: a current perspective on cardiovascular risks.

  The Canadian journal of cardiology 20070201

• Celecoxib versus ibuprofen in the prevention of heterotopic ossification following total hip replacement: a prospective randomised trial.

  The Journal of bone and joint surgery. British volume 20070201

• Chemopreventive effect of celecoxib in gastric cancer.

  Inflammopharmacology 20070201

• NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma.

  PLoS medicine 20070201

• 12 things you should know about pain relievers. A dozen take-home messages about the pills that take the hurt away.

  Harvard health letter 20070201

• Evaluation of the cancer chemopreventive efficacy of rice bran in genetic mouse models of breast, prostate and intestinal carcinogenesis.

  British journal of cancer 20070129

• Cyclooxygenase-2 inhibition increases mortality, enhances left ventricular remodeling, and impairs systolic function after myocardial infarction in the pig.

  Circulation 20070123

• Cyclooxygenase inhibition and adverse remodeling during healing after myocardial infarction.

  Circulation 20070123

• Combined neuroprotective effects of celecoxib and memantine in experimental intracerebral hemorrhage.

  Neuroscience letters 20070116

• Synthesis and biological evaluation of quinoline salicylic acids as P-selectin antagonists.

  Journal of medicinal chemistry 20070111

• Mucosal acid causes gastric mucosal microcirculatory disturbance in nonsteroidal anti-inflammatory drug-treated rats.

  European journal of pharmacology 20070105

• Thalidomide and celecoxib as potential modulators of irinotecan's activity in cancer patients.

  Cancer chemotherapy and pharmacology 20070101

• Celecoxib compared with sustained-release paracetamol for osteoarthritis: a series of n-of-1 trials.

  Rheumatology (Oxford, England) 20070101

• A prospective randomised multicentre study comparing continuous and intermittent treatment with celecoxib in patients with osteoarthritis of the knee or hip.

  Annals of the rheumatic diseases 20070101

• Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070101

• Inflammation-induced reduction of spontaneous activity by adjuvant: A novel model to study the effect of analgesics in rats.

  The Journal of pharmacology and experimental therapeutics 20070101

• A prospective phase I-II trial of the cyclooxygenase-2 inhibitor celecoxib in patients with carcinoma of the cervix with biomarker assessment of the tumor microenvironment.

  International journal of radiation oncology, biology, physics 20070101

• Long-term efficacy and safety of celecoxib in Alzheimer's disease.

  Dementia and geriatric cognitive disorders 20070101

• A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128.

  International journal of radiation oncology, biology, physics 20070101

• Celecoxib enhances doxorubicin-induced cytotoxicity in MDA-MB231 cells by NF-kappaB-mediated increase of intracellular doxorubicin accumulation.

  European journal of cancer (Oxford, England : 1990) 20070101

• Sulfonamide allergy without cross-reactivity to celecoxib.

  Allergy 20070101

• Pharmacodynamic of cyclooxygenase inhibitors in humans.

  Prostaglandins & other lipid mediators 20070101

• GADD153 mediates celecoxib-induced apoptosis in cervical cancer cells.

  Carcinogenesis 20070101

• FDA advisers endorse Celebrex for juvenile rheumatoid arthritis: lack of studies in children raises safety concerns.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20070101

• Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials.

  The American journal of cardiology 20070101

• Potential antioxidant activity of celecoxib and amtolmetin guacyl: in vitro studies.

  Autonomic & autacoid pharmacology 20070101

• Radiosensitization by 2-benzoyl-3-phenyl-6,7-dichloroquinoxaline 1,4-dioxide under oxia and hypoxia in human colon cancer cells.

  Radiation oncology (London, England) 20070101

• Review: risk for cardiovascular events is increased with rofecoxib, diclofenac, and indomethacin but not celecoxib.

  ACP journal club 20070101

• Modification of the crystal habit of celecoxib for improved processability.

  The Journal of pharmacy and pharmacology 20070101

• Intra-articular injection of a nutritive mixture solution protects articular cartilage from osteoarthritic progression induced by anterior cruciate ligament transection in mature rabbits: a randomized controlled trial.

  Arthritis research & therapy 20070101

• The efficacy of oral nonsteroidal anti-inflammatory medication (NSAID) in the treatment of plantar fasciitis: a randomized, prospective, placebo-controlled study.

  Foot & ankle international 20070101

• Early onset pauciarticular arthritis is the major risk factor for naproxen-induced pseudoporphyria in juvenile idiopathic arthritis.

  Arthritis research & therapy 20070101

• Evaluation of the patient acceptable symptom state in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis.

  Arthritis research & therapy 20070101

• Effects of specific inhibition of cyclooxygenease-2 on kidney in bilateral adrenalectomized rats.

  International urology and nephrology 20070101

• Antinociceptive efficacy of lacosamide in the monosodium iodoacetate rat model for osteoarthritis pain.

  Arthritis research & therapy 20070101

• [COX-2 and HO-1 are involved in the delayed preconditioning elicited by bradykinin in rat hearts].

  Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences 20070101

• Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.

  American journal of therapeutics 20070101

• COX-2 inhibitors celecoxib and parecoxib: valuable options for postoperative pain management.

  Current topics in medicinal chemistry 20070101

• Unilateral conjunctival chemosis as a unique symptom of nonsteroidal anti-inflammatory drug intolerance.

  Journal of investigational allergology & clinical immunology 20070101

• Handgrip performance in relation to self-perceived fatigue, physical functioning and circulating IL-6 in elderly persons without inflammation.

  BMC geriatrics 20070101

• Use of celecoxib immediately post marketing in Canada: acute or chronic pain?

  The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique 20070101

• An exploratory study of primary care physician decision making regarding total joint arthroplasty.

  Journal of general internal medicine 20070101

• Cell culture model for colon cancer prevention and therapy: an alternative approach to animal experimentation.

  ALTEX 20070101

• Effects of celecoxib on migration, proliferation and collagen expression of tendon cells.

  Connective tissue research 20070101

• Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo.

  BMC cancer 20070101

• Evidence for placebo effects on physical but not on biochemical outcome parameters: a review of clinical trials.

  BMC medicine 20070101

• Effect of celecoxib on fasciocutaneous flap survival and revascularization.

  Archives of facial plastic surgery 20070101

• Maintenance treatment with esomeprazole following initial relief of non-steroidal anti-inflammatory drug-associated upper gastrointestinal symptoms: the NASA2 and SPACE2 studies.

  Arthritis research & therapy 20070101

• Apoptotic effect of celecoxib dependent upon p53 status in human ovarian cancer cells.

  Annals of the New York Academy of Sciences 20070101

• The cyclooxygenase-2 selective inhibitor celecoxib suppresses proliferation and invasiveness in the human oral squamous carcinoma.

  Annals of the New York Academy of Sciences 20070101

• [The best of clinical pharmacology in 2006].

  Archives des maladies du coeur et des vaisseaux 20070101

• Effects of celecoxib on human chondrocytes--enhanced production of chemokines.

  Clinical and experimental rheumatology 20070101

• Decisions by regulatory agencies: are they evidence-based?

  Trials 20070101

• Celecoxib prevents juxta-articular osteopenia and growth plate destruction adjacent to inflamed joints in rats with collagen-induced arthritis.

  Modern rheumatology 20070101

• Polymeric nanoparticle-encapsulated curcumin ('nanocurcumin'): a novel strategy for human cancer therapy.

  Journal of nanobiotechnology 20070101

• Protective role of fish oil (Maxepa) on early events of rat mammary carcinogenesis by modulation of DNA-protein crosslinks, cell proliferation and p53 expression.

  Cancer cell international 20070101

• Inhibition of Akt pathways in the treatment of prostate cancer.

  Prostate cancer and prostatic diseases 20070101

• Development and evaluation of a gastroretentive drug delivery system for the low-absorption-window drug celecoxib.

  PDA journal of pharmaceutical science and technology 20070101

• Celecoxib:nicotinamide dissociation: using excipients to capture the cocrystal's potential.

  Molecular pharmaceutics 20070101

• Dual carbonic anhydrase--cyclooxygenase-2 inhibitors.

  Current topics in medicinal chemistry 20070101

• Effect of celecoxib on cyclooxygenase-2 expression and possible variants in a patient with Barrett's esophagus.

  Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus 20070101

• Cyclooxygenase 2 expression in pterygium.

  Molecular vision 20070101

• Proton-pump inhibitors are associated with a reduced risk for bleeding and perforated gastroduodenal ulcers attributable to non-steroidal anti-inflammatory drugs: a nested case-control study.

  Arthritis research & therapy 20070101

• Generic drug policy in Australia: a community pharmacy perspective.

  Australia and New Zealand health policy 20070101

• Simultaneous inhibition of COX-2 and 5-LOX activities augments growth arrest and death of premalignant and malignant human lung cell lines.

  Journal of experimental therapeutics & oncology 20070101

• Arthritis and pain. Future targets to control osteoarthritis pain.

  Arthritis research & therapy 20070101

• Prevention of posterior capsular opacification through cyclooxygenase-2 inhibition.

  Molecular vision 20070101

• Reduced risk of human lung cancer by selective cyclooxygenase 2 (COX-2) blockade: results of a case control study.

  International journal of biological sciences 20070101

• Celebrex approved for juvenile arthritis.

  FDA consumer 20070101

• Bayesian confidence propagation neural network.

  Drug safety 20070101

• An economic model of long-term use of celecoxib in patients with osteoarthritis.

  BMC gastroenterology 20070101

• The flavonoid luteolin worsens chemical-induced colitis in NF-kappaB(EGFP) transgenic mice through blockade of NF-kappaB-dependent protective molecules.

  PloS one 20070101

• Cyclooxygenase-2 (cox-2) and the inflammogenesis of cancer.

  Sub-cellular biochemistry 20070101

• Strategies for colon cancer prevention: combination of chemopreventive agents.

  Sub-cellular biochemistry 20070101

• Adenovirus type 5 E1A-induced apoptosis in COX-2-overexpressing breast cancer cells.

  Breast cancer research : BCR 20070101

• Findings in patients with chronic intestinal dysmotility investigated by capsule endoscopy.

  BMC gastroenterology 20070101

• Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer.

  Breast cancer research : BCR 20070101

• The cytotoxicity of celecoxib towards cardiac myocytes is cyclooxygenase-2 independent.

  Cardiovascular toxicology 20070101

• Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice.

  BMC neuroscience 20070101

• Anti-inflammatory and side effects of cyclooxygenase inhibitors.

  Pharmacological reports : PR 20070101

• Glucosamine and chondroitin sulfate as therapeutic agents for knee and hip osteoarthritis.

  Drugs & aging 20070101

• Safety of celecoxib in patients with cutaneous reactions due to ASA-NSAIDs intolerance.

  Allergologia et immunopathologia 20070101

• Medical treatment and other combination regimens.

  Tumori 20070101

• Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk.

  BMC musculoskeletal disorders 20070101

• Exploring effects of different nonsteroidal antiinflammatory drugs on lipid peroxidation. Part II. 4-HNE profile.

  Acta poloniae pharmaceutica 20070101

• Celecoxib increased expression of 14-3-3sigma and induced apoptosis of glioma cells.

  Anticancer research 20070101

• Atypical antipsychotics in bipolar disorder: systematic review of randomised trials.

  BMC psychiatry 20070101

• Effectiveness of compression stockings to prevent the post-thrombotic syndrome (the SOX Trial and Bio-SOX biomarker substudy): a randomized controlled trial.

  BMC cardiovascular disorders 20070101

• Effect of the COX-2 inhibitor celecoxib on behavioural and immune changes in an olfactory bulbectomised rat model of depression.

  Neuroimmunomodulation 20070101

• Anithrombotic prevention in vascular disease: bases for a new strategy in antithrombotic therapy.

  Thrombosis journal 20070101

• Celecoxib combined with esomeprazole prevented recurrent ulcer bleeding in patients with previous NSAID-induced ulcer bleeding.

  ACP journal club 20070101

• Enhanced retention of celecoxib-loaded solid lipid nanoparticles after intra-articular administration.

  Drugs in R&D 20070101

• The tell-tale heart: population-based surveillance reveals an association of rofecoxib and celecoxib with myocardial infarction.

  PloS one 20070101

• Effect of hydroalcoholic extract of Zingiber officinalis rhizomes on LPS-induced rat airway hyperreactivity and lung inflammation.

  Prostaglandins, leukotrienes, and essential fatty acids 20070101

• [Acute pancreatitis after treatment by celecoxib].

  Gastroenterologie clinique et biologique 20070101

• Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer.

  Nutrition and cancer 20070101

• Chemopreventive effects of nonsteroidal anti-inflammatory drugs in the membrane lipid composition and fluidity parameters of the 1,2-dimethylhydrazine-induced colon carcinogenesis in rats.

  Drug and chemical toxicology 20070101

• Single dose oral lumiracoxib for postoperative pain.

  The Cochrane database of systematic reviews 20070101

• Inflammatory response and meningioma tumorigenesis and the effect of cyclooxygenase-2 inhibitors.

  Neurosurgical focus 20070101

• Intestinal toxicity of non-steroidal anti-inflammatory drugs with differential cyclooxygenase inhibition selectivity.

  Nutricion hospitalaria 20070101

• Comparison of glucosamine sulfate and a polyherbal supplement for the relief of osteoarthritis of the knee: a randomized controlled trial [ISRCTN25438351].

  BMC complementary and alternative medicine 20070101

• Celecoxib: a review of its use in the management of arthritis and acute pain.

  Drugs 20070101

• Cells of the synovium in rheumatoid arthritis. Chondrocytes.

  Arthritis research & therapy 20070101

• Effects of acetylsalicylic acid and celecoxib on the N-nitrosodiethylamine induced carcinogenesis in rat liver and esophagus.

  Bulletin of experimental biology and medicine 20070101

• Transcriptional profiling of non-small cell lung cancer cells with activating EGFR somatic mutations.

  PloS one 20070101

• Mechanical properties during healing of Achilles tendon ruptures to predict final outcome: a pilot Roentgen stereophotogrammetric analysis in 10 patients.

  BMC musculoskeletal disorders 20070101

• The effects of a cyclooxygenase-2 (COX-2) expression and inhibition on human uveal melanoma cell proliferation and macrophage nitric oxide production.

  Journal of carcinogenesis 20070101

• Preparation and physicochemical and preclinical evaluations of recrystallized celecoxib.

  PDA journal of pharmaceutical science and technology 20070101

• Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial.

  BMC cancer 20070101

• Apoptosis is not the major death mechanism induced by celecoxib on rheumatoid arthritis synovial fibroblasts.

  Arthritis research & therapy 20070101

• Cyclooxygenase inhibition lowers prostaglandin E2 release from articular cartilage and reduces apoptosis but not proteoglycan degradation following an impact load in vitro.

  Arthritis research & therapy 20070101

• Adverse drug interactions involving common prescription and over-the-counter analgesic agents.

  Clinical therapeutics 20070101

• Analgesic efficacy of celecoxib in postoperative oral surgery pain: a single-dose, two-center, randomized, double-blind, active- and placebo-controlled study.

  Clinical therapeutics 20070101

• Cells of the synovium in rheumatoid arthritis. Synovial fibroblasts.

  Arthritis research & therapy 20070101

• Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy.

  Experimental diabetes research 20070101

• [Reactivity and communication of Health Authorities toward health professionals: a public health priority].

  Therapie 20070101

• The immune response is involved in atherosclerotic plaque calcification: could the RANKL/RANK/OPG system be a marker of plaque instability?

  Clinical & developmental immunology 20070101

• Comparison of antinociceptive efficacy and gastroprotection between celecoxib and diclofenac plus misoprostol in rats.

  Proceedings of the Western Pharmacology Society 20070101

• [Articular cartilage in osteoarthritic patients: effects of diclofenac, celecoxib and glucosamine sulfate on inflammatory markers].

  Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina) 20070101

• Cyclooxygenase-2 (COX-2) in carcinogenesis and selective COX-2 inhibitors for chemoprevention in gastrointestinal cancers.

  Journal of gastrointestinal cancer 20070101

• Chemopreventive effects of nonsteroidal anti-inflammatory drugs on 1,2-dimethylhydrazine-induced colon carcinogenesis in rats.

  Toxicology mechanisms and methods 20070101

• Alterations in the lipid profile and membrane dynamics of rat intestinal brush border membrane induced by different classes of nonsteroidal anti-inflammatory drugs.

  Toxicology mechanisms and methods 20070101

• Nonsteroidal anti-inflammatory drug hypersensitivity in preschool children.

  Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 20070101

• Clinical management of adult patients with a history of nonsteroidal anti-inflammatory drug-induced urticaria/angioedema: update.

  Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 20070101

• Statistical fallacies in orthopedic research.

  Indian journal of orthopaedics 20070101

• Lumiracoxib: the evidence of its clinical impact on the treatment of osteoarthritis.

  Core evidence 20070101

• Adalimumab in ankylosing spondylitis: an evidence-based review of its place in therapy.

  Core evidence 20070101

• Microscopic modes and free energies of 3-phosphoinositide-dependent kinase-1 (PDK1) binding with celecoxib and other inhibitors.

  The journal of physical chemistry. B 20061228

• Nitric oxide deficiency promotes vascular side effects of cyclooxygenase inhibitors.

  Blood 20061215

• Intestinal effects of nonselective and selective cyclooxygenase inhibitors in the rat.

  European journal of pharmacology 20061215

• Stability of the patient acceptable symptomatic state over time in outcome criteria in ankylosing spondylitis.

  Arthritis and rheumatism 20061215

• [The inhibitive effects of celecoxib combined with octreotide on the metastasis of human gastric cancer in vivo].

  Zhonghua yi xue za zhi 20061212

• Effects of non-steroidal anti-inflammatory drugs on cell proliferation and death in cultured epiphyseal-articular chondrocytes of fetal rats.

  Toxicology 20061207

• Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations.

  Gut 20061201

• Prostaglandin E2 is a potent inhibitor of epithelial-to-mesenchymal transition: interaction with hepatocyte growth factor.

  American journal of physiology. Renal physiology 20061201

• Synthesis and biological evaluation of a novel class of rofecoxib analogues as dual inhibitors of cyclooxygenases (COXs) and lipoxygenases (LOXs).

  Bioorganic & medicinal chemistry 20061201

• Design, synthesis, and biological evaluation of (E)-3-(4-methanesulfonylphenyl)-2-(aryl)acrylic acids as dual inhibitors of cyclooxygenases and lipoxygenases.

  Bioorganic & medicinal chemistry 20061201

• Comparison of antinociceptive actions of standard analgesics in attenuating capsaicin and nerve-injury-induced mechanical hypersensitivity.

  Neuroscience 20061201

• Low-grade systemic inflammation causes endothelial dysfunction in patients with Hashimoto's thyroiditis.

  The Journal of clinical endocrinology and metabolism 20061201

• Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group.

  Annals of oncology : official journal of the European Society for Medical Oncology 20061201

• Coupled atomic charge selectivity for optimal ligand-charge distributions at protein binding sites.

  Journal of computational chemistry 20061201

• The impact of NSAID or COX-2 inhibitor use on the initiation of antihypertensive therapy.

  Pharmacoepidemiology and drug safety 20061201

• Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations. Implications for COX-2 cardiovascular profile.

  Pharmacoepidemiology and drug safety 20061201

• Cyclooxygenase-2 inhibition attenuates antibody responses against human papillomavirus-like particles.

  Journal of immunology (Baltimore, Md. : 1950) 20061201

• Safety and efficacy of short-term celecoxib before elective percutaneous coronary intervention for stable angina pectoris.

  The American journal of cardiology 20061201

• Platelet-derived growth factor receptor-beta in Gorham's disease.

  Nature clinical practice. Oncology 20061201

• Cellular FLICE-inhibitory protein down-regulation contributes to celecoxib-induced apoptosis in human lung cancer cells.

  Cancer research 20061201

• Conformal radiotherapy of the dominant liver metastasis: a viable strategy for treatment of unresectable chemotherapy refractory colorectal cancer liver metastases.

  American journal of clinical oncology 20061201

• Chemoprevention of colorectal cancer: two steps forward, one step back?

  Future oncology (London, England) 20061201

• Clinical activity of celecoxib in metastatic malignant melanoma.

  Cancer investigation 20061201

• Assessment of celecoxib pharmacodynamics in pancreatic cancer.

  Molecular cancer therapeutics 20061201

• Do selective COX-2 inhibitors increase the risk of cerebrovascular events? A meta-analysis of randomized controlled trials.

  Journal of clinical pharmacy and therapeutics 20061201

• The cyclooxygenase 2 genetic variant -765G>C does not modulate the effects of celecoxib on prostaglandin E2 production.

  Clinical pharmacology and therapeutics 20061201

• Is the demonstration of adenoma reduction with rofecoxib a pyrrhic victory?

  Gastroenterology 20061201

• The suspension of treatments in ADAPT: concerns beyond the cardiovascular safety of celecoxib or naproxen.

  PLoS clinical trials 20061201

• Pro- and anti-inflammatory activities of the latex from Calotropis procera (Ait.) R.Br. are triggered by compounds fractionated by dialysis.

  Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20061201

• Dissolution of celecoxib from mucoadhesive disks based on polyaspartamide derivatives.

  Acta pharmaceutica (Zagreb, Croatia) 20061201

• Risks and benefits of celecoxib to prevent colorectal adenomas.

  The New England journal of medicine 20061130

• 9-cis-Retinoic acid inhibition of lung carcinogenesis in the A/J mouse model is accompanied by increased expression of RAR-beta but no change in cyclooxygenase-2.

  Cancer letters 20061128

• Acute pulmonary inflammation induced by exposure of the airways to staphylococcal enterotoxin type B in rats.

  Toxicology and applied pharmacology 20061115

• Gene expression profiling in R-flurbiprofen-treated prostate cancer: R-Flurbiprofen regulates prostate stem cell antigen through activation of AKT kinase.

  Biochemical pharmacology 20061115

• Outcome of peptic ulcer bleeding among users of traditional non-steroidal anti-inflammatory drugs and selective cyclo-oxygenase-2 inhibitors.

  Alimentary pharmacology & therapeutics 20061115

• Efficacy of celecoxib in the treatment of CNS lymphomas: an in vivo model.

  Neurosurgical focus 20061115

• Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis--a population-based survey.

  Clinical rheumatology 20061101

• A randomized double-blind placebo-controlled phase II trial of the cyclooxygenase-2 inhibitor Celecoxib in the treatment of cervical dysplasia.

  Gynecologic oncology 20061101

• Simultaneous quantitation of rosuvastatin and gemfibrozil in human plasma by high-performance liquid chromatography and its application to a pharmacokinetic study.

  Biomedical chromatography : BMC 20061101

• Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.

  Molecular pharmacology 20061101

• Urine PGE-M: A metabolite of prostaglandin E2 as a potential biomarker of advanced colorectal neoplasia.

  Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20061101

• Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: A population-based, nested case-control analysis.

  American journal of epidemiology 20061101

• Celecoxib reduces microvessel density in patients treated with nasopharyngeal carcinoma and induces changes in gene expression.

  Annals of oncology : official journal of the European Society for Medical Oncology 20061101

• Does celecoxib have an adverse effect on bone remodeling and ingrowth in humans?

  Clinical orthopaedics and related research 20061101

• A feasibility study of the efficacy and tolerability of the combination of Exemestane with the COX-2 inhibitor Celecoxib in post-menopausal patients with advanced breast cancer.

  European journal of cancer (Oxford, England : 1990) 20061101

• Celecoxib allergies and cross-reactivity.

  Internal medicine journal 20061101

• The analgesic efficacy of celecoxib, pregabalin, and their combination for spinal fusion surgery.

  Anesthesia and analgesia 20061101

• Transcriptional profiling of tumor biopsies in oncology trials--a 'window' of opportunity for evaluating new drugs in nasopharyngeal cancer?

  Annals of oncology : official journal of the European Society for Medical Oncology 20061101

• Is ranitidine therapy sufficient for healing peptic ulcers associated with non-steroidal anti-inflammatory drug use?

  International journal of clinical practice 20061101

• Case of acrodermatitis continua accompanied by psoriatic arthritis.

  The Journal of dermatology 20061101

• Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.

  Arthritis and rheumatism 20061101

• The use of celecoxib and dexamethasone for the prevention and control of postoperative pain after periodontal surgery.

  Journal of periodontology 20061101

• [Chemopreventive effect of tamoxifen combined with celecoxib on DMBA-induced breast cancer in rats].

  Ai zheng = Aizheng = Chinese journal of cancer 20061101

• Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT).

  PLoS clinical trials 20061101

• ADAPT: the wrong way to stop a clinical trial.

  PLoS clinical trials 20061101

• A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors.

  Journal of pediatric hematology/oncology 20061101

• [Chemopreventive effect of celecoxib against DMBA-induced breast cancer and its mechanism].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20061101

• Inhibition of 5-lipoxygenase by MK886 augments the antitumor activity of celecoxib in human colon cancer cells.

  Molecular cancer therapeutics 20061101

• Nonsteroidal anti-inflammatory drugs: cyclooxygenase 2 inhibitors.

  Jornal de pediatria 20061101

• Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.

  Clinical therapeutics 20061101

• Inhibitors of cyclooxygenases: mechanisms, selectivity and uses.

  Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20061101

• [Inhibited proliferation and expression of human nasopharyngeal carcinoma line induced by celecoxib in vitro].

  Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery 20061101

• [Non-steroidal anti-inflammatory drug induced gastropathy and preventive effects of teprenone on the gastropathy in rats].

  Zhonghua yi xue za zhi 20061031

• Tolerance to celecoxib in patients with a history of adverse reactions to nonsteroidal anti-inflammatory drugs.

  Swiss medical weekly 20061028

• Differential effect of celecoxib on tissue factor expression in human endothelial and vascular smooth muscle cells.

  Biochemical and biophysical research communications 20061020

• Did targeted therapy fail cyclooxygenase too?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20061020

• Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20061020

• Effect of simultaneous inhibition of epidermal growth factor receptor and cyclooxygenase-2 in HER-2/neu-positive breast cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20061015

• Celecoxib could reverse the hypoxia-induced Angiopoietin-2 upregulation in gastric cancer.

  Cancer letters 20061008

• Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.

  JAMA 20061004

• Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials.

  JAMA 20061004

• Simultaneous estimation of six anti-diabetic drugs--glibenclamide, gliclazide, glipizide, pioglitazone, repaglinide and rosiglitazone: development of a novel HPLC method for use in the analysis of pharmaceutical formulations and its application to human plasma assay.

  Biomedical chromatography : BMC 20061001

• GADD153 mediates celecoxib-induced apoptosis in cervical cancer cells.

  Carcinogenesis 20061001

• Roles of COX-2 and iNOS in the bony repair of the injured growth plate cartilage.

  Journal of cellular biochemistry 20061001

• Docosahexaenoic acid in combination with celecoxib modulates HSP70 and p53 proteins in prostate cancer cells.

  International journal of cancer 20061001

• Inhibition profiling of human carbonic anhydrase II by high-throughput screening of structurally diverse, biologically active compounds.

  Journal of biomolecular screening 20061001

• Neutrophil migration in mice induced by a mannose-binding lectin isolated from Annona coriacea seeds.

  Toxicon : official journal of the International Society on Toxinology 20061001

• Risk of hospitalization for angio-oedema among users of newer COX-2 selective inhibitors and other nonsteroidal anti-inflammatory drugs.

  British journal of clinical pharmacology 20061001

• Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen.

  Kidney international 20061001

• Can the blood pressure effects of COX-2 selective inhibitors be explained by changes in plasma aldosterone levels?

  Journal of hypertension 20061001

• Cyclooxygenase-2 directly regulates gene expression of P450 Cyp19 aromatase promoter regions pII, pI.3 and pI.7 and estradiol production in human breast tumor cells.

  Prostaglandins & other lipid mediators 20061001

• Nonsteroidal antiinflammatory drugs and acute myocardial infarction in patients with no major risk factors.

  Pharmacotherapy 20061001

• The associations between severity of early postoperative pain, chronic postsurgical pain and plasma concentration of stable nitric oxide products after breast surgery.

  Anesthesia and analgesia 20061001

• Extent of renal effect of cyclo-oxygenase-2-selective inhibitors is pharmacokinetic dependent.

  Clinical and experimental pharmacology & physiology 20061001

• Bovine and porcine transscleral solute transport: influence of lipophilicity and the Choroid-Bruch's layer.

  Investigative ophthalmology & visual science 20061001

• Chemopreventive effect of celecoxib in oral precancers and cancers.

  The Laryngoscope 20061001

• COX-2 inhibitors and cardiovascular risk. Inferences based on biology and clinical studies.

  Thrombosis and haemostasis 20061001

• Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic anti-inflammatory drugs? Arguments in favor.

  Thrombosis and haemostasis 20061001

• Selective COX-2 inhibitors and risk of thromboembolic events - regulatory aspects.

  Thrombosis and haemostasis 20061001

• Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Cox-independent mechanism.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20061001

• Cyclooxygenase-2 inhibition and regression of metastatic melanoma.

  Melanoma research 20061001

• Involvement of mitochondrial and Akt signaling pathways in augmented apoptosis induced by a combination of low doses of celecoxib and N-(4-hydroxyphenyl) retinamide in premalignant human bronchial epithelial cells.

  Cancer research 20061001

• Different eicosanoid profile of the hypersensitivity reactions triggered by aspirin and celecoxib in a patient with sinusitis, asthma, and urticaria.

  The Journal of allergy and clinical immunology 20061001

• Inhibition of the cyclooxygenase pathway attenuates morphine-induced conditioned place preference in mice.

  Pharmacology, biochemistry, and behavior 20061001

• [Prophylactic effect of a selective COX-2 inhibitor celecoxib on carcinogen-induced gastric premalignant lesions in rats].

  Ai zheng = Aizheng = Chinese journal of cancer 20061001

• Trying times for painkiller choices. Vioxx, Bextra, and Celebrex can increase the risk for heart attack and other cardiovascular problems. So can the old standbys, like ibuprofen and acetaminophen.

  Harvard heart letter : from Harvard Medical School 20061001

• Increased Leishmania replication in HIV-1-infected macrophages is mediated by tat protein through cyclooxygenase-2 expression and prostaglandin E2 synthesis.

  The Journal of infectious diseases 20060915

• CCL3/macrophage inflammatory protein-1alpha induces fever and increases prostaglandin E2 in cerebrospinal fluid of rats: effect of antipyretic drugs.

  Brain research 20060913

• Inhibition of cyclooxygenase (COX)-2 affects endothelial progenitor cell proliferation.

  Experimental cell research 20060910

• Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas.

  Circulation 20060905

• Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medications.

  Pharmacoepidemiology and drug safety 20060901

• Celecoxib inhibits nitric oxide production in chondrocytes of ligament-damaged osteoarthritic rat joints.

  Rheumatology international 20060901

• Effect of COX-2 inhibitors and non-steroidal anti-inflammatory drugs on a mouse fracture model.

  Injury 20060901

• Involvement of the 5-lipoxygenase/leukotriene A4 hydrolase pathway in 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamster cheek pouch, and inhibition of carcinogenesis by its inhibitors.

  Carcinogenesis 20060901

• Role of the cyclooxygenase pathway in the protection against postischemic stunning in conscious sheep.

  Molecular and cellular biochemistry 20060901

• Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern.

  Neuroscience 20060901

• Tumour necrosis factor-alpha blockers: potential limitations in the management of advanced endometriosis? A case report.

  Human reproduction (Oxford, England) 20060901

• Design and synthesis of new water-soluble tetrazolide derivatives of celecoxib and rofecoxib as selective cyclooxygenase-2 (COX-2) inhibitors.

  Bioorganic & medicinal chemistry letters 20060901

• Selective COX-2 inhibitors. Part 1: synthesis and biological evaluation of phenylazobenzenesulfonamides.

  Bioorganic & medicinal chemistry letters 20060901

• Inhalation delivery and anti-tumor activity of celecoxib in human orthotopic non-small cell lung cancer xenograft model.

  Pharmaceutical research 20060901

• Celecoxib in the treatment of haemophilic synovitis, target joints, and pain in adults and children with haemophilia.

  Haemophilia : the official journal of the World Federation of Hemophilia 20060901

• Cyclooxygenase-2 inhibitors and coronary occlusion--exploring dose-response relationships.

  British journal of clinical pharmacology 20060901

• The effect of the withdrawal of rofecoxib on prescribing patterns of COX-2 inhibitors in Scotland.

  British journal of clinical pharmacology 20060901

• High-Dose celecoxib and metronomic 'low-dose' cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060901

• Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease.

  Clinical pharmacology and therapeutics 20060901

• Is celecoxib an inducer of cytochrome P450 3A4 in subjects carrying the CYP2C9*3 allele?

  Clinical pharmacology and therapeutics 20060901

• Cyclooxygenase-2 plays an essential part in cardioprotection of delayed phase of recombinant human erythropoietin preconditioning in rats.

  Postgraduate medical journal 20060901

• Are COX-2 inhibitors safe for anyone.

  Inflammatory bowel diseases 20060901

• Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis.

  The Journal of rheumatology 20060901

• Liquid-chromatographic separation and determination of process-related impurities, including a regio-specific isomer of celecoxib on reversed-phase C18 column dynamically coated with hexamethyldisilazane.

  Analytical sciences : the international journal of the Japan Society for Analytical Chemistry 20060901

• Proteomic profiling identifies cyclooxygenase-2-independent global proteomic changes by celecoxib in colorectal cancer cells.

  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20060901

• Valdecoxib does not interfere with the CYP2D6 substrate metoprolol.

  International journal of clinical pharmacology and therapeutics 20060901

• [A case of complete regression of hepatocellular carcinoma during administration of COX-2 inhibitor].

  The Korean journal of hepatology 20060901

• Impact of cyclooxygenase inhibitors in the Women's Health Initiative hormone trials: secondary analysis of a randomized trial.

  PLoS clinical trials 20060901

• Influence of hydrophilic polymers on celecoxib complexation with hydroxypropyl beta-cyclodextrin.

  AAPS PharmSciTech 20060901

• [Effects of nonsteroidal anti-inflammatory drug celecoxib on expression of cyclooxygenase-2 (COX-2) in ovarian carcinoma cell].

  Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20060901

• Predictors of the selection of coxibs over nonselective NSAIDs in an older Medicaid cohort.

  The American journal of geriatric pharmacotherapy 20060901

• [What do we know about the cardiovascular toxicity of the NSAIDs?].

  Presse medicale (Paris, France : 1983) 20060901

• [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].

  Presse medicale (Paris, France : 1983) 20060901

• Paired drugs give advanced lung cancer a double punch.

  Health news (Waltham, Mass.) 20060901

• Critical appraisal of C-reactive protein throughout the spectrum of cardiovascular disease.

  Vascular health and risk management 20060901

• [What do we know about the cardiovascular toxicity of the NSAIDs?].

  Presse medicale (Paris, France : 1983) 20060901

• [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].

  Presse medicale (Paris, France : 1983) 20060901

• Prophylaxis of migraine.

  Neuropsychiatric disease and treatment 20060901

• Celecoxib for the prevention of sporadic colorectal adenomas.

  The New England journal of medicine 20060831

• Celecoxib for the prevention of colorectal adenomatous polyps.

  The New England journal of medicine 20060831

• Risks and benefits of celecoxib to prevent recurrent adenomas.

  The New England journal of medicine 20060831

• Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO.

  Journal of immunology (Baltimore, Md. : 1950) 20060815

• Radiosensitivity enhancement by combined treatment of celecoxib and gefitinib on human lung cancer cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060815

• Ariad Pharmaceuticals wins first round over Eli Lilly, patents on methods can be far-reaching.

  Journal of the National Cancer Institute 20060802

• Long term NSAID treatment inhibits COX-2 synthesis in the knee synovial membrane of patients with osteoarthritis: differential proinflammatory cytokine profile between celecoxib and aceclofenac.

  Annals of the rheumatic diseases 20060801

• Reversible binding of celecoxib and valdecoxib with human serum albumin using fluorescence spectroscopic technique.

  Pharmacological research 20060801

• Prevention of nephrolithiasis by Lactobacillus in stone-forming rats: a preliminary study.

  Urological research 20060801

• Covalent binding of radioactivity from [14C]rofecoxib, but not [14C]celecoxib or [14C]CS-706, to the arterial elastin of rats.

  Drug metabolism and disposition: the biological fate of chemicals 20060801

• N-acylated sulfonamide sodium salt: a prodrug of choice for the bifunctional 2-hydroxymethyl-4-(5-phenyl-3-trifluoromethyl-pyrazol-1-yl) benzenesulfonamide class of COX-2 inhibitors.

  Bioorganic & medicinal chemistry letters 20060801

• Cyclooxygenase-2 inhibitor, celecoxib, inhibits the altered hippocampal neurogenesis with attenuation of spontaneous recurrent seizures following pilocarpine-induced status epilepticus.

  Neurobiology of disease 20060801

• Celecoxib inhibits cellular growth, decreases Ki-67 expression and modifies apoptosis in ovarian cancer cell lines.

  Archives of medical research 20060801

• Selective COX-2 inhibitor celecoxib prevents experimental autoimmune encephalomyelitis through COX-2-independent pathway.

  Brain : a journal of neurology 20060801

• Prevention of intra-abdominal adhesions using the antiangiogenic COX-2 inhibitor celecoxib.

  Annals of surgery 20060801

• Perioperative cyclooxygenase 2 inhibition to reduce tumor cell adhesion and metastatic potential of circulating tumor cells in non-small cell lung cancer.

  The Journal of thoracic and cardiovascular surgery 20060801

• The COX-2 inhibitors--an update.

  American heart journal 20060801

• CD24 is a new oncogene, early at the multistep process of colorectal cancer carcinogenesis.

  Gastroenterology 20060801

• Molecular responses of rectal cancer to preoperative chemoradiation.

  Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20060801

• Interaction of macrophages with apoptotic cells enhances HIV Type 1 replication through PGE2, PAF, and vitronectin receptor.

  AIDS research and human retroviruses 20060801

• Fracture risk associated with use of nonsteroidal anti-inflammatory drugs, acetylsalicylic acid, and acetaminophen and the effects of rheumatoid arthritis and osteoarthritis.

  Calcified tissue international 20060801

• How specific are 'target-specific' drugs? Celecoxib as a case in point.

  Molecular interventions 20060801

• Celecoxib-loaded poly(D,L-lactide-co-glycolide) nanoparticles prepared using a novel and controllable combination of diffusion and emulsification steps as part of the salting-out procedure.

  Journal of microencapsulation 20060801

• Hepatic disorders in patients treated with COX-2 selective inhibitors or nonselective NSAIDs: a case/noncase analysis of spontaneous reports.

  Clinical therapeutics 20060801

• Interleukin-13 enhances cyclooxygenase-2 expression in activated rat brain microglia: implications for death of activated microglia.

  Journal of immunology (Baltimore, Md. : 1950) 20060715

• Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma.

  Cancer research 20060715

• Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice.

  Cancer research 20060715

• Therapy switching and associated costs in elderly patients receiving COX-2 selective inhibitors or non-selective non-steroidal anti-inflammatory drugs in Quebec, Canada.

  Rheumatology (Oxford, England) 20060701

• Green tea polyphenol stimulates cancer preventive effects of celecoxib in human lung cancer cells by upregulation of GADD153 gene.

  International journal of cancer 20060701

• Low-intensity pulsed ultrasound accelerates and a nonsteroidal anti-inflammatory drug delays knee ligament healing.

  The American journal of sports medicine 20060701

• Cyclooxygenase-2 selective inhibition suppresses restoration of tibial trabecular bone formation in association with restriction of osteoblast maturation in skeletal reloading after hindlimb elevation of mice.

  Bone 20060701

• The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine.

  Molecular psychiatry 20060701

• Improved solubilization of Celecoxib in U-type nonionic microemulsions and their structural transitions with progressive aqueous dilution.

  Journal of colloid and interface science 20060701

• Orofacial cold hyperalgesia due to infraorbital nerve constriction injury in rats: reversal by endothelin receptor antagonists but not non-steroidal anti-inflammatory drugs.

  Pain 20060701

• Endogenous opioids mediate the hypoalgesia induced by selective inhibitors of cyclo-oxygenase 2 in rat paws treated with carrageenan.

  Neuropharmacology 20060701

• Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study.

  Stroke 20060701

• NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland.

  European heart journal 20060701

• Trial of celecoxib in amyotrophic lateral sclerosis.

  Annals of neurology 20060701

• Newer cyclo-oxygenase-2 selective inhibitors, other non-steroidal anti-inflammatory drugs and the risk of acute pancreatitis.

  Alimentary pharmacology & therapeutics 20060701

• Increases in circulating VEGF levels during COX-2 inhibitor treatment in breast cancer patients.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20060701

• Gastric mucosal cell model for estimating relative gastrointestinal toxicity of non-steroidal anti-inflammatory drugs.

  Prostaglandins, leukotrienes, and essential fatty acids 20060701

• Celecoxib.

  Journal of the Royal Society of Medicine 20060701

• The crucial role of cyclooxygenase-2 in osteopontin-induced protein kinase C alpha/c-Src/IkappaB kinase alpha/beta-dependent prostate tumor progression and angiogenesis.

  Cancer research 20060701

• Gene expression differences in normal esophageal mucosa associated with regression and progression of mild and moderate squamous dysplasia in a high-risk Chinese population.

  Cancer research 20060701

• Development and in vitro evaluation of oral controlled release formulations of celecoxib using optimization techniques.

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20060701

• Rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg in the treatment of symptomatic osteoarthritis: results of two similarly designed studies.

  Current medical research and opinion 20060701

• Celecoxib treatment alters the gene expression profile of normal colonic mucosa.

  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20060701

• Determine whether perioperative celecoxib administration would reduce opioid consumption and provide effective pain relief in patients undergoing arthroscopic knee surgery.

  Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association 20060701

• Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study.

  Onkologie 20060701

• [Effects of selective and non-selective cyclooxygenase-2 inhibitor on the growth of colon cancer cells].

  Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20060701

• Celecoxib can induce cell death independently of cyclooxygenase-2, p53, Mdm2, c-Abl and reactive oxygen species.

  Anti-cancer drugs 20060701

• [Cyclooxygenase inhibitors: a never ending story?].

  Giornale italiano di cardiologia (2006) 20060701

• Subacute toxicity of celecoxib on thyroid and testis of rats: Hormonal and histopathological changes.

  Environmental toxicology and pharmacology 20060701

• Heterogeneous nuclear ribonuclear protein C is increased in the celecoxib-induced growth inhibition of human oral squamous cell carcinoma.

  Experimental & molecular medicine 20060630

• Role of p21CIP1 as a determinant of SC-560 response in human HCT116 colon carcinoma cells.

  Experimental & molecular medicine 20060630

• Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.

  Circulation 20060627

• Cyclooxygenase-2 selective inhibitors and prostate cancer: what is the clinical benefit?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060620

• Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060620

• Changes in antitumor response in C57BL/6J-Min/+ mice during long-term administration of a selective cyclooxygenase-2 inhibitor.

  Cancer research 20060615

• Increased expression of cyclooxygenase-2 mediates enhanced contraction to endothelin ETA receptor stimulation in endothelial nitric oxide synthase knockout mice.

  Circulation research 20060609

• Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors.

  Journal of the National Cancer Institute 20060607

• Pharmacological separation between peripheral and central functions of cyclooxygenase-2 with CIAA, a novel cyclooxygenase-2 inhibitor.

  European journal of pharmacology 20060606

• The effects of celecoxib augmentation on cytokine levels in schizophrenia.

  The international journal of neuropsychopharmacology 20060601

• Heregulin-alpha and heregulin-beta expression is linked to a COX-2-PGE2 pathway in human gastric fibroblasts.

  American journal of physiology. Gastrointestinal and liver physiology 20060601

• Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance.

  Blood 20060601

• Phase II study of celecoxib in metastatic differentiated thyroid carcinoma.

  The Journal of clinical endocrinology and metabolism 20060601

• Luminal delivery and dosing considerations of local celecoxib administration to colorectal cancer.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20060601

• Getting it right: being smarter about clinical trials.

  PLoS medicine 20060601

• Interferon-alpha resistance can be reversed by inhibition of IFN-alpha-induced COX-2 expression potentially via STAT1 activation in A549 cells.

  Oncology reports 20060601

• A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060601

• Design and evaluation of celecoxib porous particles using melt sonocrystallization.

  Pharmaceutical research 20060601

• Efficacy and tolerability of celecoxib compared with diclofenac slow release in the treatment of acute ankle sprain in an Asian population.

  Singapore medical journal 20060601

• Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival?

  American journal of clinical oncology 20060601

• Effect of indomethacin and selective cyclooxygenase-2 inhibitors on proteinuria and renal function in patients with AA type renal amyloidosis.

  Nephrology (Carlton, Vic.) 20060601

• FOLFIRI with or without celecoxib in advanced colorectal cancer: a randomized phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM).

  Annals of oncology : official journal of the European Society for Medical Oncology 20060601

• Analgesic efficacy of perioperative celecoxib in ambulatory arthroscopic knee surgery: a double-blind, placebo-controlled study.

  Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association 20060601

• Ankylosing spondylitis and symptom-modifying vs disease-modifying therapy.

  Best practice & research. Clinical rheumatology 20060601

• Low-intensity electromagnetic millimeter waves for pain therapy.

  Evidence-based complementary and alternative medicine : eCAM 20060601

• Cyclooxygenase-2 inhibitors: a painful lesson.

  Cardiovascular & hematological disorders drug targets 20060601

• Use of accelerating solvent extraction for detecting non-steroidal anti-inflammatory drugs in horse feces.

  Journal of analytical toxicology 20060601

• [Molecular-targeted therapy for hormone-refractory prostate cancer].

  Hinyokika kiyo. Acta urologica Japonica 20060601

• Changes in the immune system in depression and dementia: causal or coincidental effects?

  Dialogues in clinical neuroscience 20060601

• Detection of overexpressed COX-2 in precancerous lesions of hamster pancreas and lungs by molecular imaging: implications for early diagnosis and prevention.

  ChemMedChem 20060601

• Risk of cardiovascular events and cyclooxygenase-2 inhibitors.

  Vascular health and risk management 20060601

• Clinical implications of angiogenesis in cancers.

  Vascular health and risk management 20060601

• Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer-Part 2.

  Current oncology (Toronto, Ont.) 20060601

• Inhibition of phorbol ester-induced mouse skin tumor promotion and COX-2 expression by celecoxib: C/EBP as a potential molecular target.

  Cancer research and treatment : official journal of Korean Cancer Association 20060601

• [Cytotoxic activities of Celecoxib on leukemic cells and the synergistic effects of Celecoxib with Imatinib thereupon].

  Zhonghua yi xue za zhi 20060530

• Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20060523

• Celecoxib shown effective in preventing colon polyps.

  Journal of the National Cancer Institute 20060517

• Celecoxib induces anoikis in human colon carcinoma cells associated with the deregulation of focal adhesions and nuclear translocation of p130Cas.

  International journal of cancer 20060515

• The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor.

  Alimentary pharmacology & therapeutics 20060515

• Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer.

  Cancer research 20060515

• HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism.

  Cancer research 20060515

• Influence of modified cyclodextrins on solubility and percutaneous absorption of celecoxib through human skin.

  International journal of pharmaceutics 20060511

• RNA interference as a key to knockdown overexpressed cyclooxygenase-2 gene in tumour cells.

  British journal of cancer 20060508

• Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer.

  Investigational new drugs 20060501

• Short-term dietary administration of celecoxib enhances the efficacy of tumor lysate-pulsed dendritic cell vaccines in treating murine breast cancer.

  International journal of cancer 20060501

• Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme.

  Journal of neuro-oncology 20060501

• Celecoxib inhibits interleukin-12 alphabeta and beta2 folding and secretion by a novel COX2-independent mechanism involving chaperones of the endoplasmic reticulum.

  Molecular pharmacology 20060501

• Selective cyclooxygenase-2 inhibition with celecoxib decreases angiotensin II-induced abdominal aortic aneurysm formation in mice.

  Arteriosclerosis, thrombosis, and vascular biology 20060501

• Simple and rapid high-performance liquid chromatographic method for determination of celecoxib in plasma using UV detection: application in pharmacokinetic studies.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20060501

• Update on nonsteriodal anti-inflammatory drugs.

  Current opinion in rheumatology 20060501

• Microsphere-based protease assays and screening application for lethal factor and factor Xa.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

• COX-2 in cardiovascular disease.

  Arteriosclerosis, thrombosis, and vascular biology 20060501

• A randomized database study in general practice yielded quality data but patient recruitment in routine consultation was not practical.

  Journal of clinical epidemiology 20060501

• Neuroprotective agents in schizophrenia and affective disorders.

  Expert opinion on pharmacotherapy 20060501

• Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.

  Arthritis and rheumatism 20060501

• A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress.

  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20060501

• Motexafin gadolinium modulates levels of phosphorylated Akt and synergizes with inhibitors of Akt phosphorylation.

  Molecular cancer therapeutics 20060501

• Celecoxib exposures reported to Texas poison control centers from 1999 to 2004.

  Human & experimental toxicology 20060501

• Simultaneous determination of celecoxib, meloxicam, and rofecoxib using capillary electrophoresis with surfactant and application in drug formulations.

  Journal of separation science 20060501

• The role of the New Zealand Intensive Medicines Monitoring Programme in identification of previously unrecognised signals of adverse drug reactions.

  Current drug safety 20060501

• Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction.

  Circulation 20060425

• COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer.

  British journal of cancer 20060424

• Bile acid-mediated induction of cyclooxygenase-2 and Mcl-1 in hepatic stellate cells.

  Biochemical and biophysical research communications 20060421

• Design, synthesis, and biological evaluation of substituted 3-alkylthio-4,5-diaryl-4H-1,2,4-triazoles as selective COX-2 inhibitors.

  Bioorganic & medicinal chemistry 20060415

• Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats.

  Cancer research 20060415

• Antitumor properties of dimethyl-celecoxib, a derivative of celecoxib that does not inhibit cyclooxygenase-2: implications for glioma therapy.

  Neurosurgical focus 20060415

• Differential regulation of anti-inflammatory proteins in human rheumatoid synoviocyte MH7A cell by celecoxib and ibuprofen.

  Life sciences 20060404

• Immune modulatory effects of cyclooxygenase type 2 inhibitors in HIV patients on combination antiretroviral treatment.

  AIDS (London, England) 20060404

• COX-2 inhibitors and pain after oral surgery - pertinent papers 2002-2003.

  The British journal of oral & maxillofacial surgery 20060401

• Roles of cyclooxygenase 2 and microsomal prostaglandin E synthase 1 in rat acid reflux oesophagitis.

  Gut 20060401

• Inhibition of COX-2 by celecoxib in the canine groove model of osteoarthritis.

  Rheumatology (Oxford, England) 20060401

• 5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-trifluoromethylpyrazole acts in a reactive oxygen species-dependent manner to suppress human lung cancer growth.

  Journal of cancer research and clinical oncology 20060401

• COX-2 induces IL-11 production in human breast cancer cells.

  The Journal of surgical research 20060401

• Cytotoxicity of a non-cyclooxygenase-2 inhibitory derivative of celecoxib in non-small-cell lung cancer A549 cells.

  Lung cancer (Amsterdam, Netherlands) 20060401

• Selective cyclo-oxygenase 2 inhibition affects ileal but not colonic anastomotic healing in the early postoperative period.

  The British journal of surgery 20060401

• Effect of cyclooxygenase inhibitors on the micturition reflex in rats: correlation with inhibition of cyclooxygenase isozymes.

  BJU international 20060401

• Tolerance of diclofenac after hypersensitivity to celecoxib and to nabumetone.

  British journal of clinical pharmacology 20060401

• Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.

  American journal of hematology 20060401

• Arthritis supplement combination falls short in study.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20060401

• COX-2 induction in mice with experimental nutritional steatohepatitis: Role as pro-inflammatory mediator.

  Hepatology (Baltimore, Md.) 20060401

• Unconvincing Pfizer and uncertain crucifixions.

  Journal of the Royal Society of Medicine 20060401

• Effects of selective cyclooxygenase-2 inhibitor and omega-3 fatty acid on serum interleukin-1beta, osteocalcin, and C-reactive protein levels in rats.

  Journal of periodontology 20060401

• Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?

  Naunyn-Schmiedeberg's archives of pharmacology 20060401

• Discordance between availability of pharmacogenetics studies and pharmacogenetics-based prescribing information for the top 200 drugs.

  The Annals of pharmacotherapy 20060401

• Disease mongering in drug promotion: do governments have a regulatory role?

  PLoS medicine 20060401

• COX-2 inhibitors and the heart: are all coxibs the same?

  Postgraduate medical journal 20060401

• Celecoxib up-regulates the expression of the zeta chain of T cell receptor complex in tumor-infiltrating lymphocytes in human cervical cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060401

• Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060401

• [Inhibitory effects of cyclooxygenase-2 inhibitor celecoxib on growth and angiogenesis of human liver cancer HepG2 cell xenografts in small nude mice].

  Ai zheng = Aizheng = Chinese journal of cancer 20060401

• Effects of cyclooxygenase-2 inhibition on serum and tumor gastrins and expression of apoptosis-related proteins in colorectal cancer.

  Digestive diseases and sciences 20060401

• Side-locked headache as the chief complaint of inflammatory orbital pseudotumor (myositic form): a case report.

  Headache 20060401

• [Three-dimensional trabecular bone microarchitecture in inflammatory bone destruction].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20060401

• COX-2 has a critical role during incorporation of structural bone allografts.

  Annals of the New York Academy of Sciences 20060401

• Are there differences in the renal effects of selective cyclo-oxygenase 2 inhibitors?

  Nature clinical practice. Nephrology 20060401

• Genetic tools to tailor cancer prevention by NSAIDs.

  Discovery medicine 20060401

• Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer.

  British journal of cancer 20060327

• Promotion of prostatic metastatic migration towards human bone marrow stoma by Omega 6 and its inhibition by Omega 3 PUFAs.

  British journal of cancer 20060327

• Effect of glutamate receptor antagonists and antirheumatic drugs on proliferation of synoviocytes in vitro.

  European journal of pharmacology 20060327

• [Intestinal side effects of COX-2 inhibitors].

  Ugeskrift for laeger 20060327

• Glycine-extended gastrin stimulates proliferation and inhibits apoptosis in colon cancer cells via cyclo-oxygenase-independent pathways.

  Regulatory peptides 20060315

• Molecular dynamics simulations of arachidonic acid-derived pentadienyl radical intermediate complexes with COX-1 and COX-2: insights into oxygenation regio- and stereoselectivity.

  Biochemistry 20060314

• Glycine-extended gastrin inhibits apoptosis in colon cancer cells via separate activation of Akt and JNK pathways.

  Molecular and cellular endocrinology 20060309

• Synthesis and structure-activity relationship studies of 1,3-diarylprop-2-yn-1-ones: dual inhibitors of cyclooxygenases and lipoxygenases.

  Journal of medicinal chemistry 20060309

• Role of cyclooxygenase-2 in the carcinogenesis of gastrointestinal tract cancers: a review and report of personal experience.

  World journal of gastroenterology 20060307

• Indomethacin and celecoxib impair rotator cuff tendon-to-bone healing.

  The American journal of sports medicine 20060301

• Kynurenic acid, an endogenous constituent of rheumatoid arthritis synovial fluid, inhibits proliferation of synoviocytes in vitro.

  Rheumatology international 20060301

• Involvement of cyclooxygenase-2 in gastric mucosal hypertrophy in gastrin transgenic mice.

  American journal of physiology. Gastrointestinal and liver physiology 20060301

• A time course analysis of cyclooxygenase-2 suggests a role in spatial memory retrieval in rats.

  Neuroscience research 20060301

• Influence of plasma protein on the potencies of inhibitors of cyclooxygenase-1 and -2.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20060301

• Utilization and cost comparison of current and optimal prescribing of nonsteroidal antiinflammatory drugs in Quebec, Canada.

  The Journal of rheumatology 20060301

• Cyclooxygenase-2 inhibitors: what went wrong?

  Current opinion in clinical nutrition and metabolic care 20060301

• Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study.

  The American journal of medicine 20060301

• Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage.

  Investigative ophthalmology & visual science 20060301

• Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis.

  Journal of the Royal Society of Medicine 20060301

• Accumulation of celecoxib with a 7-fold higher drug exposure in individuals homozygous for CYP2C9*3.

  Clinical pharmacology and therapeutics 20060301

• Glucosamine & chondroitin use questioned in mild cases. Drug combo benefits moderate-to-severe knee osteoarthritis, but not so with lesser cases.

  Health news (Waltham, Mass.) 20060301

• Anti-cancer effect of celecoxib and aerosolized docetaxel against human non-small cell lung cancer cell line, A549.

  The Journal of pharmacy and pharmacology 20060301

• Cyclooxygenase-2 inhibitors in human skeletal fracture healing.

  Orthopedics 20060301

• Determination of valdecoxib in serum using a HPLC-diode array detector and its application in a pharmacokinetic study.

  Die Pharmazie 20060301

• [COX-2 mediates U50488H-induced delayed cardioprotection in isolated rat heart].

  Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences 20060301

• Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction.

  Basic & clinical pharmacology & toxicology 20060301

• Chronic effects of celecoxib, a cyclooxygenase-2 inhibitor, cause enhanced alcohol-induced liver steatosis in rats.

  Inflammopharmacology 20060301

• Etoricoxib for arthritis and pain management.

  Therapeutics and clinical risk management 20060301

• [Clinical management of adenomatous polyposis in patients with hereditary non-polyposis colorectal cancer and familial adenomatous polyposis].

  Zhonghua yi xue za zhi 20060227

• Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis.

  The New England journal of medicine 20060223

• Celecoxib upregulates endoplasmic reticulum chaperones that inhibit celecoxib-induced apoptosis in human gastric cells.

  Oncogene 20060216

• Adenocarcina of the mouse prostate growth inhibition by celecoxib: downregulation of transcription factors involved in COX-2 inhibition.

  The Prostate 20060215

• Deficient E-cadherin adhesion in C57BL/6J-Min/+ mice is associated with increased tyrosine kinase activity and RhoA-dependent actomyosin contractility.

  Experimental cell research 20060215

• Retrospective analysis of utilization patterns and cost implications of coxibs among seniors in Quebec, Canada: what is the potential impact of the withdrawal of rofecoxib?

  Arthritis and rheumatism 20060215

• COX inhibitors and breast cancer.

  British journal of cancer 20060213

• Targeting prostaglandin E2 receptors as an alternative strategy to block cyclooxygenase-2-dependent extracellular matrix-induced matrix metalloproteinase-9 expression by macrophages.

  The Journal of biological chemistry 20060210

• Bcl-2 switches the type of demise from apoptosis to necrosis via cyclooxygenase-2 upregulation in HeLa cell induced by hydrogen peroxide.

  Cancer letters 20060208

• Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib.

  Clinical rheumatology 20060201

• The renal effects of the addition of low-dose aspirin to COX-2 selective and nonselective antiinflammatory drugs.

  Clinical rheumatology 20060201

• Retinoid-mediated stimulation of steroid sulfatase activity in myeloid leukemic cell lines requires RARalpha and RXR and involves the phosphoinositide 3-kinase and ERK-MAP kinase pathways.

  Journal of cellular biochemistry 20060201

• Curcumin synergistically potentiates the growth-inhibitory and pro-apoptotic effects of celecoxib in osteoarthritis synovial adherent cells.

  Rheumatology (Oxford, England) 20060201

• Characterization of a novel polymorphic form of celecoxib.

  Journal of pharmaceutical sciences 20060201

• Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma.

  Cancer 20060201

• The effect of celecoxib, a selective COX-2 inhibitor, on liver ischemia/reperfusion-induced oxidative stress in rats.

  Hepatology research : the official journal of the Japan Society of Hepatology 20060201

• Selective cyclooxygenase-2 inhibitors inhibit growth and induce apoptosis of bladder cancer.

  Oncology reports 20060201

• Suppression of adjuvant-induced arthritic bone destruction by cyclooxygenase-2 selective agents with and without inhibitory potency against carbonic anhydrase II.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20060201

• Effect of celecoxib on experimental liver fibrosis in rat.

  Liver international : official journal of the International Association for the Study of the Liver 20060201

• Celecoxib leads to G2/M arrest by induction of p21 and down-regulation of cyclin B1 expression in a p53-independent manner.

  European journal of cancer (Oxford, England : 1990) 20060201

• Analgesic effects of intrathecally administered celecoxib, a cyclooxygenase-2 inhibitor, in the tail flick test and the formalin test in rats.

  Acta anaesthesiologica Scandinavica 20060201

• Cyclooxygenase-2 expression and effect of celecoxib in flurothyl-induced neonatal seizure.

  International journal of experimental pathology 20060201

• tNOX, an alternative target to COX-2 to explain the anticancer activities of non-steroidal anti-inflammatory drugs (NSAIDS).

  Molecular and cellular biochemistry 20060201

• A structurally optimized celecoxib derivative inhibits human pancreatic cancer cell growth.

  Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 20060201

• Selective use of selective nonsteroidal anti-inflammatory drugs in inflammatory bowel disease.

  Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20060201

• Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study.

  Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20060201

• Ocular adverse effects associated with cyclooxygenase-2 inhibitors.

  Archives of ophthalmology (Chicago, Ill. : 1960) 20060201

• [A case report of unresectable gallbladder cancer that responded remarkably to the combination of thalidomide, celecoxib, and gemcitabine].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060201

• Cyclooxygenase inhibitors in urinary bladder cancer: in vitro and in vivo effects.

  Molecular cancer therapeutics 20060201

• [Pseudoporphyria and coxib].

  Annales de dermatologie et de venereologie 20060201

• Selective inhibition of COX-2 by a standardized CO2 extract of Humulus lupulus in vitro and its activity in a mouse model of zymosan-induced arthritis.

  Planta medica 20060201

• Celecoxib: new indication. Colorectal cancer: no preventive benefit.

  Prescrire international 20060201

• Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence.

  British journal of cancer 20060130

• Scientific misconduct. Fraud upends oral cancer field, casting doubt on prevention trial.

  Science (New York, N.Y.) 20060127

• Acetaminophen for osteoarthritis.

  The Cochrane database of systematic reviews 20060125

• [Non-steroidal anti-inflammatory agents and prevention of colorectal adenomas and carcinomas].

  Ugeskrift for laeger 20060123

• [Nonspecific interstitial pneumonia: epidemiologic and clinical characteristics].

  Medicina clinica 20060121

• Determination of celecoxib in human plasma and breast milk by high-performance liquid chromatographic assay.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20060118

• Years of research come to fruition with launch of oral cancer prevention trial.

  Journal of the National Cancer Institute 20060118

• Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors.

  International journal of cancer 20060115

• Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II 'selective' inhibitor celecoxib.

  Bioorganic & medicinal chemistry letters 20060115

• Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection.

  Biomedical chromatography : BMC 20060101

• Monocyte chemoattractant protein 1 and macrophage cyclooxygenase 2 expression in colonic adenoma.

  Gut 20060101

• Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial.

  Cancer chemotherapy and pharmacology 20060101

• Ultrastructural and immunohistochemical analysis of rat uroepithelial cell junctions after partial bladder outlet obstruction and selective COX-2 inhibitor treatment.

  Acta histochemica 20060101

• R(+)-methanandamide elicits a cyclooxygenase-2-dependent mitochondrial apoptosis signaling pathway in human neuroglioma cells.

  Pharmaceutical research 20060101

• Effects of cyclooxygenase-1 and -2 inhibition on gastric acid secretion and cardiovascular functions in rats.

  Pharmacology 20060101

• Combination celecoxib and temozolomide in C6 rat glioma orthotopic model.

  Oncology reports 20060101

• Differential direct effects of cyclo-oxygenase-1/2 inhibition on proteoglycan turnover of human osteoarthritic cartilage: an in vitro study.

  Arthritis research & therapy 20060101

• Lipopolysaccharide induces cyclooxygenase-2 in intestinal epithelium via a noncanonical p38 MAPK pathway.

  Journal of immunology (Baltimore, Md. : 1950) 20060101

• COX-2 selective drugs and cardiovascular risks: same data but discrepant conclusions?

  Expert opinion on drug safety 20060101

• Comparative cardiovascular safety of traditional nonsteroidal anti-inflammatory drugs.

  Expert opinion on drug safety 20060101

• More pronounced inhibition of cyclooxygenase 2, increase in blood pressure, and reduction of heart rate by treatment with diclofenac compared with celecoxib and rofecoxib.

  Arthritis and rheumatism 20060101

• Asthma attacks induced by low doses of celecoxib, aspirin, and acetaminophen.

  The Journal of allergy and clinical immunology 20060101

• Quantification of infant exposure to celecoxib through breast milk.

  British journal of clinical pharmacology 20060101

• Systematic review: coxibs, non-steroidal anti-inflammatory drugs or no cyclooxygenase inhibitors in gastroenterological high-risk patients?

  Alimentary pharmacology & therapeutics 20060101

• Prostanoid receptor EP1 and Cox-2 in injured human nerves and a rat model of nerve injury: a time-course study.

  BMC neurology 20060101

• Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies.

  Current medical research and opinion 20060101

• Celecoxib decreases Ki-67 proliferative index in active smokers.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060101

• The COX-2 story: is any drug completely 'safe?'.

  Gastroenterology 20060101

• Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2.

  Gastroenterology 20060101

• Erdheim-Chester's disease of the heart: a diagnostic conundrum and collision with the same mass in the orbit.

  The heart surgery forum 20060101

• The selective Cox-2 inhibitor Celecoxib suppresses angiogenesis and growth of secondary bone tumors: an intravital microscopy study in mice.

  BMC cancer 20060101

• Synthesis of 5-phenyl-1-(3-pyridyl)-1H-1,2,4-triazole-3-carboxylic acid derivatives of potential anti-inflammatory activity.

  Archiv der Pharmazie 20060101

• Chemoprevention of colorectal cancer with nonsteroidal anti-inflammatory drugs.

  Chinese journal of digestive diseases 20060101

• Importance of the EP(1) receptor in cutaneous UVB-induced inflammation and tumor development.

  The Journal of investigative dermatology 20060101

• Preventing chronic pain after surgery: who, how, and when?

  Regional anesthesia and pain medicine 20060101

• The effect of cyclooxygenase-2 inhibition on acute and chronic donor-site pain after spinal-fusion surgery.

  Regional anesthesia and pain medicine 20060101

• Postoperative pain scores and analgesic requirements after thyroid surgery: comparison of three intraoperative opioid regimens.

  International journal of medical sciences 20060101

• Resection and use of a cyclooxygenase-2 inhibitor for treatment of pancreatic adenocarcinoma in a cockatiel.

  Journal of the American Veterinary Medical Association 20060101

• Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors.

  BMC cancer 20060101

• Topotecan is a substrate for multidrug resistance associated protein 4.

  Current drug metabolism 20060101

• First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215].

  Arthritis research & therapy 20060101

• Selected science: an industry campaign to undermine an OSHA hexavalent chromium standard.

  Environmental health : a global access science source 20060101

• Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: an observational study.

  Drug safety 20060101

• Pancytopenia after low dose methotrexate therapy in a hemodialysis patient: case report and review of literature.

  Renal failure 20060101

• Coxibs and cardiovascular side-effects: from light to shadow.

  Current pharmaceutical design 20060101

• Patients, their doctors, nonsteroidal anti-inflammatory drugs and the perception of risk.

  Arthritis research & therapy 20060101

• Do coxibs reduce prescription of gastroprotective agents? Results of a record linkage study.

  Cost effectiveness and resource allocation : C/E 20060101

• Development of pulsatile systems for targeted drug delivery of celecoxib for prophylaxis of colorectal cancer.

  Drug delivery 20060101

• Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease.

  Journal of neuroinflammation 20060101

• Cyclooxygenase expression is not required for release of arachidonic acid from cells by some nonsteroidal anti-inflammatory drugs and cancer preventive agents.

  BMC pharmacology 20060101

• The chrondoprotective actions of a natural product are associated with the activation of IGF-1 production by human chondrocytes despite the presence of IL-1beta.

  BMC complementary and alternative medicine 20060101

• Celecoxib induces regression of putative preneoplastic lesions in rat liver.

  Anticancer research 20060101

• Folate-targeted immunotherapy effectively treats established adjuvant and collagen-induced arthritis.

  Arthritis research & therapy 20060101

• Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo.

  Molecular cancer 20060101

• Gene expression profiling of lymphoblastoid cell lines from monozygotic twins discordant in severity of autism reveals differential regulation of neurologically relevant genes.

  BMC genomics 20060101

• Anti-inflammatory and immunosuppressive drugs and reproduction.

  Arthritis research & therapy 20060101

• Prognostic significance of cyclooxygenase-2 (COX-2) expression in patients with surgically resectable adenocarcinoma of the oesophagus.

  BMC cancer 20060101

• Radiosensitizers in cervical cancer. Cisplatin and beyond.

  Radiation oncology (London, England) 20060101

• Combination of celecoxib with percutaneous radiotherapy in patients with localised prostate cancer - a phase I study.

  Radiation oncology (London, England) 20060101

• Cutaneous and intra-abdominal abscess formation in rats following radio frequency [corrected] ablation of liver tumors in combination with celecoxib treatment.

  In vivo (Athens, Greece) 20060101

• Accounting for the increase in NSAID expenditure: substitution or leakage?

  Cost effectiveness and resource allocation : C/E 20060101

• Omeprazole and misoprostol for preventing gastric mucosa effects caused by indomethacin and celecoxib in rats.

  Acta cirurgica brasileira 20060101

• Cell density influences the effect of celecoxib in two carcinoma cell lines.

  Biotechnic & histochemistry : official publication of the Biological Stain Commission 20060101

• Prophylaxis for pseudophakic cystoid macular oedema: a long way to go.

  Clinical & experimental ophthalmology 20060101

• Use of a cyclo-oxygenase 2 inhibitor for prophylaxis of cystoid macular oedema following cataract surgery: a randomized placebo-controlled trial.

  Clinical & experimental ophthalmology 20060101

• Effects of the selective cyclooxygenase-2 inhibitor analgesic celecoxib on renal carbonic anhydrase enzyme activity: a randomized, controlled trial.

  American journal of therapeutics 20060101

• Human pregnancy safety for agents used to treat rheumatoid arthritis: adequacy of available information and strategies for developing post-marketing data.

  Arthritis research & therapy 20060101

• Blood pressure effects of COX-2 inhibitors.

  Journal of cardiovascular pharmacology 20060101

• Expectations from patients with rheumatoid arthritis regarding COX-2s: cutting to the heart of the matter.

  Journal of cardiovascular pharmacology 20060101

• Rofecoxib increases susceptibility of human LDL and membrane lipids to oxidative damage: a mechanism of cardiotoxicity.

  Journal of cardiovascular pharmacology 20060101

• Integration of chemotherapy into current treatment strategies for brain metastases from solid tumors.

  Radiation oncology (London, England) 20060101

• Does celecoxib potentiate the anticoagulant effect of warfarin? A randomized, double-blind, controlled trial.

  The Annals of pharmacotherapy 20060101

• Increase in nonfatal digestive perforations and haemorrhages following introduction of selective NSAIDs: a public health concern.

  Drug safety 20060101

• Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk.

  Drug safety 20060101

• The inflammatory process of gout and its treatment.

  Arthritis research & therapy 20060101

• COX-2 inhibitors celecoxib and rofecoxib prevent oxidative DNA fragmentation.

  Anticancer research 20060101

• Inhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression.

  BMC cancer 20060101

• Cyclo-oxygenase-2 (Cox-2) expression and resistance to platinum versus platinum/paclitaxel containing chemotherapy in advanced ovarian cancer.

  BMC cancer 20060101

• COX-inhibitors relieve the immunosuppressive effect of tumor cells and improve functions of immune effectors.

  International journal of immunopathology and pharmacology 20060101

• MUC1 alters oncogenic events and transcription in human breast cancer cells.

  Breast cancer research : BCR 20060101

• Serious skin reactions and selective COX-2 inhibitors: a case series from prescription-event monitoring in England.

  Drug safety 20060101

• Antiangiogenic effect of sulindac sulfide could be secondary to induction of apoptosis and cell cycle arrest.

  Anticancer research 20060101

• Inhibition of large intestinal cancers by celecoxib using a serial sacrifice technique.

  In vivo (Athens, Greece) 20060101

• C-reactive protein (CRP)-lowering agents.

  Cardiovascular drug reviews 20060101

• Effects of dexamethasone and celecoxib on calcium homeostasis and expression of cyclooxygenase-2 mRNA in MG-63 human osteosarcoma cells.

  Clinical and experimental rheumatology 20060101

• Induction of cell cycle changes and modulation of apoptogenic/anti-apoptotic and extracellular signaling regulatory protein expression by water extracts of I'm-Yunity (PSP).

  BMC complementary and alternative medicine 20060101

• How direct-to-consumer television advertising for osteoarthritis drugs affects physicians' prescribing behavior.

  Health affairs (Project Hope) 20060101

• [Problems of cardiovascular toxicity of coxibs and non-selective NSA].

  Vnitrni lekarstvi 20060101

• Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications.

  BMC medicine 20060101

• Risk of acute myocardial infarction with nonselective non-steroidal anti-inflammatory drugs: a meta-analysis.

  Arthritis research & therapy 20060101

• [Clinical pharmacogenomics for CYP2C8 and CYP2C9: general concepts and application to the use of NSAIDs].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20060101

• Celecoxib decreases prostaglandin E2 concentrations in nipple aspirate fluid from high risk postmenopausal women and women with breast cancer.

  BMC cancer 20060101

• Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice.

  BMC musculoskeletal disorders 20060101

• Acetylsalicylic acid as an adjuvant therapy for schizophrenia.

  Trials 20060101

• Evaluation of anti-inflammatory and analgesic activity of a new class of biphenyl analogs in animal models of inflammation.

  Arzneimittel-Forschung 20060101

• Impact of rofecoxib withdrawal on cyclooxygenase-2 utilization among patients with and without cardiovascular risk.

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20060101

• A celecoxib derivative potently inhibits proliferation of colon adenocarcinoma cells by induction of apoptosis.

  Anticancer research 20060101

• A novel copper complex induces ROS generation in doxorubicin resistant Ehrlich ascitis carcinoma cells and increases activity of antioxidant enzymes in vital organs in vivo.

  BMC cancer 20060101

• Exogenous glucosamine globally protects chondrocytes from the arthritogenic effects of IL-1beta.

  Arthritis research & therapy 20060101

• Effects of non steroidal anti-inflammatory drugs on the antioxidant defense system and the membrane functions in the rat intestine.

  Nutricion hospitalaria 20060101

• Photodynamic therapy and tumor imaging of hypericin-treated squamous cell carcinoma.

  World journal of surgical oncology 20060101

• Meloxicam tolerance in hypersensitivity to nonsteroidal anti-inflammatory drugs.

  Journal of investigational allergology & clinical immunology 20060101

• Use of nonsteroidal anti-inflammatory drugs in patients with aspirin hypersensitivity : safety of cyclo-oxygenase-2 inhibitors.

  Treatments in respiratory medicine 20060101

• A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cells.

  Breast cancer research : BCR 20060101

• Initial experience with stapled hemorrhoidopexy for treatment of hemorrhoids.

  Arquivos de gastroenterologia 20060101

• Celecoxib versus a non-selective NSAID plus proton-pump inhibitor: what are the considerations?

  Journal of pain & palliative care pharmacotherapy 20060101

• A comparative study on the cost of new antibiotics and drugs of other therapeutic categories.

  PloS one 20060101

• COX-2 inhibitor celecoxib suppresses tumor growth and lung metastasis of a murine mammary cancer.

  Anticancer research 20060101

• Ligand-based design, synthesis and primary in vivo screening of pyrrole derivatives as potential tricyclic anti-inflammatory agents.

  Arzneimittel-Forschung 20060101

• Celecoxib and curcumin additively inhibit the growth of colorectal cancer in a rat model.

  Digestion 20060101

• Association of hypogammaglobulinemia with DRESS (Drug Rash with Eosinophilia and Systemic Symptoms).

  European journal of dermatology : EJD 20060101

• Adverse cutaneous reactions to selective cyclooxygenase 2 inhibitors: experience of an Italian drug-surveillance center.

  Journal of cutaneous medicine and surgery 20060101

• Celecoxib inhibits Cdx2 expression and prevents gastric cancer in Helicobacter pylori-infected Mongolian gerbils.

  Digestion 20060101

• Tumor necrosis factor-alpha in temporomandibular joint synovial fluid predicts treatment effects on pain by intra-articular glucocorticoid treatment.

  Mediators of inflammation 20060101

• Exploring effects of different nonsteroidal antiinflammatory drugs on malondialdehyde profile.

  Acta poloniae pharmaceutica 20060101

• Celecoxib reduces narcotic use and pain following augmentation mammaplasty.

  Aesthetic surgery journal 20060101

• A case of intranasal meningocele.

  McGill journal of medicine : MJM : an international forum for the advancement of medical sciences by students 20060101

• C-reactive Protein in Patients with Metastatic Clear Cell Renal Carcinoma: An Important Biomarker for Tumor-associated Inflammation.

  Biomarker insights 20060101

• [Effect of short-term nonsteroidal antiinflammatory therapy on mean blood pressure. A prospective, randomized clinical trial].

  Reumatologia clinica 20060101

• What clinical pharmacology means to us.

  Mens sana monographs 20060101

• Cardiac hypertrophy induced by prostaglandin F(2alpha) may be mediated by calcineurin signal transduction pathway in rats.

  Sheng li xue bao : [Acta physiologica Sinica] 20051225

• Drug testing. Massive trial of Celebrex seeks to settle safety concerns.

  Science (New York, N.Y.) 20051223

• Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: study conclusions do not reflect findings for celecoxib.

  BMJ (Clinical research ed.) 20051217

• Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: what does evidence from randomised trials show about celecoxib?

  BMJ (Clinical research ed.) 20051217

• Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2 inhibitory analog of celecoxib.

  Blood 20051215

• Helicobacter pylori-Induced invasion and angiogenesis of gastric cells is mediated by cyclooxygenase-2 induction through TLR2/TLR9 and promoter regulation.

  Journal of immunology (Baltimore, Md. : 1950) 20051215

• Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20051215

• Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis.

  BMJ (Clinical research ed.) 20051203

• A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer.

  Cancer chemotherapy and pharmacology 20051201

• A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer.

  Investigational new drugs 20051201

• Design, synthesis, and biological evaluation of linear 1-(4-, 3- or 2-methylsulfonylphenyl)-2-phenylacetylenes: a novel class of cyclooxygenase-2 inhibitors.

  Bioorganic & medicinal chemistry 20051201

• Cloning, expression, and functional characterization of human cyclooxygenase-1 splicing variants: evidence for intron 1 retention.

  The Journal of pharmacology and experimental therapeutics 20051201

• Modification of eicosanoid profile in human blood treated by dual COX/LOX inhibitors.

  Prostaglandins, leukotrienes, and essential fatty acids 20051201

• Chemopreventive agent-induced modulation of death receptors.

  Apoptosis : an international journal on programmed cell death 20051201

• A new method of oral drug provocation testing for determining safe alternatives for patients with non-steroidal anti-inflammatory drug intolerance: the triple test.

  International archives of allergy and immunology 20051201

• Efficacy of COX-2 inhibitors in a case of congenital nephrogenic diabetes insipidus.

  Pediatric nephrology (Berlin, Germany) 20051201

• Anti-angiogenic effects of Hypericin-photodynamic therapy in combination with Celebrex in the treatment of human nasopharyngeal carcinoma.

  International journal of molecular medicine 20051201

• The influence of Celecoxib on matrix synthesis by chondrocytes under mechanical stress in vitro.

  International journal of molecular medicine 20051201

• Evaluation of 2 celecoxib derivatives: analgesic effect and selectivity to cyclooxygenase-2/1.

  Acta pharmacologica Sinica 20051201

• An animal model of calcium oxalate urolithiasis based on a cyclooxygenase 2 selective inhibitor.

  Urological research 20051201

• Response of refractory osteosarcoma to thalidomide and celecoxib.

  The Lancet. Oncology 20051201

• Neoadjuvant selective COX-2 inhibition down-regulates important oncogenic pathways in patients with esophageal adenocarcinoma.

  Annals of surgery 20051201

• Selective cyclooxygenase-2 inhibition produces heterogeneous erythema response to ultraviolet irradiation.

  The Journal of investigative dermatology 20051201

• Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy.

  Molecular cancer therapeutics 20051201

• Celebrex offers a small protection from root resorption associated with orthodontic movement.

  Journal of the California Dental Association 20051201

• Prolonged cholestasis associated with short-term use of celecoxib.

  Gastroenterologie clinique et biologique 20051201

• [Acute colitis closely following the beginning of celecoxib treatment].

  Gastroenterologie clinique et biologique 20051201

• Inhibition of prostaglandin F(2alpha) by selective cyclooxygenase 2 inhibitors accounts for reduced rat leukocyte migration.

  Inflammation 20051201

• Management of oxaliplatin-induced peripheral neuropathy.

  Therapeutics and clinical risk management 20051201

• Discrepancy between effects of milligram and nanogram doses of a COX-2 inhibitor (celecoxib) on morphine state-dependent memory of passive avoidance in mice.

  Brain research bulletin 20051130

• [Do selective COX-2 inhibitors have adverse renal and cardiovascular effects?].

  Praxis 20051123

• Resolution of inflammation: prostaglandin E2 dissociates nuclear trafficking of individual NF-kappaB subunits (p65, p50) in stimulated rheumatoid synovial fibroblasts.

  Journal of immunology (Baltimore, Md. : 1950) 20051115

• In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20051115

• Front-line paclitaxel and irinotecan combination chemotherapy in advanced non-small-cell lung cancer: a phase I-II trial.

  British journal of cancer 20051114

• Extraction and visualization of potential pharmacophore points using support vector machines: application to ligand-based virtual screening for COX-2 inhibitors.

  Journal of medicinal chemistry 20051103

• Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same?

  Drug metabolism and disposition: the biological fate of chemicals 20051101

• Human multidrug resistance associated protein 4 confers resistance to camptothecins.

  Pharmaceutical research 20051101

• Post-training intrahippocampal infusion of nicotine prevents spatial memory retention deficits induced by the cyclo-oxygenase-2-specific inhibitor celecoxib in rats.

  Journal of neurochemistry 20051101

• Inflammatory mechanisms underlying the rat pulmonary neutrophil influx induced by airway exposure to staphylococcal enterotoxin type A.

  British journal of pharmacology 20051101

• Celecoxib inhibits urokinase-type plasminogen activator (uPA) production in MDA-MB-231 breast cancer cells.

  Breast cancer research and treatment 20051101

• Cyclooxygenase-2 inhibitors.

  Current opinion in gastroenterology 20051101

• Effects of specific COX-2-inhibition on renin release and renal and systemic prostanoid synthesis in healthy volunteers.

  Kidney international 20051101

• Expression of COX-2 mRNA in peripheral blood monocytes from patients with acute myocardial infarction and its significance.

  Clinical chemistry 20051101

• A real time quantitative PCR analysis and correlation of COX-1 and COX-2 enzymes in inflamed dental pulps following administration of three different NSAIDs.

  Journal of endodontics 20051101

• Celecoxib and cardiovascular risks.

  Expert opinion on drug safety 20051101

• Dimethyl celecoxib as a novel non-cyclooxygenase 2 therapy in the treatment of non-small cell lung cancer.

  The Journal of thoracic and cardiovascular surgery 20051101

• Avoiding glucocorticoid administration in a neurooncological case.

  Cancer biology & therapy 20051101

• Circadian pattern of spontaneous behavior in monarthritic rats: a novel global approach to evaluation of chronic pain and treatment effectiveness.

  Arthritis and rheumatism 20051101

• Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.

  The American journal of medicine 20051101

• Cyclooxygenase-2 inhibitory phenylbutenoids from the rhizomes of Zingiber cassumunar.

  Chemical & pharmaceutical bulletin 20051101

• A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer.

  Journal of pediatric hematology/oncology 20051101

• Celecoxib approved for pain relief for AS.

  Health news (Waltham, Mass.) 20051101

• Cardiovascular issues of COX-2 inhibitors and NSAIDs.

  Australian family physician 20051101

• Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine.

  International journal of clinical pharmacology and therapeutics 20051101

• Ternary amorphous composites of celecoxib, poly(vinyl pyrrolidone) and meglumine with enhanced solubility.

  Die Pharmazie 20051101

• Clinical Questions #6. Does celecoxib increase cardiovascular risk?

  WMJ : official publication of the State Medical Society of Wisconsin 20051101

• [Innovation of anti-inflammatory drugs--inhibition of cyclooxygenases].

  Yao xue xue bao = Acta pharmaceutica Sinica 20051101

• [Atorvastatin reduces the expression of COX-2 mRNA in peripheral blood monocytes in patients with acute myocardial infarction and modulates the early inflammatory response].

  Zhonghua xin xue guan bing za zhi 20051101

• The cardiovascular safety of celecoxib.

  Future cardiology 20051101

• Molecular targets of dietary polyphenols with anti-inflammatory properties.

  Yonsei medical journal 20051031

• Overexpression of cyclooxygenase-2 in human HepG2, Bel-7402 and SMMC-7721 hepatoma cell lines and mechanism of cyclooxygenase-2 selective inhibitor celecoxib-induced cell growth inhibition and apoptosis.

  World journal of gastroenterology 20051028

• [Natural substances and pharmaceutical preparations can prevent cancer. Chemoprevention instead of chemotherapy].

  MMW Fortschritte der Medizin 20051027

• NSAIDs in neuroblastoma therapy.

  Cancer letters 20051018

• Allellic variants in regulatory regions of cyclooxygenase-2: association with advanced colorectal adenoma.

  British journal of cancer 20051017

• Celecoxib and NS-398 enhance photodynamic therapy by increasing in vitro apoptosis and decreasing in vivo inflammatory and angiogenic factors.

  Cancer research 20051015

• Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels.

  Cancer research 20051015

• Coxibs and cardiovascular risk.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20051011

• Going against the flow: the impact of PHARMAC not funding COX-2 inhibitors for chronic arthritis.

  The New Zealand medical journal 20051007

• Cancer chemoprevention: lessons learned and future directions.

  British journal of cancer 20051003

• Cyclooxygenase inhibitors modulate NK activities that control metastatic disease.

  Cancer immunology, immunotherapy : CII 20051001

• Celecoxib, a cyclooxygenase-2 inhibitor, prevents induction of liver preneoplastic lesions in rats.

  Journal of hepatology 20051001

• Ethyl caffeate suppresses NF-kappaB activation and its downstream inflammatory mediators, iNOS, COX-2, and PGE2 in vitro or in mouse skin.

  British journal of pharmacology 20051001

• Nitric oxide induces apoptosis via AP-1-driven upregulation of COX-2 in rat pheochromocytoma cells.

  Free radical biology & medicine 20051001

• Bleeding complications in patients on celecoxib and warfarin.

  Journal of clinical pharmacy and therapeutics 20051001

• Chemoprophylaxis of colon cancer.

  Current gastroenterology reports 20051001

• Inhibition of DNA repair as a mechanism of enhanced radioresponse of head and neck carcinoma cells by a selective cyclooxygenase-2 inhibitor, celecoxib.

  International journal of radiation oncology, biology, physics 20051001

• Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20051001

• Antimutagenic and anti-oxidant activities of the non-steroidal anti-inflammatory drug celecoxib.

  Clinical and experimental pharmacology & physiology 20051001

• Low direct cytotoxicity and cytoprotective effects of nitric oxide releasing indomethacin.

  Digestive diseases and sciences 20051001

• Prescriptions for chronic high-dose cyclooxygenase-2 inhibitors are often inappropriate and potentially dangerous.

  Journal of general internal medicine 20051001

• The role of cyclooxygenase-2 in mediating the effects of histamine on cell proliferation and vascular endothelial growth factor production in colorectal cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20051001

• Celecoxib does not affect osteointegration of cementless total hip stems.

  The Journal of arthroplasty 20051001

• [A case report of chemotherapy with thalidomide, celecoxib and gemcitabine in the treatment of patients with brain metastases from lung cancer].

  No shinkei geka. Neurological surgery 20051001

• Does celecoxib use increase the risk of cardiovascular events?

  Gastroenterology 20051001

• Selective cyclooxygenase-2 inhibitors from Calophyllum membranaceum.

  Journal of natural products 20051001

• Differential molecular interactions between the crystalline and the amorphous phases of celecoxib.

  The Journal of pharmacy and pharmacology 20051001

• Celecoxib still on the market: but for whose benefit?

  Prescrire international 20051001

• [Celecoxib-induced aquagenic keratoderma].

  Actas dermo-sifiliograficas 20051001

• Celecoxib induces dose dependent growth inhibition in nasopharyngeal carcinoma cell lines independent of cyclooxygenase-2 expression.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20051001

• Curcumin synergistically potentiates the growth inhibitory and pro-apoptotic effects of celecoxib in pancreatic adenocarcinoma cells.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20051001

• Current directions for COX-2 inhibition in breast cancer.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20051001

• Cyclooxygenase-2 inhibitors suppress angiogenesis and growth of gastric cancer xenografts.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20051001

• Cytostatic and cytotoxic effects of cyclooxygenase inhibitors and their synergy with docosahexaenoic acid on the growth of human skin melanoma A-375 cells.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20051001

• Study of COX-2, Ki67, and p53 expression to predict effectiveness of 5-flurouracil, epirubicin and cyclophosphamide with celecoxib treatment in breast cancer patients.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20051001

• Serum lipid profiles in patients receiving endocrine treatment for breast cancer--the results from the Celecoxib Anti-Aromatase Neoadjuvant (CAAN) Trial.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20051001

• Taxanes and COX-2 inhibitors: from molecular pathways to clinical practice.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20051001

• CC 05, a novel anti-inflammatory compound, exerts its effect by inhibition of cyclooxygenase-2 activity.

  European journal of pharmacology 20050927

• Cyclo-oxygenase-2 expression and prostaglandin E2 production in experimental chronic gastric ulcer healing.

  European journal of pharmacology 20050920

• An overview of the recent developments in analytical methodologies for determination of COX-2 inhibitors in bulk drugs, pharmaceuticals and biological matrices.

  Journal of pharmaceutical and biomedical analysis 20050915

• Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050915

• Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050915

• Does the pro-hypertensive effect of cyclooxygenase-2 inhibitors account for the increased risk in cardiovascular disease?

  The American journal of cardiology 20050915

• Carbonic anhydrase inhibitors: stacking with Phe131 determines active site binding region of inhibitors as exemplified by the X-ray crystal structure of a membrane-impermeant antitumor sulfonamide complexed with isozyme II.

  Journal of medicinal chemistry 20050908

• Involvement of intracellular Ca2+ levels in nonsteroidal anti-inflammatory drug-induced apoptosis.

  The Journal of biological chemistry 20050902

• Connexin43 is overexpressed in Apc(Min/+)-mice adenomas and colocalises with COX-2 in myofibroblasts.

  International journal of cancer 20050901

• In vitro antiproliferative activity against human colon cancer cell lines of representative 4-thiazolidinones. Part I.

  Bioorganic & medicinal chemistry letters 20050901

• Feasibility of performing chemoprevention trials in women at elevated risk of ovarian carcinoma: initial examination of celecoxib as a chemopreventive agent.

  Gynecologic oncology 20050901

• Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells.

  Biochemical pharmacology 20050901

• Sulfotransferase 2A1 forms estradiol-17-sulfate and celecoxib switches the dominant product from estradiol-3-sulfate to estradiol-17-sulfate.

  The Journal of steroid biochemistry and molecular biology 20050901

• How celecoxib could be safer, how valdecoxib might have been.

  The Annals of pharmacotherapy 20050901

• Cross-talk between cyclooxygenase-2 and epidermal growth factor receptor in non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20050901

• Effects of celecoxib in human retinoblastoma cell lines and in a transgenic murine model of retinoblastoma.

  The British journal of ophthalmology 20050901

• Preoperative use of selective COX-II inhibitors for pain management in laparoscopic nissen fundoplication.

  Surgical endoscopy 20050901

• COX-2 inhibitors and arterial hypertension: an analysis of spontaneous case reports in the Pharmacovigilance database.

  European journal of clinical pharmacology 20050901

• Low direct cytotoxicity of nabumetone on gastric mucosal cells.

  Digestive diseases and sciences 20050901

• Blood-nourishing and hard-softening capsule costs less in the management of osteoarthritic knee pain: a randomized controlled trial.

  Evidence-based complementary and alternative medicine : eCAM 20050901

• Prevention of colon cancer by low doses of celecoxib, a cyclooxygenase inhibitor, administered in diet rich in omega-3 polyunsaturated fatty acids.

  Cancer research 20050901

• Randomized, placebo-controlled, esophageal squamous cell cancer chemoprevention trial of selenomethionine and celecoxib.

  Gastroenterology 20050901

• Combined targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050901

• Epidermal growth factor-induced cyclooxygenase-2 expression is mediated through phosphatidylinositol-3 kinase, not mitogen-activated protein/extracellular signal-regulated kinase kinase, in recurrent respiratory papillomas.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050901

• Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050901

• Cytochrome P450 2C9 genotype: impact on celecoxib safety and pharmacokinetics in a pediatric patient.

  Clinical pharmacology and therapeutics 20050901

• The Vioxx debacle revisited.

  The American journal of medicine 20050901

• Cyclooxygenase-independent down-regulation of multidrug resistance-associated protein-1 expression by celecoxib in human lung cancer cells.

  Molecular cancer therapeutics 20050901

• [COX-2 inhibitors in cancer prevention].

  Revista clinica espanola 20050901

• [Cardiovascular events: a class effect by COX-2 inhibitors].

  Arquivos brasileiros de cardiologia 20050901

• Nonsteroidal anti-inflammatory drugs: confusion, controversy and dental implications.

  Journal (Canadian Dental Association) 20050901

• Synergistic tumoricidal effect between celecoxib and adenoviral-mediated delivery of mda-7 in human breast cancer cells.

  Surgery 20050901

• A new stability--indicating RP-HPLC method to determine assay and known impurity of Celecoxib API.

  Drug development and industrial pharmacy 20050901

• Ubiquitous expression of cyclooxygenase-2 in meningiomas and decrease in cell growth following in vitro treatment with the inhibitor celecoxib: potential therapeutic application.

  Journal of neurosurgery 20050901

• The use and safety profile of non-steroidal antiinflammatory drugs among Turkish patients with osteoarthritis.

  The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology 20050901

• Calotropis procera latex-induced inflammatory hyperalgesia--effect of antiinflammatory drugs.

  Mediators of inflammation 20050831

• Transcriptional induction of cyclooxygenase-2 in osteoclast precursors is involved in RANKL-induced osteoclastogenesis.

  Blood 20050815

• Need for common internal controls when assessing the relative efficacy of pharmacologic agents using a meta-analytic approach: case study of cyclooxygenase 2-selective inhibitors for the treatment of osteoarthritis.

  Arthritis and rheumatism 20050815

• [The efficacy of selective Cox-2-inhibitors in comparison with conventional NSAIDs].

  MMW Fortschritte der Medizin 20050804

• A novel celecoxib derivative potently induces apoptosis of human synovial fibroblasts.

  The Journal of pharmacology and experimental therapeutics 20050801

• Cyclooxygenase-2 inhibitors decrease vascular endothelial growth factor expression in colon cancer cells by enhanced degradation of Sp1 and Sp4 proteins.

  Molecular pharmacology 20050801

• Targeting the beta-catenin/APC pathway: a novel mechanism to explain the cyclooxygenase-2-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20050801

• Effects of selective COX-2 and 5-LOX inhibition on prostaglandin and leukotriene synthesis in ductal pancreatic cancer in Syrian hamster.

  Prostaglandins, leukotrienes, and essential fatty acids 20050801

• The molecular basis for coxib inhibition of p38alpha MAP kinase.

  Bioorganic & medicinal chemistry letters 20050801

• Celecoxib inhibits ureteral contractility and prostanoid release.

  The Journal of urology 20050801

• Is COX-2 a perpetrator or a protector? Selective COX-2 inhibitors remain controversial.

  Acta pharmacologica Sinica 20050801

• Neuroprotective effects of cyclooxygenase-2 inhibitor celecoxib against toxicity of LPS-stimulated macrophages toward motor neurons.

  Acta pharmacologica Sinica 20050801

• Is COX-2 a 'collateral' target in cancer prevention?

  Biochemical Society transactions 20050801

• Drug intervention can correct subnormal retinal oxygenation response in experimental diabetic retinopathy.

  Investigative ophthalmology & visual science 20050801

• A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050801

• Killing pain, not neurons.

  Nature medicine 20050801

• Update on cyclooxygenase inhibitors: has a third COX isoform entered the fray?

  Current medical research and opinion 20050801

• Oncogenic potential of MEK1 in rat intestinal epithelial cells is mediated via cyclooxygenase-2.

  Gastroenterology 20050801

• PSA and clinical responses to celecoxib in a patient with prostate cancer and bone metastases.

  Mayo Clinic proceedings 20050801

• Role of aromatase inhibitors in breast cancer.

  British journal of cancer 20050801

• Potential use of COX-2-aromatase inhibitor combinations in breast cancer.

  British journal of cancer 20050801

• Sequencing of aromatase inhibitors.

  British journal of cancer 20050801

• [A COX-2 inhibitor suppresses esophageal inflammation-metaplasia-adenocarcinoma sequence in rats].

  Nihon rinsho. Japanese journal of clinical medicine 20050801

• Role of COX-2 selective inhibitors for prevention and treatment of cancer.

  Die Pharmazie 20050801

• Thrombosis and priapism in a patient with Henoch-Schonlein purpura.

  Rheumatology international 20050801

• Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema.

  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20050801

• Plasma pharmacokinetics and synovial fluid concentrations after oral administration of single and multiple doses of celecoxib in greyhounds.

  American journal of veterinary research 20050801

• Simultaneous determination of rofecoxib and celecoxib in human plasma by high-performance liquid chromatography.

  Journal of chromatographic science 20050801

• [Significance and expression of cyclooxygenase-2 mRNA in peripheral blood monocytes in patients with acute coronary syndrome].

  Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 20050801

• Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.

  Clinical therapeutics 20050801

• Could the combination of celecoxib and 4HPR be an effective lung cancer treatment?

  Cancer biology & therapy 20050801

• [Therapeutic strategies using VEGF inhibitors in colorectal cancer].

  Bulletin du cancer 20050801

• PGE2 produced by lung cancer suppresses immune function through T-regulatory cells and can be blocked by the COX2 inhibitor Celebrex.

  Cancer biology & therapy 20050801

• SKI306X, an oriental herbal mixture, suppresses gastric leukotriene B4 synthesis without causing mucosal injury and the diclofenac-induced gastric lesions.

  Life sciences 20050729

• Antitumoral effect of celecoxib in hepatocellular carcinoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050720

• [The role of hypoxia on expression of cyclooxygenase-2 in synovial fibroblasts derived from human temporomandular joint].

  Zhonghua yi xue za zhi 20050706

• A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.

  Rheumatology (Oxford, England) 20050701

• Selective cyclooxygenase (COX) inhibition causes damage to portal hypertensive gastric mucosa: roles of nitric oxide and NF-kappaB.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20050701

• Safety of short-term administration of celecoxib in decompensated cirrhosis.

  Hepatology (Baltimore, Md.) 20050701

• Licofelone, a novel 5-LOX/COX-inhibitor, attenuates leukocyte rolling and adhesion on endothelium under flow.

  Biochemical pharmacology 20050701

• Preparation of celecoxib-dimethyl-beta-cyclodextrin inclusion complex: characterization and in vitro permeation study.

  European journal of medicinal chemistry 20050701

• Fibroblasts express RANKL and support osteoclastogenesis in a COX-2-dependent manner after stimulation with titanium particles.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20050701

• The cardiovascular toxicity of selective and nonselective cyclooxygenase inhibitors: comparisons, contrasts, and aspirin confounding.

  Journal of clinical pharmacology 20050701

• Design, synthesis, and anti-inflammatory evaluation of a series of novel amino acid-binding 1,5-diarylpyrazole derivatives.

  Acta pharmacologica Sinica 20050701

• Prevention of intra-abdominal adhesions using the antiangiogenic COX-2 inhibitor celecoxib.

  Annals of surgery 20050701

• Non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory agents in the treatment of neurodegenerative disease.

  Current Alzheimer research 20050701

• Selection of topically applied non-steroidal anti-inflammatory drugs for oral cancer chemoprevention.

  Oral oncology 20050701

• Neovascularization and neoinnervation of subcutaneously placed nucleus pulposus and the inhibitory effects of certain drugs.

  Spine 20050701

• Celecoxib is often combined with cytochrome P450 2D6 substrates in general clinical practice.

  Clinical pharmacology and therapeutics 20050701

• Pulmonary embolism in a woman taking oral contraceptives and valdecoxib.

  PLoS medicine 20050701

• T-cell lymphopenia associated with infliximab and cyclophosphamide.

  The American journal of the medical sciences 20050701

• A Thrombelastograph whole blood assay for clinical monitoring of NSAID-insensitive transcellular platelet activation by arachidonic acid.

  The Journal of laboratory and clinical medicine 20050701

• Spectral markers in preneoplastic intestinal mucosa: an accurate predictor of tumor risk in the MIN mouse.

  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20050701

• Effect of concomitant polyethylene glycol and celecoxib on colonic aberrant crypt foci and tumors in F344 rats.

  Digestive diseases and sciences 20050701

• Comparative gastrointestinal toxicity of selective cyclooxygenase (COX-2) inhibitors.

  Indian journal of experimental biology 20050701

• Long-term use and tolerability of cyclooxygenase-2 inhibitors in patients with analgesic intolerance.

  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20050701

• The furoxan system: design of selective nitric oxide (NO) donor inhibitors of COX-2 endowed with anti-aggregatory and vasodilating activities.

  Chemistry & biodiversity 20050701

• Inconsistency in the editorial process in Archives of Internal Medicine?

  Archives of internal medicine 20050627

• Tailoring arthritis therapy in the wake of the NSAID crisis.

  The New England journal of medicine 20050623

• Cardiovascular risk associated with celecoxib.

  The New England journal of medicine 20050623

• Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells.

  International journal of cancer 20050620

• Anti-proliferative and apoptotic effects of celecoxib on human chronic myeloid leukemia in vitro.

  Cancer letters 20050616

• Beta-amyloid-induced apoptosis is associated with cyclooxygenase-2 up-regulation via the mitogen-activated protein kinase-NF-kappaB signaling pathway.

  Free radical biology & medicine 20050615

• Celecoxib augmentation of continuously ill patients with schizophrenia.

  Biological psychiatry 20050615

• Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis.

  BMJ (Clinical research ed.) 20050611

• Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study.

  BMJ (Clinical research ed.) 20050611

• Combining exercise and cyclooxygenase-2 inhibition does not ameliorate learning deficits after brain insult, despite an increase in BDNF levels.

  Brain research 20050607

• [Selective cyclooxygenase-2 inhibitors. A population-based analysis of use in France over a three-year period and comparison with randomised clinical trials].

  Presse medicale (Paris, France : 1983) 20050604

• 3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)(2-pyridyl) phenyl ketone as a potent and orally active cyclooxygenase-2 selective inhibitor: synthesis and biological evaluation.

  Journal of medicinal chemistry 20050602

• The effects of colchicine and hydroxychloroquine on the cyclo-oxygenases COX-1 and COX-2.

  Rheumatology international 20050601

• Development and validation of a reversed-phase liquid chromatographic method for separation and simultaneous determination of COX-2 inhibitors in pharmaceuticals and its application to biological fluids.

  Biomedical chromatography : BMC 20050601

• Adipose differentiation-related protein: a gonadotropin- and prostaglandin-regulated protein in primate periovulatory follicles.

  Biology of reproduction 20050601

• A pharmacological study of celecoxib and gemcitabine in patients with advanced pancreatic cancer.

  Cancer chemotherapy and pharmacology 20050601

• A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20050601

• Celecoxib-induced deep-vein thrombosis.

  The Annals of pharmacotherapy 20050601

• Celecoxib tolerability in patients with hypersensitivity (mainly cutaneous reactions) to nonsteroidal anti-inflammatory drugs.

  International archives of allergy and immunology 20050601

• Tumor-associated down-regulation of 15-lipoxygenase-1 is reversed by celecoxib in colorectal cancer.

  Annals of surgery 20050601

• Selective COX-2 inhibition is favorable to human early and late-stage osteoarthritic cartilage: a human in vitro study.

  Osteoarthritis and cartilage 20050601

• Rescuing COX-2 inhibitors from the waste bin.

  Journal of the National Cancer Institute 20050601

• Chemotherapy induces the expression of cyclooxygenase-2 in non-small cell lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050601

• Prospects for disease modification in ankylosing spondylitis: do nonsteroidal antiinflammatory drugs do more than treat symptoms?

  Arthritis and rheumatism 20050601

• Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial.

  Arthritis and rheumatism 20050601

• Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studies.

  The Journal of rheumatology 20050601

• Evaluation of cyclooxygenase-2 inhibition in an orthotopic murine model of lung cancer for dose-dependent effect.

  The Journal of thoracic and cardiovascular surgery 20050601

• Adverse drug reactions to nonsteroidal anti-inflammatory drugs, COX-2 inhibitors and paracetamol in a paediatric hospital.

  British journal of clinical pharmacology 20050601

• Celecoxib, a selective inhibitor of cyclooxygenase 2 for therapy of diffuse anterior scleritis.

  American journal of ophthalmology 20050601

• Perspectives on novel therapies for bronchial carcinoma.

  Expert opinion on pharmacotherapy 20050601

• Prediction of genotoxicity of chemical compounds by statistical learning methods.

  Chemical research in toxicology 20050601

• Drug insight: cyclo-oxygenase 2 inhibitors and cardiovascular risk--where are we now?

  Nature clinical practice. Cardiovascular medicine 20050601

• Devitrification of amorphous celecoxib.

  AAPS PharmSciTech 20050601

• Increased serum interleukin-1beta and interleukin-6 in elderly, chronic schizophrenic patients on stable antipsychotic medication.

  Neuropsychiatric disease and treatment 20050601

• Pfizer Australia is fined for misleading promotion of celecoxib.

  BMJ (Clinical research ed.) 20050528

• Systematic overview of warfarin and its drug and food interactions.

  Archives of internal medicine 20050523

• New restrictions on celecoxib (Celebrex) use and the withdrawal of valdecoxib (Bextra).

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20050510

• Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study.

  Archives of internal medicine 20050509

• Physiological effects of indomethacin and celecobix: an S-transform laser Doppler flowmetry signal analysis.

  Physics in medicine and biology 20050507

• 1,5-Diarylpyrrole-3-acetic acids and esters as novel classes of potent and highly selective cyclooxygenase-2 inhibitors.

  Journal of medicinal chemistry 20050505

• Chemoprevention of 4-NQO-induced oral carcinogenesis by co-administration of all-trans retinoic acid loaded microspheres and celecoxib.

  Journal of controlled release : official journal of the Controlled Release Society 20050505

• Inhibition of COX-2 by celecoxib enhances glucocorticoid receptor function.

  Molecular psychiatry 20050501

• The effect of analgesic agents on the healing rat medial collateral ligament.

  The American journal of sports medicine 20050501

• Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis.

  Rheumatology (Oxford, England) 20050501

• Blood pressure in Native Americans switched from celecoxib to rofecoxib.

  The Annals of pharmacotherapy 20050501

• Safety of celecoxib in patients with adverse reactions to nimesulide.

  Allergy 20050501

• Vioxx, Celebrex, Bextra....do we have a new target for anti-inflammatory and antipyretic therapy?

  American journal of physiology. Regulatory, integrative and comparative physiology 20050501

• Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial.

  Lung cancer (Amsterdam, Netherlands) 20050501

• Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production.

  Nature medicine 20050501

• Effect of preoperative Cox-II-selective NSAIDs (coxibs) on postoperative outcomes: a systematic review of randomized studies.

  Acta anaesthesiologica Scandinavica 20050501

• Dimethyl-celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-inhibitory function, potently mimics the anti-tumor effects of celecoxib on Burkitt's lymphoma in vitro and in vivo.

  Cancer biology & therapy 20050501

• COX-2 inhibitors still eyed for cancer prevention.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20050501

• Feasibility of RNA collection for micro-array gene expression analysis in the treatment of cervical carcinoma: a scientific correlate of RTOG C-0128.

  Gynecologic oncology 20050501

• A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050501

• Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer.

  Cancer research 20050501

• Supra-additive growth inhibition by a celecoxib analogue and carboxyamido-triazole is primarily mediated through apoptosis.

  Cancer research 20050501

• Re: Efficacy of celecoxib, a COX-2-specific inhibitor, and naproxen in the management of acute ankle sprain: results of a double-blind, randomized controlled trial.

  Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine 20050501

• Effects of indomethacin and celecoxib on renal function in athletes.

  Medicine and science in sports and exercise 20050501

• High dose nonsteroidal anti-inflammatory drugs compromise spinal fusion.

  Canadian journal of anaesthesia = Journal canadien d'anesthesie 20050501

• Nonsteroidal anti-inflammatory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients.

  Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20050501

• Celecoxib-induced nephrotoxicity in a renal transplant recipient.

  Pharmacotherapy 20050501

• Cyclooxygenase-2 inhibitor-associated minimal-change disease.

  Clinical nephrology 20050501

• COX-2 inhibitors and acute interstitial nephritis: case report and review of the literature.

  Clinical nephrology 20050501

• FOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell'Italia Meridionale (GOIM).

  Annals of oncology : official journal of the European Society for Medical Oncology 20050501

• Translational studies on aromatase, cyclooxygenases, and enzyme inhibitors in breast cancer.

  The Journal of steroid biochemistry and molecular biology 20050501

• Celecoxib induces heme-oxygenase expression in glomerular mesangial cells.

  Annals of the New York Academy of Sciences 20050501

• COX-2 inhibitors and genetic background reduce mammary tumorigenesis in cyclooxygenase-2 transgenic mice.

  Prostaglandins & other lipid mediators 20050501

• DMC: novel celecoxib derivatives to rap cancer.

  Cancer biology & therapy 20050501

• Enhanced in vitro percutaneous absorption and in vivo anti-inflammatory effect of a selective cyclooxygenase inhibitor using microemulsion.

  Drug development and industrial pharmacy 20050501

• Clinical pharmacokinetic of celecoxib in healthy Thai volunteers.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20050501

• What are the effects of cyclooxygenase-2-specific inhibitors on the small bowel?

  Nature clinical practice. Gastroenterology & hepatology 20050501

• Indomethacin-induced activation of the death receptor-mediated apoptosis pathway circumvents acquired doxorubicin resistance in SCLC cells.

  British journal of cancer 20050425

• Effect of celecoxib, a cyclooxygenase-2 inhibitor, on the pathophysiology of adjuvant arthritis in rat.

  European journal of pharmacology 20050425

• Researchers plan to continue to study COX-2 inhibitors in cancer treatment and prevention.

  Journal of the National Cancer Institute 20050420

• Synthesis and biological evaluation of 3,4-diphenyl-1,2,5-oxadiazole-2-oxides and 3,4-diphenyl-1,2,5-oxadiazoles as potential hybrid COX-2 inhibitor/nitric oxide donor agents.

  Bioorganic & medicinal chemistry 20050415

• Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups.

  Arthritis and rheumatism 20050415

• [Enhancing effects of celecoxib on the growth inhibition of pancreatic carcinoma by gemcitabine treatment].

  Zhonghua yi xue za zhi 20050413

• Does the dose make the poison?

  Science (New York, N.Y.) 20050408

• [COX-2 inhibitors--one step forward and two steps back].

  Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20050407

• Celecoxib decreases endothelial tissue factor expression through inhibition of c-Jun terminal NH2 kinase phosphorylation.

  Circulation 20050405

• The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults.

  Annals of internal medicine 20050405

• Clinical effects of COX-2 inhibitors on cognition in schizophrenia.

  European archives of psychiatry and clinical neuroscience 20050401

• Early vasodilator response to anodal current application in human is not impaired by cyclooxygenase-2 blockade.

  American journal of physiology. Heart and circulatory physiology 20050401

• Suppression of accelerated tumor growth in surgical wounds by celecoxib and indomethacin.

  Head & neck 20050401

• Preemptive analgesia by zaltoprofen that inhibits bradykinin action and cyclooxygenase in a post-operative pain model.

  Neuroscience research 20050401

• Design, synthesis, and biological evaluation of N-acetyl-2-carboxybenzenesulfonamides: a novel class of cyclooxygenase-2 (COX-2) inhibitors.

  Bioorganic & medicinal chemistry 20050401

• Factors associated with celecoxib and rofecoxib utilization.

  The Annals of pharmacotherapy 20050401

• Acute tocolysis.

  Current opinion in obstetrics & gynecology 20050401

• Development and pharmacological characterization of a rat model of osteoarthritis pain.

  Pain 20050401

• Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammatory agents.

  Bioorganic & medicinal chemistry letters 20050401

• Patient characteristics associated with outpatient prescriptions for nabumetone and oxaprozin versus celecoxib and rofecoxib.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20050401

• Adoption of celecoxib and rofecoxib: a nationwide database study.

  Journal of clinical pharmacy and therapeutics 20050401

• Integrative role of cPLA with COX-2 and the effect of non-steriodal anti-inflammatory drugs in a transgenic mouse model of amyotrophic lateral sclerosis.

  Journal of neurochemistry 20050401

• Enhanced growth inhibition and apoptosis induction in NSCLC cell lines by combination of celecoxib and 4HPR at clinically relevant concentrations.

  Cancer biology & therapy 20050401

• Inhibition of cyclooxygenase 2 synthesis suppresses Herpes simplex virus type 1 reactivation.

  Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20050401

• An unusual case of diarrhoea.

  Australian family physician 20050401

• Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor.

  Expert opinion on investigational drugs 20050401

• Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib.

  Current medical research and opinion 20050401

• Raising the safety bar--the FDA's coxib meeting.

  The New England journal of medicine 20050331

• Post-training intrahippocampal infusion of the COX-2 inhibitor celecoxib impaired spatial memory retention in rats.

  European journal of pharmacology 20050328

• Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model.

  European journal of pharmacology 20050328

• [Ulcerating haemorrhagic colitis induced by celecoxib].

  Presse medicale (Paris, France : 1983) 20050326

• Reassessment of the benefit/risk-ratio of selective COX-2-inhibitors.

  Swiss medical weekly 20050319

• Inhibitory avoidance memory retention in the elevated T-maze is impaired after perivascular manipulation of the common carotid arteries.

  Life sciences 20050318

• Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.

  The New England journal of medicine 20050317

• COX-2 inhibitors--lessons in drug safety.

  The New England journal of medicine 20050317

• COX-2 inhibitors--a lesson in unexpected problems.

  The New England journal of medicine 20050317

• A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism.

  Blood 20050315

• Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure.

  Archives of internal medicine 20050314

• Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity.

  The Journal of pharmacology and experimental therapeutics 20050301

• The effects of selective and nonselective cyclooxygenase inhibitors on endothelin-1-induced fever in rats.

  American journal of physiology. Regulatory, integrative and comparative physiology 20050301

• A COX-2 inhibitor prevents the esophageal inflammation-metaplasia-adenocarcinoma sequence in rats.

  Carcinogenesis 20050301

• The cyclooxygenase-2 inhibitor GW406381X [2-(4-ethoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-pyrazolo[1,5-b]pyridazine] is effective in animal models of neuropathic pain and central sensitization.

  The Journal of pharmacology and experimental therapeutics 20050301

• Complexation of celecoxib with beta-cyclodextrin: characterization of the interaction in solution and in solid state.

  Journal of pharmaceutical sciences 20050301

• A combination of docosahexaenoic acid and celecoxib prevents prostate cancer cell growth in vitro and is associated with modulation of nuclear factor-kappaB, and steroid hormone receptors.

  International journal of oncology 20050301

• The restorative effect of a selective cyclooxygenase-2 inhibitor on urothelial cell-cell interactions after partial bladder outlet obstruction in rats.

  BJU international 20050301

• Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites.

  Hepatology (Baltimore, Md.) 20050301

• Celecoxib improves the efficiency of the locomotor mechanism in patients with knee osteoarthritis. A randomised, placebo, double-blind and cross-over trial.

  Osteoarthritis and cartilage 20050301

• A placebo-controlled screening trial of celecoxib for the treatment of cocaine dependence.

  Addiction (Abingdon, England) 20050301

• Modulation of celecoxib pharmacokinetics by food in pediatric patients.

  Clinical pharmacology and therapeutics 20050301

• The effect of cyclooxygenase-2 inhibition on analgesia and spinal fusion.

  The Journal of bone and joint surgery. American volume 20050301

• Painful lessons.

  Nature structural & molecular biology 20050301

• The safety of the perioperative administration of cyclooxygenase-2 inhibitors for post-surgical pain.

  Acta anaesthesiologica Scandinavica 20050301

• Induction of claudin-4 by nonsteroidal anti-inflammatory drugs and its contribution to their chemopreventive effect.

  Cancer research 20050301

• Anaphylactic shock caused by a selective allergy to celecoxib, with no allergy to rofecoxib or sulfamethoxazole.

  The Journal of allergy and clinical immunology 20050301

• Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050301

• Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050301

• [Anti-angiogenic therapy for gastrointestinal tumours].

  Zeitschrift fur Gastroenterologie 20050301

• Cyclooxygenase-2 inhibitors and cardiovascular risk.

  The Canadian journal of cardiology 20050301

• Uptake of new drugs in rural and urban areas of Queensland, Australia: the example of COX-2 inhibitors.

  European journal of clinical pharmacology 20050301

• A tale of two coxibs.

  JAAPA : official journal of the American Academy of Physician Assistants 20050301

• COX-2 inhibitors and cardiovascular toxicity: a class effect?

  South Dakota journal of medicine 20050301

• Molecular interactions in celecoxib-PVP-meglumine amorphous system.

  The Journal of pharmacy and pharmacology 20050301

• Formulation and evaluation of aerosolized celecoxib for the treatment of lung cancer.

  Pharmaceutical research 20050301

• Tolerability of selective cyclooxygenase inhibitor, celecoxib, in patients with analgesic intolerance.

  The Journal of asthma : official journal of the Association for the Care of Asthma 20050301

• Albumin microspheres as carriers for the antiarthritic drug celecoxib.

  AAPS PharmSciTech 20050301

• Lessons to learn from the COX-2 saga. Yes, FDA reforms are needed. And marketing distorts how medications are used. But one moral to the story is that all drugs have risks.

  Harvard health letter 20050301

• Coxibs: can this class of drugs survive?

  Vascular health and risk management 20050301

• Drug safety. FDA panel urges caution on many anti-inflammatory drugs.

  Science (New York, N.Y.) 20050225

• Vioxx may go back on sale after scraping past FDA panel.

  Nature 20050224

• Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9.

  International journal of cancer 20050220

• Sulindac and its metabolites inhibit invasion of glioblastoma cells via down-regulation of Akt/PKB and MMP-2.

  Journal of cellular biochemistry 20050215

• Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides.

  Bioorganic & medicinal chemistry letters 20050215

• Cytochrome P4502C9-derived epoxyeicosatrienoic acids induce the expression of cyclooxygenase-2 in endothelial cells.

  Arteriosclerosis, thrombosis, and vascular biology 20050201

• Coxib medications to be handled with care.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20050201

• Are all COX-2 inhibitors created equal?

  Hypertension (Dallas, Tex. : 1979) 20050201

• In vivo endothelial interaction between ACE and COX inhibitors.

  Prostaglandins, leukotrienes, and essential fatty acids 20050201

• Selective COX-2 inhibitors and renal injury in salt-sensitive hypertension.

  Hypertension (Dallas, Tex. : 1979) 20050201

• Selective COX-2 inhibitor regulates the MAP kinase signaling pathway in human osteoarthritic chondrocytes after induction of nitric oxide.

  International journal of molecular medicine 20050201

• Central nervous system concentrations of cyclooxygenase-2 inhibitors in humans.

  Anesthesiology 20050201

• Summaries for patients. Cyclooxygenase-2 inhibitors and heart attacks: varying effects?

  Annals of internal medicine 20050201

• Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction.

  Annals of internal medicine 20050201

• Celecoxib and ketoprofen for pain management during tonsillectomy: a placebo-controlled clinical trial.

  Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 20050201

• Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo.

  Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20050201

• COX-2 inhibitors: cancer prevention or cardiovascular risk?

  The Lancet. Oncology 20050201

• COX-2 selective inhibitors--important lessons learned.

  Lancet (London, England) 20050201

• Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study.

  Lancet (London, England) 20050201

• Reduction of opioid-related adverse events using opioid-sparing analgesia with COX-2 inhibitors lacks documentation: a systematic review.

  Acta anaesthesiologica Scandinavica 20050201

• Extracolonic manifestations of familial adenomatous polyposis after proctocolectomy.

  Archives of surgery (Chicago, Ill. : 1960) 20050201

• Colorectal cancer prevention: is an ounce of prevention worth a pound of cure?

  Seminars in oncology 20050201

• Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer.

  Seminars in oncology 20050201

• Cyclooxygenase-2 inhibition in colorectal cancer: boom or bust?

  Seminars in oncology 20050201

• Pfizer: Celebrex increases heart attack risk.

  Health news (Waltham, Mass.) 20050201

• Coxib toxicity: a likely class effect.

  Prescrire international 20050201

• [Prevention of heterotopic ossifications in hip arthroplasty: effectiveness of selective Cox-2 inhibitors (celecoxib) versus ketoprofen].

  Revue de chirurgie orthopedique et reparatrice de l'appareil moteur 20050201

• Institutional review boards must conduct safety review.

  Human research report 20050201

• Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and nimesulide associated or not with common non-steroidal anti-inflammatory drugs.

  European annals of allergy and clinical immunology 20050201

• Rofecoxib for osteoarthritis.

  The Cochrane database of systematic reviews 20050125

• The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.

  Archives of internal medicine 20050124

• Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors.

  Archives of internal medicine 20050124

• Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition.

  International journal of cancer 20050120

• Arthritis medicines and cardiovascular events--'house of coxibs'.

  JAMA 20050119

• A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment.

  British journal of cancer 20050117

• Design and synthesis of (E)-1,1,2-triarylethenes: novel inhibitors of the cyclooxygenase-2 (COX-2) isozyme.

  Bioorganic & medicinal chemistry letters 20050117

• NSAID alternatives.

  The Medical letter on drugs and therapeutics 20050117

• Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.

  Cancer 20050115

• Targeting cyclooxygenase-2 reduces overt toxicity toward low-dose vinblastine and extends survival of juvenile mice with Friend disease.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050115

• Celecoxib does not induce convulsions nor does it affect GABAA receptor binding activity in the presence of new quinolones in mice.

  European journal of pharmacology 20050110

• The effects of selective cyclooxygenase-2 inhibitors, celecoxib and rofecoxib, on experimental colitis induced by acetic acid in rats.

  European journal of pharmacology 20050110

• Different cell kinetic changes in rat stomach cancer after treatment with celecoxib or indomethacin: implications on chemoprevention.

  World journal of gastroenterology 20050107

• Dietary zinc modulation of COX-2 expression and lingual and esophageal carcinogenesis in rats.

  Journal of the National Cancer Institute 20050105

• R-130823, a novel inhibitor of p38 MAPK, ameliorates hyperalgesia and swelling in arthritis models.

  European journal of pharmacology 20050104

• Distinct cAMP signaling pathways differentially regulate alpha2C-adrenoceptor expression: role in serum induction in human arteriolar smooth muscle cells.

  American journal of physiology. Heart and circulatory physiology 20050101

• Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization?

  Hypertension (Dallas, Tex. : 1979) 20050101

• Signaling via the angiotensin-converting enzyme enhances the expression of cyclooxygenase-2 in endothelial cells.

  Hypertension (Dallas, Tex. : 1979) 20050101

• Celecoxib, a selective cyclooxygenase-2 inhibitor, decreases monocyte chemoattractant protein-1 expression and neointimal hyperplasia in the rabbit atherosclerotic balloon injury model.

  Journal of cardiovascular pharmacology 20050101

• The prevention of post-surgical neuralgia.

  Pain 20050101

• The selective cyclooxygenase-2 inhibitor celecoxib modulates the formation of vasoconstrictor eicosanoids and activates PPARgamma. Influence of albumin.

  Journal of hepatology 20050101

• Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials.

  The Journal of rheumatology 20050101

• Survivin: a novel target for indomethacin-induced gastric injury.

  Gastroenterology 20050101

• Clinical consequences of cytochrome P450 2C9 polymorphisms.

  Clinical pharmacology and therapeutics 20050101

• Do early premalignant changes in normal breast epithelial cells predict cancer development?

  Breast cancer research : BCR 20050101

• Efficacy of lumiracoxib in osteoarthritis: a review of nine studies.

  The Journal of international medical research 20050101

• Nonsteroidal antiinflammatory drugs differentially suppress endometriosis in a murine model.

  Fertility and sterility 20050101

• Celecoxib inhibits ureteral contractility and prostanoid release.

  Urology 20050101

• Effect of maternal administration of selective cyclooxygenase (COX)-2 inhibitors on renal size, growth factors, proteinases, and COX-2 secretion in the fetal rabbit.

  Biology of the neonate 20050101

• [Vision impairment by COX-2 inhibitor and the sequelae of voluntary Vioxx recall].

  Klinische Monatsblatter fur Augenheilkunde 20050101

• Taking stock of coxibs.

  Drug and therapeutics bulletin 20050101

• Effect of specific and non-specific inhibition of COX-2 on renal oxygenation before and after water diuresis.

  Nephron. Physiology 20050101

• Phase I/II study of selective cyclooxygenase-2 inhibitor celecoxib as a radiation sensitizer in patients with unresectable brain metastases.

  Journal of neuro-oncology 20050101

• Long-term follow-up of a randomized clinical trial assessing the efficacy of medication, acupuncture, and spinal manipulation for chronic mechanical spinal pain syndromes.

  Journal of manipulative and physiological therapeutics 20050101

• Do selective cyclo-oxygenase-2 inhibitors have a future?

  Drug safety 20050101

• Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study.

  Arthritis research & therapy 20050101

• Clinical trial update: National Cancer Institute of Canada.

  Breast cancer research : BCR 20050101

• JTE-522, a selective COX-2 inhibitor, inhibits growth of pulmonary metastases of colorectal cancer in rats.

  BMC cancer 20050101

• Drug fiasco highlights need for more openness.

  British journal of community nursing 20050101

• Effect of nonsteroidal anti-inflammatory drugs with varying extent of COX-2-COX-1 selectivity on urinary sodium and potassium excretion in the rat.

  Canadian journal of physiology and pharmacology 20050101

• Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo.

  Clinical therapeutics 20050101

• Celecoxib-cyclodextrin systems: characterization and evaluation of in vitro and in vivo advantage.

  Drug development and industrial pharmacy 20050101

• [Tubulointerstitial nephritis associated with treatment with selective Cox-2 inhibitors, celecoxib and rofecoxib].

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20050101

• [Nephrotic syndrome associated to celecoxib].

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20050101

• A phase I study of 5-fluorouracil, leucovorin, and celecoxib in patients with incurable colorectal cancer.

  Prostaglandins & other lipid mediators 20050101

• The effects of Celecoxib on inflammation and synovial microcirculation in murine antigen-induced arthritis.

  Clinical and experimental rheumatology 20050101

• Cyclo-oxygenase-2 inhibitors: when should they be used in the elderly?

  Drugs & aging 20050101

• Growth inhibitory effect of celecoxib and rofecoxib on human colorectal carcinoma cell lines.

  Anticancer research 20050101

• Individual and combined effects of selective cyclooxygenase-2 inhibitor and omega-3 fatty acid on endotoxin-induced periodontitis in rats.

  Journal of periodontology 20050101

• Incidence of thrombotic cardiovascular events in patients taking celecoxib compared with those taking rofecoxib: interim results from the New Zealand Intensive Medicines Monitoring Programme.

  Drug safety 20050101

• Celecoxib was noninferior to diclofenac plus omeprazole for preventing gastroduodenal ulcer recurrence in high-risk patients with arthritis.

  ACP journal club 20050101

• Assessing the cost-effectiveness of COX-2 specific inhibitors for arthritis in the Veterans Health Administration.

  Current medical research and opinion 20050101

• The effects of non-steroidal anti-inflammatory drugs (selective and non-selective) on the treatment of periodontal diseases.

  Current pharmaceutical design 20050101

• Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands.

  BMC cancer 20050101

• Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports.

  Arthritis research & therapy 20050101

• Can chronic use of anti-inflammatory agents paradoxically promote chronic inflammation through compensatory host response?

  Medical hypotheses 20050101

• Study on the inclusion complex between beta-cyclodextrin and celecoxib by spectrofluorimetry and its analytical application.

  Farmaco (Societa chimica italiana : 1989) 20050101

• Spray drying for generation of a ternary amorphous system of celecoxib, PVP, and meglumine.

  Pharmaceutical development and technology 20050101

• [Celecoxib prescription: data from the 'Sécurité Sociale' database of the Aquitaine Region, South-Western, France].

  Therapie 20050101

• Celecoxib inhibits proliferation and induces apoptosis via cyclooxygenase-2 pathway in human pancreatic carcinoma cells.

  Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban 20050101

• In vivo effect of celecoxib and tenoxicam on oxidant/ anti-oxidant status of patients with knee osteoarthritis.

  Annals of clinical and laboratory science 20050101

• SuperLigands - a database of ligand structures derived from the Protein Data Bank.

  BMC bioinformatics 20050101

• Relative thromboembolic risks associated with COX-2 inhibitors.

  The Annals of pharmacotherapy 20050101

• Effect of LLLT Ga-Al-As (685 nm) on LPS-induced inflammation of the airway and lung in the rat.

  Lasers in medical science 20050101

• COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective.

  Current topics in medicinal chemistry 20050101

• Impact of COX-2 inhibitors in common clinical practice a gastroenterologist's perspective.

  Current topics in medicinal chemistry 20050101

• Selective COX-2 inhibitors and risk of myocardial infarction.

  Journal of vascular research 20050101

• Tetrandrine and thapsigargin release arachidonic acid from cells in culture and stimulate prostacyclin production in rat liver cells, but may do so by different pathways.

  BMC pharmacology 20050101

• Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells.

  Breast cancer research : BCR 20050101

• [Gastroduodenal safety of selective inhibitors of cyclooxigenase-2: practical validation].

  Terapevticheskii arkhiv 20050101

• Celecoxib increased cardiovascular events in patients with colorectal adenomas.

  ACP journal club 20050101

• [Role of prostaglandins in the pathogenesis of stomach ulcer and gastropathy caused by non-steroid anti-inflammatory drugs].

  Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology 20050101

• Quantification and characterisation of cyclo-oxygenase and lipid peroxidation inhibitory anthocyanins in fruits of Amelanchier.

  Phytochemical analysis : PCA 20050101

• Utilization of non-steroidal anti-inflammatory drugs in Quebec: adherence to the Canadian consensus on prescription guidelines.

  The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique 20050101

• Prevention of tumors of the large intestine by celecoxib in mice.

  In vivo (Athens, Greece) 20050101

• Anti-inflammatory effects of specific cyclooxygenase 2,5-lipoxygenase, and inducible nitric oxide synthase inhibitors on experimental autoimmune anterior uveitis (EAAU).

  Ocular immunology and inflammation 20050101

• New agents in intravesical chemotherapy of superficial bladder cancer.

  Scandinavian journal of urology and nephrology 20050101

• Analgesic effects of nonsteroidal antiinflammatory drugs, acetaminophen, and morphine in a mouse model of bone cancer pain.

  Journal of anesthesia 20050101

• Usefulness of montelukast to prevent adverse reactions to COX-2 selective inhibitors: a case report.

  Journal of investigational allergology & clinical immunology 20050101

• Regulatory paternalism in the market for drugs: lessons from Vioxx and Celebrex.

  Yale journal of health policy, law, and ethics 20050101

• The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: a phase II study with biological correlates.

  Cancer journal (Sudbury, Mass.) 20050101

• Pharmacological profile of celecoxib, a specific cyclooxygenase-2 inhibitor.

  Arzneimittel-Forschung 20050101

• Pancreatic stellate cells (PSCs) express cyclooxygenase-2 (COX-2) and pancreatic cancer stimulates COX-2 in PSCs.

  Molecular cancer 20050101

• Treatment of osteoarthritis of the knee with a topical diclofenac solution: a randomised controlled, 6-week trial [ISRCTN53366886].

  BMC musculoskeletal disorders 20050101

• A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer.

  Oncology 20050101

• Inhibitory effects of Celecoxib and Sc-58125 on proliferation of human carcinoma of larynx Hep-2 in vitro.

  Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban 20050101

• A comparison of reported gastrointestinal and thromboembolic events between rofecoxib and celecoxib using observational data.

  Drug safety 20050101

• FDA announces changes affecting the marketing of non-steroidal anti-inflammatory drugs.

  FDA consumer 20050101

• Potential protective effects of NSAIDs/ASA in oxidatively stressed human lens epithelial cells and intact mouse lenses in culture.

  Ophthalmic research 20050101

• [Relapsing polychondritis. A case report of a patient treated with methotrexate and celecoxib].

  Revista medica del Instituto Mexicano del Seguro Social 20050101

• Establishment and characterization of a pancreatic carcinoma cell line derived from malignant pleural effusion.

  Oncology 20050101

• The effect of conflict of interest on biomedical research and clinical practice guidelines: can we trust the evidence in evidence-based medicine?

  The Journal of the American Board of Family Practice 20050101

• Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer.

  BMC cancer 20050101

• Current state of therapy for pain and inflammation.

  Arthritis research & therapy 20050101

• Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance.

  Arthritis research & therapy 20050101

• Practical approaches to minimizing gastrointestinal and cardiovascular safety concerns with COX-2 inhibitors and NSAIDs.

  Arthritis research & therapy 20050101

• Balancing the gastrointestinal benefits and risks of nonselective NSAIDs.

  Arthritis research & therapy 20050101

• Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours.

  Breast cancer research : BCR 20050101

• The Fourth International Symposium on the Intraductal Approach to Breast Cancer, Santa Barbara, California, 10-13 March 2005.

  Breast cancer research : BCR 20050101

• Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathway.

  Breast cancer research : BCR 20050101

• Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors.

  Drug safety 20050101

• COX-2 inhibitors as adjunctive therapy in schizophrenia: rationale for use and evidence to date.

  CNS drugs 20050101

• [Sex-related differences in the antinociceptive effect of some non-narcotic analgetics in rats: the role of biotransformation].

  Eksperimental'naia i klinicheskaia farmakologiia 20050101

• Role of molecular interaction in stability of celecoxib-PVP amorphous systems.

  Molecular pharmaceutics 20050101

• Influence of Helicobacter pylori and omeprazole on celecoxib-induced gastroduodenal mucosal injury.

  Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology 20050101

• Early relief of osteoarthritis symptoms with a natural mineral supplement and a herbomineral combination: a randomized controlled trial [ISRCTN38432711].

  Journal of inflammation (London, England) 20050101

• Cardiovascular complications of non-steroidal anti-inflammatory drugs.

  Annals of clinical and laboratory science 20050101

• Prostanoids as friends, not foes: further evidence from the interference by cycloxygenase-inhibitory drugs when inducing tolerance to experimental arthritigens in rats.

  Inflammopharmacology 20050101

• Single subject pharmacological-MRI (phMRI) study: modulation of brain activity of psoriatic arthritis pain by cyclooxygenase-2 inhibitor.

  Molecular pain 20050101

• TOIB Study. Are topical or oral ibuprofen equally effective for the treatment of chronic knee pain presenting in primary care: a randomised controlled trial with patient preference study. [ISRCTN79353052].

  BMC musculoskeletal disorders 20050101

• The efficacy and toleration of celecoxib (Celebrex) in the treatment of osteoarthritis in Nigeria: a multicentre study.

  West African journal of medicine 20050101

• Comparative study of anti-inflammatory and ulcerogenic activities of different cyclo-oxygenase inhibitors.

  Inflammopharmacology 20050101

• [Cyclooxygenase-2 inhibitors and the ethics of research].

  Medicina 20050101

• A comparison between the effects of acetaminophen and celecoxib on bone fracture healing in rats.

  Journal of orthopaedic trauma 20050101

• Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population.

  BMC medicine 20050101

• Etoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, active-comparator controlled trial [NCT00242489].

  BMC musculoskeletal disorders 20050101

• The use of celecoxib for reduction of pain after subpectoral breast augmentation.

  Aesthetic plastic surgery 20050101

• Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer.

  BMC cancer 20050101

• Introduction - The coxib controversies.

  Inflammopharmacology 20050101

• The use of NSAIDs in rheumatic disorders 2005: a global perspective.

  Inflammopharmacology 20050101

• COX-2 inhibitors: a story of greed, deception and death.

  Inflammopharmacology 20050101

• Mechanisms involved in the anti-inflammatory effect of a standardized willow bark extract.

  Arzneimittel-Forschung 20050101

• Effect of celecoxib on Ca2+ fluxes and proliferation in MDCK renal tubular cells.

  Journal of receptor and signal transduction research 20050101

• Gastrointestinal safety of amtolmetin guacyl in comparison with celecoxib in patients with rheumatoid arthritis.

  Clinical and experimental rheumatology 20050101

• The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain.

  Pharmacological reports : PR 20050101

• Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and other non-steroidal anti-inflammatory drugs.

  Journal of investigational allergology & clinical immunology 20050101

• [Docetaxel and novel strategies in the treatment of NSCLC].

  Tumori 20050101

• Modeling of drug release from celecoxib-PVP-meglumine amorphous systems.

  PDA journal of pharmaceutical science and technology 20050101

• [Untoward interactions between antihypertensives and nonsteroidal anti-inflammatory drugs].

  Lijecnicki vjesnik 20050101

• Varied response of spontaneous tumors to antiangiogenic agents.

  Advances in experimental medicine and biology 20050101

• [Nonsteroidal antirheumatics and the kidney].

  Reumatizam 20050101

• The risks and benefits of cyclo-oxygenase-2 inhibitors in prostate cancer: a review.

  International journal of surgery (London, England) 20050101

• Effect of celecoxib, a cyclooxygenase-2-specific inhibitor, on insulin sensitivity, C-reactive protein, homocysteine, and metabolic profile in overweight or obese subjects.

  Metabolic syndrome and related disorders 20050101

• COX-2 selective inhibitors and heart health.

  Postgraduate medicine 20050101

• Design, synthesis, and pharmacological evaluation of pyridinic analogues of nimesulide as cyclooxygenase-2 selective inhibitors.

  Journal of medicinal chemistry 20041230

• Rofecoxib, Merck, and the FDA.

  The New England journal of medicine 20041230

• Clinical trials. Halt of Celebrex study threatens drug's future, other trials.

  Science (New York, N.Y.) 20041224

• Carbonic anhydrase inhibitors. Inhibition of the prokariotic beta and gamma-class enzymes from Archaea with sulfonamides.

  Bioorganic & medicinal chemistry letters 20041220

• 3-(2-Methoxytetrahydrofuran-2-yl)pyrazoles: a novel class of potent, selective cyclooxygenase-2 (COX-2) inhibitors.

  Bioorganic & medicinal chemistry letters 20041220

• Role of cyclooxygenase-2 in cytokine-induced beta-cell dysfunction and damage by isolated rat and human islets.

  The Journal of biological chemistry 20041217

• [Criteria for administration of Lantus, Levemir and Lyrica. Guidelines for administration of Celebra and Arcoxia].

  Ugeskrift for laeger 20041213

• Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation.

  Oncogene 20041209

• Clinical trials. Nail-biting time for trials of COX-2 drugs.

  Science (New York, N.Y.) 20041203

• New COX-2/5-LOX inhibitors: apoptosis-inducing agents potentially useful in prostate cancer chemotherapy.

  Journal of medicinal chemistry 20041202

• ABT-963 [2-(3,4-difluoro-phenyl)-4-(3-hydroxy-3-methyl-butoxy)-5-(4-methanesulfonyl-phenyl)-2H-pyridazin-3-one], a highly potent and selective disubstituted pyridazinone cyclooxgenase-2 inhibitor.

  The Journal of pharmacology and experimental therapeutics 20041201

• Nitric oxide (NO)-releasing naproxen (HCT-3012 [(S)-6-methoxy-alpha-methyl-2-naphthaleneacetic Acid 4-(nitrooxy)butyl ester]) interactions with aspirin in gastric mucosa of arthritic rats reveal a role for aspirin-triggered lipoxin, prostaglandins, and NO in gastric protection.

  The Journal of pharmacology and experimental therapeutics 20041201

• Up-regulation of cyclooxygenase-2 expression is involved in R(+)-methanandamide-induced apoptotic death of human neuroglioma cells.

  Molecular pharmacology 20041201

• Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts.

  Cancer biology & therapy 20041201

• Pharmacotherapy for diabetic retinopathy.

  Current opinion in ophthalmology 20041201

• Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs.

  Atherosclerosis 20041201

• Current approaches to prevent NSAID-induced gastropathy--COX selectivity and beyond.

  British journal of clinical pharmacology 20041201

• Vioxx withdrawal alarms cancer prevention researchers.

  Journal of the National Cancer Institute 20041201

• Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells.

  Journal of the National Cancer Institute 20041201

• Formulation design of self-microemulsifying drug delivery systems for improved oral bioavailability of celecoxib.

  Biological & pharmaceutical bulletin 20041201

• Novel insights and therapeutical applications in the field of inhibitors of COX-2.

  Current medicinal chemistry 20041201

• Cutaneous vasculitis induced by cyclo-oxygenase-2 selective inhibitors.

  Journal of the American Academy of Dermatology 20041201

• Effect of cyclooxygenase-2 inhibitors on gastric emptying and small intestinal transit in humans.

  Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20041201

• [Inhibitory effects of celecoxib combined with octreotide on growth of multidrug resistant human gastric cancer cell line SGC7901/ADR].

  Ai zheng = Aizheng = Chinese journal of cancer 20041201

• [A case report of disseminated malignant mesothelioma of peritoneum responding remarkably to thalidomide, celecoxib, vinorelbine and CDDP].

  Gan to kagaku ryoho. Cancer & chemotherapy 20041201

• Growth inhibitory effects of celecoxib in human umbilical vein endothelial cells are mediated through G1 arrest via multiple signaling mechanisms.

  Molecular cancer therapeutics 20041201

• Celecoxib and radiation therapy in non-small-cell lung cancer.

  Oncology (Williston Park, N.Y.) 20041201

• Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results.

  Oncology (Williston Park, N.Y.) 20041201

• Gemcitabine/Irinotecan/celecoxib in pancreatic cancer.

  Oncology (Williston Park, N.Y.) 20041201

• A painkiller is pulled from the market. So what do you do now?

  Heart advisor 20041201

• The influence of celecoxib on muscle fatigue resistance and mobility in elderly patients with inflammation.

  The American journal of geriatric pharmacotherapy 20041201

• Transparency in drug regulation: mirage or oasis?

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20041123

• A new class of acyclic 2-alkyl-1,1,2-triaryl (Z)-olefins as selective cyclooxygenase-2 inhibitors.

  Journal of medicinal chemistry 20041118

• Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer.

  Analytical biochemistry 20041115

• Design and synthesis of acyclic triaryl (Z)-olefins: a novel class of cyclooxygenase-2 (COX-2) inhibitors.

  Bioorganic & medicinal chemistry 20041115

• Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20041115

• Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib.

  Annals of the rheumatic diseases 20041101

• Identification of 2,3-diaryl-pyrazolo[1,5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitors.

  Bioorganic & medicinal chemistry letters 20041101

• The potential role of cyclooxygenase-2 inhibitors in the treatment of experimentally-induced mammary tumour: does celecoxib enhance the anti-tumour activity of doxorubicin?

  Pharmacological research 20041101

• Resveratrol analogues as selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationship.

  Bioorganic & medicinal chemistry 20041101

• Transfer of celecoxib into human milk.

  Journal of human lactation : official journal of International Lactation Consultant Association 20041101

• Increased expression of cyclooxygenase (COX)-2 in DMBA-induced hamster cheek pouch carcinogenesis and chemopreventive effect of a selective COX-2 inhibitor celecoxib.

  Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 20041101

• Heterotropic modulation of sulfotransferase 2A1 activity by celecoxib: product ratio switching of ethynylestradiol sulfation.

  Drug metabolism and disposition: the biological fate of chemicals 20041101

• The potential role of non-steroidal anti-inflammatory drugs in treating Alzheimer's disease.

  Expert opinion on investigational drugs 20041101

• Disturbance of vision by COX-2 inhibitors.

  Expert opinion on drug safety 20041101

• Upper gastrointestinal adverse drug reactions and cyclo-oxygenase-2 inhibitors (celecoxib and rofecoxib): a case/non-case study from the French Pharmacovigilance Database.

  European journal of clinical pharmacology 20041101

• Risks of clinically significant upper gastrointestinal events with etodolac and naproxen: a historical cohort analysis.

  Gastroenterology 20041101

• Up-regulation of the enzymes involved in prostacyclin synthesis via Ras induces vascular endothelial growth factor.

  Gastroenterology 20041101

• Lack of effect of celecoxib on prostaglandin E2 concentrations in nipple aspirate fluid from women at increased risk of breast cancer.

  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20041101

• Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines.

  Molecular cancer therapeutics 20041101

• Psychotropic effects of COX-2 inhibitors--a possible new approach for the treatment of psychiatric disorders.

  Pharmacopsychiatry 20041101

• Pain management in osteoarthritis: a focus on onset of efficacy--a comparison of rofecoxib, celecoxib, acetaminophen, and nabumetone across four clinical trials.

  The journal of pain : official journal of the American Pain Society 20041101

• Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer.

  Molecular cancer research : MCR 20041101

• Effect of processing on Celecoxib and its solvates.

  Pharmaceutical development and technology 20041101

• [Is there a future for COX-2 inhibitors?].

  Harefuah 20041101

• [Role of prostaglandin E2 in regulation of urine excretion in saluresis, water and osmotic diuresis in rat].

  Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova 20041101

• Docking studies on NSAID/COX-2 isozyme complexes using contact statistics analysis.

  Journal of computer-aided molecular design 20041101

• Protein kinase CbetaII regulates its own expression in rat intestinal epithelial cells and the colonic epithelium in vivo.

  The Journal of biological chemistry 20041029

• Prevention by celecoxib of secondary hyperalgesia induced by formalin in rats.

  Life sciences 20041022

• Coxibs and cardiovascular disease.

  The New England journal of medicine 20041021

• Multiple comparisons with a control in families with both one-sided and two-sided hypotheses.

  Statistics in medicine 20041015

• Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivo.

  Cancer research 20041015

• Apoptosis protease activator protein-1 expression is dispensable for response of human melanoma cells to distinct proapoptotic agents.

  Cancer research 20041015

• Modulation of pulmonary leukotriene B4 production by cyclooxygenase-2 inhibitors and lipopolysaccharide.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20041015

• Apc deficiency is associated with increased Egfr activity in the intestinal enterocytes and adenomas of C57BL/6J-Min/+ mice.

  The Journal of biological chemistry 20041008

• Despite positive studies, popularity of chemoprevention drugs increasing slowly.

  Journal of the National Cancer Institute 20041006

• A new class of acyclic 2-alkyl-1,2-diaryl (E)-olefins as selective cyclooxygenase-2 (COX-2) inhibitors.

  Bioorganic & medicinal chemistry letters 20041004

• Modulation by celecoxib and difluoromethylornithine of the methylation of DNA and the estrogen receptor-alpha gene in rat colon tumors.

  Carcinogenesis 20041001

• Celecoxib-induced methemoglobinemia.

  The Annals of pharmacotherapy 20041001

• Aggravation of inflammatory bowel disease by cyclooxygenase-2 inhibitors in rats.

  Pharmacology 20041001

• HPLC method for determination of DRF-4367 in rat plasma: validation and its application to pharmacokinetics in Wistar rats.

  Biomedical chromatography : BMC 20041001

• Reduced sulfur mustard-induced skin toxicity in cyclooxygenase-2 knockout and celecoxib-treated mice.

  Toxicology and applied pharmacology 20041001

• Cancer-related anorexia/cachexia syndrome and oxidative stress: an innovative approach beyond current treatment.

  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20041001

• Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20041001

• Effect of chronic intake of NSAIDs and cyclooxygenase 2-selective inhibitors on esophageal cancer incidence.

  Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20041001

• Characterization of pristane-induced arthritis, a murine model of chronic disease: response to antirheumatic agents, expression of joint cytokines, and immunopathology.

  Arthritis and rheumatism 20041001

• Suppression of Peutz-Jeghers polyposis by inhibition of cyclooxygenase-2.

  Gastroenterology 20041001

• Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial.

  Gastroenterology 20041001

• COX-2-specific inhibitor or proton pump inhibitor plus traditional NSAID: is either approach sufficient for patients at highest risk of NSAID-induced ulcers?

  Gastroenterology 20041001

• Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model.

  Fundamental & clinical pharmacology 20041001

• Celecoxib: a novel treatment for lung cancer.

  Expert review of anticancer therapy 20041001

• COX-2 inhibitors and risk of heart failure.

  Lancet (London, England) 20041001

• Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs.

  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20041001

• Stability and solubility of celecoxib-PVP amorphous dispersions: a molecular perspective.

  Pharmaceutical research 20041001

• Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration.

  Pharmaceutical research 20041001

• [Withdrawal of rofecoxib (Vioxx): what about cardiovascular safety of COX-2 selective non-steroidal anti-inflammatory drugs?].

  Revue medicale de Liege 20041001

• The cyclooxygenase-2 inhibitor celecoxib is a potent inhibitor of human carbonic anhydrase II.

  Inflammation 20041001

• Effects of the celecoxib on the acute necrotizing pancreatitis in rats.

  Inflammation 20041001

• [Effect of celecoxib on enhancing the chemotherapic sensitivity of hydroxyurea to K562 cells and its mechanism].

  Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 20041001

• Delayed exercise-induced protection against arrhythmias in dogs--effect of celecoxib.

  European journal of pharmacology 20040919

• Involvement of spinal neurokinins, excitatory amino acids, proinflammatory cytokines, nitric oxide and prostanoids in pain facilitation induced by Phoneutria nigriventer spider venom.

  Brain research 20040917

• Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention.

  Biochemical pharmacology 20040915

• Cyclooxygenase-2 modulates the insulin-like growth factor axis in non-small-cell lung cancer.

  Cancer research 20040915

• Risk assessment of NSAID-induced gastrointestinal toxicity in ambulatory care patients.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20040915

• RNA profiling of cyclooxygenases 1 and 2 in colorectal cancer.

  British journal of cancer 20040913

• Inhibition of cyclooxygenase-2, but not cyclooxygenase-1, reduces prostaglandin E2 secretion from diabetic rat retinas.

  European journal of pharmacology 20040913

• Aspirin-triggered, cyclooxygenase-2-dependent lipoxin synthesis modulates vascular tone.

  Circulation 20040907

• 2-hydroxymethyl-4-[5-(4-methoxyphenyl)-3-trifluoromethyl-1H-1-pyrazolyl]-1-benzenesulfonamide (DRF-4367): an orally active COX-2 inhibitor identified through pharmacophoric modulation.

  Organic & biomolecular chemistry 20040907

• Endoplasmic reticulum stress response is involved in nonsteroidal anti-inflammatory drug-induced apoptosis.

  Cell death and differentiation 20040901

• [Treatment of osteoarthritis of the knee joint. Efficacy and tolerance to acemetacin slow release in comparison to celecoxib].

  Der Orthopade 20040901

• Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-kappaB as a possible target.

  Journal of cancer research and clinical oncology 20040901

• Effect of anti-inflammatory drugs on pleurisy induced by latex of Calotropis procera in rats.

  Pharmacological research 20040901

• Eicosanoid metabolism in squamous cell carcinoma cell lines derived from primary and metastatic head and neck cancer and its modulation by celecoxib.

  Cancer biology & therapy 20040901

• Safety profile of celecoxib as used in general practice in England: results of a prescription-event monitoring study.

  European journal of clinical pharmacology 20040901

• A combination of selective COX-2 inhibitors and hydrogen peroxide increase the reactive oxygen species formation in osteosarcoma cells after X-ray irradiation.

  International journal of molecular medicine 20040901

• Chemoprevention of colorectal cancer.

  Cancer chemotherapy and pharmacology 20040901

• The effect of celecoxib on intrathecal morphine-induced pruritus in patients undergoing Caesarean section.

  Anaesthesia 20040901

• Molecular targeting therapy for pancreatic cancer.

  Cancer chemotherapy and pharmacology 20040901

• Efficacy of chitosan microspheres for controlled intra-articular delivery of celecoxib in inflamed joints.

  The Journal of pharmacy and pharmacology 20040901

• Treatment of painful temporomandibular joints with a cyclooxygenase-2 inhibitor: a randomized placebo-controlled comparison of celecoxib to naproxen.

  Pain 20040901

• Snake venom components enhance pain upon subcutaneous injection: an initial examination of spinal cord mediators.

  Pain 20040901

• Cost-effectiveness of treatment strategies for osteoarthritis of the knee in Taiwan.

  The Journal of rheumatology 20040901

• Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis.

  The Journal of rheumatology 20040901

• 1-[4-(Methylsulfonyl)phenyl]-5-phenyl-1H-pyrazole derivatives.

  Acta crystallographica. Section C, Crystal structure communications 20040901

• Prevention of colorectal cancer using COX-2 inhibitors: basic science and clinical applications.

  Frontiers in bioscience : a journal and virtual library 20040901

• Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040901

• Vitamin E analog alpha-TEA and celecoxib alone and together reduce human MDA-MB-435-FL-GFP breast cancer burden and metastasis in nude mice.

  Breast cancer research and treatment 20040901

• [A case report of metastatic pancreatic cancer that responded remarkably to the combination of thalidomide, celecoxib and irinotecan].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040901

• Effects of a prior-authorization policy for celecoxib on medical service and prescription drug use in a managed care Medicaid population.

  Clinical therapeutics 20040901

• Use of gastrointestinal preventive therapy among elderly persons receiving antiarthritic agents in Nova Scotia, Canada.

  The American journal of geriatric pharmacotherapy 20040901

• Celecoxib enhances brain tumour cell radiosensitivity leading to massive tumour necrosis.

  Annals of the Academy of Medicine, Singapore 20040901

• Pharmacological characterisation of the rat brachial plexus avulsion model of neuropathic pain.

  Brain research 20040827

• Clinical implication of expression of cyclooxygenase-2 and peroxisome proliferator activated-receptor gamma in epithelial ovarian tumours.

  British journal of cancer 20040816

• Targeting the epidermal growth factor receptor.

  British journal of cancer 20040802

• Chemopreventive activity of parthenolide against UVB-induced skin cancer and its mechanisms.

  Carcinogenesis 20040801

• Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis.

  Annals of the rheumatic diseases 20040801

• Promoter hypermethylation silences cyclooxygenase-2 (Cox-2) and regulates growth of human hepatocellular carcinoma cells.

  Laboratory investigation; a journal of technical methods and pathology 20040801

• Is there an inhibitory effect of COX-2 inhibitors on bone healing?

  Pharmacological research 20040801

• Hypertension associated with therapies to treat arthritis and pain.

  Hypertension (Dallas, Tex. : 1979) 20040801

• Relationship between COX-2 specific inhibitors and hypertension.

  Hypertension (Dallas, Tex. : 1979) 20040801

• Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-kappa B activation through inhibition of activation of I kappa B alpha kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis.

  Journal of immunology (Baltimore, Md. : 1950) 20040801

• Interleukin-1beta-induced mucin production in human airway epithelium is mediated by cyclooxygenase-2, prostaglandin E2 receptors, and cyclic AMP-protein kinase A signaling.

  Molecular pharmacology 20040801

• COX-2 inhibitors as adjunctive therapy in schizophrenia.

  Expert opinion on investigational drugs 20040801

• First and second generations of COX-2 selective inhibitors.

  Mini reviews in medicinal chemistry 20040801

• COX-2 selective inhibitors, carbonic anhydrase inhibition and anticancer properties of sulfonamides belonging to this class of pharmacological agents.

  Mini reviews in medicinal chemistry 20040801

• Celecoxib effectively treats patients with acute shoulder tendinitis/bursitis.

  The Journal of rheumatology 20040801

• Comparison of the anti-proliferation and apoptosis-induction activities of sulindac, celecoxib, curcumin, and nifedipine in mismatch repair-deficient cell lines.

  Journal of the Formosan Medical Association = Taiwan yi zhi 20040801

• [Influence of non-selective and cyclooxygenase-II-selective cyclooxygenase-inhibitors on primary human osteoblasts].

  Zentralblatt fur Chirurgie 20040801

• Celecoxib induces functional recovery after intracerebral hemorrhage with reduction of brain edema and perihematomal cell death.

  Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20040801

• Improvement of physical stability and dissolution rate of celecoxib suspensions by complexation with beta-cyclodextrins.

  Die Pharmazie 20040801

• Risk of Upper Gastrointestinal Injury and Events in Patients Treated With Cyclooxygenase (COX)-1/COX-2 Nonsteroidal Antiinflammatory Drugs (NSAIDs), COX-2 Selective NSAIDs, and Gastroprotective Cotherapy: An Appraisal of the Literature.

  Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20040801

• Design, synthesis, and structure-activity relationship studies of 3,4,6-triphenylpyran-2-ones as selective cyclooxygenase-2 inhibitors.

  Journal of medicinal chemistry 20040729

• Inhibition of cyclooxygenase-2 activity in head and neck cancer cells by genistein.

  Cancer letters 20040728

• Reduction of tumor progression and paraneoplastic syndrome development in murine lung adenocarcinoma by nonsteroidal antiinflammatory drugs.

  International journal of cancer 20040720

• Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling.

  Circulation 20040720

• Antimetastatic activity of a cyclooxygenase-2 inhibitor.

  British journal of cancer 20040719

• Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells.

  Biochemical pharmacology 20040715

• Pruned receptor surface models and pharmacophores for three-dimensional database searching.

  Journal of medicinal chemistry 20040715

• Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-kappaB by suppressing activation of IkappaBalpha kinase in human non-small cell lung carcinoma: correlation with suppression of cyclin D1, COX-2, and matrix metalloproteinase-9.

  Cancer research 20040715

• Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: subgroup analysis from celecoxib antiaromatase neoadjuvant trial.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040715

• Effect of nonsteroidal anti-inflammatory drugs on beta-catenin protein levels and catenin-related transcription in human colorectal cancer cells.

  British journal of cancer 20040705

• Inhibitory effect of cyclo-oxygenase-2 inhibitor on the production of matrix metalloproteinases in rheumatoid fibroblast-like synoviocytes.

  Rheumatology international 20040701

• Lipopolysaccharide-induced paw edema model for detection of cytokine modulating anti-inflammatory agents.

  International immunopharmacology 20040701

• Effects of cyclooxygenase 2 inhibitors on biological traits of nasopharyngeal carcinoma cells.

  Acta pharmacologica Sinica 20040701

• Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma.

  Cancer 20040701

• The cost-effectiveness of aspirin versus cyclooxygenase-2-selective inhibitors for colorectal carcinoma chemoprevention in healthy individuals.

  Cancer 20040701

• Anti-cancer effects of COX-2 inhibitors and their correlation with angiogenesis and invasion in gastric cancer.

  World journal of gastroenterology 20040701

• Efficacy of celecoxib, a COX-2-specific inhibitor, and naproxen in the management of acute ankle sprain: results of a double-blind, randomized controlled trial.

  Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine 20040701

• Attenuation of mechanical allodynia by clinically utilized drugs in a rat chemotherapy-induced neuropathic pain model.

  Pain 20040701

• Neuronal expression of cyclooxygenase-2, a pro-inflammatory protein, in the hippocampus of patients with schizophrenia.

  Progress in neuro-psychopharmacology & biological psychiatry 20040701

• Therapeutic interchange involving replacement of rofecoxib or celecoxib with valdecoxib.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20040701

• Acute generalized exanthematous pustulosis caused by celecoxib.

  Journal of the Formosan Medical Association = Taiwan yi zhi 20040701

• Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations.

  Alimentary pharmacology & therapeutics 20040701

• Utilization patterns of cyclooxygenase-2 inhibitors among patients with arthritis in a managed care setting.

  Managed care interface 20040701

• COX-2 inhibitory treatment in chronic lymphocytic leukemia: a preliminary clinical study.

  Leukemia & lymphoma 20040701

• [Cyclooxygenase-2 inhibitors in postoperative pain management].

  Agri : Agri (Algoloji) Dernegi'nin Yayin organidir = The journal of the Turkish Society of Algology 20040701

• Effects of celecoxib on high-sensitivity C-reactive protein in chronic peritoneal dialysis patients.

  Renal failure 20040701

• The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease.

  Inflammatory bowel diseases 20040701

• Gastrointestinal-related complications in a long-term care population taking NSAIDs versus COX-2 inhibitor therapy.

  The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20040701

• Isolation, synthesis and characterization of impurities in celecoxib, a COX-2 inhibitor.

  Journal of pharmaceutical and biomedical analysis 20040629

• Nonsteroidal anti-inflammatory drugs increase expression of inducible COX-2 isoform of cyclooxygenase in spinal cord of rats with adjuvant induced inflammation.

  Brain research. Molecular brain research 20040618

• From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors.

  Cancer research 20040615

• Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040615

• Cyclooxygenase as a target in lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040615

• Over-the-counter pain reliever and aspirin use within a sample of long-term cyclooxygenase 2 users.

  Archives of internal medicine 20040614

• Cooperation between aspirin-triggered lipoxin and nitric oxide (NO) mediates antiadhesive properties of 2-(Acetyloxy)benzoic acid 3-(nitrooxymethyl)phenyl ester (NCX-4016) (NO-aspirin) on neutrophil-endothelial cell adherence.

  The Journal of pharmacology and experimental therapeutics 20040601

• Formation and antiproliferative effect of prostaglandin E(3) from eicosapentaenoic acid in human lung cancer cells.

  Journal of lipid research 20040601

• Vascular and cellular responses to pro-inflammatory stimuli in rat dental pulp.

  Archives of oral biology 20040601

• Pulmonary edema and possible pneumonitis associated with celecoxib.

  The Annals of pharmacotherapy 20040601

• Systematic review of the analgesic efficacy and tolerability of COX-2 inhibitors in post-operative pain control.

  Journal of clinical pharmacy and therapeutics 20040601

• Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis.

  Alimentary pharmacology & therapeutics 20040601

• Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care.

  The Journal of rheumatology 20040601

• Treatment with 5-fluorouracil and celecoxib displays synergistic regression of ultraviolet light B-induced skin tumors.

  The Journal of investigative dermatology 20040601

• Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients.

  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20040601

• Celecoxib-induced photoallergic drug eruption.

  International journal of dermatology 20040601

• [A case of advanced pancreatic cancer with remarkable response to thalidomide, celecoxib and gemcitabine].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040601

• Involvement of prostaglandins in inflammation induced by latex of Calotropis procera.

  Mediators of inflammation 20040601

• Effects of celecoxib on acid-challenged gastric mucosa of rats: comparison with metamizol and piroxicam.

  Digestive diseases and sciences 20040601

• Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients.

  European annals of allergy and clinical immunology 20040601

• Glucosamine for osteoarthritis: part I, review of the clinical evidence.

  Medicine and health, Rhode Island 20040601

• [Effects of celecoxib on the proliferation and apoptosis of human colorectal cancer cell line HT-29].

  Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 20040601

• Prostaglandins: modulators of inflammation and cardiovascular risk.

  Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20040601

• Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study.

  Lancet (London, England) 20040529

• Determination of celecoxib in human plasma by high-performance liquid chromatography.

  Journal of pharmaceutical and biomedical analysis 20040528

• [Celecoxib in the symptomatic treatment of active osteo- or rheumatoid arthritis. Results of a post-marketing surveillance].

  Deutsche medizinische Wochenschrift (1946) 20040521

• Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice.

  Cancer research 20040515

• Differential up-regulation of cytosolic and membrane-bound heat shock protein 70 in tumor cells by anti-inflammatory drugs.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040515

• Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.

  Circulation 20040504

• 2,3-diarylpyran-4-ones: a new series of selective cyclooxygenase-2 inhibitors.

  Bioorganic & medicinal chemistry letters 20040503

• Celecoxib inhibits phorbol ester-induced expression of COX-2 and activation of AP-1 and p38 MAP kinase in mouse skin.

  Carcinogenesis 20040501

• Celecoxib 200 mg q.d. is efficacious in the management of osteoarthritis of the knee or hip regardless of the time of dosing.

  Rheumatology (Oxford, England) 20040501

• The balloon catheter induces an increase in contralateral carotid artery reactivity to angiotensin II and phenylephrine.

  British journal of pharmacology 20040501

• Nonsteroidal anti-inflammatory drugs and aspirin for the prevention of colorectal adenomas and cancer: a systematic review.

  Diseases of the colon and rectum 20040501

• Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice.

  Experimental neurology 20040501

• A systematic review of COX-2 inhibitors compared with traditional NSAIDs, or different COX-2 inhibitors for post-operative pain.

  Acta anaesthesiologica Scandinavica 20040501

• COX-2 dependent PGE(2) downregulates alpha(v) integrin expression via the EP(3) receptor in cultured mesangial cells.

  Journal of clinical pathology 20040501

• Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20040501

• Celecoxib can prevent tumor growth and distant metastasis in postoperative setting.

  Cancer research 20040501

• Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model.

  Cancer research 20040501

• Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs.

  Pharmacoepidemiology and drug safety 20040501

• Changes in osteoarthritis management by general practitioners in the COX2-inhibitor era-concomitant gastroprotective therapy.

  Joint, bone, spine : revue du rhumatisme 20040501

• NSAIDs: gastroprotection or selective COX-2 inhibitor?

  Palliative medicine 20040501

• [Cyclooxygenase 2 and breast cancer. From biological concepts to therapeutic trials].

  Bulletin du cancer 20040501

• [Cyclooxygenase 2 inhibitors and lung carcinoma].

  Bulletin du cancer 20040501

• [Safety of selective inhibitors of inducible cyclooxygenase-2 taken for a long period].

  Bulletin du cancer 20040501

• [Analgesic effects of cyclooxygenase 2 inhibitors].

  Bulletin du cancer 20040501

• [Etoricoxib (Arcoxia)].

  Revue medicale de Liege 20040501

• [Cyclooxygenase 2 and breast cancer. From biological concepts to clinical trials].

  Bulletin du cancer 20040501

• [Cyclooxygenase 2 inhibitors and lung carcinoma].

  Bulletin du cancer 20040501

• [Safety of selective cyclooxygenase-2 inhibitors taken for a long time].

  Bulletin du cancer 20040501

• [Analgesic effects of cyclooxygenase 2 inhibitors].

  Bulletin du cancer 20040501

• Synthesis and selective cyclooxygenase-2 inhibitory activity of a series of novel, nitric oxide donor-containing pyrazoles.

  Journal of medicinal chemistry 20040422

• Design of acyclic triaryl olefins: a new class of potent and selective cyclooxygenase-2 (COX-2) inhibitors.

  Bioorganic & medicinal chemistry letters 20040419

• Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells.

  Biochemical pharmacology 20040415

• Serum proteomic profiles suggest celecoxib-modulated targets and response predictors.

  Cancer research 20040415

• Correspondence re: M. V. Swamy et al., Inhibition of COX-2 in colon cancer cell lines by celecoxib increases the nuclear localization of active p53. Cancer Res 2003;63:5239-42.

  Cancer research 20040415

• Preclinical evaluation of the nonsteroidal anti-inflammatory agent celecoxib on malignant mesothelioma chemoprevention.

  International journal of cancer 20040410

• [Renal and cardiovascular effects of non-steroidal anti-inflammatories and selective cox 2 inhibitors].

  Presse medicale (Paris, France : 1983) 20040410

• [Selective cox-2 inhibitors. Better tolerance than NSAID plus antacid].

  MMW Fortschritte der Medizin 20040408

• Methanesulfonamide group at position-4 of the C-5-phenyl ring of 1,5-diarylpyrazole affords a potent class of cyclooxygenase-2 (COX-2) inhibitors.

  Bioorganic & medicinal chemistry letters 20040405

• Hepatotoxicity induced by celecoxib and amlodipine.

  Swiss medical weekly 20040403

• Growth inhibition of breast epithelial cells by celecoxib is associated with upregulation of insulin-like growth factor binding protein-3 expression.

  Biochemical and biophysical research communications 20040402

• Overexpression of cyclooxygenase-2 is associated with radioresistance in oral squamous cell carcinoma.

  Oral oncology 20040401

• Involvement of bradykinin, cytokines, sympathetic amines and prostaglandins in formalin-induced orofacial nociception in rats.

  British journal of pharmacology 20040401

• Acute tubulointerstitial nephritis associated with celecoxib.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20040401

• COX-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: a population-based case-control study.

  Alimentary pharmacology & therapeutics 20040401

• Mechanisms of nonsteroidal anti-inflammatory drug-induced gastrointestinal injury and repair: a window of opportunity for cyclooxygenase-inhibiting nitric oxide donors.

  Canadian journal of gastroenterology = Journal canadien de gastroenterologie 20040401

• Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation.

  Hepatology (Baltimore, Md.) 20040401

• Tramadol pharmacokinetics and its possible interactions with cyclooxygenase 2-selective nonsteroidal anti-inflammatory drugs.

  Clinical pharmacology and therapeutics 20040401

• A randomized, controlled comparison of ibuprofen at the maximal over-the-counter dose compared with prescription-dose celecoxib on upper gastrointestinal mucosal injury.

  Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20040401

• Impact of selective cyclooxygenase-2 inhibitors on anti-ulcer medication and non-steroidal anti-inflammatory drug use in patients with rheumatic disease.

  Internal medicine journal 20040401

• [Report of two cases with pleural effusion and ascites that responded dramatically to the combination of thalidomide, celecoxib, irinotecan, and CDDP infused in thoracic and abdominal cavities].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040401

• Gastric effects of the selective cyclooxygenase-2 inhibitor, celecoxib, in the rat.

  Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20040401

• Effect of celecoxib on renal function in cirrhotic patients with ascites. A pilot study.

  Scandinavian journal of gastroenterology 20040401

• [Results of treatment with COX-2 inhibitors and lanreotide in a patient with Menetrier's hypertrophic gastropathy].

  Gastroenterologie clinique et biologique 20040401

• [Clinical evaluation of celecoxib in treating type IIIA chronic prostatitis].

  Zhonghua nan ke xue = National journal of andrology 20040401

• Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy.

  Seminars in oncology 20040401

• The role of COX-2 inhibition in breast cancer treatment and prevention.

  Seminars in oncology 20040401

• COX-2 inhibition and lung cancer.

  Seminars in oncology 20040401

• COX-2 inhibition and colorectal cancer.

  Seminars in oncology 20040401

• Invasive and angiogenic phenotype of MCF-7 human breast tumor cells expressing human cyclooxygenase-2.

  Prostaglandins & other lipid mediators 20040401

• [Selective COX-2 inhibitors: do they retain any gastroduodenal toxicity].

  Gastroenterologie clinique et biologique 20040401

• Induction of microsomal prostaglandin E synthase-1 in human gingival fibroblasts.

  Inflammation 20040401

• Phosphorylation status of c-Kit and Epo receptors, and the presence of wild-type p53 confer in vitro resistance of murine erythroleukemic cells to Celecoxib.

  Oncogene 20040325

• Effect of celecoxib on Ca2+ movement and cell proliferation in human osteoblasts.

  Biochemical pharmacology 20040315

• Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners.

  The Medical journal of Australia 20040315

• Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity.

  Cancer research 20040315

• Preferential expression of hPGFS in primary SCCHN and tumour cell lines derived from respiratory and digestive organs.

  British journal of cancer 20040308

• [Capsule endoscopy study of gastrointestinal tolerance. Coxibes superior to NSAID plus antacid].

  MMW Fortschritte der Medizin 20040304

• Aromatase inhibitors for chemoprevention.

  Best practice & research. Clinical endocrinology & metabolism 20040301

• Inhibition of cyclooxygenase-2 by celecoxib reverses tumor-induced wasting.

  The Journal of pharmacology and experimental therapeutics 20040301

• Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics.

  Hypertension (Dallas, Tex. : 1979) 20040301

• Drug interaction with T-cell receptors: T-cell receptor density determines degree of cross-reactivity.

  The Journal of allergy and clinical immunology 20040301

• Assessment of cyclooxygense-2 expression with 99mTc-labeled celebrex.

  Anti-cancer drugs 20040301

• Solubility enhancement of celecoxib using beta-cyclodextrin inclusion complexes.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20040301

• The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells.

  Molecular cancer therapeutics 20040301

• Uptake of COX-2 selective inhibitors and influence on NSAID prescribing in Northern Ireland.

  Pharmacoepidemiology and drug safety 20040301

• Effects of bile from patient with transduodenal sphincteroplasty on the growth of human cholangiocarcinoma cell line.

  Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih 20040301

• Isoflurane produces delayed preconditioning against myocardial ischemia and reperfusion injury: role of cyclooxygenase-2.

  Anesthesiology 20040301

• Cyclooxygenase-2 mediates ischemic, anesthetic, and pharmacologic preconditioning in vivo.

  Anesthesiology 20040301

• The preemptive analgesic effect of celecoxib for day-case diagnostic laparoscopy.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20040301

• Analgesic efficacy of a single dose of lumiracoxib compared with rofecoxib, celecoxib and placebo in the treatment of post-operative dental pain.

  International journal of clinical practice 20040301

• Cardiovascular effects of selective cyclooxygenase-2 inhibitors.

  Expert review of cardiovascular therapy 20040301

• Beta-cyclodextrin complexes of celecoxib: molecular-modeling, characterization, and dissolution studies.

  AAPS pharmSci 20040301

• Cyclooxygenase-2-mediated prostaglandin E2 production in mesenteric lymph nodes and in cultured macrophages and dendritic cells after infection with Salmonella.

  Journal of immunology (Baltimore, Md. : 1950) 20040215

• Cyclooxygenase-2 in the pathogenesis of murine cerebral malaria.

  The Journal of infectious diseases 20040215

• Cyclooxygenase-2 promotes human cholangiocarcinoma growth: evidence for cyclooxygenase-2-independent mechanism in celecoxib-mediated induction of p21waf1/cip1 and p27kip1 and cell cycle arrest.

  Cancer research 20040215

• 3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells.

  Cancer research 20040215

• In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives.

  Journal of medicinal chemistry 20040212

• Simultaneous expression of COX-2 and mPGES-1 in mouse gastrointestinal hamartomas.

  British journal of cancer 20040209

• Cyclooxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer.

  British journal of cancer 20040209

• Cerivastatin inhibits proliferation of interleukin-1 beta-induced rat mesangial cells by enhanced formation of nitric oxide.

  European journal of pharmacology 20040206

• Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners.

  The Medical journal of Australia 20040202

• Studies on the anti-inflammatory effect of fluoxetine in the rat.

  Pharmacological research 20040201

• Evaluation of the anti-inflammatory, anti-nociceptive and gastric effects of Ginkgo biloba in the rat.

  Pharmacological research 20040201

• Increased cyclooxygenase-2 (COX-2): a potential role in the pathogenesis of lymphoma.

  Leukemia research 20040201

• Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention.

  The Journal of urology 20040201

• Intracranial inhibition of glioma cell growth by cyclooxygenase-2 inhibitor celecoxib.

  Oncology reports 20040201

• Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis.

  Journal of neurochemistry 20040201

• Chemoprevention of gastric cancer by celecoxib in rats.

  Gut 20040201

• Effects of a selective cyclooxygenase-2 inhibitor on cancer cells in vitro.

  Cancer biology & therapy 20040201

• Potentiation of tumor response to radiation or chemoradiation by selective cyclooxygenase-2 enzyme inhibitors.

  International journal of radiation oncology, biology, physics 20040201

• Licofelone--clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis.

  Rheumatology (Oxford, England) 20040201

• Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice.

  The Journal of rheumatology 20040201

• A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy.

  BJU international 20040201

• Inhibition of rat mammary gland carcinogenesis by simultaneous targeting of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma.

  Cancer research 20040201

• NSAIDs and chemoprevention.

  Current cancer drug targets 20040201

• Warfarin and celecoxib interaction in the setting of cytochrome P450 (CYP2C9) polymorphism with bleeding complication.

  Postgraduate medical journal 20040201

• Effects of a high-selenium yeast supplement on celecoxib plasma levels: a randomized phase II trial.

  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20040201

• Improvement strategies for molecular targeting: Cyclooxygenase-2 inhibitors as radiosensitizers for non-small cell lung cancer.

  Seminars in oncology 20040201

• Side effects of conventional nonsteroidal anti-inflammatory drugs and celecoxib: more similarities than differences.

  Southern medical journal 20040201

• Modulation of cyclooxygenase-2 activities by the combined action of celecoxib and decosahexaenoic acid: novel strategies for colon cancer prevention and treatment.

  Molecular cancer therapeutics 20040201

• COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy.

  European archives of psychiatry and clinical neuroscience 20040201

• Bony metastases of anaplastic oligodendroglioma respond to temozolomide.

  The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 20040201

• Cyclooxygenase-2 inhibitors: do they have a role in emergency department prescribing?

  Emergency medicine Australasia : EMA 20040201

• Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition.

  Journal of medicinal chemistry 20040129

• [Homeopathy suppresses COX- and LOX activity. Soft therapy for arthrosis ills].

  MMW Fortschritte der Medizin 20040129

• Determination of celecoxib in human plasma using solid-phase extraction and high-performance liquid chromatography.

  Journal of pharmaceutical and biomedical analysis 20040127

• COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ.

  British journal of cancer 20040126

• Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with the antipsychotic drug sulpiride.

  Bioorganic & medicinal chemistry letters 20040119

• Polar substitutions in the benzenesulfonamide ring of celecoxib afford a potent 1,5-diarylpyrazole class of COX-2 inhibitors.

  Bioorganic & medicinal chemistry letters 20040119

• Celecoxib simulates respiratory burst through pertussis toxin-sensitive G-protein, a possible signal for beta 2-integrin expression on human neutrophils.

  European journal of pharmacology 20040119

• First-line endocrine treatment of breast cancer: aromatase inhibitor or antioestrogen?

  British journal of cancer 20040112

• Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis.

  British journal of cancer 20040112

• Discovery of a potent, selective and orally active canine COX-2 inhibitor, 2-(3-difluoromethyl-5-phenyl-pyrazol-1-yl)-5-methanesulfonyl-pyridine.

  Bioorganic & medicinal chemistry letters 20040105

• The effect of COX-2 inhibitors on periprosthetic osteolysis.

  Biomaterials 20040101

• Pharmacological characterisation of a rat model of incisional pain.

  British journal of pharmacology 20040101

• Genetic deficiency or pharmacological inhibition of cyclooxygenase-1 or -2 induces mouse keratinocyte differentiation in vitro and in vivo.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20040101

• PGE2 and IL-6 production by fibroblasts in response to titanium wear debris particles is mediated through a Cox-2 dependent pathway.

  Journal of orthopaedic research : official publication of the Orthopaedic Research Society 20040101

• Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation.

  American journal of physiology. Gastrointestinal and liver physiology 20040101

• Differences between clinical trials and postmarketing use.

  British journal of clinical pharmacology 20040101

• Cyclooxygenase 2 selective inhibitor induced bowel stricture: a case report.

  Gut 20040101

• Modulation of beta-amyloid metabolism by non-steroidal anti-inflammatory drugs in neuronal cell cultures.

  Journal of neurochemistry 20040101

• Cyclooxygenase inhibition in nerve-injury- and TNF-induced hyperalgesia in the rat.

  Experimental neurology 20040101

• Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double-blind, placebo-controlled trial.

  The Journal of rheumatology 20040101

• Effects of celecoxib, medroxyprogesterone, and dietary intervention on systemic syndromes in patients with advanced lung adenocarcinoma: a pilot study.

  Journal of pain and symptom management 20040101

• Effect of COX-2-specific inhibition on fracture-healing in the rat femur.

  The Journal of bone and joint surgery. American volume 20040101

• Pharmacological treatments for persistent non-malignant pain in older persons.

  Drugs & aging 20040101

• Celecoxib versus indomethacin in the prevention of heterotopic ossification after total hip arthroplasty.

  The Journal of arthroplasty 20040101

• Comparison of nonselective cyclo-oxygenase (COX) inhibitor and selective COX-2 inhibitors on preimplantation loss, postimplantation loss and duration of gestation: an experimental study.

  Contraception 20040101

• Differential effects of selective COX-2 inhibitors on cell cycle regulation and proliferation of glioblastoma cell lines.

  Cancer biology & therapy 20040101

• Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygenase-2-derived prostaglandin E2, a survival factor for tumor and associated vasculature.

  Cancer research 20040101

• Effects of dexamethasone or celecoxib on biliary toxicity after hepatic arterial infusion of 5-fluorodeoxyuridine in a canine model.

  Cancer research 20040101

• Celecoxib but not rofecoxib inhibits the growth of transformed cells in vitro.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040101

• Prevention strategies with aromatase inhibitors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040101

• Neoadjuvant endocrine therapy as a drug development strategy.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040101

• Aseptic meningitis possibly associated with celecoxib.

  The Annals of pharmacotherapy 20040101

• Benefit-risk assessment of rofecoxib in the treatment of osteoarthritis.

  Drug safety 20040101

• Clinical pharmacology of novel selective COX-2 inhibitors.

  Current pharmaceutical design 20040101

• [Non-steroidal anti-inflammatory agents for chemoprevention of colorectal polyps: a meta-analysis].

  Zhonghua nei ke za zhi 20040101

• Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials.

  Clinical therapeutics 20040101

• A cross-media content analysis of motivational themes in direct-to-consumer prescription drug advertising.

  Clinical therapeutics 20040101

• Cyclooxygenase-2 inhibitors in glioma therapy.

  American journal of therapeutics 20040101

• Role of cyclooxygenase-2 in colorectal cancer.

  Cancer metastasis reviews 20040101

• Triptolide, an active compound identified in a traditional Chinese herb, induces apoptosis of rheumatoid synovial fibroblasts.

  BMC pharmacology 20040101

• [Toxic epidermal necrolysis and celecoxib (Celebrex)].

  Annales de dermatologie et de venereologie 20040101

• Cutaneous reaction to oral celecoxib with positive patch test.

  Contact dermatitis 20040101

• Post-treatment, but not pre-treatment, with the selective cyclooxygenase-2 inhibitor celecoxib markedly enhances functional recovery from kainic acid-induced neurodegeneration.

  Neuroscience 20040101

• Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention.

  Cancer detection and prevention 20040101

• Modulation of intracellular calcium signaling and mitochondrial function in cultured osteoblastic cells by dexamethasone and celecoxib during mechanical stimulation.

  Clinical and experimental rheumatology 20040101

• Analgesics for acute pain: Meeting the United States Food and Drug Administration's requirements for proof of efficacy.

  The Clinical journal of pain 20040101

• Update on nonprescription pain relievers for dental pain.

  General dentistry 20040101

• S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. [ISRCTN36233495].

  BMC musculoskeletal disorders 20040101

• Non steroidal anti-inflammatory drugs (NSAID) and Aspirin for preventing colorectal adenomas and carcinomas.

  The Cochrane database of systematic reviews 20040101

• Do COX-2 inhibitors reduce renal fibrosis?

  Journal of hypertension 20040101

• Chronic cyclooxygenase-2 inhibition does not alter blood pressure and kidney function in renovascular hypertensive rats.

  Journal of hypertension 20040101

• [Bupivacaine for continuous interscalene brachial plexus analgesia after shoulder surgery].

  Medicina (Kaunas, Lithuania) 20040101

• Spontaneous reports of hypertension leading to hospitalisation in association with rofecoxib, celecoxib, nabumetone and oxaprozin.

  Drugs & aging 20040101

• A mechanistic perspective on the specificity and extent of COX-2 inhibition in pregnancy.

  Drug safety 20040101

• Do some inhibitors of COX-2 increase the risk of thromboembolic events?: Linking pharmacology with pharmacoepidemiology.

  Drug safety 20040101

• Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents.

  Drug safety 20040101

• Lithium intoxication as a result of an interaction with rofecoxib.

  The Annals of pharmacotherapy 20040101

• [Capecitabine and irinotecan].

  I supplementi di Tumori : official journal of Societa italiana di cancerologia ... [et al.] 20040101

• COX-2 inhibitors: a CLASS act or Just VIGORously promoted.

  MedGenMed : Medscape general medicine 20040101

• Diosgenin, a plant steroid, induces apoptosis in human rheumatoid arthritis synoviocytes with cyclooxygenase-2 overexpression.

  Arthritis research & therapy 20040101

• Expanding the armamentarium for the spondyloarthropathies.

  Arthritis research & therapy 20040101

• Acute generalized exanthematic pustulosis: a case and an overview of side effects affecting the skin caused by celecoxib and other COX-2 inhibitors reported so far.

  Dermatology (Basel, Switzerland) 20040101

• Cancer, oncogenes and signal transduction.

  Genome biology 20040101

• Proteasome inhibitors: their effects on arachidonic acid release from cells in culture and arachidonic acid metabolism in rat liver cells.

  BMC pharmacology 20040101

• Impact on drug costs and utilization of a clinical pharmacist in a multisite primary care medical group.

  Journal of managed care pharmacy : JMCP 20040101

• Tamoxifen and the Rafoxifene analog LY117018: their effects on arachidonic acid release from cells in culture and on prostaglandin I2 production by rat liver cells.

  BMC cancer 20040101

• Encouraging physician appropriate prescribing of non-steroidal anti-inflammatory therapies: protocol of a randomized controlled trial [ISRCTN43532635].

  BMC health services research 20040101

• [Therapeutic advances with coxibs: few certainties and a lot of doubts].

  Therapie 20040101

• [Coxibs, which real therapeutic advance?: Recent pharmacoepidemiological data].

  Therapie 20040101

• Lumiracoxib.

  Drugs 20040101

• Tackling publication bias and selective reporting in health informatics research: register your eHealth trials in the International eHealth Studies Registry.

  Journal of medical Internet research 20040101

• Inhibition of cyclooxygenase-2 by diallyl sulfides (DAS) in HEK 293T cells.

  Journal of applied genetics 20040101

• Anti-inflammatory therapy with a COX-2 inhibitor in Tourette's syndrome.

  Inflammopharmacology 20040101

• Control of pulmonary metastases of rat mammary cancer by inhibition of uPA and COX-2, singly and in combination.

  Clinical & experimental metastasis 20040101

• Linking pharmacovigilance with pharmacogenetics.

  Drug safety 20040101

• Effects and mechanism of the selective COX-2 inhibitor, celecoxib, on rat colitis induced by trinitrobenzene sulfonic acid.

  Chinese journal of digestive diseases 20040101

• Celecoxib incorporated chitosan microspheres: in vitro and in vivo evaluation.

  Journal of drug targeting 20040101

• Novel opportunities in the treatment and prevention of scarring.

  Journal of cutaneous medicine and surgery 20040101

• Anti-inflammatory effects of selective COX-2 inhibitors.

  Polish journal of pharmacology 20040101

• Multiple comparisons in drug efficacy studies: scientific or marketing principles?

  Ethical human psychology and psychiatry 20040101

• Topical delivery of celecoxib using microemulsion.

  Acta poloniae pharmaceutica 20040101

• Carbonic anhydrase inhibitors that directly inhibit anion transport by the human Cl-/HCO3- exchanger, AE1.

  Molecular membrane biology 20040101

• [Celecoxib and Tramadol as an alternative osteoarthrosis therapy in patients with NSAID gastropathy].

  Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology 20040101

• Physical stability and solubility advantage from amorphous celecoxib: the role of thermodynamic quantities and molecular mobility.

  Molecular pharmaceutics 20040101

• Effect of nimesulide-a preferential COX-2 inhibitor on arterial blood pressure, compared to ketoprofen.

  Annales Universitatis Mariae Curie-Sklodowska. Sectio D: Medicina 20040101

• Safety and efficacy of oral nonsteroidal anti-inflammatory drugs in patients with rheumatoid arthritis : a six-month randomised study.

  Clinical drug investigation 20040101

• In the beginning there was colectomy: current surgical options in familial adenomatous polyposis.

  Hereditary cancer in clinical practice 20040101

• [New prevention strategies against breast cancer and cervical carcinoma. What can you advice to your patients].

  MMW Fortschritte der Medizin 20031211

• Synthesis and structure-activity relationship of novel, highly potent metharyl and methcycloalkyl cyclooxygenase-2 (COX-2) selective inhibitors.

  Journal of medicinal chemistry 20031204

• Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20031201

• Cyclooxygenase-2 (COX-2) inhibition limits abnormal COX-2 expression and progressive injury in the remnant kidney.

  Kidney international 20031201

• Cyclooxygenase 2 mediates post-inflammatory colonic secretory and barrier dysfunction.

  Gut 20031201

• Discovery of 2-phenyl-3-sulfonylphenyl-indole derivatives as a new class of selective COX-2 inhibitors.

  Bioorganic & medicinal chemistry 20031201

• [Clinical pharmacology of the selective COX-2 inhibitors].

  Der Orthopade 20031201

• Safety of cyclooxygenase 2 inhibitors and increased leukotriene synthesis in chronic idiopathic urticaria with sensitivity to nonsteroidal anti-inflammatory drugs.

  Archives of dermatology 20031201

• Celecoxib modulates the capacity for prostaglandin E2 and interleukin-10 production in alveolar macrophages from active smokers.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20031201

• Cyclooxygenase inhibition and mechanisms of colorectal cancer prevention.

  Current cancer drug targets 20031201

• Incidence of outpatient physician claims for upper gastrointestinal symptoms among new users of celecoxib, ibuprofen, and naproxen in an insured population in the United States.

  The American journal of gastroenterology 20031201

• The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice.

  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20031201

• Tolerability of cyclooxygenase 2 inhibitors and the advisability of oral challenge.

  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20031201

• Targeting cyclooxygenase-2 in human neoplasia: rationale and promise.

  Cancer cell 20031201

• Effect of the antenatal administration of celecoxib during the second and third trimesters of pregnancy on prostaglandin, cytokine, and nitric oxide levels in rabbits.

  American journal of obstetrics and gynecology 20031201

• Response of fetal prostanoids, nitric oxide, and ductus arteriosus to the short- and long-term antenatal administration of celecoxib, a selective cyclo-oxygenase-2 inhibitor, in the pregnant rabbit.

  American journal of obstetrics and gynecology 20031201

• Cox-2 is needed but not sufficient for apoptosis induced by Cox-2 selective inhibitors in colon cancer cells.

  Apoptosis : an international journal on programmed cell death 20031201

• 'Open access' generic method for continuous determination of major human CYP450 probe substrates/metabolites and its application in drug metabolism studies.

  Xenobiotica; the fate of foreign compounds in biological systems 20031201

• An observational, retrospective, cohort study of dosing patterns for rofecoxib and celecoxib in the treatment of arthritis.

  Clinical therapeutics 20031201

• Toxic epidermal necrolysis as a complication of treatment with celecoxib.

  Dermatology online journal 20031201

• Patient perception of the burden of weight gain and blood pressure increase among RA patients using celecoxib, rofecoxib, and non-specific NSAIDs.

  Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20031201

• Why don't we initiate more large simple randomized controlled trials?

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20031125

• Celecoxib, rofecoxib, and acute temporary visual impairment.

  BMJ (Clinical research ed.) 20031122

• [Celecoxib in NSAID-induced cutaneous and respiratory adverse reactions].

  Medicina clinica 20031122

• [Role of Helicobacter pylori in drug-induced gastrointestinal bleeding].

  Presse medicale (Paris, France : 1983) 20031122

• Design and synthesis of novel celecoxib analogues as selective cyclooxygenase-2 (COX-2) inhibitors: replacement of the sulfonamide pharmacophore by a sulfonylazide bioisostere.

  Bioorganic & medicinal chemistry 20031117

• Tempol, an antioxidant, restores endothelium-derived hyperpolarizing factor-mediated vasodilation during hypertension.

  European journal of pharmacology 20031114

• Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension.

  Circulation 20031111

• [Prevention of colorectal cancer: acetylsalicyclic acid and cyclo-oxygenase-2 inhibitors are only partially effective].

  Nederlands tijdschrift voor geneeskunde 20031108

• Design, synthesis, and biological evaluation of 6-substituted-3-(4-methanesulfonylphenyl)-4-phenylpyran-2-ones: a novel class of diarylheterocyclic selective cyclooxygenase-2 inhibitors.

  Journal of medicinal chemistry 20031106

• Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data.

  Rheumatology (Oxford, England) 20031101

• Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data.

  Rheumatology (Oxford, England) 20031101

• Effects of valeryl salicylate, a COX-1 inhibitor, on models of acute inflammation in mice.

  Pharmacological research 20031101

• Use of NSAIDs for the chemoprevention of colorectal cancer.

  The Annals of pharmacotherapy 20031101

• Arachidonic acid cascade inhibitors modulate phorbol ester-induced oxidative stress in female ICR mouse skin: differential roles of 5-lipoxygenase and cyclooxygenase-2 in leukocyte infiltration and activation.

  Free radical biology & medicine 20031101

• Drug utilization review of celecoxib in Ontario.

  Rheumatology (Oxford, England) 20031101

• Persistency of use of COX-2-specific inhibitors and non-specific non-steroidal anti-inflammatory drugs (NSAIDs) in Quebec.

  Rheumatology (Oxford, England) 20031101

• Underutilization of preventive strategies in patients receiving NSAIDs.

  Rheumatology (Oxford, England) 20031101

• Measuring dyspepsia-related health in randomized trials: the Severity of Dyspepsia Assessment (SODA) and its use in treatment with NSAIDs and COX-2-specific inhibitors.

  Rheumatology (Oxford, England) 20031101

• The burden of acute postoperative pain and the potential role of the COX-2-specific inhibitors.

  Rheumatology (Oxford, England) 20031101

• Characterization of solid-state forms of celecoxib.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20031101

• Gastroprotection by coxibs: what do the Celecoxib Long-Term Arthritis Safety Study and the Vioxx Gastrointestinal Outcomes Research Trial tell us?

  Rheumatic diseases clinics of North America 20031101

• Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial.

  Arthritis and rheumatism 20031101

• Comparison of changes in blood pressure measurements and antihypertensive therapy in older, hypertensive, ambulatory care patients prescribed celecoxib or rofecoxib.

  Pharmacotherapy 20031101

• Drug-induced bilateral transient myopia with the sulphonamide sulphasalazine.

  Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) 20031101

• COX-2 inhibition and prostaglandin receptors in experimental nephritis.

  European journal of clinical investigation 20031101

• [Protective effect of selective cyclooxygenase-2 inhibitor on alcohol-induced liver injury in rats].

  Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 20031101

• Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs.

  The Journal of clinical psychiatry 20031101

• Effect of itraconazole on the pharmacokinetics of celecoxib in healthy human volunteers.

  Die Pharmazie 20031101

• Regulation of cell growth by selective COX-2 inhibitors in oral carcinoma cell lines.

  Prostaglandins & other lipid mediators 20031101

• Celecoxib has a positive effect on the overall metabolism of hyaluronan and proteoglycans in human osteoarthritic cartilage.

  The Journal of rheumatology 20031101

• Differential regulation of cyclooxygenase-2 expression by phytosphingosine derivatives, NAPS and TAPS, and its role in the NAPS or TAPS-mediated apoptosis.

  The Journal of investigative dermatology 20031101

• [Severe cutaneous drug reactions to celecoxib (Celebrex)].

  Annales de dermatologie et de venereologie 20031101

• Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners.

  The Medical journal of Australia 20031020

• Chronic inhibition of cyclooxygenase-2 does not alter plaque composition in a mouse model of advanced unstable atherosclerosis.

  Cardiovascular research 20031015

• Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway.

  Cancer research 20031015

• Increased NF-kappaB DNA binding but not transcriptional activity during apoptosis induced by the COX-2-selective inhibitor NS-398 in colorectal carcinoma cells.

  British journal of cancer 20031006

• Neutrophil elastase stimulates human airway epithelial cells to produce PGE2 through activation of p44/42 MAPK and upregulation of cyclooxygenase-2.

  American journal of physiology. Lung cellular and molecular physiology 20031001

• Inhibition of cutaneous ultraviolet light B-mediated inflammation and tumor formation with topical celecoxib treatment.

  Molecular carcinogenesis 20031001

• Anaphylactic drug reaction to celecoxib and sulfamethoxazole: cross reactivity or coincidence?

  Allergy 20031001

• Effects of rofecoxib, celecoxib, and parecoxib on anti-IgE-induced histamine release from human skin mast cells and basophils.

  Allergy 20031001

• Safety of COX-2 inhibitors in asthma patients with aspirin hypersensitivity.

  The Annals of pharmacotherapy 20031001

• Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance?

  Journal of the National Cancer Institute 20031001

• Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20031001

• [Effect of selective cyclooxygenase-2 inhibitor celebrex on expression of vascular endothelial growth factor (VEGF) in pancreatic carcinoma].

  Ai zheng = Aizheng = Chinese journal of cancer 20031001

• Cyclooxygenase-2 inhibition decreases primary and metastatic tumor burden in a murine model of orthotopic lung adenocarcinoma.

  The Journal of thoracic and cardiovascular surgery 20031001

• Chemotherapeutic and biologic agents as radiosensitizers in rectal cancer.

  Seminars in radiation oncology 20031001

• Introduction to monitoring. What is what you prescribed actually doing?

  Australian family physician 20031001

• Persistence with COX-2 inhibitors in managed care: an analysis of claims data.

  Managed care interface 20031001

• Cyclooxygenase-2 and gastric carcinogenesis.

  APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 20031001

• Histamine mediates the pro-inflammatory effect of latex of Calotropis procera in rats.

  Mediators of inflammation 20031001

• [Cyclooxygenases in the spinal cord and the relationship with pain].

  Sheng li ke xue jin zhan [Progress in physiology] 20031001

• [New studies of COX-inhibitors, yet issues remain].

  Lakartidningen 20030918

• Synthesis and cyclooxygenase-2 inhibiting property of 1,5-diarylpyrazoles with substituted benzenesulfonamide moiety as pharmacophore: Preparation of sodium salt for injectable formulation.

  Journal of medicinal chemistry 20030911

• Carcinogenesis and cyclooxygenase: the potential role of COX-2 inhibition in upper aerodigestive tract cancer.

  Oral oncology 20030901

• Cyclo-oxygenase-2 mediated prostaglandin release regulates blood flow in connective tissue during mechanical loading in humans.

  The Journal of physiology 20030901

• Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension.

  Hypertension (Dallas, Tex. : 1979) 20030901

• Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines.

  International journal of oncology 20030901

• Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs.

  Gut 20030901

• Adverse Drug Events Involving COX-2 Inhibitors.

  The Annals of pharmacotherapy 20030901

• Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis.

  Hepatology (Baltimore, Md.) 20030901

• NSAIDs and Alzheimer's disease: how far to generalise from trials?

  The Lancet. Neurology 20030901

• Chemotherapeutic efficacy of topical celecoxib in a murine model of ultraviolet light B-induced skin cancer.

  Molecular carcinogenesis 20030901

• Comparative protection against rat intestinal reperfusion injury by a new inhibitor of sPLA2, COX-1 and COX-2 selective inhibitors, and an LTC4 receptor antagonist.

  British journal of pharmacology 20030901

• Effect of combined cyclooxygenase-2 and matrix metalloproteinase inhibition on human sarcoma xenografts.

  Journal of pediatric hematology/oncology 20030901

• 4-substituted 1,5-diarylpyrazole, analogues of celecoxib: synthesis and preliminary evaluation of biological properties.

  Farmaco (Societa chimica italiana : 1989) 20030901

• Differential effects of aspirin and misoprostol on 15-hydroxyeicosatetraenoic acid generation by leukocytes from aspirin-sensitive asthmatic patients.

  The Journal of allergy and clinical immunology 20030901

• Inhibition of cyclooxygenase (COX) enzymes by compounds from Daucus carota L. Seeds.

  Phytotherapy research : PTR 20030901

• Simple method for the determination of rosiglitazone in human plasma using a commercially available internal standard.

  Biomedical chromatography : BMC 20030901

• Inhibition of COX-2 in colon cancer cell lines by celecoxib increases the nuclear localization of active p53.

  Cancer research 20030901

• Irinotecan in esophageal cancer.

  Oncology (Williston Park, N.Y.) 20030901

• Solubility enhancement of Cox-2 inhibitors using various solvent systems.

  AAPS PharmSciTech 20030901

• Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: preliminary report.

  The Journal of steroid biochemistry and molecular biology 20030901

• Breast cancer prevention--clinical trials strategies involving aromatase inhibitors.

  The Journal of steroid biochemistry and molecular biology 20030901

• [Lower gastrointestinal hemorrhage associated with celecoxib].

  Anales de medicina interna (Madrid, Spain : 1984) 20030901

• Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib.

  The American journal of cardiology 20030815

• Suppression of N-methyl-N-nitrosourea/testosterone-induced rat prostate cancer growth by celecoxib: effects on cyclooxygenase-2, cell cycle regulation, and apoptosis mechanism(s).

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030815

• Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery.

  Circulation 20030805

• Celecoxib activates a novel mitochondrial apoptosis signaling pathway.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20030801

• A validated spectrofluorometric method for the determination of celecoxib in capsules.

  Analytical and bioanalytical chemistry 20030801

• Angiogenesis inhibitors under study for the treatment of lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20030801

• Targeted therapies for stage III non-small cell lung cancer: integration in the combined modality setting.

  Lung cancer (Amsterdam, Netherlands) 20030801

• Evidence that 5-lipoxygenase and acetylated cyclooxygenase 2-derived eicosanoids regulate leukocyte-endothelial adherence in response to aspirin.

  British journal of pharmacology 20030801

• Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans.

  Clinical pharmacology and therapeutics 20030801

• The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence.

  Gastroenterology 20030801

• Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites.

  Pharmacogenetics 20030801

• COX-2 inhibitors and cancer therapeutics: potential roles for inhibitors of COX-2 in combination with cytotoxic therapy: reports from a symposium held in conjunction with the Radiation Therapy Oncology Group June 2001 Meeting.

  American journal of clinical oncology 20030801

• Initial experience combining cyclooxygenase-2 inhibition with chemoradiation for locally advanced pancreatic cancer.

  American journal of clinical oncology 20030801

• Combination of a COX-2 inhibitor with radiotherapy or radiochemotherapy in the treatment of thoracic cancer.

  American journal of clinical oncology 20030801

• Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth.

  American journal of clinical oncology 20030801

• COX-2 inhibitors as radiation sensitizers for upper GI tract cancers: esophagus, stomach, and pancreas.

  American journal of clinical oncology 20030801

• Celecoxib reduces skin damage after radiation: selective reduction of chemokine and receptor mRNA expression in irradiated skin but not in irradiated mammary tumor.

  American journal of clinical oncology 20030801

• Preparation and characterization of glassy celecoxib.

  Drug development and industrial pharmacy 20030801

• [Celecoxib as well as Diclofenac in Combination with Omeprazole can Prevent the Recurrence of NSAIDs-Induced Gastrointestinal Bleeding].

  Zeitschrift fur Gastroenterologie 20030801

• The cyclooxygenase 2-specific nonsteroidal anti-inflammatory drugs celecoxib and nimesulide inhibit androgen receptor activity via induction of c-Jun in prostate cancer cells.

  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20030801

• Effect of celecoxib and dexamethasone on postoperative pain after lumbar disc surgery.

  Neurosurgery 20030801

• [Selective COX-2 inhibition improves endothelial function in coronary artery disease].

  Zeitschrift fur Rheumatologie 20030801

• In vivo effects of meloxicam, celecoxib, and ibuprofen on free radical metabolism in human erythrocytes.

  Drug and chemical toxicology 20030801

• COX-2 inhibitors in oncology.

  Seminars in oncology 20030801

• Current and ongoing trials with irinotecan in the United States.

  Seminars in oncology 20030801

• Indomethacin and celecoxib improve tendon healing in rats.

  Acta orthopaedica Scandinavica 20030801

• Selective inhibition of cyclooxygenase 2 induces p27kip1 and skp2 in oral squamous cell carcinoma.

  The Journal of otolaryngology 20030801

• [Clinical pharmacology of selective inhibitors of cyclooxygenase-2].

  Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale 20030801

• Synthesis and structure-activity relationship of a new series of COX-2 selective inhibitors: 1,5-diarylimidazoles.

  Journal of medicinal chemistry 20030731

• Topical inhibition of oral carcinoma cell with polymer delivered celecoxib.

  Cancer letters 20030730

• Adsorptive stripping voltammetric determination of the anti-inflammatory drug celecoxib in pharmaceutical formulation and human serum.

  Talanta 20030727

• Non-steroidal anti-inflammatory drugs and molecular carcinogenesis of colorectal carcinomas.

  Lancet (London, England) 20030719

• Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030715

• Chronic spinal pain: a randomized clinical trial comparing medication, acupuncture, and spinal manipulation.

  Spine 20030715

• Economic analysis of celecoxib versus diclofenac plus omeprazole for the treatment of arthritis in patients at risk of ulcer disease.

  Alimentary pharmacology & therapeutics 20030715

• Inhibition of cancer cell proliferation and prostaglandin E2 synthesis by Scutellaria baicalensis.

  Cancer research 20030715

• 6-Alkyl, alkoxy, or alkylthio-substituted 3-(4-methanesulfonylphenyl)-4-phenylpyran-2-ones: a novel class of diarylheterocyclic selective cyclooxygenase-2 inhibitors.

  Bioorganic & medicinal chemistry letters 20030707

• Pain management in patients with osteoarthritis.

  JAMA 20030702

• Effects of nonsteroidal anti-inflammatory drugs on prostacyclin and thromboxane in the kidney.

  Pharmacology 20030701

• Celecoxib associated esophagitis: review of gastrointestinal side effects from cox-2 inhibitors.

  Journal of clinical gastroenterology 20030701

• Celecoxib-induced fixed drug eruption.

  Clinical and experimental dermatology 20030701

• Celecoxib-induced lupus-like syndrome.

  Rheumatology (Oxford, England) 20030701

• Synthesis of novel 1,3,4-trisubstituted pyrazole derivatives and their evaluation as antitumor and antiangiogenic agents.

  Chemical & pharmaceutical bulletin 20030701

• Tissue-specific plantar fascia-stretching exercise enhances outcomes in patients with chronic heel pain. A prospective, randomized study.

  The Journal of bone and joint surgery. American volume 20030701

• Irinotecan, cisplatin/carboplatin, and COX-2 inhibition in small-cell lung cancer.

  Oncology (Williston Park, N.Y.) 20030701

• Interaction of rofecoxib and celecoxib with warfarin.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20030701

• Celecoxib and rofecoxib potentiate chronic colitis and premalignant changes in interleukin 10 knockout mice.

  Inflammatory bowel diseases 20030701

• [The effects of selective cyclooxygenase-2 inhibitors on the growth of gastric adenocarcinoma].

  Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20030701

• Quadriparesis in a young female suffering from rheumatoid arthritis.

  The Journal of the Association of Physicians of India 20030701

• The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.

  Arthritis and rheumatism 20030615

• Celecoxib inhibits proliferation and induces apoptosis via prostaglandin E2 pathway in human cholangiocarcinoma cell lines.

  World journal of gastroenterology 20030615

• Cyclooxygenase-2 expression and effect of celecoxib in gastric adenomas of trefoil factor 1-deficient mice.

  Cancer research 20030615

• Mechanisms of angiotensin-converting enzyme inhibitor induced thrombolysis in Wistar rats.

  Thrombosis research 20030615

• Celecoxib versus diclofenac and omeprazole to prevent recurrent ulcer bleeding.

  The New England journal of medicine 20030612

• Celecoxib versus diclofenac and omeprazole to prevent recurrent ulcer bleeding.

  The New England journal of medicine 20030612

• Celecoxib versus diclofenac and omeprazole to prevent recurrent ulcer bleeding.

  The New England journal of medicine 20030612

• Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study.

  British journal of cancer 20030602

• Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes.

  European journal of clinical pharmacology 20030601

• Relative contribution of acetylated cyclo-oxygenase (COX)-2 and 5-lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20030601

• The efficacy of celecoxib premedication on postoperative pain and recovery times after ambulatory surgery: a dose-ranging study.

  Anesthesia and analgesia 20030601

• Selective celecoxib-associated anaphylactoid reaction.

  The Journal of allergy and clinical immunology 20030601

• COX-2: an in vivo evidence of its participation in heat stress-induced myocardial preconditioning.

  Cardiovascular research 20030601

• Preoperative oral celecoxib versus preoperative oral rofecoxib for pain relief after thyroid surgery.

  European journal of anaesthesiology 20030601

• Rofecoxib in rheumatoid arthritis: new indication. No better that other NSAIDS.

  Prescrire international 20030601

• The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.

  Annals of internal medicine 20030520

• Summaries for patients. The cost-effectiveness of cyclooxygenase-2 inhibitors for treating chronic arthritis.

  Annals of internal medicine 20030520

• Blood pressure control and rates of edema following the administration of the cyclooxygenase-2 specific inhibitors celecoxib versus rofecoxib in patients with systemic hypertension and osteoarthritis.

  The American journal of cardiology 20030515

• Cooperative effects of matrix metalloproteinase and cyclooxygenase-2 inhibition on intestinal adenoma reduction.

  British journal of cancer 20030506

• Age-related difference in susceptibility of Apc(Min/+) mice towards the chemopreventive efficacy of dietary aspirin and curcumin.

  British journal of cancer 20030506

• PAR1-dependent and independent increases in COX-2 and PGE2 in human colonic myofibroblasts stimulated by thrombin.

  American journal of physiology. Cell physiology 20030501

• Comment: acute cholestatic hepatitis associated with celecoxib.

  The Annals of pharmacotherapy 20030501

• Does the release of arachidonic acid from cells play a role in cancer chemoprevention?

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20030501

• Hyperalgesia induced by Asp49 and Lys49 phospholipases A2 from Bothrops asper snake venom: pharmacological mediation and molecular determinants.

  Toxicon : official journal of the International Society on Toxinology 20030501

• Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib.

  The Journal of allergy and clinical immunology 20030501

• Point: From animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system.

  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20030501

• Possible international normalized ratio elevation associated with celecoxib and warfarin in an elderly psychiatric patient.

  Journal of the American Geriatrics Society 20030501

• Celecoxib and difluoromethylornithine in combination have strong therapeutic activity against UV-induced skin tumors in mice.

  Carcinogenesis 20030501

• Motion--Cyclo-oxygenase-2 selective nonsteroidal anti-inflammatory drugs are as safe as placebo for the stomach: arguments against the motion.

  Canadian journal of gastroenterology = Journal canadien de gastroenterologie 20030501

• Motion--Cyclo-oxygenase-2 selective nonsteroidal anti-inflammatory drugs are as safe as placebo for the stomach: arguments for the motion.

  Canadian journal of gastroenterology = Journal canadien de gastroenterologie 20030501

• Effect of vehicles and penetration enhancers on the in vitro percutaneous absorption of celecoxib through human skin.

  Die Pharmazie 20030501

• Improvement of radiotherapy or chemoradiotherapy by targeting COX-2 enzyme.

  Oncology (Williston Park, N.Y.) 20030501

• [Adverse effect-free analgesia. New COX-2 inhibitor is even more selective].

  MMW Fortschritte der Medizin 20030501

• [Adverse cutaneous reaction to celecoxib: 6 cases].

  Annales de dermatologie et de venereologie 20030501

• [Hypersensitivity to celecoxib].

  Annales de medecine interne 20030501

• Aspirin and other cyclooxygenase inhibitors: new therapeutic insights.

  Seminars in vascular medicine 20030501

• Drugs in the news: an analysis of Canadian newspaper coverage of new prescription drugs.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20030429

• [The selective cyclooxygenase-2 inhibitor celecoxib is a safe alternative in patients with pseudo-allergic reactions to nonsteroidal anti-inflammatory drugs].

  Medizinische Klinik (Munich, Germany : 1983) 20030425

• Oesophageal squamous cell neoplasia in head and neck cancer patients: upregulation of COX-2 during carcinogenesis.

  British journal of cancer 20030422

• Intrahippocampal infusion of a cyclooxygenase-2 inhibitor attenuates memory acquisition in rats.

  Brain research 20030411

• Theoretical studies on the inhibition mechanism of cyclooxygenase-2. Is there a unique recognition site?

  Journal of medicinal chemistry 20030410

• Do altering in ornithine decarboxylase activity and gene expression contribute to antiproliferative properties of COX inhibitors?

  British journal of cancer 20030407

• Synthesis and biological evaluation of substituted 2-sulfonyl-phenyl-3-phenyl-indoles: a new series of selective COX-2 inhibitors.

  Bioorganic & medicinal chemistry 20030403

• Toward safer methodologies for the synthesis of polyheterocyclic systems: intramolecular arylation of arenes under Mizoroki-Heck reaction conditions.

  Organic letters 20030403

• The anti-inflammatory effects of the phosphodiesterase inhibitor pentoxifylline in the rat.

  Pharmacological research 20030401

• Characterization of celecoxib and valdecoxib binding to cyclooxygenase.

  Molecular pharmacology 20030401

• Costs and effectiveness of rofecoxib, celecoxib, and acetaminophen for preventing pain after ambulatory otolaryngologic surgery.

  Anesthesia and analgesia 20030401

• Effects of selective COX-2 inhibitors on the gastric permeability of sucrose: a controlled study with placebo and ibuprofen.

  European journal of gastroenterology & hepatology 20030401

• No success with the SUCCESS trial.

  The American journal of cardiology 20030401

• Prevention and treatment of reactions to NSAIDs.

  Clinical reviews in allergy & immunology 20030401

• A life-threatening interaction between lithium and celecoxib.

  British journal of clinical pharmacology 20030401

• Chemoprevention of colorectal cancer: slow, steady progress.

  Cleveland Clinic journal of medicine 20030401

• Comparison of the efficacy and tolerability of dexibuprofen and celecoxib in the treatment of osteoarthritis of the hip.

  International journal of clinical pharmacology and therapeutics 20030401

• Relative efficacy of selective COX-2 inhibitors compared with over-the-counter ibuprofen.

  International journal of clinical practice. Supplement 20030401

• Risk factors associated with the development of gastroduodenal ulcers due to the use of NSAIDs.

  International journal of clinical practice. Supplement 20030401

• A side effect of COX-2 inhibitors.

  Harvard health letter 20030401

• The cox-2-specific inhibitor celecoxib inhibits adenylyl cyclase.

  Inflammation 20030401

• [Coxibs: highly selective cyclooxygenase-2 inhibitors. Part I. Clinical efficacy].

  Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 20030401

• [Coxibs: highly selective cyclooxygenase-2 inhibitors. Part II. Side effects].

  Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 20030401

• Role of cyclooxygenase 2 in protein kinase C beta II-mediated colon carcinogenesis.

  The Journal of biological chemistry 20030328

• Cyclooxygenase inhibitory and antioxidant compounds from crabapple fruits.

  Journal of agricultural and food chemistry 20030326

• 3,4-Diaryl-5-hydroxyfuranones: highly selective inhibitors of cyclooxygenase-2 with aqueous solubility.

  Bioorganic & medicinal chemistry letters 20030324

• Nonsteroidal anti-inflammatory drugs in colorectal cancer: from prevention to therapy.

  British journal of cancer 20030324

• Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats.

  Brain research 20030321

• [The future of peptic ulcer disease without Helicobacter].

  Praxis 20030319

• Intellectual property. Judge turns Rochester's golden patent into lead.

  Science (New York, N.Y.) 20030314

• [Selective Cox-2 inhibitor in osteoarthritis and rheumatoid arthritis. No increased risk for the heart].

  MMW Fortschritte der Medizin 20030313

• [Gastrointestinal complications caused by NSAIDs. Over 60% of arthrosis patients are endangered].

  MMW Fortschritte der Medizin 20030306

• Cyclooxygenase-2 inhibitors: is there an association with coronary or renal events?

  Current atherosclerosis reports 20030301

• Effect of cyclooxygenase-2 inhibitors on blood pressure.

  The Annals of pharmacotherapy 20030301

• Anti-inflammatory drugs may put on the pressure.

  Harvard heart letter : from Harvard Medical School 20030301

• Celecoxib acts in a cyclooxygenase-2-independent manner and in synergy with emodin to suppress rat cholangiocarcinoma growth in vitro through a mechanism involving enhanced Akt inactivation and increased activation of caspases-9 and -3.

  Molecular cancer therapeutics 20030301

• Toxic epidermal necrolysis due to administration of celecoxib (Celebrex).

  Southern medical journal 20030301

• Selective COX-2 inhibitors as chemopreventive and therapeutic agents.

  Drugs of today (Barcelona, Spain : 1998) 20030301

• Anticonvulsant action of celecoxib (alone and in combination with sub-threshold dose of phenytoin) in electroshock induced convulsion.

  Methods and findings in experimental and clinical pharmacology 20030301

• Valdecoxib: a review.

  Clinical therapeutics 20030301

• Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly.

  Archives of internal medicine 20030224

• 2,3-Diarylbenzopyran derivatives as a novel class of selective cyclooxygenase-2 inhibitors.

  Bioorganic & medicinal chemistry letters 20030210

• Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. Problems compromise review's validity.

  BMJ (Clinical research ed.) 20030208

• Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. Celecoxib's relative gastrointestinal safety is overstated.

  BMJ (Clinical research ed.) 20030208

• Effects of nabumetone, celecoxib, and ibuprofen on blood pressure control in hypertensive patients on angiotensin converting enzyme inhibitors.

  American journal of hypertension 20030201

• Cyclooxygenase 2: a molecular target for cancer prevention and treatment.

  Trends in pharmacological sciences 20030201

• Bad medicine. Why data from drug companies may be hard to swallow.

  Scientific American 20030201

• Review article: NSAIDs, gastroprotection and cyclo-oxygenase-II-selective inhibitors.

  Alimentary pharmacology & therapeutics 20030201

• Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030201

• Role of cyclooxygenases COX-1 and COX-2 in modulating adipogenesis in 3T3-L1 cells.

  Journal of lipid research 20030201

• Comparing celecoxib with traditional nonsteroidal anti-inflammatory drugs.

  The Journal of family practice 20030201

• Selective cyclooxygenase-2 inhibition does not affect the healing of cutaneous full-thickness incisional wounds in SKH-1 mice.

  The British journal of dermatology 20030201

• Membranous glomerulopathy and acute interstitial nephritis following treatment with celecoxib.

  Clinical nephrology 20030201

• Role of gastric mucosal and gastric juice cytokine concentrations in development of bisphosphonate damage to gastric mucosa.

  Digestive diseases and sciences 20030201

• A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a Medicare Choice population.

  Clinical therapeutics 20030201

• Acidic nonsteroidal anti-inflammatory drugs inhibit rat brain fatty acid amide hydrolase in a pH-dependent manner.

  Journal of enzyme inhibition and medicinal chemistry 20030201

• [When the cardiac patient with arthritis needs aspirin and NSAID: how to protect the stomach?].

  MMW Fortschritte der Medizin 20030130

• Selective COX-2 inhibition improves endothelial function in coronary artery disease.

  Circulation 20030128

• [Rapid, strong and long-term effectiveness. Coxib also effective in toothache].

  MMW Fortschritte der Medizin 20030116

• Modulation of cyclooxygenase-2 on glycine- and glutamate-induced ion currents in rat periaqueductal gray neurons.

  Brain research bulletin 20030115

• Proliferative activity of bile from congenital choledochal cyst patients.

  World journal of gastroenterology 20030115

• Celecoxib-related renal papillary necrosis.

  Archives of internal medicine 20030113

• Simultaneous determination of celecoxib, hydroxycelecoxib, and carboxycelecoxib in human plasma using gradient reversed-phase liquid chromatography with ultraviolet absorbance detection.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030105

• Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model.

  European journal of pharmacology 20030105

• Why aren't lower, effective, OTC doses available earlier by prescription?

  The Annals of pharmacotherapy 20030101

• A randomized, clinical trial comparing oral celecoxib 200 mg, celecoxib 400 mg, and ibuprofen 600 mg for acute pain.

  Academic emergency medicine : official journal of the Society for Academic Emergency Medicine 20030101

• Recent progress in ankylosing spondylitis treatment.

  Expert opinion on pharmacotherapy 20030101

• American pain society pain questionnaire and other pain measures in the assessment of osteoarthritis pain: a pooled analysis of three celecoxib pivotal studies.

  American journal of therapeutics 20030101

• Celecoxib in human milk: a case report.

  Pharmacotherapy 20030101

• Cancer chemoprevention drug targets.

  Current drug targets 20030101

• Role of endogenous glucocorticoids in hyperalgesia and edema in old arthritic rats.

  Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 20030101

• Drug-induced hypertension.

  Journal of clinical hypertension (Greenwich, Conn.) 20030101

• Lipoxygenase and cyclooxygenase metabolism: new insights in treatment and chemoprevention of pancreatic cancer.

  Molecular cancer 20030101

• Safety of celecoxib in individuals allergic to sulfonamide: a pilot study.

  Drug safety 20030101

• Reduction of scar formation in full-thickness wounds with topical celecoxib treatment.

  Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society 20030101

• Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib.

  Clinical pharmacokinetics 20030101

• Cancer 'photo-chemoprevention' with pulsed dye laser and celecoxib.

  Lasers in surgery and medicine 20030101

• [Cost-effectiveness analysis of the use of celecoxib for the treatment of osteoarthritis].

  Gaceta sanitaria 20030101

• Antenatal administration of celecoxib, a selective cyclooxygenase (COX)-2 inhibitor, appears to improve placental perfusion in the pregnant rabbit.

  Prostaglandins & other lipid mediators 20030101

• COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease.

  Pharmacoepidemiology and drug safety 20030101

• Synthesis of 4-(5-iodo-3-methylpyrazolyl) phenylsulfonamide and its elaboration to a COX II inhibitor library by solution-phase suzuki coupling using Pd/C as a solid-supported catalyst.

  Journal of combinatorial chemistry 20030101

• Selective cyclooxygenase-2 inhibition upregulates renal cortical alpha V integrin expression.

  Nephron. Experimental nephrology 20030101

• Cyclooxygenase-2: from arthritis treatment to new indications for the prevention and treatment of cancer.

  Clinical journal of oncology nursing 20030101

• The impact of nonsteroidal anti-inflammatory drugs on blood pressure, with an emphasis on newer agents.

  Clinical therapeutics 20030101

• The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care.

  Clinical therapeutics 20030101

• The cost-effectiveness of acetaminophen, NSAIDs, and selective COX-2 inhibitors in the treatment of symptomatic knee osteoarthritis.

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20030101

• Statins stimulate arachidonic acid release and prostaglandin I2 production in rat liver cells.

  Lipids in health and disease 20030101

• [Pharmacology of cyclooxygenase 2 inhibition].

  Wiener medizinische Wochenschrift (1946) 20030101

• [Cyclooxygenase 2 selective antirheumatic analgesics].

  Wiener medizinische Wochenschrift (1946) 20030101

• Selective COX-2 inhibitors: a health economic perspective.

  Wiener medizinische Wochenschrift (1946) 20030101

• Studies on the applicability of tamarind kernel powder as a carrier in the dissolution enhancement of poorly water soluble drug, celecoxib.

  Bollettino chimico farmaceutico 20030101

• Cox-2: Where are we in 2003? - The role of cyclooxygenase-2 in bone repair.

  Arthritis research & therapy 20030101

• Cox-2: where are we in 2003? - Cardiovascular risk and Cox-2 inhibitors.

  Arthritis research & therapy 20030101

• COX-2: Where are we in 2003? - Specific cyclooxygenase-2 inhibitors and aspirin-exacerbated respiratory disease.

  Arthritis research & therapy 20030101

• COX-2: Where are we in 2003? - Be strong and resolute: continue to use COX-2 selective inhibitors at recommended dosages in appropriate patients.

  Arthritis research & therapy 20030101

• COX-2: where are we in 2003?--distinction from NSAIDs becoming blurred.

  Arthritis research & therapy 20030101

• Medication errors caused by confusion of drug names.

  Drug safety 20030101

• Evaluation of cyclooxygenase 2 inhibitor use in patients admitted to a large teaching hospital.

  Internal medicine journal 20030101

• Celecoxib is as efficacious as naproxen in the management of acute shoulder pain.

  The Journal of international medical research 20030101

• Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis.

  Progress in experimental tumor research 20030101

• Single dose oral celecoxib for postoperative pain.

  The Cochrane database of systematic reviews 20030101

• Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers.

  Annals of oncology : official journal of the European Society for Medical Oncology 20030101

• Intolerance reactions due to the selective cyclooxygenase type II inhibitors rofecoxib and celecoxib. Results of oral provocation tests in patients with NSAID hypersensitivity.

  Acta dermato-venereologica 20030101

• Celecoxib was as effective as diclofenac plus omeprazole in reducing recurrent ulcer bleeding in arthritis.

  ACP journal club 20030101

• [Interactions of nonsteroid anti-inflammatory drugs with inhibitors of angiotensin-converting enzyme in patients with rheumatic diseases (a review)].

  Terapevticheskii arkhiv 20030101

• Prenatal effects of DuP-697-the irreversible, highly selective cyclooxygenase-2 inhibitor.

  Reproductive toxicology (Elmsford, N.Y.) 20030101

• [Effectiveness and tolerability of celecoxib in outpatient department practice].

  La Clinica terapeutica 20030101

• [COX-2 inhibitors: a new treatment in rheumatic diseases].

  La Clinica terapeutica 20030101

• The influence of a cyclooxygenase-1 inhibitor on injured and uninjured ligaments in the rat.

  The American journal of sports medicine 20030101

• Scratch-patch and patch testing in drug allergy--an assessment of specificity.

  Journal of investigational allergology & clinical immunology 20030101

• Celecoxib, a highly selective COX-2 inhibitor, is safe in aspirin-induced asthma patients.

  Journal of investigational allergology & clinical immunology 20030101

• Inhibition of proliferation of human cancer cells and cyclooxygenase enzymes by anthocyanidins and catechins.

  Nutrition and cancer 20030101

• Effects of selective cyclooxygenase inhibitors on ischemia/reperfusion-induced hepatic microcirculatory dysfunction in mice.

  European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes 20030101

• Current chemotherapy for glioblastoma.

  Cancer journal (Sudbury, Mass.) 20030101

• [Possible problems of lack of objectivity, transparency, duplicate publication and authorship in the cost-effectiveness analysis of celecoxib].

  Gaceta sanitaria 20030101

• A retrospective review of the effect of COX-2 inhibitors on blood pressure change.

  American journal of therapeutics 20030101

• Improved control of osteoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain.

  Current medical research and opinion 20030101

• Tamoxifen stimulates arachidonic acid release from rat liver cells by an estrogen receptor-independent, non-genomic mechanism.

  BMC cancer 20030101

• [Aromatase inhibitors--theoretical concept and present experiences in the treatment of endometriosis].

  Zentralblatt fur Gynakologie 20030101

• A randomised, double-blind, clinical trial comparing the efficacy of nimesulide, celecoxib and rofecoxib in osteoarthritis of the knee.

  Drugs 20030101

• Chemoprevention strategies using NSAIDs and COX-2 inhibitors.

  Cancer biology & therapy 20030101

• Gastroduodenal safety of cyclooxygenase-2 inhibitors.

  Current pharmaceutical design 20030101

• COX-2 inhibition, H. pylori infection and the risk of gastrointestinal complications.

  Current pharmaceutical design 20030101

• COX-2 specific inhibitors in NSAID-intolerant patients.

  International journal of immunopathology and pharmacology 20030101

• Clinical pharmacology of selective COX-2 inhibitors.

  International journal of immunopathology and pharmacology 20030101

• Effect of nimesulide, rofecoxib and celecoxib on gastric tissue glutathione level in rats with indomethacin-induced gastric ulcerations.

  Polish journal of pharmacology 20030101

• Balancing gastroprotection and cardioprotection with selective cyclo-oxygenase-2 inhibitors: clinical implications.

  Drug safety 20030101

• Prostaglandin levels in seminal plasma and sperm extracts of the domestic turkey, and the effects of cyclooxygenase inhibitors on sperm mobility.

  Reproductive biology and endocrinology : RB&E 20030101

• Case report: multiple physicians, polypharmacy, and patient counseling.

  Journal of the American Pharmacists Association : JAPhA 20030101

• Chemoprevention for Barrett's esophagus trial. Design and outcome measures.

  Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus 20030101

• Effect of cyclooxygenase-2 (COX-2) inhibitors on prostate cancer cell proliferation.

  Anticancer research 20030101

• Effect of cyclooxygenase and NO synthase inhibitors administered centrally on antinociceptive action of acetaminophen (Part II).

  Polish journal of pharmacology 20030101

• Influence of rifampicin pretreatment on the pharmacokinetics of celecoxib in healthy male volunteers.

  Drug metabolism and drug interactions 20030101

• Fructooligosaccharide associated with celecoxib reduces the number of aberrant crypt foci in the colon of rats.

  Reproduction, nutrition, development 20030101

• Target definition and contouring in carcinoma of the lung and esophagus.

  Rays 20030101

• Assessment of the safety of selective cyclo-oxygenase-2 inhibitors: where are we in 2003?

  Inflammopharmacology 20030101

• Dexibuprofen: pharmacology, therapeutic uses and safety.

  Inflammopharmacology 20030101

• Celecoxib to decrease urinary retention associated with prostate brachytherapy.

  Brachytherapy 20030101

• Utilisation Pattern of Nonspecific Nonsteroidal Anti-Inflammatory Drugs and COX-2 Inhibitors in a Local Health Service Unit in Northeast Italy.

  Clinical drug investigation 20030101

• Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis.

  The New England journal of medicine 20021226

• NSAIDs, Helicobacter pylori, and Pandora's Box.

  The New England journal of medicine 20021226

• Insulin-like growth factor-I antagonizes the antiproliferative effects of cyclooxygenase-2 inhibitors on BxPC-3 pancreatic cancer cells.

  Cancer research 20021215

• Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents.

  Journal of the National Cancer Institute 20021204

• Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS.

  Annals of neurology 20021201

• Acute cholestatic hepatitis associated with celecoxib.

  The Annals of pharmacotherapy 20021201

• Arthritis treatment in Hong Kong--cost analysis of celecoxib versus conventional NSAIDS, with or without gastroprotective agents.

  Alimentary pharmacology & therapeutics 20021201

• Disease modifying and anti-nociceptive effects of the bisphosphonate, zoledronic acid in a model of bone cancer pain.

  Pain 20021201

• Nuclear receptor agonists stimulate release of arachidonic acid from rat liver cells.

  Prostaglandins, leukotrienes, and essential fatty acids 20021201

• Allergic vasculitis associated with celecoxib.

  Rheumatology (Oxford, England) 20021201

• Severe ulcers on celecoxib.

  Prescrire international 20021201

• Celecoxib and the CLASS trial: data massaging by industry.

  Prescrire international 20021201

• Induction of apoptosis in rheumatoid synovial fibroblasts by celecoxib, but not by other selective cyclooxygenase 2 inhibitors.

  Arthritis and rheumatism 20021201

• Modifiable risk factors for colon cancer.

  Gastroenterology clinics of North America 20021201

• Cyclooxygenase (COX)-2 and granulosa cell apoptosis in vitro.

  Journal of assisted reproduction and genetics 20021201

• Acute pancreatitis: a rare complication of celecoxib.

  Internal medicine journal 20021201

• Practical considerations for the use of nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors in hypertension and kidney disease.

  The Canadian journal of cardiology 20021201

• Capecitabine and radiation therapy for advanced gastrointestinal malignancies.

  Oncology (Williston Park, N.Y.) 20021201

• Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity.

  Oncology (Williston Park, N.Y.) 20021201

• Enthalpy relaxation studies of celecoxib amorphous mixtures.

  Pharmaceutical research 20021201

• New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.

  Seminars in arthritis and rheumatism 20021201

• Anti-inflammatory agents and renal function.

  Seminars in arthritis and rheumatism 20021201

• Effect of the selective COX-2 inhibitors, celecoxib and rofecoxib in rat acute models of inflammation.

  Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20021201

• A 12-month, multicenter, prospective, open-label trial of radiographic analysis of disease progression in osteoarthritis of the knee or hip in patients receiving celecoxib.

  Clinical therapeutics 20021201

• Celecoxib-induced upper gastrointestinal hemorrhage and ulceration.

  Southern medical journal 20021201

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20021201

• The design of a randomized, placebo-controlled trial of celecoxib in preprostatectomy men with clinically localized adenocarcinoma of the prostate.

  Clinical prostate cancer 20021201

• Developments in antipsychotic therapy with regard to hypotheses for schizophrenia.

  Dialogues in clinical neuroscience 20021201

• Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.

  Cancer research 20021115

• [A new drug approach approved in the USA. Cox-2 inhibitor in intestinal cancer].

  MMW Fortschritte der Medizin 20021114

• Initial patterns of use of COX-2 inhibitors by elderly patients in Ontario: findings and implications.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20021112

• The double-edged sword of COX-2 selective NSAIDs.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20021112

• [Celebra and the CLASS trial--a scandal!].

  Ugeskrift for laeger 20021111

• Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells.

  FEBS letters 20021106

• Expression of cyclooxygenase-2 (COX-2) in tumour and stroma compartments in cervical cancer: clinical implications.

  British journal of cancer 20021104

• Rofecoxib improves quality of life in patients with hip or knee osteoarthritis.

  Swiss medical weekly 20021102

• Celecoxib, safe in NSAID intolerance.

  Allergy 20021101

• Inhibition of cyclooxygenase-2 ameliorates the severity of pancreatitis and associated lung injury.

  American journal of physiology. Gastrointestinal and liver physiology 20021101

• Delta-opioid receptor-induced late preconditioning is mediated by cyclooxygenase-2 in conscious rabbits.

  American journal of physiology. Heart and circulatory physiology 20021101

• Ulcerogenic influence of selective cyclooxygenase-2 inhibitors in the rat stomach with adjuvant-induced arthritis.

  The Journal of pharmacology and experimental therapeutics 20021101

• Cellular distribution and contribution of cyclooxygenase COX-2 to diabetogenesis in NOD mouse.

  Cell and tissue research 20021101

• Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis.

  The American journal of cardiology 20021101

• Cyclooxygenase-2-derived lipoxin A4 increases gastric resistance to aspirin-induced damage.

  Gastroenterology 20021101

• Nephrotic syndrome and interstitial nephritis associated with celecoxib.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20021101

• Selective inhibitors of cyclo-oxygenase-2 (COX-2) induce hypoalgesia in a rat paw model of inflammation.

  British journal of pharmacology 20021101

• Rapid potentiation of endothelium-dependent vasodilation by estradiol in postmenopausal women is mediated via cyclooxygenase 2.

  The Journal of clinical endocrinology and metabolism 20021101

• Single-dose and steady-state pharmacokinetics of celecoxib in children.

  Clinical pharmacology and therapeutics 20021101

• A clinical audit of the prescribing of celecoxib and rofecoxib in Australian rural general practice.

  British journal of clinical pharmacology 20021101

• COX-2 inhibitors and their role in gynecology.

  Obstetrical & gynecological survey 20021101

• Treatment of rheumatoid arthritis and osteoarthritis with COX-2-selective inhibitors: a managed care perspective.

  The American journal of managed care 20021101

• Gastrointestinal outcomes: evidence for risk reduction in patients using coxibs.

  The American journal of managed care 20021101

• Spherical crystallization of celecoxib.

  Drug development and industrial pharmacy 20021101

• Induction of cyclooxygenase-2 in Ras-transformed human mammary epithelial cells undergoing apoptosis.

  Annals of the New York Academy of Sciences 20021101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20021101

• Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11.

  Cancer research 20021015

• [At what care level are cyclo-oxygenase-2 inhibitors prescribed?].

  Atencion primaria 20021015

• [Reduction of severe gastro-intestinal complications after the use of celecoxib:evidence available in the literature].

  Atencion primaria 20021015

• Cyclooxygenase-2 inhibitor celecoxib inhibits promotion of mammary tumorigenesis in rats fed a high fat diet rich in n-6 polyunsaturated fatty acids.

  Cancer letters 20021008

• Isomeric acetoxy analogues of rofecoxib: a novel class of highly potent and selective cyclooxygenase-2 inhibitors.

  Bioorganic & medicinal chemistry letters 20021007

• [Celecoxib and the CLASS trial].

  Ugeskrift for laeger 20021007

• COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease.

  Lancet (London, England) 20021005

• [Financial interests characterize published reports on coxiber. Whom can we rely on?].

  Lakartidningen 20021003

• [The CLASS study and its scientific statement. Ethical publishing rules neglected].

  Lakartidningen 20021003

• Blue rubber bleb nevus syndrome.

  Gastrointestinal endoscopy 20021001

• Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells.

  Hepatology (Baltimore, Md.) 20021001

• Pharmacological and pharmacokinetic evaluation of celecoxib prodrugs in rats.

  Biopharmaceutics & drug disposition 20021001

• Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer.

  Cancer research 20021001

• Celecoxib reduces pulmonary inflammation but not lung tumorigenesis in mice.

  Carcinogenesis 20021001

• The effect of cyclooxygenase-2 inhibitors on spinal fusion.

  The Journal of bone and joint surgery. American volume 20021001

• Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase.

  British journal of clinical pharmacology 20021001

• COX-2-specific inhibitors: prescribing patterns in a large managed care health system and strategies to minimize costs.

  The American journal of managed care 20021001

• HMO drug formulary access increases for COX-2s.

  Managed care (Langhorne, Pa.) 20021001

• Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.

  The American journal of managed care 20021001

• Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors.

  The American journal of managed care 20021001

• Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.

  The American journal of managed care 20021001

• Differences between COX-2-specific inhibitors: clinical and economic implications.

  The American journal of managed care 20021001

• Toxic epidermal necrolysis due to administration of celecoxib (Celebrex).

  Southern medical journal 20021001

• A comparison of rofecoxib versus celecoxib in treating pain after dental surgery: a single-center, randomized, double-blind, placebo- and active-comparator-controlled, parallel-group, single-dose study using the dental impaction pain model.

  Clinical therapeutics 20021001

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20021001

• [Anti-inflammatory non-steroidal selective cyclooxygenase 2 inhibitors and gastroduodenal lesions].

  Presse medicale (Paris, France : 1983) 20020928

• Efficacy and safety of COX 2 inhibitors.

  BMJ (Clinical research ed.) 20020921

• Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials.

  BMJ (Clinical research ed.) 20020921

• Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs.

  BMJ (Clinical research ed.) 20020921

• [Celecoxib and the CLASS study--a statement].

  Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20020920

• [Celecoxib and the CLASS study--worse and worse...].

  Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20020920

• The cyclo-oxygenase-2 inhibitor celecoxib perturbs intracellular calcium by inhibiting endoplasmic reticulum Ca2+-ATPases: a plausible link with its anti-tumour effect and cardiovascular risks.

  The Biochemical journal 20020915

• [Analgesic in osteoporosis. Why so conservative with dosage?].

  MMW Fortschritte der Medizin 20020905

• Anti-inflammatory agents in Alzheimer's disease.

  Current neurology and neuroscience reports 20020901

• Ca2+- and PKC-dependent stimulation of PGE2 synthesis by deoxycholic acid in human colonic fibroblasts.

  American journal of physiology. Gastrointestinal and liver physiology 20020901

• Pharmacology of celecoxib in rat brain after kainate administration.

  The Journal of pharmacology and experimental therapeutics 20020901

• Distinct roles for cyclooxygenases 1 and 2 in interleukin-1-induced behavioral changes.

  The Journal of pharmacology and experimental therapeutics 20020901

• Renal effects on a solitary kidney of specific inhibition of cyclooxygenease-2 after 24 h of complete ureteric obstruction in rats.

  Urological research 20020901

• Robin goodfellow.

  Rheumatology (Oxford, England) 20020901

• Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers.

  Journal of clinical pharmacology 20020901

• Effects of celecoxib and diclofenac on blood pressure, renal function, and vasoactive prostanoids in young and elderly subjects.

  Journal of clinical pharmacology 20020901

• Toxic epidermal necrolysis after celecoxib therapy.

  Pharmacotherapy 20020901

• A prospective randomized safety trial of celecoxib for treatment of preterm labor.

  American journal of obstetrics and gynecology 20020901

• Chemoprevention of superficial bladder cancer.

  Critical reviews in oncology/hematology 20020901

• Effect of selective cyclooxygenase-2 inhibition on the development of ligature-induced periodontitis in rats.

  Journal of periodontology 20020901

• Validated HPLC method for the determination of celecoxib in human serum and its application in a clinical pharmacokinetic study.

  Die Pharmazie 20020901

• The AGS' fondness for celecoxib.

  Journal of the American Geriatrics Society 20020901

• Celecoxib (celebrex) increases canine lower esophageal sphincter pressure.

  The Journal of surgical research 20020901

• Gateways to Clinical Trials.

  Methods and findings in experimental and clinical pharmacology 20020901

• Differential regulation of prostacyclin and thromboxane by dexamethasone and celecoxib during oxidative stress in newborn rabbits.

  Prostaglandins & other lipid mediators 20020901

• COX-2 inhibition and the control of pain.

  Current opinion in investigational drugs (London, England : 2000) 20020901

• Do selective cyclo-oxygenase inhibitors eliminate the adverse events associated with nonsteroidal anti-inflammatory drug therapy?

  European journal of gastroenterology & hepatology 20020901

• Clinical profiles of celecoxib and rofecoxib in the rheumatic diseases.

  Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20020901

• COX-2-specific inhibitors and the kidney: effect on hypertension and oedema.

  Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20020901

• NSAIDS for prevention? Protecting the brain while killing pain?

  Science (New York, N.Y.) 20020823

• Inflammation and cancer, the mastocytoma P815 tumor model revisited: triggering of macrophage activation in vivo with pro-tumorigenic consequences.

  International journal of cancer 20020810

• Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line.

  The Journal of biological chemistry 20020802

• Efficacy and tolerability of nonprescription ibuprofen versus celecoxib for dental pain.

  Journal of clinical pharmacology 20020801

• Tracing the origins of COX-2 inhibitors' structures.

  Current medicinal chemistry 20020801

• Selecting new drugs for pain control: evidence-based decisions or clinical impressions?

  Journal of the American Dental Association (1939) 20020801

• COX-2 inhibitors: better than traditional NSAIDs? Vioxx and Celebrex may be no less risky than NSAIDs.

  Health news (Waltham, Mass.) 20020801

• The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitors.

  Arthritis and rheumatism 20020801

• The safety of celecoxib in patients with aspirin-sensitive asthma.

  Arthritis and rheumatism 20020801

• Efficacy of celecoxib versus ibuprofen in the treatment of acute pain: a multicenter, double-blind, randomized controlled trial in acute ankle sprain.

  American journal of orthopedics (Belle Mead, N.J.) 20020801

• A stability-indicating HPLC method to determine Celecoxib in capsule formulations.

  Drug development and industrial pharmacy 20020801

• Positive patch test reactions to celecoxib may be due to irritation and do not correlate with the results of oral provocation.

  Contact dermatitis 20020801

• Non-steroidal anti-inflammatory drugs in orofacial pain management--an update.

  SADJ : journal of the South African Dental Association = tydskrif van die Suid-Afrikaanse Tandheelkundige Vereniging 20020801

• Chemopreventive effect of celecoxib and expression of cyclooxygenase-1 and cyclooxygenase-2 on chemically-induced rat mammary tumours.

  International journal of experimental pathology 20020801

• Chemoprevention of large bowel carcinogenesis; the role of control of cell proliferation and significance of beta-catenin-accumulated crypts as a new biomarker.

  European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) 20020801

• [Selective cyclooxygenase-2 inhibitors and the digestive tract].

  La Tunisie medicale 20020801

• The role of rofecoxib, a cyclooxygenase-2-specific inhibitor, for the treatment of non-cancer pain: a review.

  The journal of pain : official journal of the American Pain Society 20020801

• Cholestatic hepatitis in association with celecoxib. Classification of drug associated liver dysfunction is questionable.

  BMJ (Clinical research ed.) 20020727

• [Mobility and quality of life for arthrosis and rheumatism patients. Modern pain management with selective cox-2 inhibition].

  MMW Fortschritte der Medizin 20020726

• Are selective COX 2 inhibitors superior to traditional NSAIDs? Rofecoxib did not provide unequivocal benefit over traditional NSAIDs.

  BMJ (Clinical research ed.) 20020720

• Are selective COX 2 inhibitors superior to traditional NSAIDs? Pharmacia's response to editorial.

  BMJ (Clinical research ed.) 20020720

• Are selective COX 2 inhibitors superior to traditional NSAIDs? Little is known about COX 2 inhibitors.

  BMJ (Clinical research ed.) 20020720

• Are selective COX 2 inhibitors superior to traditional NSAIDs? Both the CLASS and VIGOR trials support the COX 2 hypothesis.

  BMJ (Clinical research ed.) 20020720

• Cyclo-oxygenase inhibition reduces tumour growth and metastasis in an orthotopic model of breast cancer.

  British journal of cancer 20020715

• Seminal pharmaceutical trials: maintaining masking in analysis.

  Lancet (London, England) 20020713

• N-acetylcysteine and celecoxib lessen cadmium cytotoxicity which is associated with cyclooxygenase-2 up-regulation in mouse neuronal cells.

  The Journal of biological chemistry 20020712

• Celecoxib-induced cholestatic hepatotoxicity in a patient with cirrhosis.

  Annals of internal medicine 20020702

• Selective COX-2 inhibition prevents proinflammatory cytokine-induced cartilage damage.

  Rheumatology (Oxford, England) 20020701

• Nonsteroidal antiinflammatory drug starter packs for chronic musculoskeletal pain.

  Pharmacotherapy 20020701

• In vivo selectivity of a selective cyclooxygenase 2 inhibitor in the oral surgery model.

  Clinical pharmacology and therapeutics 20020701

• Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet.

  Clinical pharmacology and therapeutics 20020701

• Anti-hyperalgesic effects of nimesulide: studies in rats and humans.

  International journal of clinical practice. Supplement 20020701

• Designing selective COX-2 inhibitors: molecular modeling approaches.

  Current opinion in drug discovery & development 20020701

• Role of COX-2 inhibitors in the evolution of acute pain management.

  Journal of pain and symptom management 20020701

• [Allergic vasculitis following ingestion of celecoxib?].

  Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 20020701

• Review of the selective COX-2 inhibitors celecoxib and rofecoxib: focus on clinical aspects.

  CJEM 20020701

• Digging for data from the COX-2 trials.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20020625

• What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex).

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20020625

• Medication toxicity among patients with ankylosing spondylitis.

  Arthritis and rheumatism 20020615

• [Hyperkalemia and celecoxib].

  Medicina clinica 20020608

• Overexpression of cyclooxygenase-2 (COX-2) in human primitive neuroectodermal tumors: effect of celecoxib and rofecoxib.

  Cancer letters 20020606

• A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis.

  Gut 20020601

• Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?

  BMJ (Clinical research ed.) 20020601

• Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia.

  The American journal of psychiatry 20020601

• Celecoxib-induced acute interstitial nephritis.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20020601

• COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice.

  Gastroenterology 20020601

• Celecoxib, a cyclooxygenase 2 inhibitor as a potential chemopreventive to UV-induced skin cancer: a study in the hairless mouse model.

  Archives of dermatology 20020601

• Cyclooxygenase inhibitors for skin cancer prevention: are they beneficial enough?

  Archives of dermatology 20020601

• Coxibs + oral anticoagulants: risk of interaction.

  Prescrire international 20020601

• New studies highlight benefit of Xeloda in new combination treatments for colorectal cancer.

  Expert review of anticancer therapy 20020601

• Physician-reported management of edema and destabilized blood pressure in cyclooxygenase-2-specific inhibitor users with osteoarthritis and treated hypertension.

  Clinical therapeutics 20020601

• Hemicrania continua responds to cyclooxygenase-2 inhibitors.

  Headache 20020601

• Effect of cyclooxygenase inhibitors in postoperative ileus: an experimental study.

  Methods and findings in experimental and clinical pharmacology 20020601

• Gateways to Clinical Trials. June 2002.

  Methods and findings in experimental and clinical pharmacology 20020601

• Myopathy Associated With HMG-CoA Reductase Inhibitors (Statins): A Series of 10 Patients and Review of the Literature.

  Journal of clinical neuromuscular disease 20020601

• Cost-effectiveness of replacing NSAIDs with coxibs: diclofenac and celecoxib in rheumatoid arthritis.

  Expert review of pharmacoeconomics & outcomes research 20020601

• [Coxib spares the stomach. This is true also for patients with preventive aspirin administration].

  MMW Fortschritte der Medizin 20020516

• Determination of celecoxib, a COX-2 inhibitor, in pharmaceutical dosage forms by MEKC.

  Journal of pharmaceutical and biomedical analysis 20020515

• Determination of celecoxib in pharmaceutical formulations using UV spectrophotometry and liquid chromatography.

  Journal of pharmaceutical and biomedical analysis 20020515

• Chronic gastric ulcer healing in rats subjected to selective and non-selective cyclooxygenase-2 inhibitors.

  European journal of pharmacology 20020503

• Cyclooxygenase inhibition: between the devil and the deep blue sea.

  Gut 20020501

• Selective cyclooxygenase-2 inhibition impairs glomerular capillary healing in experimental glomerulonephritis.

  Journal of the American Society of Nephrology : JASN 20020501

• Hyaluronan increases glomerular cyclooxygenase-2 protein expression in a p38 MAP-kinase-dependent process.

  Kidney international 20020501

• The efficacy of premedication with celecoxib and acetaminophen in preventing pain after otolaryngologic surgery.

  Anesthesia and analgesia 20020501

• Translational medicine: targetting cyclo-oxygenase isozymes to prevent cancer.

  QJM : monthly journal of the Association of Physicians 20020501

• Migratory pulmonary infiltrates in a patient with rheumatoid arthritis.

  Thorax 20020501

• Cyclooxygenase-2 overexpression in the skin of transgenic mice results in suppression of tumor development.

  Cancer research 20020501

• Regulation of retinal vascular endothelial growth factor and receptors in rabbits exposed to hyperoxia.

  Investigative ophthalmology & visual science 20020501

• Specific cyclooxygenase-2 inhibitors: what have we learned since they came into widespread clinical use?

  Current opinion in rheumatology 20020501

• Celecoxib-induced erythema multiforme with glyburide cross-reactivity.

  Pharmacotherapy 20020501

• Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis.

  The Journal of rheumatology 20020501

• Anti-implantation effects of indomethacin and celecoxib in rats.

  Contraception 20020501

• [Specific inhibitors of cyclooxygenase type 2] ].

  Vnitrni lekarstvi 20020501

• Studies on the development of colon-targeted delivery systems for celecoxib in the prevention of colorectal cancer.

  Journal of drug targeting 20020501

• Alteration of gastric ulcerogenic and healing responses in rats with adjuvant-induced arthritis.

  Japanese journal of pharmacology 20020501

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20020501

• Current application of selective COX-2 inhibitors in cancer prevention and treatment.

  Oncology (Williston Park, N.Y.) 20020501

• Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat.

  Journal of neuroscience research 20020501

• [Dexketoprofene, selective cox-1 inhibitor nsaids, without gastrointestinal injury in rats].

  Acta gastroenterologica Latinoamericana 20020501

• Antiangiogenic and chemopreventive activities of celecoxib in oral carcinoma cell.

  The Laryngoscope 20020501

• Cardiovascular hazard of selective COX-2 inhibitors: myth or reality?

  Expert opinion on drug safety 20020501

• Characterization, quantification, and bioactivities of anthocyanins in Cornus species.

  Journal of agricultural and food chemistry 20020424

• COX-2 in cancer--a player that's defining the rules.

  Journal of the National Cancer Institute 20020417

• Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells.

  Journal of the National Cancer Institute 20020417

• Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer.

  Cancer research 20020415

• [Celecoxib].

  Deutsche medizinische Wochenschrift (1946) 20020412

• Rofecoxib vs celecoxib vs acetaminophen for treatment of osteoarthritis.

  JAMA 20020410

• Rofecoxib vs celecoxib vs acetaminophen for treatment of osteoarthritis.

  JAMA 20020410

• Inhibitor of cyclooxygenase-2 induces cell-cycle arrest in the epithelial cancer cell line via up-regulation of cyclin dependent kinase inhibitor p21.

  British journal of cancer 20020408

• Cyclooxygenase inhibition in cancer--a blind alley or a new therapeutic reality?

  The New England journal of medicine 20020404

• [Symptomatic therapy of arthrosis and rheumatoid arthritis. Who will benefit from Coxib?].

  MMW Fortschritte der Medizin 20020404

• Lamin B, caspase-3 activity, and apoptosis induction by a combination of HMG-CoA reductase inhibitor and COX-2 inhibitors: a novel approach in developing effective chemopreventive regimens.

  International journal of oncology 20020401

• The MDR phenotype is associated with the expression of COX-2 and iNOS in a human hepatocellular carcinoma cell line.

  Hepatology (Baltimore, Md.) 20020401

• The role of cyclooxygenase-1 and -2 in the rat formalin test.

  Anesthesia and analgesia 20020401

• Dyspepsia tolerability from the patients' perspective: a comparison of celecoxib with diclofenac.

  Alimentary pharmacology & therapeutics 20020401

• Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines.

  Cancer research 20020401

• Metabolism of human articular chondrocytes cultured in alginate beads. Longterm effects of interleukin 1beta and nonsteroidal antiinflammatory drugs.

  The Journal of rheumatology 20020401

• Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors.

  Hypertension (Dallas, Tex. : 1979) 20020401

• Which is most effective of osteoarthritis of the knee: rofecoxib, celecoxib, or acetaminophen?

  The Journal of family practice 20020401

• Gastrointestinal safety of coxibs and outcomes studies: what's the verdict?

  Journal of pain and symptom management 20020401

• Renal effects of cyclooxygyenase-2-selective inhibitors.

  Journal of pain and symptom management 20020401

• Cox-2 inhibitors: today and tomorrow.

  The American journal of the medical sciences 20020401

• Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease.

  The American journal of gastroenterology 20020401

• Considerations for the safe prescribing and use of COX-2-specific inhibitors.

  The Medical journal of Australia 20020401

• Celecoxib with chemotherapy in colorectal cancer.

  Oncology (Williston Park, N.Y.) 20020401

• Modulation of inflammatory paw oedema by cysteamine in the rat.

  Pharmacological research 20020401

• Bioactivity of alkamides isolated from Echinacea purpurea (L.) Moench.

  Phytomedicine : international journal of phytotherapy and phytopharmacology 20020401

• COX-2 inhibitor for the treatment of idiopathic stabbing headache secondary to cerebrovascular diseases.

  Cephalalgia : an international journal of headache 20020401

• Clinical experience with cyclooxygenase-2 inhibitors.

  Rheumatology (Oxford, England) 20020401

• Athletes, nonsteroidal anti-inflammatory drugs, coxibs, and the gastrointestinal tract.

  Current sports medicine reports 20020401

• Case of cholestatic hepatitis with celecoxib did not fulfil international criteria.

  BMJ (Clinical research ed.) 20020330

• [First spontaneous reports of adverse reactions to the new selective COX-2 non-steroidal anti-inflammatory drugs].

  Medicina clinica 20020330

• Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models.

  Journal of medicinal chemistry 20020328

• 4-(4-cycloalkyl/aryl-oxazol-5-yl)benzenesulfonamides as selective cyclooxygenase-2 inhibitors: enhancement of the selectivity by introduction of a fluorine atom and identification of a potent, highly selective, and orally active COX-2 inhibitor JTE-522(1).

  Journal of medicinal chemistry 20020328

• Inducible nitric oxide synthase modulates cyclooxygenase-2 activity in the heart of conscious rabbits during the late phase of ischemic preconditioning.

  Circulation research 20020322

• Nonsteroidal anti-inflammatory drugs, coxibs, and cardio-renal physiology: a mechanism-based approach.

  The American journal of cardiology 20020321

• An evidence-based evaluation of the gastrointestinal safety of coxibs.

  The American journal of cardiology 20020321

• Cyclooxygenase-2 inhibition and renal physiology.

  The American journal of cardiology 20020321

• Effects of nonsteroidal anti-inflammatory drug therapy on blood pressure and peripheral edema.

  The American journal of cardiology 20020321

• Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20020315

• Fatal allergic vasculitis associated with celecoxib.

  Lancet (London, England) 20020309

• Simple and sensitive method for the determination of celecoxib in human serum by high-performance liquid chromatography with fluorescence detection.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20020305

• Up-regulation of cyclooxygenase-2 by inhibition of cyclooxygenase-1: a key to nonsteroidal anti-inflammatory drug-induced intestinal damage.

  The Journal of pharmacology and experimental therapeutics 20020301

• The advancement of cancer chemoprevention by revision of clinical trial strategies.

  Panminerva medica 20020301

• Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigens on colon cancer cells and enhanced liver metastasis.

  Cancer research 20020301

• Selective cyclooxygenase-2 blocker delays healing of esophageal ulcers in rats and inhibits ulceration-triggered c-Met/hepatocyte growth factor receptor induction and extracellular signal-regulated kinase 2 activation.

  The American journal of pathology 20020301

• Nitric oxide, anti-inflammatory drugs on renal prostaglandins and cyclooxygenase-2.

  Hypertension (Dallas, Tex. : 1979) 20020301

• Anaphylaxis to celecoxib.

  Allergy 20020301

• Inhibition of cyclo-oxygenase-2 exacerbates ischaemia-induced acute myocardial dysfunction in the rabbit.

  British journal of pharmacology 20020301

• Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.

  The Journal of rheumatology 20020301

• Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events.

  Biochemical pharmacology 20020301

• A rat model of bone cancer pain.

  Pain 20020301

• A comparison of the renal and cardiovascular safety of celecoxib and rofecoxib.

  Clinical therapeutics 20020301

• Structure-based design of cyclooxygenase-2 selectivity into ketoprofen.

  Bioorganic & medicinal chemistry letters 20020225

• [Safety of celecoxib and rofecoxib: a critical overview].

  Medicina clinica 20020223

• Comparison of the antinociceptive effect of celecoxib, diclofenac and resveratrol in the formalin test.

  Life sciences 20020222

• COX-2 inhibitors: cancer trials test new uses for pain drug.

  Journal of the National Cancer Institute 20020220

• Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues.

  Journal of the National Cancer Institute 20020220

• [A critical evaluation of side effect data on COX-2 inhibitors].

  Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20020220

• Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac.

  The American journal of cardiology 20020215

• [Improper use of selective COX-2 inhibitor NSAIDs].

  Atencion primaria 20020215

• Protective effects of Celecoxib on lung injury and red blood cells modification induced by carrageenan in the rat.

  Biochemical pharmacology 20020215

• Estimation of binding affinities for celecoxib analogues with COX-2 via Monte Carlo-extended linear response.

  Bioorganic & medicinal chemistry letters 20020211

• Why do cyclo-oxygenase-2 inhibitors cause cardiovascular events?

  Journal of the American College of Cardiology 20020206

• Stability-indicating methods for the determination of doxazosin mezylate and celecoxib.

  Journal of pharmaceutical and biomedical analysis 20020201

• Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry.

  Biomedical chromatography : BMC 20020201

• Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo.

  Cancer research 20020201

• Effects of a selective cyclooxygenase-2 inhibitor, celecoxib, on bone resorption and osteoclastogenesis in vitro.

  Biochemical pharmacology 20020201

• Cyclooxygenase-1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites.

  British journal of pharmacology 20020201

• New cyclooxygenase-2 inhibitors for treatment of experimental autoimmune neuritis.

  Muscle & nerve 20020201

• Selective inhibition of COX-2 is beneficial to mice infected intranasally with VSV.

  Prostaglandins & other lipid mediators 20020201

• [Celecoxib induced toxiderma with positive patch-test].

  Annales de dermatologie et de venereologie 20020201

• [Neutrophil-endothelium interaction].

  Nihon rinsho. Japanese journal of clinical medicine 20020201

• Highlights of the 22nd French pharmacovigilance meeting.

  Prescrire international 20020201

• [New nonsteroidal antiinflammatory drugs in rheumatoid arthritis].

  Annales de medecine interne 20020201

• Valdecoxib (Pharmacia).

  Current opinion in investigational drugs (London, England : 2000) 20020201

• Chemoprevention of bladder cancer.

  The Urologic clinics of North America 20020201

• New directions in pain management.

  Drugs of today (Barcelona, Spain : 1998) 20020201

• COX-2 inhibition and thrombotic tendency.

  The Medical journal of Australia 20020121

• Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial.

  JAMA 20020102

• Current treatment of juvenile rheumatoid arthritis.

  Pediatrics 20020101

• Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.

  Cancer research 20020101

• Chemoprevention of colorectal cancer.

  The American journal of gastroenterology 20020101

• Celecoxib-induced nonoliguric acute renal failure.

  The Annals of pharmacotherapy 20020101

• Cutaneous drug reaction case reports: from the world literature.

  American journal of clinical dermatology 20020101

• Acute manic psychosis induced by triple therapy for H. pylori.

  The Journal of the American Board of Family Practice 20020101

• Upper gastrointestinal tolerability of celecoxib compared with diclofenac in the treatment of osteoarthritis and rheumatoid arthritis.

  Clinical and experimental rheumatology 20020101

• Anti-inflammatory medications: selective COX-2 inhibitors.

  The Journal of the American Academy of Orthopaedic Surgeons 20020101

• Cyclo-oxygenase-2 inhibitors and the kidney: a case for caution.

  Drug safety 20020101

• Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib and acetaminophen (paracetamol).

  Current pharmaceutical design 20020101

• Gastrointestinal safety of selective COX-2 inhibitors.

  Current pharmaceutical design 20020101

• Celecoxib: a specific COX-2 inhibitor with anticancer properties.

  Cancer control : journal of the Moffitt Cancer Center 20020101

• [Current post-marketing information. Effects and adverse effects of celecoxib].

  Pharmazie in unserer Zeit 20020101

• Do standard doses of frequently prescribed drugs cause preventable adverse effects in women?

  Journal of the American Medical Women's Association (1972) 20020101

• Should celecoxib be contraindicated in patients who are allergic to sulfonamides?

  Drug safety 20020101

• A cyclooxegenase-2 inhibitor impairs ligament healing in the rat.

  The American journal of sports medicine 20020101

• Efficacy of celecoxib in treating symptoms of viral pharyngitis: a double-blind, randomized study of celecoxib versus diclofenac.

  The Journal of international medical research 20020101

• A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273].

  BMC family practice 20020101

• Sildenafil (Viagra) for male erectile dysfunction: a meta-analysis of clinical trial reports.

  BMC urology 20020101

• Reducing the risk of colorectal cancer by intervening in the process of carcinogenesis: a status report.

  Cancer journal (Sudbury, Mass.) 20020101

• Cutaneous vasculitis related to celecoxib.

  Dermatology (Basel, Switzerland) 20020101

• COX-2-selective inhibitors in the treatment of arthritis.

  Cleveland Clinic journal of medicine 20020101

• Gastrointestinal safety and tolerability of nonselective nonsteroidal anti-inflammatory agents and cyclooxygenase-2-selective inhibitors.

  Cleveland Clinic journal of medicine 20020101

• Outcomes studies of the gastrointestinal safety of cyclooxygenase-2 inhibitors.

  Cleveland Clinic journal of medicine 20020101

• Current perspective on the cardiovascular effects of coxibs.

  Cleveland Clinic journal of medicine 20020101

• Development and clinical application of COX-2-selective inhibitors for the treatment of osteoarthritis and rheumatoid arthritis.

  Cleveland Clinic journal of medicine 20020101

• COX-2 and prostanoid receptors: good targets for chemoprevention.

  Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer 20020101

• Novel approaches for colon cancer prevention by cyclooxygenase-2 inhibitors.

  Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer 20020101

• Is cyclooxygenase-2 important in skin carcinogenesis?

  Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer 20020101

• Celecoxib-associated torsade de pointes.

  The Annals of pharmacotherapy 20020101

• Rofecoxib, 25 mg/d, was more effective than rofecoxib, 12.5 mg/d, celecoxib, or acetaminophen in osteoarthritis of the knee.

  ACP journal club 20020101

• Renal failure associated with the use of celecoxib and rofecoxib.

  Drug safety 20020101

• New reports on dental analgesics. NSAIDs and cardiovascular effects, celecoxib for dental pain, and a new analgesic--tramadol with acetaminophen.

  General dentistry 20020101

• Effects of Celebrex and Zyflo on BOP-induced pancreatic cancer in Syrian hamsters.

  Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 20020101

• Celecoxib for systemic lupus erythematosus: case series and literature review of the use of NSAIDs in SLE.

  Lupus 20020101

• Chemoprevention in colorectal neoplasias: what is practical and feasible?

  Digestive diseases (Basel, Switzerland) 20020101

• Therapeutic utility of aspirin in the ApcMin/+ murine model of colon carcinogenesis.

  BMC cancer 20020101

• [Reactive polyarthritis and painful dermatographism caused by Helicobacter pylori].

  Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993) 20020101

• [Case report: reversible acute renal failure following therapy with both ketorolac (non-selective non-steroidal anti-inflammatory drug NSAID) and celecoxib (COX-2 selective) in the same patient].

  Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia 20020101

• Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches.

  Arthritis research 20020101

• Valdecoxib.

  Reviews in gastroenterological disorders 20020101

• Selective cyclo-oxygenase-2 inhibitors and myocardial infarction: how strong is the link?

  Drug safety 20020101

• Lithium toxicity: a potential interaction with celecoxib.

  Internal medicine journal 20020101

• Renal effects of cyclooxygenase-2 inhibition in fetal lambs.

  Biology of the neonate 20020101

• Labeling changes for arthritis drug.

  FDA consumer 20020101

• Efficacy and safety of diclofenac-cholestyramine and celecoxib in osteoarthritis.

  Proceedings of the Western Pharmacology Society 20020101

• COX-2-selective inhibitors: clinical relevance in surgical and acute pain.

  European journal of anaesthesiology. Supplement 20020101

• Do non-steroidal anti-inflammatory drugs and COX-2 selective inhibitors have different renal effects?

  Journal of nephrology 20020101

• Etoricoxib.

  Drugs 20020101

• Most effective colon cancer chemopreventive agents in rats: a systematic review of aberrant crypt foci and tumor data, ranked by potency.

  Nutrition and cancer 20020101

• [Safety of celecoxib administration].

  Reumatizam 20020101

• Celecoxib for rheumatoid arthritis.

  The Cochrane database of systematic reviews 20020101

• Effects of Celebrex and Zyflo on liver metastasis and lipidperoxidation in pancreatic cancer in Syrian hamsters.

  Clinical & experimental metastasis 20020101

• The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity.

  Current medical research and opinion 20020101

• In vivo evaluation of guargum-based colon-targeted oral drug delivery systems of celecoxib in human volunteers.

  European journal of drug metabolism and pharmacokinetics 20020101

• Inhibition of ultraviolet light B-induced cutaneous inflammation by a specific cyclooxygenase-2 inhibitor.

  Advances in experimental medicine and biology 20020101

• Mechanism of inhibition of novel COX-2 inhibitors.

  Advances in experimental medicine and biology 20020101

• Ulcers, Helicobacter pylori infection, platelets and gastrointestinal complications of non-steroidal anti-inflammatory drugs: what are the connections?

  The European journal of surgery. Supplement. : = Acta chirurgica. Supplement 20020101

• Concerns about COX-2 painkillers. They're easier on the stomach, potentially harder on your heart.

  Heart advisor 20020101

• Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. Involvement of phosphatidylinositol 3-kinase/Akt pathway.

  The Journal of biological chemistry 20011228

• Cardiovascular events and COX-2 inhibitors.

  JAMA 20011212

• [A pop-up menu linked to a computerized drug prescribing system. Prescribing pattern's feedback via a simple and quick method].

  Lakartidningen 20011212

• The coxibs, selective inhibitors of cyclooxygenase-2.

  The New England journal of medicine 20011206

• COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20011201

• Journals should see original protocols for clinical trials.

  BMJ (Clinical research ed.) 20011201

• Effects of NSAIDs on cryoprobe-induced gastric ulcer healing in rats.

  Alimentary pharmacology & therapeutics 20011201

• Gastro-duodenal protection in an era of cyclo-oxygenase-2-selective nonsteroidal anti-inflammatory drugs.

  European journal of gastroenterology & hepatology 20011201

• A protective role for cyclooxygenase-2 in drug-induced liver injury in mice.

  Chemical research in toxicology 20011201

• COX-2 inhibitors: no pain, no heart gain?

  Harvard heart letter : from Harvard Medical School 20011201

• Quantification of nimesulide in human plasma by high-performance liquid chromatography/tandem mass spectrometry. Application to bioequivalence studies.

  Journal of mass spectrometry : JMS 20011201

• COX-2 inhibitors. Are they nonsteroidal anti-inflammatory drugs with a better safety profile?

  Gastroenterology clinics of North America 20011201

• GI events leading to death in association with celecoxib and rofecoxib.

  The American journal of gastroenterology 20011201

• The use and effect of analgesics in patients who regularly drink alcohol.

  The American journal of managed care 20011201

• Intracerebral hemorrhage following possible interaction between celecoxib and clopidogrel.

  The Annals of pharmacotherapy 20011201

• Celecoxib as adjunctive therapy for treatment of colorectal cancer.

  The Annals of pharmacotherapy 20011201

• Cyclooxygenase-1 and cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: investigation using human peripheral monocytes.

  The Journal of pharmacy and pharmacology 20011201

• [Pharmacology of non-steroidal anti-inflammatory drugs and ENT pathology].

  Presse medicale (Paris, France : 1983) 20011201

• [Current status of COX II inhibitors in therapy of rheumatoid arthritis in comparison with conventional non-steroidal anti-inflammatory agents. Attempt at an evaluation with regard to evidence-based medicine].

  Zeitschrift fur Rheumatologie 20011201

• Reporting of 6-month vs 12-month data in a clinical trial of celecoxib.

  JAMA 20011121

• Reporting of 6-month vs 12-month data in a clinical trial of celecoxib.

  JAMA 20011121

• Pharmacological therapies for the treatment of osteoarthritis.

  The Medical journal of Australia 20011119

• Interstitial nephritis associated with celecoxib.

  Lancet (London, England) 20011117

• [Cox-2 inhibitors in the focus. Rofecoxib as effective as the 'classics'].

  MMW Fortschritte der Medizin 20011115

• [Side effects cause enormous costs. Expensive arthritis therapy].

  MMW Fortschritte der Medizin 20011115

• Cardiovascular safety of COX-2 inhibitors.

  The Medical letter on drugs and therapeutics 20011112

• Celecoxib, a selective cyclo-oxygenase-2 inhibitor reduces the severity of experimental colitis induced by dinitrobenzene sulfonic acid in rats.

  European journal of pharmacology 20011109

• Acute gastrointestinal permeability responses to different non-steroidal anti-inflammatory drugs.

  Gut 20011101

• In vitro effects of cyclooxygenase inhibitors in whole blood of horses, dogs, and cats.

  American journal of veterinary research 20011101

• Urticaria and angioedema from cyclooxygenase-2 inhibitors.

  The Journal of rheumatology 20011101

• Inhibition of beta-catenin translocation in rodent colorectal tumors: a novel explanation for the protective effect of nonsteroidal antiinflammatory drugs in colorectal cancer.

  Digestive diseases and sciences 20011101

• Selective cyclo-oxygenase-2 inhibitor-induced oliguria: a postoperative complication.

  Internal medicine journal 20011101

• Effects of selective COX-1 and -2 inhibition on formalin-evoked nociceptive behaviour and prostaglandin E(2) release in the spinal cord.

  Journal of neurochemistry 20011101

• Arthritis. Should you be taking a COX-2 inhibitor?

  Harvard health letter 20011101

• Pain treatment with NSAIDs, primary focus on ibuprofen.

  Clinical rheumatology 20011101

• Celecoxib and rofecoxib.

  Journal of the American Dental Association (1939) 20011101

• COX-2 inhibitors compared and contrasted.

  Expert opinion on pharmacotherapy 20011101

• Aspirin and non-steroidal anti-inflammatory drugs inhibit amyloid-beta aggregation.

  Neuroreport 20011029

• Naphthalene derivatives: A new series of selective cyclooxygenase-2 inhibitors.

  Bioorganic & medicinal chemistry letters 20011022

• [Renal tolerance of selective inhibitors of cyclooxygenase type 2].

  Presse medicale (Paris, France : 1983) 20011020

• Simultaneous quantification of arachidonic acid metabolites in cultured tumor cells using high-performance liquid chromatography/electrospray ionization tandem mass spectrometry.

  Analytical biochemistry 20011015

• Anaphylactoid reactions associated with menstruation affecting two sisters.

  The Medical journal of Australia 20011015

• COX-1 and COX-2 inhibitors.

  Best practice & research. Clinical gastroenterology 20011001

• COX-2 inhibition and prevention of cancer.

  Best practice & research. Clinical gastroenterology 20011001

• Uterine relaxant effects of cyclooxygenase-2 inhibitors in vitro.

  Obstetrics and gynecology 20011001

• Targeting angiogenic processes by combination rofecoxib and ionizing radiation.

  American journal of clinical oncology 20011001

• Characterization of the effects of antiangiogenic agents on tumor pathophysiology.

  American journal of clinical oncology 20011001

• Chronotherapy and chronotoxicity of the cyclooxygenase-2 inhibitor, celecoxib, in athymic mice bearing human breast cancer xenografts.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20011001

• Degradation products of cyanidin glycosides from tart cherries and their bioactivities.

  Journal of agricultural and food chemistry 20011001

• Clinical implications of drug interactions with coxibs.

  Pharmacotherapy 20011001

• [Changes in ulcerogenic response to non-steroidal anti-inflammatory drugs (NSAIDs) in adjuvant arthritic rats].

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20011001

• Nonsteroidal anti-inflammatory drugs for perioperative pain control.

  Medicine and health, Rhode Island 20011001

• Is concern about cardiovascular events with the new coxib class of drugs justified?

  Medscape women's health 20011001

• Stimulated release of arachidonic acid by agonists of the peroxisome proliferator-activated receptor and retinoic acid receptors.

  Prostaglandins, leukotrienes, and essential fatty acids 20011001

• Three-dimensional quantitative structure-activity relationships of cyclo-oxygenase-2 (COX-2) inhibitors: a comparative molecular field analysis.

  Journal of medicinal chemistry 20010927

• Determination of celecoxib in human plasma and rat microdialysis samples by liquid chromatography tandem mass spectrometry.

  Journal of chromatography. B, Biomedical sciences and applications 20010925

• [New study of selective COX-2 inhibitors. Protecting the stomach while risking the heart? (interview by Dr. Beate Schumacher)].

  MMW Fortschritte der Medizin 20010906

• Pain relief at a price. A blow to the heart?

  U.S. news & world report 20010903

• Arthritis: what it is, why you get it and how to stop the pain.

  Newsweek 20010903

• How safe are your prescription pills?

  Time 20010903

• Role of inducible cyclooxygenase and prostaglandins in Clostridium difficile toxin A-induced secretion and inflammation in an animal model.

  The Journal of infectious diseases 20010901

• A review of cancer chemopreventive agents.

  Current medicinal chemistry 20010901

• Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions.

  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20010901

• [Cyclooxygenase (COX)-2 selective inhibitors: aspirin, a dual COX-1/COX-2 inhibitor, to COX-2 selective inhibitors].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20010901

• A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database.

  Clinical therapeutics 20010901

• [Anaphylactic shock induced by celecoxib].

  Annales de medecine interne 20010901

• [COX-2 inhibitor non-steroidal anti-inflammatory drugs, myth or reality?].

  Revue medicale de Bruxelles 20010901

• Renocortical expression of renin and of cyclooxygenase-2 in response to angiotensin II AT1 receptor blockade is closely coordinated but not causally linked.

  Pflugers Archiv : European journal of physiology 20010901

• The growth of malignant keratinocytes depends on signaling through the PGE(2) receptor EP1.

  Neoplasia (New York, N.Y.) 20010901

• Drug interactions update: drugs, herbs, and oral anticoagulation.

  Journal of thrombosis and thrombolysis 20010901

• [Thinking about the specific cyclooxygenase-2 inhibitors since its recommendation].

  Zhonghua nei ke za zhi 20010901

• Design and synthesis of 4,5-diphenyl-4-isoxazolines: novel inhibitors of cyclooxygenase-2 with analgesic and antiinflammatory activity.

  Journal of medicinal chemistry 20010830

• Design and synthesis of celecoxib and rofecoxib analogues as selective cyclooxygenase-2 (COX-2) inhibitors: replacement of sulfonamide and methylsulfonyl pharmacophores by an azido bioisostere.

  Journal of medicinal chemistry 20010830

• Selective and rapid liquid chromatography-mass spectrometry method for the quantification of rofecoxib in pharmacokinetic studies with humans.

  Journal of chromatography. B, Biomedical sciences and applications 20010825

• COX-2 inhibition and thrombotic tendency: a need for surveillance.

  The Medical journal of Australia 20010820

• [Coxibs: cyclooxygenase-2 inhibitors].

  Wiener klinische Wochenschrift 20010816

• Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries.

  Circulation 20010814

• Researchers deny any attempt to mislead the public over JAMA article on arthritis drug.

  BMJ (Clinical research ed.) 20010811

• The coxibs, selective inhibitors of cyclooxygenase-2.

  The New England journal of medicine 20010809

• A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors.

  The Biochemical journal 20010801

• Celecoxib-induced Sweet's syndrome.

  Journal of the American Academy of Dermatology 20010801

• Familiar drugs may prevent cancer.

  Postgraduate medical journal 20010801

• Acute hepatocellular and cholestatic injury in a patient taking celecoxib.

  Postgraduate medical journal 20010801

• Effects of COX-2 inhibitors on aortic prostacyclin production in cholesterol-fed rabbits.

  Atherosclerosis 20010801

• Risk of cardiovascular events associated with selective COX-2 inhibitors.

  JAMA 20010801

• Visual disturbance associated with celecoxib--a comment.

  Pharmacotherapy 20010801

• New combination promising against colon cancer.

  Expert review of anticancer therapy 20010801

• [Safety of specific cyclo-oxygenase 2 inhibitors].

  Nederlands tijdschrift voor geneeskunde 20010728

• Drug Points: Cholestatic hepatitis in association with celecoxib.

  BMJ (Clinical research ed.) 20010707

• Acute renal failure related to high-dose celecoxib.

  Annals of internal medicine 20010703

• Effect of cyclooxygenase-2 inhibitor (celecoxib) on the infarcted heart in situ.

  Pharmacology 20010701

• Comparative analysis of pharmacologic and/or genetic disruption of cyclooxygenase-1 and cyclooxygenase-2 function in female reproduction in mice.

  Endocrinology 20010701

• Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-kappaB.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20010701

• Chemoprevention of colorectal cancer.

  Current opinion in oncology 20010701

• Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs.

  The Journal of clinical investigation 20010701

• Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs.

  The American journal of medicine 20010701

• A new class of COX-2 inhibitors offer an alternative to NSAIDS in pain management after spinal surgery.

  Spine 20010701

• Anaphylaxis to celecoxib.

  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20010701

• Stimulated release of arachidonic acid from rat liver cells by celecoxib and indomethacin.

  Prostaglandins, leukotrienes, and essential fatty acids 20010701

• Cyclooxygenase (COX-2) selective inhibitors. Any better than NSAIDs?

  Canadian family physician Medecin de famille canadien 20010701

• Rationale for the observed COX-2/COX-1 selectivity of celecoxib from Monte Carlo simulations.

  Bioorganic & medicinal chemistry letters 20010618

• A stable prostacyclin analog enhances ectopic activity in rat sensory neurons following neuropathic injury.

  Brain research 20010615

• Cyclooxygenase-2 inhibition and renal function.

  Annals of internal medicine 20010605

• [Safety of specific cyclo-oxygenase 2 inhibitors].

  Nederlands tijdschrift voor geneeskunde 20010602

• Rat colorectal tumours treated with a range of non-steroidal anti-inflammatory drugs show altered cyclooxygenase-2 and cyclooxygenase-1 splice variant mRNA expression levels.

  Carcinogenesis 20010601

• Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth.

  Gastroenterology 20010601

• Cyclooxygenase-1 vs. cyclooxygenase-2 inhibitors in the induction of antinociception in rodent withdrawal reflexes.

  Neuropharmacology 20010601

• Evaluation of the tocolytic effect of a selective cyclooxygenase-2 inhibitor in a mouse model of lipopolysaccharide-induced preterm delivery.

  Molecular human reproduction 20010601

• T-cell involvement in drug-induced acute generalized exanthematous pustulosis.

  The Journal of clinical investigation 20010601

• Cyclooxygenase-2: a target for the prevention and treatment of breast cancer.

  Endocrine-related cancer 20010601

• Possible celecoxib-induced gastroduodenal ulceration.

  The Annals of pharmacotherapy 20010601

• Suppression of occurrence and advancement of beta-catenin-accumulated crypts, possible premalignant lesions of colon cancer, by selective cyclooxygenase-2 inhibitor, celecoxib.

  Japanese journal of cancer research : Gann 20010601

• Celecoxib--the debate rages on.

  South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 20010601

• Celecoxib-- the debate ranges on.

  South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 20010601

• [Clinical application of cyclooxygenase-2 inhibitors].

  Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 20010601

• Celecoxib and rofecoxib: a distinction with a difference?

  Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20010601

• COX-2 specific inhibitors in the management of osteoarthritis of the knee: a placebo-controlled, randomized, double-blind study.

  Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20010601

• Non-steroidal anti-inflammatory drugs with activity against either cyclooxygenase 1 or cyclooxygenase 2 inhibit colorectal cancer in a DMH rodent model by inducing apoptosis and inhibiting cell proliferation.

  Gut 20010501

• Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption.

  The Journal of pharmacology and experimental therapeutics 20010501

• Surveillance colonoscopy or chemoprevention with COX-2 inhibitors in average-risk post-polypectomy patients: a decision analysis.

  Alimentary pharmacology & therapeutics 20010501

• EULAR recommendations for the management of knee osteoarthritis.

  Annals of the rheumatic diseases 20010501

• Cyclooxygenase 2 inhibitors and thrombogenicity production: comment on the article by Crofford et al.

  Arthritis and rheumatism 20010501

• Osteoarthritis. A primary care approach for physicians in 2000 and beyond.

  Saudi medical journal 20010501

• Preventing gastrointestinal complications of NSAIDs. Risk factors, recent advances, and latest strategies.

  Postgraduate medicine 20010501

• Current concepts regarding pharmacologic treatment of rheumatoid and osteoarthritis.

  Hand clinics 20010501

• NSAIDS and selective COX-2 inhibitors: competition between gastroprotection and cardioprotection.

  Lancet (London, England) 20010421

• Renal safety of combined cyclooxygenase 2 (COX-2) inhibitor and angiotensin II receptor blocker administration in mild volume depletion.

  Swiss medical weekly 20010407

• Liquid chromatographic-mass spectrometric determination of celecoxib in plasma using single-ion monitoring and its use in clinical pharmacokinetics.

  Journal of chromatography. B, Biomedical sciences and applications 20010405

• COX-2 inhibitors.

  The Medical journal of Australia 20010402

• COX-2 inhibitors and the gastrointestinal tract.

  Gut 20010401

• Substrate inhibition kinetics for cytochrome P450-catalyzed reactions.

  Drug metabolism and disposition: the biological fate of chemicals 20010401

• LC separation of ortho and meta isomers of celecoxib in bulk and formulations using a chiral column.

  Journal of pharmaceutical and biomedical analysis 20010401

• Middermal elastolysis in two patients with lupus erythematosus.

  The American Journal of dermatopathology 20010401

• Proapoptotic anti-inflammatory drugs.

  Urology 20010401

• Trial endpoints for drug approval in oncology: Chemoprevention.

  Urology 20010401

• Selective COX-2 inhibitors.

  The American journal of nursing 20010401

• Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice.

  Journal of the American Dental Association (1939) 20010401

• Cyclooxygenase 2 inhibition and thrombosis: comment on the article by Crofford et al.

  Arthritis and rheumatism 20010401

• Evidence for a direct role of cyclo-oxygenase 2 in implant wear debris-induced osteolysis.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20010401

• Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.

  The American journal of gastroenterology 20010401

• Exacerbation of inflammatory bowel disease associated with use of celecoxib.

  The American journal of gastroenterology 20010401

• Gastrointestinal damage induced by celecoxib and rofecoxib in rats.

  Digestive diseases and sciences 20010401

• In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics.

  Pharmacogenetics 20010401

• [Effect of celecoxib, a COX-2 inhibitor, in familial adenomatous polyposis].

  Zeitschrift fur Gastroenterologie 20010401

• Inhibition of cyclooxygenase-1 or -2 on insulin sensitivity in healthy subjects.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20010401

• [The coxibs, third generation anti-inflammatories].

  Revue medicale de Bruxelles 20010401

• Celecoxib--the debate rages on.

  South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 20010401

• [COX-2 specific inhibitors: are NSAIDs and the stomach become reconcilied?].

  Gastroenterologie clinique et biologique 20010401

• Celecoxib in osteoarthritis and rheumatoid arthritis: new preparation. As disappointing as rofecoxib.

  Prescrire international 20010401

• Selective inhibitors of cyclooxygenase-2: a growing class of anti-inflammatory drugs.

  Molecular interventions 20010401

• COX-2 inhibitors and the kidney.

  Hospital practice (1995) 20010315

• Where is the evidence that cyclooxygenase inhibition is the primary cause of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal injury? Topical injury revisited.

  Biochemical pharmacology 20010315

• Functional status and health-related quality of life of elderly osteoarthritic patients treated with celecoxib.

  The journals of gerontology. Series A, Biological sciences and medical sciences 20010301

• [64th Congress of the American College of Rheumatology, Philadelphia, October 28-November 2, 2000].

  La Revue de medecine interne 20010301

• [Therapy with preferential and specific COX-2 inhibitors].

  Der Internist 20010301

• COX-2 inhibition in clinical cancer prevention.

  Oncology (Williston Park, N.Y.) 20010301

• Osteoarthritis management: the role of cyclooxygenase-2-selective inhibitors.

  Clinical therapeutics 20010301

• Discovery and design of selective cyclooxygenase-2 inhibitors as non-ulcerogenic, anti-inflammatory drugs with potential utility as anti-cancer agents.

  Current drug targets 20010301

• Cyclo-oxygenase 2 inhibitors: an important new drug classification.

  Pain management nursing : official journal of the American Society of Pain Management Nurses 20010301

• Efficacy of cyclooxygenase-2-specific inhibitors.

  The American journal of medicine 20010219

• Gastrointestinal toxic side effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2-specific inhibitors.

  The American journal of medicine 20010219

• FDA refuses companies' request to drop ulcer warning.

  BMJ (Clinical research ed.) 20010217

• Celecoxib-induced cholestatic hepatitis.

  Annals of internal medicine 20010206

• Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2.

  The Journal of pharmacology and experimental therapeutics 20010201

• COX-2 inhibitors in rheumatoid arthritis.

  Current rheumatology reports 20010201

• Successful use of cyclooxygenase-2 inhibitor in a patient with aspirin-induced asthma.

  Southern medical journal 20010201

• Comparison of once-daily and twice-daily administration of celecoxib for the treatment of osteoarthritis of the knee.

  Clinical therapeutics 20010201

• Efficacy and tolerability of celecoxib versus hydrocodone/acetaminophen in the treatment of pain after ambulatory orthopedic surgery in adults.

  Clinical therapeutics 20010201

• Synthesis and SAR of a new series of COX-2-selective inhibitors: pyrazolo[1,5-a]pyrimidines.

  Journal of medicinal chemistry 20010201

• COX-2 inhibitors: new drugs for the management of pain and inflammation.

  Dentistry today 20010201

• Celecoxib in patients with asthma and aspirin intolerance. The Celecoxib in Aspirin-Intolerant Asthma Study Group.

  The New England journal of medicine 20010111

• Acute upregulation of COX-2 by renal artery stenosis.

  American journal of physiology. Renal physiology 20010101

• Hyaluronan-induced cyclooxygenase-2 expression promotes thromboxane A2 production by renal cells.

  Kidney international 20010101

• Colorectal cancer chemoprevention: biochemical targets and clinical development of promising agents.

  European journal of cancer (Oxford, England : 1990) 20010101

• Visual disturbance associated with celecoxib.

  Pharmacotherapy 20010101

• Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug.

  Arthritis and rheumatism 20010101

• Celecoxib--a rational alternative to NSAIDs.

  South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 20010101

• Breast cancer chemoprevention: beyond tamoxifen.

  Breast cancer research : BCR 20010101

• Celecoxib versus diclofenac in the management of osteoarthritis of the knee.

  Scandinavian journal of rheumatology 20010101

• [Pharma-clinics. The drug of the month. Celecoxib (Celebrex)].

  Revue medicale de Liege 20010101

• Effect of the cyclooxygenase-2 inhibitor celecoxib on bronchial responsiveness and cough reflex sensitivity in asthmatics.

  Pulmonary pharmacology & therapeutics 20010101

• Renal effects of COX-2-selective inhibitors.

  American journal of nephrology 20010101

• A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis.

  PharmacoEconomics 20010101

• An economic model for determining the costs and consequences of using various treatment alternatives for the management of arthritis in Canada.

  PharmacoEconomics 20010101

• Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland.

  PharmacoEconomics 20010101

• Pharmacokinetics of celecoxib in the presence and absence of interferon-induced acute inflammation in the rat: application of a novel HPLC assay.

  Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 20010101

• Cardiovascular and renal effects of COX-2-specific inhibitors: recent insights and evolving clinical implications.

  American journal of therapeutics 20010101

• Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients.

  American journal of therapeutics 20010101

• Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis.

  Neoplasia (New York, N.Y.) 20010101

• Should celecoxib be contraindicated in patients who are allergic to sulfonamides? Revisiting the meaning of 'sulfa' allergy.

  Drug safety 20010101

• Anti-inflammatory drugs, cyclooxygenases and other factors.

  Expert opinion on pharmacotherapy 20010101

• Celecoxib: a new option in the treatment of arthropathies and familial adenomatous polyposis.

  Expert opinion on pharmacotherapy 20010101

• Apoptosis signaling pathways mediated by cyclooxygenase-2 inhibitors in prostate cancer cells.

  Advances in enzyme regulation 20010101

• Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis.

  Drugs 20010101

• Alzheimer's disease, inflammation and non-steroidal anti-inflammatory drugs.

  Bratislavske lekarske listy 20010101

• Potential adverse effects of cyclooxygenase-2 inhibition: evidence from animal models of inflammation.

  BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 20010101

• Celecoxib- and rofecoxib-induced delirium.

  The Journal of neuropsychiatry and clinical neurosciences 20010101

• [Selective cyclooxygenase 2 inhibitors (COX-2)].

  Postepy higieny i medycyny doswiadczalnej 20010101

• Cyclooxygenase inhibitors: any reservations?

  Internal medicine journal 20010101

• Upper gastroduodenal ulceration in arthritis patients treated with celecoxib.

  The Annals of pharmacotherapy 20010101

• [Celecoxib].

  Revista de medicina de la Universidad de Navarra 20010101

• [The coxibs, third generation of non-steroidal anti-inflammatory agents].

  Journal de pharmacie de Belgique 20010101

• [Role of cyclooxygenase-2 (COG-2) in the etiology of pain].

  Terapevticheskii arkhiv 20010101

• [Celebrex: confirmed effectiveness and safety (new data)].

  Terapevticheskii arkhiv 20010101

• [Effectiveness and tolerance of celebrex in osteoarthrosis (data of a Russian study)].

  Terapevticheskii arkhiv 20010101

• [Gastroduodenal tolerance of celecoxib (celebrex) in patients with osteoarthrosis: an endoscopic evaluation].

  Terapevticheskii arkhiv 20010101

• [Clinical use of COX-2 inhibitors].

  Vojnosanitetski pregled 20010101

• The ever-emerging anti-inflammatories. Have there been any real advances?

  Journal of physiology, Paris 20010101

• NSAIDs inhibit the activation of egr-1 gene in microvascular endothelial cells. A key to inhibition of angiogenesis?

  Journal of physiology, Paris 20010101

• What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.

  Clinical and experimental rheumatology 20010101

• COX-2 inhibitors and the cardiovascular system.

  Clinical and experimental rheumatology 20010101

• Analgesia and COX-2 inhibition.

  Clinical and experimental rheumatology 20010101

• A cyclooxygenase-2 inhibitor impairs ligament healing in the rat.

  The American journal of sports medicine 20010101

• Approach to angiogenesis inhibition based on cyclooxygenase-2.

  Cancer journal (Sudbury, Mass.) 20010101

• Participation of COX, IL-1 beta and TNF alpha in formalin-induced inflammatory pain.

  Proceedings of the Western Pharmacology Society 20010101

• Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip.

  The Journal of international medical research 20010101

• Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis.

  Anticancer research 20010101

• [Specific inhibitors of cyclooxygenase-2 (COX-2): current knowledge and perspectives].

  Acta bio-medica de L'Ateneo parmense : organo della Societa di medicina e scienze naturali di Parma 20010101

• Identification of sulfonamide-like adverse drug reactions to celecoxib in the World Health Organization database.

  Current medical research and opinion 20010101

• Effect of cyclooxygenase and NO synthase inhibitors on antinociceptive action of acetaminophen.

  Polish journal of pharmacology 20010101

• An update on specific COX-2 inhibitors: the COXIBs.

  Bulletin on the rheumatic diseases 20010101

• [Celecoxib].

  Reumatizam 20010101

• Celecoxib.

  Dimensions of critical care nursing : DCCN 20010101

• Non-steroidal anti-inflammatory drugs with different cyclooxygenase inhibitory profiles that prevent aberrant crypt foci formation but vary in acute gastrotoxicity in a rat model.

  Journal of gastroenterology and hepatology 20001201

• Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

  JAMA 20000913

• Acute onset of auditory hallucinations after initiation of celecoxib therapy.

  The American journal of psychiatry 20000601

• Novel antiarthritic agents with 1,2-isothiazolidine-1,1-dioxide (gamma-sultam) skeleton: cytokine suppressive dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase.

  Journal of medicinal chemistry 20000518

• The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2.

  The Journal of biological chemistry 20000414

• Selective cyclo-oxygenase-2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence.

  British journal of pharmacology 20000401

• 4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2.

  Journal of medicinal chemistry 20000309

• Cyclooxygenase-2 selective inhibitors aggravate kainic acid induced seizure and neuronal cell death in the hippocampus.

  Brain research 19991002